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ii Abstract 
Cytokines  are  small  proteins  or  glycoproteins  that  mediate  cellular  growth  and 
differentiation  and  regulate  immune  responses.  Upon  encounter  with  antigen,  CD4+  T 
cells  are  able  to  influence  the  character  of  the  immune  response  elicited  through  the 
expression  of  distinct  types  of  cytokines.  Thi  cytokines,  especially  IFN-y  but  also  TNF-P 
and  IL-2,  constitute  one  such  pattern  of  expression,  promoting  cell  mediated  immune 
responses.  In  a  broader  sense,  interleukin-12  and  interleukin-18  can  also  be  classified  as 
type  I  cytokines  in  as  much  as  they  are  able  to  shift  the  CD4+  cytokine  expression  pattern 
to  a  Thl  phenotype  and  specifically  stimulate  IFN-y  production  not  only  by  T  helper 
cells,  but  also  by  cytotoxic  T  cells  and  natural  killer  cells. 
The  purpose  of  the  present  project  was  to  develop  equine  Thl  cytokines,  making  them 
available  for  dissecting  the  equine  immune  system,  particularly  in  what  concerns  to 
defence  mechanisms  against  infectious  micro-organisms.  Following  the  trend  in  human 
medicine,  the  cytokines  produced  will  be  useful  for  the  development  of  new 
therapeuticals  and  prophylactics  to  be  used  in  the  control  and  prevention  of  infectious 
diseases  of  the  horse.  For  this  effect  we  have  initiated  studies  on  equine  interferon- 
gamma  and  related  cytokines  and  obtained  the  following  results.  Equine  interferon- 
gamma  was  cloned  and  produced  in  a  variety  of  heterologous  protein  expression  systems. 
The  biological  activity  of  recombinant  equine  interferon-gamma  was  assessed  in  vitro. 
Polyclonal  serum  preparations  against  equine  interferon-gamma,  obtained  by 
immunization  with  recombinant  protein,  were  recovered'  and  characterised.  Also 
described  is  the  cloning  of  the  interferon-gamma  inducing  cytokines  equine  interleukin- 
12  and  equine  interleukin-18.  The  potential  use  of  the  cloned  equine  cytokine  genes  as 
vaccine  adjuvants  was  evaluated  by  DNA  co-administration  with  plasmids  encoding  the 
equine  influenza  virus  antigens  haernagglutinin  and  nucleoprotein,  followed  by  viral 
challenge. 
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MEM  minimum  essential  medium 
mg  milligram(s) 
mm  micromolar 
M-MuLV  Moloney  murine  leukaemia  virus 
mRNA  messenger  ribonucleic  acid 
NEAA  non  essential  amino  acids 
rim  nanometre 
oligo(dT)  oligodeoxythymidylic  acid 
ORF  open  reading  frame 
PAGE  polyacrylamide  gel  electrophoresis 
PBL  peripheral  blood  lymphocytes 
PBS  phosphate  buffered  saline 
PCR  polymerase  chain  reaction 
PFA  paraformaldehyde 
p  fa  plaque  forming  units 
PHA  phytohaemagglutinin 
PMA  phorbol  myristate  acetate 
PMSF  pheny1methylsulphonyl.  fluoride 
poly(A)  polyadenylated  (mRNA) 
xviii RBC  red  blood  cell 
RIA  radioimmunoassay 
RNA  ribonucleic  acid 
RNAse  ribonuclease 
rpm  revolutions  per  minute 
RPMI  Rosewell  Park  Memorial  Institute 
rRNA  ribosomal.  ribonucleic  acid 
RSV  Roux  sarcoma  virus 
RT  reverse  transcriptase 
SDS  sodium  dodecyl  sulphate 
SDS-PAGE  sodium  dodecyl  sulphate  polyacrylamide  gel  electrophoresis 
T  thymine  or  thymidine 
TBE  Tris/borate/EDTA 
TBS-T  tris  buffered  saline-tween  solution 
TCID  tissue  culture  infectious  dose 
TE  Tris-EDTA  buffer 
TEA  Tris/EDTA/acetate 
TEMED  N,  N,  N',  Ný-  tetramethyl-ethylenediamine 
T,  melting  (or  midpoint)  temperature 
Tris  tris(hydroxymethyl)aminomethane 
Tris-HCl  Tris  hydrochloride 
UV  ultraviolet 
UWGCG  University  of  Wisconsin  Genetics  Computer  Group 
VSV  vesicular  stomatitis  virus 
WHO  World  Health  Organisation 
Xgal  5-bromo-4-chloro-3-indolyl-o-D-galactoside 
CYTOKINES 
BDNF  brain-derived  neurotrophic  factor 
CLMF  cytotoxic  lymphocyte  maturation  factor  (IL-12) 
CNTF  ciliary  neurotrophic  factor 
CSF  colony  stimulating  factor 
CSF-I  colony  stimulating  factor-1  (M-CSF) 
EGF  epidermal  growth  factor 
EPO  erythropoietin 
EqIFN  recombinant  equine  interferon 
EqIL  recombinant  equine  interleukin 
G-CSF  granulocyte  colony  stimulating  factor 
GGF  glial  growth  factor 
GH  growth  hormone 
GM-CSF  granulocyte  macrophage  colony  stimulating  factor 
HGF  hepatocyte,  growth  factor 
IFN  interferon 
IGF  insulin  like  growth  factor 
IGIF  interferon  gamma  inducing  factor  (IL-  18) 
xlx IL  interleukin 
M-CSF  macrophage  colony  stimulating  factor 
MCP  macrophage  chemoattractant  protein 
NGF  nerve  growth  factor 
NKSF  NK  stimulatory  factor  (IL-  12) 
PDGF  platelet  derived  growth  factor 
PRL  prolactin 
SCF  stem  cell  factor 
SCF-R  stem  cell  factor  receptor 
R  receptor  (cytokine  receptor) 
TGF  transforming  growth  factor 
TNF  turnour  necrosis  factor 
VEGF  vascular  endothelial  growth  factor 
AMrNO  ACIDS 
Amino  acid  Three  letter  code  One  letter  code  Solubility 
Aspartic  acid  Asp  D 
Glutamic  acid  Glu  E 
Asparagine  Asn  N 
Glutamine  Gln  Q 
Lysine  LYS  K 
Arginine  Arg  R 
Histidine  His  H  hydrophilic 
Glycine  Gly  G 
Alanine  Ala  A 
Cysteine  Cys  C 
Serine  Ser  S 
Threonine  Thr  T 
Proline  Pro  P 
Tryptophan  Trp  w 
Tyrosine  Tyr  Y 
Valine  Val  V 
Methionine  Met  M  hydrophobic 
Isoleucine  Ile  I 
Leucine  Leu  L 
Phenylalanine  Phe  F 
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I  Introduction 
The  main  objectives  of  this  project  were  the  expression  and  investigation  of  the  biological 
activity  in  vitro  of  equine  interferon  gamma  and  an  assessment  of  the  potential 
application  of  equine  interferon  gamma  and  other  Thl  type  cytkines  as  viral  vaccine 
adjuvants.  This  chapter  comprises  a  brief  overview  of  cytokines  followed  by  a  focus  on 
the  biology  of  interferon  gamma.  The  description  of  procedures  used  for  the  study  of 
equine  interferon  gamma  will  be  addressed  in  chapter  3.  Additional  work  on  the  cloning 
of  alternative  equine  cytokines,  cloning  and  expression  of  equine  influenza  virus  antigens 
to  be  used  in  a  vaccine  trial  and  the  design  of  the  trial  itself  will  be  approached  in 
chapters  4,5  and  6,  respectively,  and  pertinent  background  information  will  be 
introduced  in  the  individual  chapters.  Other  work,  including  the  cloning  of  equine 
transforming  growth  factor  beta-1,  and  interleuin-lp  and  of  porcine  interleukin-18  will 
not  be  mentioned. 
1.1  Properties  of  cytokines 
The  term  cytokine  is  loosely  applied  to  intercellular  polypeptide  messengers  including 
interleukins,  lymphokines,  monokines,  interferons,  colony  stimulation  factors  and  non- 
haernatopoietic  growth  factors  (Nicola,  1994).  Due  to  the  striking  number  of  novel 
cytokines  reported  in  recent  years  and  to  the  variability  that  they  show  at  both  structural 
and  flinctional  levels,  any  definition  that  attempts  to  cover  this  heterogeneous  group  of 
molecules  is  necessarily  ambiguous.  Cytokines  can  however  be  defined  as  secreted 
regulatory  proteins  which  bind  to  specific  receptors  on  target  cells  exerting  multiple 
effects  including  modulation  of  immune  and  inflammatory  responses.  The  pleiotropic 
activities  of  cytokines  comprise  the  survival,  growth,  differentiation  and/or  specialised 
effector  functions  -of  target  cells  (Nicola,  1994;  Vilcek,  1998).  Some  characteristic 
features  (Vilcek,  1998;  Pugh-Humphreys  and  Thomson,  1998)  that  can  be  attributed  to 
most  cytokines  are  as  follows: 
-  Cytokines 
.  are  simple  proteins  or  glycoproteins  with  a  molecular  weight 
commonly  less  then  30  kDa; 
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-  Although  some  constitutive  expression  of  cytokines  has  been  observed,  they  are 
usually  tightly  regulated  at  transcriptional  or  translational  level; 
-  The  notion  that  cytokines  act  locally  (in  an  autocrine  or  paracrine  fashion)  is 
supported  by  observations  that  they  are  expressed  transiently  and  have  a  short  half 
live  in  circulation.  Recent  data  suggests  that  cytokines  can  be  directionally 
secreted,  therefore  targeting  cells  closely  associated  with  the  producing  cell; 
-  Cytokines  are  produced  and  active  at  extremely  low  (nanomolar  to  picomolar) 
concentrations,  promoting  their  actions  through  binding  to  specific,  high-affinity, 
cell  surface  receptors; 
-  Cytokines  act  by  altering  the  pattern  of  gene  expression  of  target  cells,  leading  to 
stimulation  or  inhibition  of  cell  proliferation,  differentiation  and  effector 
functions. 
Because  some  of  these  features  also  apply  to  polypeptide  hormones  it  is  important  to 
make  a  distinction  between  this  two  groups  of  molecules  (table  1.1). 
Table  1.1  Differential  features  of  polypeptide  hormones  and  cytokines  (Vilcek,  1998). 
Hormones  Cytokines 
Feature  Exceptions  Feature  Exceptions 
Produced  by  one  type  Produced  by  more  than  IL-2,  IL-3,  IL-4, 
of  specialised  cells  one  type  of  cell  IL-5,  produced  by 
lymphoid  cells  only 
Each  hormone  is  Different  cytokines  have 
unique  in  its  actions  overlapping  activities 
Restricted  target  cell  Insulin  Multiple  target  cells  and 
specificity  and  limited  multiple  actions 
spectrum  of  actions  (pleiotropy) 
Act  at  a  distant  site  Short  action  radius  Many  (e.  g.  TGF-P, 
(endocrine  activity)  (autocrine  or  paracrine)  TNF-cc,  IL-6) 
Due  to  the  multiplicity  of  cytokines,  potential  target  cells  and  to  the  variety  of  effects 
exerted,  care  should  be  taken  in  attributing  specific  activities  to  individual  cytokines.  The 
activation  status  of  the  cells  (determined  by  antigen,  costimulatory  and  adhesion 
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molecules)  and  the  cell  cycle  stage  play  an  important  role  in  the  differential  response  to 
cytokines.  Additionally,  the  fact  that  cytokines  do  not  act  alone  but  instead  as 
components  of  a  cytokine  network  with  synergistic,  antagonistic,  overlapping  and 
transmodulating  activities,  leads  to  the  notion  of  redundancy  in  cytokine  activity. 
1.2  Classification  of  cytokines 
Table  1.2  Classification  of  cytokines  (modified  from  Nicola,  1994). 
Cytokine  class  Subgroup  Receptor  class  Examples  Bio-activities 
Short  chain  Hemopoietin  domain  IL-2,  IL-4,  IL-7,  T  cell,  B  cell,  and 
(y-subunit)  IL-9,  IL-13  MO  proliferation  and 
differentiation 
P-subunit  IL-3,  IL-5,  GM-CSF  Neutrophil, 
Eosinophil,  MO  and 
Mast  cell 
proliferation  and 
differentiation 
Ig-TK  M-CSF,  SCIF  MO  and  stem  cell 
proliferation  and 
differentiation 
4-a  helical  bundle 
IFNR  IFN-y  Immune  regulation, 
antiviral  activity 
Long  chain  Hemopoietin  domain  IL-6,  IL-  11,  CNTF  Pleiotropic  in  liver, 
(gpl30-subunit)  nerve,  muscle,  MO, 
megakaryocyte 
Epo,  G-CSF  Mono  specific, 
Erythroid, 
Neutrophil,  T  cells 
IFNR  IL-  10,  IFN-a/0  Immune  modulation- 
cytokine  synthesis 
Cystine  knot  S/T  kinases  TGF-Ps  Differentiation, 
growth  inhibition, 
tissue  repair 
Ig-TK  PDGF,  VEGF  Epithelial  and 
endothelial  cell 
growth 
Long  chain  P-sheet 
Cys-TK  NGF.  BDNF  Survival,  growth  and 
differentiation  of 
nerve  cells 
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0-jellyroll  TNFR  TNF-a/0,  CD40L,  Immune  regulation, 
FASL  cell  death 
fl-trefoil  IL-I  R  (Ig-like)  IL-  101/0'  IL-  18  Immune  regulation, 
acute  phase 
Proliferation  of 
S-S  rich  0-meander  EGF,  TGFa  epithelial  cells, 
Cys-TK  wound  healing 
Short  chain  Wo  S-S  rich  WO  Insulin,  IGF-1111  Metabolic  responses 
mesenchymal 
Chemokines  WO  G-protein  coupled  a-chemokines, 
ILA,  IP-10  Chernotaxis  and 
Innate  immune 
O,  chcmokines,  responses 
MCP-1/2/3, 
RANTES 
Ig-EGF-TM-Cyt  Cys-TK  GGIF  Growth  and 
(cell  surface)  differentiation  of 
nerve  cells 
Mosaic  4-kringle  (a)  +  Met-TY,  HGF  Growth  of 
serine  protease  (0)  hepatocytes, 
epithelial  and 
cndothelial  cells 
4-helical  (cE)  +  Ig-TK  IL-12  Immune  modulation 
hemopoictin  (P) 
I 
T  and  NK  cells 
Legend:  BDNF-  brain-derived  neurotrophic  factor,  CD40L-  CD40  ligand;  CNTF-  ciliary  neurotrophic  factor;  Cys-TK- 
cysteine  rich  tyrosine  kinase;  EGF-  epidermal  growth  factor;  Epo-  erythropoietin;  FASL-  FAS  ligand;  G-CSF- 
granulocyte  colony  stimulating  factor;  GGF-  Glial  growth  factor;  GM-CSF-  granulocyte  macrophage  colony 
stimulating  factor;  HGF-  hepatocyte  growth  factor,  IG-EGF-TM-CYT-  immunoglobulin-like,  epidermal  growth  factor, 
transmembrane  and  cytoplasmic  domains;  IGF-  insulin-like  growth  factor,  Ig-TK-  immunoglobulin-like  domain/ 
tyrosine  kinase  domain;  IFN-  interferon;  IFNR-  interferon  receptor;  IL-  interieukin;  IL-IR-  interieukin-I  receptor; 
MCP-  macrophage  chernotactic  peptide;  M-CSF-  macrophage  colony  stimulating  factor-,  Met-TK-  methionine  rich 
tyrosine  kinase;  Mý-  macrophage;  NGF-  nerve  growth  factor  PDGF-  platelet  derived  growth  factor;  SCF-  stem  cell 
factor;  S/T-  serine/threonine;  TGF-  transforming  growth  factor,  TNF-  tumour  necrosis  factor. 
In  view  of  the  small  degree  of  sequence  homology  between  different  cytokines,  attempts 
to  sub-classify  these  molecules  have  to  rely  on  similarities  on  the  induction  mechanisms, 
overall  three-dimensional  structure,  receptor  subunits  utilised  and  biological  activities 
they  stimulate  (Nicola,  1994).  A  system  for  the  classification  of  cytokines  has  been 
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proposed  based  on  initial  studies  of  protein  structure  (Bazan,  1990;  Parry  et  al,  1991; 
Young,  1992).  This  organisation.  led  to  the  establishment  of  four  main  categories  of 
cytokines  that  were  then  subdivided  on  the  basis  of  receptor  utilisation.  Groups  of 
cytokines  organised  in  this  manner  display  common  biological  activities,  as  shown  in 
table  1.2  (reviewed  in  Nicola,  1994). 
The  grouping  of  cytokines  on  the  basis  of  their  structure  and  receptor  usage  has  revealed 
an  evolutionary  relationship  amongst  cytokines  that  would  be  impossible  to  disclose  from 
biological  activity  and  amino  acid  sequence  data  alone.  It  should  be  noted  that  the 
nomenclature  of  cytokines  owes  little  to  systematic  relationships  between  the  molecules. 
It  is  rather  a  consequence  of  the  different  approaches  to  naming  new  molecules,  in  areas 
of  research  as  far  afield  as  immunology  and  developmental  biology,  which  are  based 
either  on  the  cell  of  origin  or  initial  defining  bioassay  (Callard  and  Gearing,  1994). 
1.3  Cytokine  receptors 
Cytokines  bind  high  affinity  receptors  in  order  to  exert  their  biological  effects  on  target 
cells.  The  fact  that  individual  cytokines  bind  to  singular  receptors  has  a  bearing  on  the 
specificity  of  cytokine  activity,  but,  on  the  other  hand,  highlights  the  multiplicity  of 
receptor  structures  that  exist  to  support  such  specificity.  Nevertheless,  purification  of 
receptors  and  the  cloning  of  genes  encoding  cytokine  receptors  has  facilitated  their 
grouping  into  fwnilies  on  the  basis  of  shared  structural  features  (table  1.3). 
The  most  representative  group  of  cytokine  receptors  is  the  class  I  cytokine  receptor 
family  also  known  as  "hemopoietin  receptors".  Members  of  this  family  are  often 
multimers  of  receptor  subunits,  mostly  heterodimers,  but  also  homodimers  (e.  g  G-CSFR 
and  EpoR)  and  heterotrimers  (e.  g.  IL-2R  and  IL-15R).  Some  members  of  this  family  form 
subfamilies  by  sharing  the  receptor  chain  responsible  for  the  transduction  of  signal  (P,  y 
or  gpl30  chain),  a  contributing  factor  in  cytokine  pleiotropy.  The  remaining  chain(s)  in 
each  receptor  are  unique  and  act  as  specific  binding  components  (Taga  and  Kishimoto, 
1995;  Heim,  1996). 
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TabIe  1.3  Classification  of  cytokine  receptors  (modified  from  Vilcek,  1998) 
Receptor  Family  Shared  features  Ligands 
Conserved  cysteines  and  WSXWS  IL-2,  IL-3,  IL-4,  IL-5, 
Class  I  cytokine  receptors  motif  in  the  extracellular  domain.  IL-6,  IL-7,  IL-9,  IL-  11, 
Box  I.  and  box2  in  the  intracellular  IL-12,  IL-13,  IL-14,  IL-15 
domain  GM-CSF,  G-CSF,  Epo,  etc 
Class  11  cytokine  receptors  Concerved  cysteines  in  the  IFN-cc/p,  IFN-y,  IL-  10 
extracellular  domain 
TNF  receptor  family  Partial  homology  in  the  extracellular  TNF-(x/p,  NGF,  FASL, 
domain.  CD40L 
Intracellular  "death  domains" 
IL-  I  receptor  family  Extracellular  Ig-like  domain  IL-  I  a,  IL-  I  P,  IL-  I  Ra, 
IL-18 
Extracellular  cysteine  rich  domains. 
TGF-P  receptor  family  Intracellular  serine-threonine  kinase  TGF-P 
domains 
Chemokine  receptor  family  Seven  transmembrane  domains  IL-8,  cc  and  P  chemokines 
IL-  I  Ra  -  IL-  I  receptor  antagonist. 
Members  of  the  interferon  receptor  family  are  also  termed  class  II  cytokine  receptors  due 
to  structural  similarities  to  class  I  receptors.  The  major  common  feature  to  these  two 
groups  of  receptors  is  the  presence  of  200  amino  acid  long  domains  containing  conserved 
cystein  and  proline  residues  and  a  series  of  hydrophobic  and  hydrophilic  sequences  also 
in  conserved  positions  (Bazan,  1990). 
The  members  of  the  TNF  receptor  family  are  single  chain  receptors  that  oligomerise  by 
binding  to  their  trimeric  ligands.  The  main  feature  shared  by  some  members  of  this 
group  of  receptors  (e.  g.  TNF-RI,  FAS)  is  the  presence  of  cytoplasmic  apoptosis  domains 
("death  domains")  consisting  of  90  amino  acid  sequences  involved  in  protein-protein 
interaction  with  molecules  (e.  g.  TNF-R  associated  factors  -  TRAFs)  implicated  in 
downstream  signalling  with  activation  of  proteins  such  as  caspases  responsible  for  the 
deleterious  effects  of  TNF-a  and  FAS  ligand  (reviewed  in  Wallach,  1997). 
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Members  of  the  IL-1  receptor  family  are  heterodimers  of  a  ligand  binding  class  I  receptor 
subunit  (IL-IRcc  chain),  with  the  IL-I  receptor  accessory  protein  (IL-IRAcP), 
representing  the  0  chain  essential  for  signalling  (Greenfeder  et  al,  1995)  although 
structural  details  are  still  to  be  fully  understood. 
The  most  distinctive  feature  that  members  of  TGF-PR  family  share  is  the  presence  of  a 
cytoplasmic  serine-threonine  kinase  domain  that  makes  these  receptors  unique.  Other 
features  such  as  the  location  of  cysteine  rich  domains  are  the  basis  of  the  subdivision  into 
type  I  (signalling  component)  and  type  II  (ligand  binding  component)  receptors 
(reviewed  in  Attisano  and  Wrana,  1996). 
Members  of  the  chemokine  receptor  family  are  also  named  G  protein  coupled  receptors, 
mediating  their  effects  through  the  interaction  with  guanine  nucleotide-binding  proteins 
(G  proteins).  The  main  structural  feature  of  this  group  of  receptors  is  the  presence  of 
seven  hydrophobic  motifs  that  produce  transmembrane  a  helices  (reviewed  in  Fraser  et 
al,  1994). 
1.4  Signal  transduction 
Following  specific  binding  to  receptors  on  target  cells,  cytokines  promote  transcriptional 
activation  of  responsive  genes  through  the  Jak-STAT  pathway  of  intracellular  signalling 
(reviewed  in  Gallin,  1995;  Schindler  and  Darnell,  1995;  Heim,  1996;  Bach  et  al,  1997; 
Liu  et  al,  1998;  Park  and  Schindler,  1998;  Watanabe  and  Arai,  1998).  The  Jak-STAT 
pathway  was  first  established  in  studies  aimed  at  dissecting  the  mechanism  of  action  of 
IFN-a  and  IFN-y  (Darnell  et  al,  1994).  This  system,  now  known  to  be  involved  in 
mediating  cellular  responses  to  most  cytokines  is  composed  of  two  distinct  protein 
classes: 
-  the  Janus  kinases  (Jak)  are  a  family  of  soluble  tyrosine  kinases.  Four  members  of 
this  family  have  been  identified  to  date  (Tyk2,  Jakl,  Jak2  and  Jak3)  with  molecular 
weights  ranging  between  125  and  135  kDa.  These  kinases  share  a  sequence  identity  of  35 
to  45%  and  an  overall  structural  pattern  (figure  1.1),  with  seven  Jak  homology  (JH) 
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conserved  domains,  including  two  tandem  tyrosine-kinase  domains  (JHI  and  JF12).  No 
function  has  been  attributed  to  the  remaining  domains  (JH3-JH7).  A  receptor  binding 
region  has  been  assigned  to  the  N-terminal  end  of  the  molecule.  JAKs  have  an  ubiquitous 
distribution  through  most  tissues.  Only  Jak3  expression  appears  to  be  restricted  to  cells  of 
myeloid  and  lymphoid  lineage.  Although  inactive  in  resting  cells,  Jaks  are  associated 
with  cytokine  receptor  chains.  Binding  of  ligand  to  the  receptor  leads  to  rapid 
phosphorylation  of  a  tyrosine  within  the  Jak  kinase  domain.  Jaks  have  been  found  to 
associate  and  activate  STATs. 
JH7  JH6  JH5  JH4  JHI  JH2  JHI 
NH,  COOH 
Kinase  Domains 
JH  -  Jak  homology  domains 
PTK  -  protein-kinase  domain 
KRD  -  kinase-related  domain 
Figure  1.1  Structure  of  Janus  family  kinases  (Heim,  1996;  Bach  et  al,  1997). 
-  the  signal  transducers  and  activators  of  transcription  (STATs)  are  a  versatile 
group  of  proteins  able  to  interact  with  receptor-kinase,  generate  homo  or  heterodimers, 
translocate  to  the  nucleus  and  bind  DNA  in  association  or  not  with  other  nuclear  proteins. 
STAT  proteins  are  ubiquitous,  with  the  exception  of  STAT4  expressed  mainly  in  the 
thymus  and  testes.  The  number  of  STATs  isolated  to  date  is  seven  (STAT  I  -STAT6)  with 
two  isoforms  of  STAT5  (STAT5a,  STAT5b).  STAT  proteins  are  750  to  850  residues  long 
and  have  an  overall  amino  acid  identity  of  28  to  54%,  with  many  conserved  domains,  as 
expected  by  the  amount  of  functional  requirements  that  they  share.  Common  features 
(figure  1.2),  identified  by  sequence  analysis  and  deletion  studies,  include  a  single  tyrosine 
at  around  position  700.  Residues  600  to  700  show  the  strongest  homology  between 
STATs  and  correspond  to  a  SH2  domain  that  binds  phosphotyrosine  and  appears  to 
determine  which  receptor  will  bind  a  given  STAT  protein  (the  STAT  substrate  is  then 
phosphorylated  regardless  of  which  Jak  kmases  are  associated  with  the  receptor).  Specific 
reciprocal  SH2-phosphotyrosine  interaction  of  two  STATs  leads  to  dimensation  that 
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precedes  translocation  to  the  nucleus.  The  500  to  600  residue  portion  of  the  molecule  is 
homologous  to,  SH3  domains  of  other  proteins  but  its  function  in  the  STATs  has  yet  to  be 
disclosed.  Within  residues  400  to  500  lies  the  DNA  binding  domain,  responsible  for  gene 
transcription.  Also,  carboxy-terminal  deletion  studies  have  revealed  a  transactivation 
domain  downstream  the  SH2  region.  The  only  region  with  functional  relevance  in  the  N- 
terminus  of  STATs  is  a  leucine  repeat  thought  to  facilitate  interactions  between  family 
members. 
400  500  600  700 
NH2 
DBD  -  DNA  binding  domain 
TAD  -  Transactivation  domain 
Tyr  /  Ser  -  Unique  tyrosine  and  serine  residues 
Numbers  related  to  aproximate  amino  acid  positions 
Figure  1.2  Structure  of  STAT  proteins  (Heim,  1996,  Bach  et  al,  1997). 
H 
Dimeric  STATs  activate  gene  transription  by  binding  to  responsive  elements  in  the 
promoters  of  genes  to  be  transcribed,  following  direct  or  indirect  association  with  the 
RNA  polymerase  II  complex.  DNA  motifs  that  bind  STATs  can  be  classified  in  two 
groups.  The  first  group  is  represented  by  the  interferon-stimulated  responsive  element 
(ISRE)  and  share  the  consensus  sequence  AGTTTCNNTTTCNC/T.  The  second  group 
has  the  IFN-y  activation  site  (GAS)  as  a  prototype  and  share  the  palindromic  core 
sequence  TTNNNNNAA,  where  variations  of  the  inner  residues  were  shown  to  affect 
differential  binding  to  STATs. 
In  view  of  the  restricted  numbers  of  both  Jaks  and  STATs  and  of  the  growing  number  of 
receptors  that  seem  to  signal  via  thisý  system,  it  is  clear  that  the  specificity  of  cytokine 
signal  transduction  is  not  due  to  dedicated  signalling  molecules.  Rather,  it  is  particular 
combinations  of  Jaks  and  STATs  which  expand  signalling  variability.  On  table  1.4  is 
shown  the  Jak  and  STAT  usage  by  cytokine  receptors. 
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Factors  that  increase  diversity  and  therefore  determine  specificity  of  the  signal  include  the 
selective  activation  of  STATs  by  ligands,  the  STAT  versatility  and  the  variability  at  the 
gene  level.  By  binding  only  to  specific  sets  of  STATs  the  receptors  transmit  into  the  cell 
the  specificity  of  the  ligand-receptor  interaction.  By  being  able  to  heterodimerize 
selectively  and  interact  with  non-STAT  proteins,  STATs  increase  the  potential  of  specific 
ligand  responses.  Due  to  the  variability  of  ISRE  and  GAS  responsive  elements  it  is 
plausible  that  different  STATs  (or  STAT  combinations)  may  be  able  to  discern  between 
these  elements  and  specifically  activate  certain  genes.  The  Jak-STAT  pathway  has 
therefore  the  potential  for  specific  cytokine  signal  transduction  from  the  cell  membrane  to 
the  genes.  For  a  detailed  description  of  the  mechanism  of  signal  transduction  of  IFN-Y, 
which  constitutes  a  model  of  cytokine  signalling,  can  be  found  below  (1.7.4). 
Table  1.4  Activation  of  Jaks  and  STATs  by  various  cytokines 
(modified  from  Liu  et  al,  1998) 
Cytokine  Jaks  STATs 
IFN-a  Tyk2  /  Jakl  STAT  1/2/3/5 
IF'N-y  Jakl  /  Jak2  STAT  1 
IL-2  Jakl  /  Jak3  STAT  5 
11A  Jak2  STAT  5 
HA  Jakl  /  Jak3  STAT  6 
IIA  Jak2  STAT  5 
H-,  -6  Tyk2  /  Jakl  Jak2  STAT  1/3 
IL-7  Jakl  /  Jak3  STAT  5 
IL-9  Jakl  /  Jak3  STAT  5 
11.1-10  Tyk2  STAT  3/5 
HAI  Jakl  STAT  1/3 
IL-12  Tyk2  /  Jak2  STAT  1/3/4 
11,43  Jakl  STAT  6 
11,15  Jakl  STAT  5 
GM-CSF  Jak2  STAT  5 
G-CSF  Jakl/Jak2  STAT  115 
Epo  Jak2  STAT  5 
EGF  Jakl  STAT  1/3 
1.5  The  Thl  /  Th2  paradigm 
f 
The  specific  immune  response  to  a  microbial  pathogen  is  an  active  process  that  depends 
on  factors  derived  from  both  the  microorganism  and  the  host.  An  appropriate  immune 
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response  leads  to  the  eventual  clearance  of  infection  and  generation  of  an  effective 
memory,  whereas  an  inappropriate  response  results  in  a  lack  of  protection  and  in  some 
cases  even  exacerbates  the  pathological  process  (Kemp  et  al,  1996).  Many  bacteria], 
protozoal  and  viral  infections  trigger  cell-mediated  immune  responses,  while  other 
pathogens  (such  as  helminths)  or  their  products  induce  primarily  a  humoral  response  (Del 
Prete  and  Romagnam,  1994). 
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Figure  1.3  Functions  of  CD4+  Thl  and  Th2  subsets  (modified  from  Abbas  et  al,  1996). 
Investigation  of  the  murine  immune  system  revealed  distinct  subsets  of  T  helper  cells 
with  roles  in  cell  mediated  and  humoral  responses  to  antigen,  respectively  Thl  and  Th2 
cells.  The  recognition  that  CD4+  T  cells  (T  helper  cells),  by  exhibiting  discrete  patterns 
of  cytokine  expression,  can  activate  different  immunological  effector  mechanisms  (figure 
1.3),  offered  an  explanation  for  the  differential  immune  responses  to  antigen  observed  in 
infectious  processes  ýMosmann  et  al,  1986). General  haroduction 
Two  major  T  helper  (Th)  subsets  have  been  recognised.  Th  type  I  (Th  I)  cells  produce  IL- 
2,  IFN-7  and  lymphotoxin  (TNF-P),  promoting  macrophage  activation  leading  to  delayed 
type  hypersensitivity  and  also  complement  fixing  and  opsonizing  antibodies  required  to 
clear  infection  by  intracellular  organisms  (reviewed  in  Mosmann  and  Coffinan,  1989). 
Thl  cells  have  been  implicated,  when  inappropriately  activated,  in  the  immunopathology 
of  organ  specific  autolmmune  diseases  (e.  g.  insulitis  in  insulin  dependent  diabetes 
mellitus)  (Fowell  and  Mason,  1993).  The  type  2  (Th2)  cells  secrete  IL-4,  IL-5,  IL-6,  IL- 
10  and  IL-13  that  promote  both  activation  of  mast  cells  and  eosinophils  and  help  for  the 
production  of  neutralising  antibodies  (IgGI)  and  also  IgE  class  antibodies  that  adhere  to 
mast  cells  promoting  killing  of  extracellular  parasites  such  as  helminths  (reviewed  in 
Mosmann  and  Coffman,  1989).  They  have  also  been  associated  with  the  onset  of 
inflammatory  damage  in  allergic  manifestations  and  atopy  (Robinson  and  Kay,  1996). 
The  development  of  heterogeneous  Th  cell  subsets  is  determined  by  the  pathogen  or 
allergen  invading  the  host  and  is  influenced  by  a  variety  of  factors  including  the  nature  of 
the  antigen,  dose,  route  of  entry  and  tissue  distribution  in  the  host  and  also  the  genetic 
background  of  the  host  (reviewed  in  Abbas  et  al,  1996;  Seder  and  Paul,  1994). 
Nevertheless,  the  major  factor  governing  the  skewing  of  immune  responses  towards  Thl 
or  Th2  phenotypes  are  cytokines  produced  early  in  the  immune  response  (Mosmann  et  al, 
1986).  The  understanding  of  the  heterogeneity  of  Th  cell  populations  and  the  study  of  the 
factors  involved  was  made  possible  due  to  development  of  techniques  such  as  the 
propagation  and  activation  in  vitro  of  T  cell  clones,  transgenic  models  and  assays  for 
cytokine  detection  and  quantitation  (e.  g.  capture  ELISA,  Elispot  and  intracellular  staining 
of  cytokines). 
When  naive  Th  cells  encounter  activated  antigen  presenting  cells  (APCs),  cross  linking  of 
the  T  cell  receptor  (TCR)  with  antigen  presented  in  the  context  of  major  histo- 
compatibility  complex  class  11  (MHC  11),  occurs.  This  results  in  T  cell  activation  denoted 
by  the  production  of  IL-2  (Abbas  et  al,  1996).  Also  the  expression  by  APCs  of 
costimulatory  molecules,  such  as  B7  (B7-1  and  B7-2)  that  binds  to  CD-28  expressed  by  T 
cells,  is  necessary  for  full  T  cell  activation  (reviewed  in  Constant  and  Bottomly,  1997). 
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When  antigen  presentation  occurs  in  the  presence  of  IL-12,  the  Th  cells  develop  into  the 
Thl  phenotype  (figure  1.4)  of  IFN-y  producing  cells.  IL-12  is  produced  by  activated 
macrophages  and  dendritic  cells  in  response  to  potent  microbial  adjuvants  such  as 
endotoxin  and  intracellular  bacteria  (e.  g.  Listeria,  mycobacteria),  protozoa  (e.  g. 
Toxoplasma)  and  viral  components  (Trinchieri,  1995).  Although  IL-12  is  the  most 
important  factor  in  driving  Thl  responses,  IL-I(x  was  also  identified  as  a  cofactor  in 
BALB/c  mice.  Of  importance  seems  to  be  also  the  newly  defined  cytokine  IL-18 
(formerly  known  as  IGIF  for  IFN-y  inducing  factor)  that  synergises  with  IL-  12  in  the 
induction  of  IFN-y,  suggesting  that  both  IL-12  and  IL-18  are  needed  for  optimum  Thl 
development  (reviewed  in  Abbas  et  al,  1996;  O'Garra  and  Murphy,  1996;  O'Garra, 
1998). 
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Figure  1.4  Regulation  of  Th  cell  responses  by  cytokines  (modified  from  O'Garra,  1998). 
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Conversely,  when  naive  Th  cells  encounter  antigen  in  the  presence  of  IL-4  they  develop 
into  a  Th2  phenotype  (figure  1.4).  Therefore,  IL-4  is both  required  for  Th2  development 
and  expressed  by  Th2  cells.  The  main  producers  of  IL-4  are  the  CD4+  T  cells  themselves 
(possibly  memory  and  even  naYve  cells)  although  there  is  evidence  other  cells  including 
mast  cells,  basophils,  eosinophils  and  certain  subsets  of  NK  cells  (Paul  et  al,  1993) 
produce  IL-4,  therefore  playing  a  role  in  directing  Th2  development  (reviewed  in  Abbas 
et  al,  1996;  O'Garra,  1998).  The  activity  of  IL-4  is  dominant  over  that  of  Thl  inducing 
cytokines,  resulting  that  when  the  level  of  IL-4  reaches  a  certain  threshold  Th2  will 
differentiate  despite  the  presence  or  not  of  IL-  12  and  associated  cytokines. 
This  Thl/Th2  dichotomy  is  far  from  absolute.  When  analysing  cells  from  normal 
individuals  rather  than  clones  or  cells  from  transgenic  models,  a  large  percentage  of 
individual  cells  exhibit  heterogeneous  patterns  of  cytokine  expression.  This  cells  were 
named  ThO  because  they  express  combinations  of  Thl  and  Th2  cytokines  (e.  g.  IL-2,  IL-4, 
IL-5  and  IFN-y)  and  are  now  thought  to  play  an  important  role  in  vivo,  in  the  control  of 
infections  when  a  balance  between  humoral  and  cell  mediated  immunity  is  required, 
therefore  minimising  pathology  associated  with  both  polarised  Thl  and  Th2  responses 
(reviewed  in  Romagnani,  1994;  Kelso,  1995). 
Each  subset  of  cells  cross-regulates  the  development  of  the  other  subset,  i.  e.,  IFN-y 
inhibits  Th2  development,  whereas  IL-4  and  IL-10  inhibit  that  of  Thl  cells.  Additionally, 
because  the  cytokines  produced  by  each  subset  of  Th  cells  serve  as  autocrine  growth 
factors,  once  the  cells  begin  to  diverge  into  a  particular  phenotype,  and  if  the  antigenic 
stimulus  is  maintained,  they  become  increasingly  polarised  up  to  a  point  from  which  are 
no  longer  able  to  reverse  the  phenotype  and  are  said  to  be  committed  (Murphy  et  al, 
1996).  It  should  be  noted  that  c4immitted  Thl  and  Th2  cells  represent  extreme 
populations  resulting  from  chronic  stimulation  or  disease  and  are  therefore  difficult  to 
detect  in  individuals  either  healthy  or  with  acute  processes.  These  populations  are 
characterised  by  profound  phenotypical  changes  both  in  appearance  and  in  the  expression 
of  specific  markers.  For  example  Th2  cells  downregulate  the  expression  of  IL-12R  and 
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IL-18P,  whereas  in  Thl  although  IL-4  receptor  expression  is  maintained  tyrosine 
phosphorylation  by  this  receptor  is  impaired  (Anne  O'Garra  personal  communication). 
Also,  in  vivo,  the  nature  and  dose'of  the  antigen  appears  to  have  a  bearing  on  the  outcome 
of  Th  development.  Antigen  in  low  doses  tends  to  be  processed  by  professional  APCs 
(e.  g.  dendritic  cells)  that  express  IL-12  and  therefore  drive  Thl  development.  On  the 
other  hand  antigen  in  high  doses  is  also  rescued  by  alternative  APCs  (e.  g.  B  cells)  that  do 
not  express  IL-12,  favouring  Th2  polarisation  (Abbas  et  al,  1996).  An  additional 
parameter  of  control  is  offered  by  the  so  called  regulatory  T  cells  (e.  g.  TRI)  which  by 
expressing  TGF-P  and  IL-10  are  able  to  quench  both  Thl  and  TV  development  and 
associated  pathologies  (Weiner,  1997). 
1.6  Cytokines  as  vaccine  adjuvants 
Safety  concerns  related  with  the  use  of  whole  inactivated  or  attenuated  pathogens  for 
vaccination  have  precipitated  the  development  of  subunit  vaccines  comprising 
representations  of  antigenic  components  of  pathogens  by  synthetic  peptides,  recombinant 
proteins  and,  lately,  genes  delivered  both  in  minimal  virus  vectors  or  plasmid  DNA. 
Although  much  safer,  such  vaccines  are  generally  less  immunogenic  than  live  attenuated 
vaccines  and  there  is  a  continued  search  for  substances  that  can  boost  immune  responses 
and  therefore  be  used  as  vaccine  adjuvants  (reviewed  in  Edelman,  1997).  Many 
substances  have  been  proposed  as  adjuvants,  although,  because  of  potential  toxicity,  only 
a  limited  number  as  been  approved  for  clinical  use  (Gupta  et  al,  1993;  Vogel  and  Powell, 
1997).  The  fact  that  most  adjuvants  (e.  g.  LPS,  Freund's  adjuvant)  mediate  their  activity 
through  nonspecific  induction  of  cytokines  and  the  accumulated  knowledge  of  cytokine 
biology  and  immune  modulatory  functions  has  prompted  the  use  of  cytokines  as  vaccine 
adjuvants  (Dong  et  al,  1997). 
Cytokines  have  two  major  advantages  when  compared  to  other  adjuvants.  Firstly,  because 
cytokines  are  natural  host  products  are  less  likely  to  promote  undesirable  side  effects. 
Secondly,  their  specific  immunomodulatory  activities  include  enhancement  of  antigen 
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presentation,  activation  and  growth  of  T  or  B  cells  and  appropriate  shifting  of  the  immune 
response  towards  cell  mediated  (Thl)  or  humoral  (M)  responses  (Lin  et  al,  1995;  Dong 
et  al,  1997).  Among  the  cytokines  more  thoroughly  tested  as  adjuvants  are  those  that  are 
effective  when  injected  in  a  single  dose  near  the  time  of  antigen  inoculation  (e.  g.  IL-1, 
IL-2  and  IFN-y).  The  rationale  for  using  these  cytokines  and  examples  of  their  use  are 
extensively  reviewed  in  Heath  and  Playfair,  1992;  Schijns  et  al,  1994;  Lin  et  al,  1995 
and  Heath,  1997  as  summarised  in  table  1.5. 
Table  1.5  Effects  of  cytokines  as  vaccine  adjuvants  (modified  from  Cohen  et  al,  1998). 
Cytokine  Effect  on  the  immune  response 
Type  Name  Ab  production  CTL  activity 
IL-1 
Proinflammatory  TNF-a 
TNF-P  ft  ft 
GM-CSF 
IL-2 
IL-12 
Thl  inducing  IL-15 
IL-18 
IFN-y 
IL-4 
Th2  inducing  IL-5 
IL-10  <2 
Ab-  antibody;  ft  -increased  response;  =ý  -no  change  in  response;  U-decreased  response. 
These  studies  highlight  the  importance  of  the  awareness  not  only  of  the  specific  functions 
of  individual  cytokines  but  also  of  the  type  of  immune  response  that  is  required  for 
protection.  Eliciting  the  wrong  response  might  not  only  be  futile  in  terms  of  vaccine 
efficiency  but  also  be  responsible  for  an  increase  of  severity  of  the  infectious  process 
upon  challenge  with  live  pathogen. 
In  a  veterinary  context,  the  use  of  cytokines  as  adjuvants  is  dependent  on  the  production 
of  pure  preparations  of  recombinant  cytokines,  a  costly  and  time  consuming  procedure, 
due  to  the  non-availability  of  commercial  species-specific  molecules.  The  advent  of  gene 
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therapy  has  however  facilitated  the  delivery  of  cytokines  in  a  cheap  and  easy  way,  which 
is  reflected  by  the  number  of  experiments  where  cytokines  were  used  individually  or  in 
various  combinations  to  boost  immune  responses  to  co-administered  encoded  antigen 
(reviewed  in  Cohen  et  al,  1998;  Kim  et  al,  1998).  In  one  of  such  studies  (Chow  et  al, 
1998)  the  potential  for  the  use  of  cytokines  to  shift  the  nature  of  immune  responses  to 
Hepatitis  B  DNA  vaccines  in  a  murine  model  was  evaluated.  Mice  were  immunised  with 
plasmid  DNA  encoding  HBV  major  envelope  proteins  co-administered  with  various 
plasmids  encoding  cytokine  genes.  The  results  obtained  are  summarised  in  table  1.6. 
Table  1.6  Cytokine  adjuyancy  of  hepatitis  B  DNA  vaccination  (summarised  from  Chow, 
1998). 
T  helper  response  Antibody  response  CTL  response 
Plasmid  encoding  HBV  (as  measured  by  cytokine  (in  terms  of  (as  accessed  by 
envelope  protein  plus:  proffle  of  splenocytes)  IgG  isotype)  %  of  specific  lysis) 
Plasmid  encoding  IFN-y  III  enhanced  lgG2a  increased  between  35  and  50% 
or  IL-12  Th2  inhibitited  IgGI  decreased 
Plasmid  encoding  IL4  Thl  suppressed  lgG2a  suppressed  less  than  20% 
'Ib2  enhanced  IgGI  increased 
Plasmid  encoding  IL-2  Thl  enhanced  lgG2a  increased  between  25  and  35% 
or  GM-CSF  Th2  not  affected  IgGI  increased 
It  can  be  concluded  that  while  IL-12  and  IFN-y  favoured  a  cell  mediated  immune 
response,  IL-4  favoured  humoral  immunity  whereas  IL-2  and  GM-CSF  had  an 
intermediate  effect.  The  delivery  of  cytokine  genes  in  DNA  vaccination  formulations  can 
therefore  influence  the  differentiation  of  Th  subsets  and  consequently  the  type  of  immune 
response. 
1.7  Interferon  gamma 
Interferon  gamma  (IFN-y)  or  immune-interferon  belongs  to  a  family  of  proteins  related  by 
their  ability  to  protect  cells  from  viral  infection  (Farrar  and  Schreiber,  1993).  This  activity 
requires  de  novo  synthesis  of  RNAs  and  proteins  by  stimulated  cells  (Borden,  1992). 
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Interferons  (IFNs)  are  classified  in  type  I  and  type  II  based  on  primary  structure 
similarities  and  receptor  binding  studies. 
Type  I  IFNs  include  IFN-cc  and  IFN-w  (formerly  known  as  leucocyte  IFN)  and  IFN-P 
(fibroblast  IFN)  that  share  extensive  amino  acid  sequence  homology  and  bind  to  a 
common  cell  surface  receptor.  IFN-a  constitutes,  in  itself,  a  complex  family  of  genes  and 
pseudogenes,  encoding  over  22  distinct  proteins  (Farrar  and  Schreiber,  1993  ;  Donnelly, 
1994).  Type  I  IFN  genes  do  not  contain  introns  and  are  clustered  in  a  unique 
chromosome:  human  chromosome  9  and  murine  chromosome  4.  These  genes  code  for 
proteins  with  a  23  amino  acid  signal  peptide  and  mature  proteins  between  164  and  166 
residues  in  length.  These  IFNs  share  a  potent  antiviral  activity  and  moderate 
antiproliferative  and  immunomodulatory  activities  (Donnelly,  1994).  A  further  member 
of  the  Type  I  family  is  the  trophoblast  interferon  (IFN-,  r)  of  domestic  ruminants.  IFN-,  r  is 
expressed  early  in  embryogenesis  and  may  therefore  play  a  role  in  the  implantation 
process  and  early  stages  of  the  embryo  development  (Roberts  et  al,  1991) 
IFN-y  (or immune  interferon)  is  the  sole  Type  II  IFN.  It  binds  to  a  distinct  receptor  and  is 
completely  unrelated  at  both  genetic  and  protein  levels  to  Type  I  IFNs.  IFN-y 
,  although 
originally  defined  as  an  antiviral  agent  (Wheelock,  1965),  is  primarily  an 
immunomodulatory  peptide,  playing  a  central  role  in  the  regulation  of  several  aspects  of 
an  effective  immune  response  and,  consequently,  in  the  resistance  of  mammalian  hosts  to 
pathogens. 
1.7.1  Molecular  Structure 
IFN-y  is  encoded  by  a  single  gene,  mapped  to  chromosome  12  (12q24.1)  in  humans 
(Naylor  et  al,  1983)  and  chromosome  10  in  the  mouse  (Naylor  et  al,  1984).  Both  human 
and  murine  genes  are  6  Kbp  in  size  and  contain  four  exons  and  three  introns. 
Among  the  main  features  of  the  gene  are  the  Goldberg-Hogness  element  (TATA  box) 
with  the  sequence  TATAAATA,  wich  is  located  approximately  30bp  upstream  from  the 
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transcription  start  and  is  thought  to  be  important  for  determining  the  specificity  of  the 
initiation  of  transcription.  The  sequence  (GTCACCATCT)  located  90bp  upstream  from 
the  transcription  start,  is  similar  to  the  consensus  GGC'TCAATCT  (CAAT  box)  relatively 
well  conserved  in  the  5'  end  of  many  genes  and  involved  in  the  modulation  of 
transcription  by  RNA  polymerase  11  (Gray  and  Goeddel,  1982).  Other  features  include  the 
transcription  start,  the  polyadenylation  signal  sequence  (AATAAA)  and  the 
polyadenylation  site  (Figure  1.5). 
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Figure  1.5  Representation  of  the  human  IFN-7  gene  structure  and  generation  of 
the  corresponding  mRNA  molecule  (Gray  and  Goeddel,  1982). 
DNAse  I  hypersensitivity  and  deletion  analyses  of  the  IFN-y  gene  uncovered  an  array  of 
sequences  implicated  in  the  regulation  of  transcription.  These  include  a  600bp  region 
(within  the  core  promoter)  upstream  of  the  TATA  box  displaying  a  pattern  of  enhancer- 
silencer-  enhancer  elements.  Another  enhancer  region  was  found  within  the  first  intron  of 
the  gene,  functional  in  both  T  cells  and  fibroblasts  but  appearing  to  be  inducible  only  in  T 
cells.  A  further  six  elements  capable  of  interacting  with  members  of  the  NFKB  family  of 
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DNA  binding  proteins  were  detected  in  introns  1,2  and  3.  (Hardy  et  al,  1987;  Ciccarone 
et  al,  1990;  Young,  1995). 
Activation  of  the  gene  leads  to  transcription,  splicing  and  polyadenylation  events, 
rendering  a  1.2Kbp  mRNA  transcript  containing  an  open  reading  frame  encoding  a  166 
amino  acid  polypeptide.  The  human  IFN-y  polypeptide  chain  (Figure  1.6)  is  extensively 
modified  prior  to  secretion. 
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Figure  1.6  Schematic  representation  of  the  human  IFN-y  polypeptide  and 
dimerisation  process  (modified  from  Farrar  and  Schreiber,  1993). 
Post-translational  modifications  include  N-linked  glycosylation,  signal  peptide  cleavage, 
cytoclisation  of  the  amino  terminal  glutamine  into  pyroglutamic  acid  and  enzymatic 
degradation  of  the  carboxyl  terminus  leading  to  variable  length  of  the  resulting  peptide. 
Up  to  nine  residues  can  be  removed  without  significant  loss  of  biological  activity  (Gray, 
1994).  Proteolytic  cleavage  of  the  hydrophobic  leader  sequence  (amino  terminal  23 
residues)  gives  rise  to  a  positively  charged  143  residue  mature  polypeptide  with  an 
apparent  molecular  weight  of  15  KDa  under  denaturing  conditions  (Gray  et  al,  1982; 
Rinderknecht  et  al,  1984).  The  human  IFN-7  polypeptide  contains  two  potential  N-linked 
glycosylation  sites  at  residues  25  and  97.  Natural  IFN-y  analysed  under  denaturing 
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conditions  as  an  apparent  molecular  weight,  of  25  Kda.  when  fully  glycosylated. 
Nevertheless  molecules  of  20  Kda.,  corresponding  to  the  glycosylation  of  only  one  site 
(generally  position  25)  have  also  been  detected  (Rinderknecht  et  al,  1984).  Glycosylation 
is  not  required  for  the  development  of  biological  activity  but  appears  to  influence 
clearance  of  the  molecule  from  circulation  and  therefore  its  half-life  (Farrar  and 
Schreiber,  1993). 
Studies  employing  oligopeptide  specific  monoclonal  antibodies,  synthetic  peptides  and 
enzymatic  removal  of  portions  of  the  IFN-y  molecule  indicate  that  both  the  amino  and 
carboxyl  termini  of  the  molecule  play  an  important  role  in  the  maintenance  of  biological 
activity  (Farrar  and  Schreiber,  1993),  possibly  by  contributing  to  the  correct  folding  of 
the  protein  and  generation  of  the  receptor  binding  domain  (Jarpe  and  Johnson,  1990). 
'  ,-- 
Biologically  active  IFN-y  is  generated  by  the  antiparallel  association  of  two  polypeptide 
chains  to  form  a  homodimer  with  a  molecular  weight  ranging  between  30  and  50  KDa, 
depending  on  the  extent  of  glycosylation.  The  structure  is  maintained  by  noncovalent 
forces  (Farrar  and  Schreiber,  1993).  Each  monomer  consists  of  six  cc-helices,  ranging 
from  9  to  21  residues  in  length.  The  structure  is  stabilized  by  the  intertwining  of  the 
helices  giving  it  an  overall  compact  and  globular  appearance  (Ealick  et  al,  199  1). 
1.7.2  Production  of  IFN-y 
The  main  cellular  producers  of  IFN-y  are  activated  natural  killer  (NK)  cells  (Perussia, 
1991)  and,  to  a  greater  extent,  activated  (CD30  expressing)  T  cells  (Alzona  et  al,  1994). 
Moreover,  IFN-y  production  is  the  basis  of  the  concept  of  type  I/  type  2  dichotomy  in 
cytokine  production,  originally  described  by  Mosmann  et  al  (1986)  for  mice  T  helper 
cells  and  followed  by  similar  observations  in  humans  (reviewed  in  Mosmann  and 
Coffinan,  1989;  Mosmann  and  Sad,  1996).  These  observations  show  that  T  helper  cells 
exhibit  discrete  patterns  of  cytokine  production,  with  IFN-y  secretion  associated  with 
Thl  cells  (discussed  in  1.5).  More  recently,  this  pattern  of  cytokine  release  was  observed 
in  other  T  cell  subsets  including  CD8+  (TCI  cells)  and  TCR  y/5  T  cells  (T^,,  Sl  cells) 
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(reviewed  in  Carter  and  Dutton,  1996).  Uncommitted  Th  cells  (ThO)  were  also  reported  to 
produce  significant  amounts  of  IFN-y  under  in  vitro  stimulation  conditions  (O'Garra, 
personal  communication).  As  of  late,  a  significant  amount  of  evidence,  gathered  from 
both  in  vivo  and  ex  vivo  studies,  points  towards  expression  of  IFN-y  by  other  cellular 
types,  namely  anti-CD40  activated  B  cells  (Yoshimoto  et  al,  1997)  and  bone  marrow- 
derived  macrophages  (Munder  et  al,  1998),  upon  combined  stimulation  with  IL-12  and 
IL-18. 
The  mechanism  of  IFN-y  production  is  linked  to  the  differential  activation  pathways  that 
IFN-y  producing  cells  exhibit.  In  the  case  of  NK  cells,  activation  occurs  through  binding 
of  the  NK  cell  low  affinity  receptor  (FcyRIIIA)  to  the  Fc  regions  of  IgGl  and  IgG3 
molecules  bound  to  the  surface  of  target  cells,  as  part  of  the  antibody-dependent  cell- 
mediated  cytotoxicity  (ADCC)  method  of  cell  killing  employed  by  NK  cells  (Abbas'  et 
al,  1997).  T  cell  activation  requires  specific  interaction  of  the  T  cell  receptor  (TCR  cc/0) 
with  antigen  presented  in  the  context  of  the  major  histocompatibility  complex  (MHC). 
CD8+  CTLs  interact  with  MHC  class  I,  whereas  CD4+  Th  cells  interact  with  MHC  class 
Il  (Farrar.  and  Schreiber,  1993;  Abbas'  et  al,  1997). 
The  expression  of  costimulatory  molecules  (e.  g.  B7,  ICAM-1)  by  APCs  is  of  paramount 
importance  for  the  correct  activation  of  T  cells.  Binding  of  B7  to  CD28  (expressed  by 
resting  T  cells)  enhances  T  cell  responses  to  antigen.  In  contrast,  binding  of  B7  to  CTLA- 
4  (expressed  in  a  percentage  of  activated  T  cells)  arrests  T  cell  activation  and  promotes 
apoptosis  and  is  therefore  thought  to  play  a  role  in  the  termination  of  T  cell  responses.  In 
the  absence  of  costimulatory  signals  the  T  cell  remains  anergic,  contributing  for  the 
maintenance  of  tolerance  to  self  antigens  (reviewed  in  Lenschow  et  al,  1996). 
A  second  set  of  mechanisms  of  activation  and  IFN-y  secretion  common  to  both  NK  and 
T  cells,  is  mediated  by  APCs  by  one  or  more  of  the  following  methods: 
-  the  APC  (target  cell)  interacts  through  the  adhesion  molecules  LFA-3  and 
ICAM-1  with  CD2  and  LAF-I,  respectively,  on  the  surface  of  the  lymphocyte  as  part  of 
target  cell  recognition  (Freedman  et  al,  199  1;  Wingren  et  al,  1993); 
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-  APCs  process  bacteria  (e.  g  S.  aureus,  Listeria  monocytogenes,  Mycobacterium 
tuberculosis,  Chlamydia);  bacterial  products  (e.  g.  LPS  from  Salmonella  typhi);  protozoa 
(e.  g.  Leishmania  major,  Trypanosoma  cruzi);  viruses  (e.  g.  Influenza)  and  fungi  (e.  g. 
Candida)  and  secrete  cytokines.  These  cytokines  in  conjunction  with  soluble  pathogen 
products  (in  the  case  of  NK  cells)  or  peptides  presented  in  the  context  of  the  MHC  (for  T 
cells)  will  serve  as  a  signal  for  cell  activation  and  secretion  of  IFN-7  (Morris  et  al,  1982; 
Heremans  et  al,  1994;  Sztein  et  al,  1994;  D'Orazio  et  al,  1995;  Flesh  et  al,  1995). 
Additionally,  products  of  activated  T  cells  and  macrophages  (e.  g.  hydrogen  peroxide  and 
leukotrienes  -  LTC4,  LTDO  LTEJ  enhance  IFN-7  secretion  (Farrar  and  Schreiber,  1993). 
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Figure  1.7  Cellular  sources  and  main  stimuli  for  the  production  of  IFN-y, 
showing  the  reciprocal  induction  of  IFN-y  and  IL-  I  2/IL-  18  (modi  fied  from  Vi  Icek 
and  Le,  1993;  Farrar  and  Schreiber,  1993). 
The  cytokines  IL-  I  cc,  TNF-cc,  IL-2,  IL-6,  IL-  12  and  IL-  18  are  required  for  optimal  IFN-7 
production.  IL-2  with  its  autocrine  and  paracr-me  T  cell  growth  factor  activity  and  IL-6 
acting  as  costimulator  of  T  cells,  induce  increased  production  of  IFN-7  by  the  effect  they 
have  in  T  cell  proliferation  and  degree  of  activation  (Abbas"'  et  al,  1997).  In  contrast,  IL- 
12,  by  directly  skewing  CD4+  cells  towards  a  Thl  phenotype  and  IL-Icy.,  TNF-(x  and 
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especially  IL-  18  by  their  synergism  with  IL-  12,  are  responsible  for  a  dramatic  increase  in 
the  local  secretion  of  IFN-y  (reviewed  in  Romagnani,  1994;  Fearon  and  Locksley,  1996; 
Mosmann  and  Sad,  1996;  Okamura  et  al,  1998;  Shibuya  et  al,  1998).  IFN-y  production 
can  also  be'induced  experimentally  by  direct  stimulation  of  the  T  cell  receptor  complex 
with  anti-CD3  antibodies,  by  mitogens  such  as  Concanavalin  A  (ConA), 
Lipopolysaccharide  (LPS)  and  Phytohemagglutinin  (PHA)  or  by  a  combination  of 
phorbol  myristate  acetate  (PMA)  and  ionomycin  (Farrar  and  Schreiber,  1993). 
Lymphocyte  activation  and  regulation  of  IFN-y  production  is  a  tightly  controlled  and 
complex  process  involving  soluble  extracellular  signals  (e.  g.  cytokines)  and  cell  contact 
(e.  g.  TCR)  (reviewed  in  Young,  1996;  Young  and  Ghosh,  1997).  Cellular  activation 
results  in  a  cascade  of  phosphorylation  of  successive  protein  tyrosine  kinases  culminating 
in  the  activation  of  specific  transcription  factors.  In  the  case  of  signalling  through  the 
TCR,  Ca"  also  plays  a  role  in  activation  of  transcription  factors.  -  Transcriptional 
activation  of  the  IFN-y  gene  is  now  known  to  be  mediated  by  multiple  DNA  binding 
proteins  (e.  g.  AP-1,  NFicB)  interacting  with  both  promoter  and  intronic  enhancer 
elements.  Mechanisms  are  also  in  place  to  prevent  detrimental  chronic  IFN-y  production 
through  interaction  of  DNA  binding  proteins  (e.  g.  GATA-3,  YY-I)  with  supresor 
elements  to  quench  expression  of  transcripts.  The  methylation  of  the  core  promoter  and 
introns  of  the  IFN-y  gene  also  plays  an  important  role  in  regulating  IFN-y  production, 
inhibiting  transcription,  possibly  by  blocking  interaction  with  DNA  binding  proteins 
(reviewed  inYoung,  1995).  Post-transcriptional  events  are  also  critical  for  the  expression 
of  this  cytokine  as  ilustrated  by  the  stabilisation  of  IFN-y  mRNA  mediated  by  activation 
of  protein  kinase  C  and  increased  intracellular  levels  of  cAMP  induced  by  IL-2  (Kaldy  et 
al,  1995). 
Studies  on  the  kinetics  of  IFN-y  expression  and  secretion  show  that  following  in  vitro 
stimulation  of  T  cells,  FFN-y  mRNA  starts  accumulating  after  6  to  8  hours,  peaking 
between  12  to  24  hours  post  stimulation.  The  secreted  protein  can  be  readily  detected  in 
the  cellular  medium  8  to  12  hours  post  stimulation  and  peaking  after  18  to  24  hours. 
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Moreover,  because  IFN-y  is  not  significantly  consumed  by  the  cells  in  culture,  it  remains 
detectable  long  after  the  T  cell  activation  status  declines  (Schreiber  et  al,  1983). 
1.7.3  Interferon  Gamma  Receptor 
In  order  to  exert  its  pleiotropic  biological  activities,  IFN-y  must  bind  to  specific  receptors 
expressed  on  the  surface  of  susceptible  cells.  This  interaction  is  one  of  high  affinity  (Ka 
of  10'  to  10"  M-')  as  determined  by  radioligand  binding  experiments  (Mao  et  al,  1989). 
The  cloning  of  human  and  murine  IFN-y  receptor  (IFN-yR)  cDNA  (Aguet  et  al,  1988; 
Gray  et  al,  1989)  enabled  the  study  of  its  structure  and  function. 
The  IFN-yR  is  composed  of  two  subunits  formed  by  distinct  polypeptide  chains,  (x-chain 
and  P-chain.  The  (x-chain  is  encoded  by  a  30  Kbp  gene  located  on  the  chromosome  6  in 
humans  (Pfizenmaier  et  al,  1988)  and  by  a  22  Kbp  gene  of  chromosome  10  of  the  mouse 
(Mariano  et  al,  1987).  The  gene  contains  a  noninducible  promoter  (with  no  TATA  box) 
and  seven  exons.  Transcription  of  the  human  gene  gives  rise  to  a  2.3  Kb  mRNA  (Farrar 
and  Schreiber,  1993).  The  P-chain  gene  is  located  on  human  chromosome  21  and  murine 
chromosome  16  and  contains  seven  exons  and  several  potential  binding  sites  for 
transcription  factors  in  the  promoter  region.  Transcription  of  the  gene  generates  an 
mRNA  transcript  of  1.8  Kb  in  the  human  and  2  Kb  in  the  mouse  (Hibino  et  al,  1991; 
Cook  et  al,  1994).  Both  polypeptide  chains  are  synthesized  in  the  ER  and  post- 
translationally  modified  in  the  Golgi  by  extensive  N-glycosylation  in  5  or  6  sites, 
respectively  in  the  a  and  P-chain  (Mao  et  al,  1989). 
Nearly  all  somatic  cells,  with  the  exclusion  of  erythrocytes,  are  able  to  bind  IFN-y. 
However  while  most  cells  express  vast  amounts  of  the  receptor  cc-chain  (ranging  from 
200  to  25000  sites  per  cell)  (Farrar  and  Schreiber,  1993),  P-chain  expression  is  restricted 
to  a  small  number  of  cells  that  are  responsive  to  IFN-y  (Gajewski  and  Fitch,  1988). 
Expression  of  IFN-yR  cc-chain  thus  constitutes  a  possible  mechanism  for  clearance  of 
overproduced  IFN-y  (Farrar  and  Schreiber,  1993).  Interaction  with  TCR  or  CD3  of  T 
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lymphocytes  leads  to  upregulation  of  P-chain  expression  (Sakatsume  and  Finbloom, 
1996).  In  contrast,  IFN-y  itself  appears  to  be  able  to  downregulate  the  expression  of  the 
receptor  P-chain,  thereby  limiting  the  ability  of  certain  cell  types  to  respond  to  further 
exposure  to  IFN-y  (Bach  et  al,  1995). 
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Figure  1.8  Structure  of  the  human  IFN-yR.  Both  a  and  P  subunits  are  divided  in 
extracellular,  transmembrane  and  intracellular  domains.  Numbers  relate  to  size  (in 
residues)  of  the  distinct  domains.  Functionally  important  sequences  of  both 
subunits  are  represented.  (Bach  et  al,  1997). 
The  polypeptide  chains  of  the  IFN-yR  (Figure  1.8.  )  are  organized  in  a  similar  fashion  and 
belong  to  the  class  II  cytokine  receptor  family  (Bazan,  1990).  In  the  human  and  mouse, 
the  cc-chain  comprises  an  intracellular  domain  (of  221  and  200  a.  a.  respectively),  a 
transmembrane  domain  (of  23  a.  a.  )  and  a  extracellular  domain  of  (228  a.  a.  )  It  has  a 
molecular  weight  of  90  Kda  under  denaturing  conditions.  Similarly  the  P-chain  (60  to  67 
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Kda)  has  an  extracellular  domain  of  226  a.  a.  in  the  human  and  224  a.  a.  in  the  mouse,  a 
transmembrane  domain  of  24  a.  a.  and  an  intracellular  domain  of  66  a.  a.  (Hibino  et  al, 
1991;  Cook  et  al,  1994). 
Within  the  intracellular  domain  of  the  cc-chain  there  are  three  functionally  important 
motifs:  the  first,  Leu-Ile  (residues  270-271),  plays  a  role  in  directing  receptor  trafficking 
through  the  cell;  the  second,  266Lcu-Pro-Lys-Ser269,  binds  the  tyrosine  kinase  Jak  I;  finally, 
the  motif  ,,  OTyr-Asp-Lys-Pro-His444  binds  STAT  1,  where  the  tyrosine  in  position  440  is 
responsible  for  phosphorylation  of  STATI.  Similarly  in  the  P-chain  intracellular  domain 
the  Motifs  263Pro-Pro-Ser-Ile-Pro267  and  2701le-Glu-Glu-Tyr-Leu274  (Bach  et  al,  1997)  bind 
Jak2.  The  overall  identity  between  human  and  mouse  of  the  cc  and  P  polypeptide  chains  is 
52.5  and  58%,  respectively.  However  the  intracellular  domain  of  the  P-chain  of  the 
mouse  shares  78%  of  homology  with  its  human  counterpart.  Experiments  employing 
humammurine  chimeric  receptors  revealed  that  IFN-yR  a-chain  and  P-chain  extracellular 
domains  must  match  the  host  species  of  IFN-y  for  the  development  of  biological  activity 
(Hibino  et  al,  1992;  Hemmi  et  al,  1994).  Crystallographic  studies  (Walter  et  al,  1995)  and 
the  use  of  cells  expressing  either  a  or  P-chain  (Marsters  et  al,  1995)  showed  that  the  P- 
chain  stabilizes  the  receptor  complex  increasing  binding  of  IFN-y  fourfold.  These  studies 
also  elucidated  the  general  organisation  of  the  receptor  and  structural  changes  resulting 
from  the  interaction  of  the  IFN-yR  with  its  ligand  (figures  1.8  and  1.9). 
After  signalling,  the  IFN-y:  a-chain  complex  is  internalized  and  dissociated.  Free  IFN-y  is 
trafficked  to  the  lysosome  where  it  is  degraded.  Uncoupled  receptor  a-chains  enter  a 
large  intracellular  pool  of  receptors  and  are  eventually  recycled  back  to  the  cell  surface. 
Crucially  the  receptor  0-chains  are  not  recycled  and  de  novo  expression  of  these  chains  is 
therefore  required  for  further  receptor  activity  (Bach  et  al,  1997). 
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1.7.4  Signal  Transduction  Pathway 
IFN-y  signals  through  the  Jak-STAT  pathway  in  a  process  common  to  most  cytokines 
(reviewed  in  1.4).  The  IFN-y  signalling  pathway  is  reviewed  in  Bach  et  al  (1997)  and  a 
graphic  representation  of  the  process  is  shown  in  figure  1.9. 
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Figure  1.9  JAK-STAT  signalling  pathway  in  response  to  human  IFN-y. 
Illustrating  oligomerisation  of  the  receptor  complex;  phosphorylation  and 
dimerisation  of  STATI;  translocation  of  the  STATI  complex  (GAF)  to  the 
nucleus  and  activation  of  transcription  of  genes  containing  GAS  and  ISRE 
sequences  (modified  from  Bach  et  al,  1997;  Park  and  Shindler,  1998). 
In  unstimulated  cells,  the  IFN-yR  a  and  P  subunits  are  dissociated,  binding  through  their 
intracellular  domain  to  JAKI  and  JAK2  respectively.  Binding  of  the  IFN-y  homodimer  to 
the  receptor  leads  to  dimerisation  of  two  a-chains,  generating  a  site  recognised  by  the 
receptor  P-chains  as  they  slide  towards  the  cc-chains  in  the  centre  (Kotenko  et  al,  1995). 
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Assembly  of  the  receptor  brings  JAKI  and  JAK2  into  close  association,  promoting 
transphosphorylation  and  reciprocal  activation  of  the  JAKs.  The  activated  JAKs 
phosphorylate  tyrosine  residue  440  of  the  cc-chains,  generating  two  binding  sites  for 
STAT1.  Binding  of  latent  cytoplasmic  STATI  to  the  activated  cc-chains  leads  to 
phosphorylation,  dissociation  from  the  receptor  and  dimerisation  of  STATI  (Greenlund  et 
al,  1994).  The  STAT  I  homodimer,  also  named  GAF  (gamma-interferon  activation  factor) 
is  further  phosphorylated,  presumably  by  a  MAP-kinase,  before  it  translocates  to  the 
nucleus  where  it  binds  to  specific  DNA  sequences  (Wen  et  al,  1995).  These  elements, 
present  in  the  promoter  region  of  IFN-y  inducible  genes,  are  also  named  GAS  (gamma 
activated  sites)  and  have  palindromic  sequences  with  the  consensus  71-r(C/A)CNNNAA 
(Park  and  Schindler,  1998).  Binding  of  GAF  to  GAS  elements  leads  to  activation  of  gene 
promoters  and  initiation  of  transcription. 
The  importance  of  the  activation  of  specific  genes  lies  in  de  novo  expression  of  proteins 
that  will  alter  the  physiology  of  stimulated  cells.  These  include  surface  proteins  (e.  g. 
MHC,  FcgRl),  cytoplasmic  proteins  (e.  g.  GBP-l,  nitric  oxide  synthase)  and  secreted 
proteins  (e.  g.  TNF-cc,  IL-12,  IFN-y).  IFN-y  inducible  genes  driving  significant  cellular 
responses,  will  be  mentioned  below,  in  the  section  concerning  biological  activities  of 
INF-y.  Additionally,  the  trancription  of  IFN-y  inducible  genes  is  a  biphasic  process.  The 
direct  transcriptional  activation  of  genes  by  GAF,  also  named  primary  IFN-y  response, 
controls  the  expression  of  a  number  of  proteins  (e.  g.  IL-12,  FCyRI).  On  the  other  hand, 
GAF  also  initiates  the  synthesis  of  a  number  of  secondary  transcription  factors  (e.  g. 
CIITA,  p48,  IRF-1)  that  will  in  turn  direct  protein  expression,  often  mediating 
overlapping  activities  with  other  cytokines.  For  example,  the  class  II  transactivator 
(CIITA)  is  a  transcriptional  factor  required  for  the  expression  of  MHC  class  II  molecules. 
Interferon  regulatory  factor-1  (IRF-1)  and  p48  play  a  complex  role  in  regulating  the 
expression  of  secondary  response  genes  through  promoters  containing  interferon 
stimulated  response  elements  (ISRE)  with  the  prototypic  sequence  AGMCNNTTrCNC/T. 
They  initiate  transcri  ption  of  a  number  of  genes  (e.  g.  MHC  class  1,  GBP-1,  IFN-P)  that 
overlap  IFN-cc  activity  (reviewed  in  Bach  et  al,  1997;  Gallin,  1995;  Park  and  Schindler, 
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1998).,  Although  the  role  of  the  Jak-STAT  pathway  in,  mediating  IFN-y  activity  is 
indisputable,  evidence  is  gathering  showing  that  at  least  some  activities  of  IFN-y  may  be 
mediated  not  by  the  JAK-STAT  pathway,  but  by  alternative  pathways  involving 
phosphorylation  of  PKC  and  mobilisation  of  Ca"  (Smith  et  al,  1990) 
The  restricted  number  of  transcriptional  factors  (e.  g.  STATs)  available  for  signalling,  has 
a  bearing  on  the  specificity  of  cytokine  activity  (reviewed  in  1.4).  In  fact,  a  number  of 
cytokines  (e.  g.  IFN-cc,  TNF-(x,  IL-1,  IL-2,  IL-12)  show  at  least  some  overlapping 
functions  with  IFN-y,  highlighting  the  redundancy  of  cytokine  activity  (Gallin,  1995). 
Therefore  IFN-y  actions  should  not  be  viewed  as  consequences  of  IFN-y  acting  alone  but 
rather  in  the  context  of  an  immune  response  involving  multiple  cell-surface  and  secreted 
molecules. 
1.7.5  Biological  Activities 
The  mechanisms  of  host  defence  unravelled  in  response  to  IFN-y  are  mediated  by 
proteins  produced  by  stimulated  cells.  These  proteins  can  either  alter  the  metabolic  status 
of  the  cell  or  be  responsible  for  more  specialised  activities.  Below  is  a  brief  review  on 
cellular  changes  induced  by  EFN-y  stimulation  and  their  impact  on  the  regulation  of 
immune  and  inflammatory  responses. 
BiochemicaI  changes  in  response  to  IFN-y 
Among  the  biochemical  changes  experienced  by  cells  upon  stimulation  with  IFN-y  are 
those  that  trigger  alterations  in  cellular  metabolic  pathways  involved  in  the  cellular 
response  to  pathogens. 
TRYPTOPHAN  METABOLISM 
The  proteins  indoleamine-2-3-dioxygenase  (IDO)  and  tryptophanyl-tRNA  synthetase 
(WRS)  are  two  enzymes  involved  in  the  tryptophan  metabolism  that  are  strongly  induced 
by  IFN-y.  IDO  is  the  first  enzyme  in  the  kynurenine  pathway  that  transforms  tryptophan 
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into  alanine  and  metabolites  (e.  g.  acetyl  CoA,  quinolinic  acid)  and  is  the  main  contributor 
to  the  decrease  in  serum  tryptophan  in  individuals  exposed  to  IFN-y.  Because  tryptophan 
depletion  leads  to  an  overall  reduction  of  protein  synthesis,  IDO  as  been  implicated  in  the 
antiproliferative  role  of  IFN-y.  There  is  speculation  that  induction  of  WRS  may  safeguard 
the  synthesis  of  tryptophan-rich,  immunologically  relevant  molecules  (e.  g.  IRF  family  of 
proteins)  in  face  of  IDO-mediated  depletion  of  tryptophan  (reviewed  in  Burke  et  al, 
1995). 
RESPIRATORY  BURST 
IFN-y  potentiates  the  production  of  highly  reactive  oxidants  [  e.  g.  hydrogen  peroxide 
(H202)  and  superoxide  anion  (0j)]  in  activated  macrophages  and  neutrophils.  This 
process  is  named  respiratory  burst  and  is  a  characteristic  of  the  microbicidal  state  of 
macrophages.  IFN-y  is  directly  responsible  for  the  activation  of  transcription  of  genes 
coding  for  membrane-associated  enzymes  of  the  NAPDH  oxidase  system  that  promote 
this  effect  (reviewed  in  Cassatella  et  al,  1990). 
GENERATION  OF  NITRIC  OXIDE 
Nitric  oxide  (NO)  is  a  intercellular  messenger  that  participates  in  various  cellular 
processes  (e.  g.  vascular  homeostasis,  neurotransmission,  antimicrobial  and  antiviral 
defense).  NO  is  formed  from  L-arginine  and  molecular  oxygen  in  a  reaction  catalysed  by 
the  enzyme  nitric  oxide  synthase  (iNOS),  expressed  in  most  cell  types  upon  appropriate 
stimulation.  IFN-y  controls  the  production  of  NO  via  activation  of  gene  transcription  of 
both  iNOS  and  its  cofactor  tetrahydrobiopterin.  However  maximal  activation  of  cells  to 
produce  NO  in  vitro  is  only  obtained  by  combination  of  IFN-y  and  endotoxin,  IFN-Y  and 
TNF-cc  or  IFN-y  and  IL-1.  Induction  of  NO  production  in  phagocytic  cells  is  associated 
with  reduced  survival  of  ingested  microorganisms  (e.  g.  Mycobacteria,  Toxoplasma, 
Trypanosoma,  Leishmania)  and  is  also  implicated  in  the  antiviral  effect  of  IFN-y  in 
macrophages  infected  with  vaccinia,  and  herpes  simplex  viruses.  Additionally,  NO 
secreted  by  activated  macrophages  has  been  associated  with  tumour  cell  killing.  In  this 
case,  the  cytotoxic  effect  of  induced  NO,  may  also  cause  undesirable  tissue  damage 
(Moncada  and  Higgs,  1993;  Green  et  al,  1991;  Karupiah  et  al,  1993). 
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Antiviral  effects 
IFN-y  itself  is  not  a  potent  antiviral  agent  when  compared  to  type  I  IFNs,  in  fact  it  has  10- 
100  fold  lower  specific  antiviral  activity  in  vitro,  than  either  IFN-a  or  IFN-P  (Farrar  and 
Schreiber,  1993).  Nevertheless,  IFN-y  plays  an  important  role  in  the  outcome  of  viral 
infections  in  vivo,  as  documented  in  a  series  of  experiments  including  the  prophylactic 
treatment  of  cytomegalovirus  infection  in  mice  through  exogenous  application  of  IFN-y 
(Fennie  et  al,  1988)  an  effect  neutralised  by  antibodies  against  IFN-y  in  rats  (Haagmans  et 
al,  1994)  and  the  increased  susceptibility  to  certain  viruses  (e.  g.  vaccinia  virus,  vesicular 
stomatitis  virus,  hepatitis  virus)  in  IFN-y  or  IFN-yR  gene  knock-out  mice  (Muller  et  al, 
1994;  Lucchiari  et  al,  1992). 
The  overall  antiviral  activity  of  IFN-y  can  be  divided  into  two  interdependent  sets  of 
mechanisms.  The  first  entails  direct  antiviral  effects  through  activation  of  STATI  or 
overlapping  with  the  type  I  IFN  signalling  pathway  and  the  second  those  mechanisms 
mediated  by  its  immunomodulatory  activity.  IFN-y,  through  phosphorylation  of  STATI, 
directly  activates  genes  containing  GAS  elements  that  are  involved  in  the  resolution  of 
viral  infections.  Additionally,  IFN-y  stimulation  enhances  the  expression  of  members  of 
the  interferon  regulatory  factor  (IRF)  family  of  transcription  factors  (e.  g.  IRF-I,  p48, 
ICSBP-interferon  consensus  sequence  binding  protein)  and  therefore  overlaps  IFN-cc 
activities.  The  regulation  of  secondary  response  genes  by  IRFs  is  a  complex  and  highly 
regulated  process,  still  largely  undisclosed.  IRF-  I  and  p48  are  implicated  in  the  activation 
of  gene  promoters  containing  ISRE  motifs  and  of  the  positive  regulatory  domain  (PRDI) 
of  the  IFN-P  gene  promoter,  while  ICSBP  appears  to  antagonise  their  activity,  repressing 
gene  transcription.  Although  IRF-I  has  some  DNA-binding  activity  it  appears  that  p48  is 
required  to  confer  ISRE  specificity.  ICSBP  seems  to  act  through  interaction  with  p48  to 
inhibit  DNA-binding  (Kimura  et  al,  1994;  Tanaka  and  Taniguchi,  1992;  Bovolenta  et  al, 
1994). 
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IFN-y  can  therefore,  directly  or  indirectly,  increase  the  gene  transcription  of  a  number  of 
proteins  responsible  for  the  antiviral  state  such  as  the  dsRNA  dependent  protein  kinase 
PKR,  (2'-5')  oligoadenylate  synthetase,  and  dsRNA  specific  adenosine  deaminase: 
-  PKR  is  a  serine-threonine  kinase  activated  by  binding  to  double  stranded  (ds) 
RNA  structures.  Both  DNA  and  RNA  viruses  produce  RNA  intermediate  products  that 
can  activate  PKR.  Activation  leads  to  auto-phosphorylation,  followed  by  the 
phosphorylation  of  the  cc  subunit  of  eIF2,  the  eukaryotic  protein  synthesis  initiation 
factor,  thus  inhibiting  translation  and  therefore  protein  synthesis  (Hovanessian,  1993). 
PKR  is  constitutively  expressed  in  low  amounts  in  many  cell  types,  its  promoter  contains 
both  ISRE  and  GAS  elements,  making  it  responsive  to  both  type  I  and  II  IFNs. 
Additionally,  NFkB  elements  in  the  promoter  of  this  gene,  reveal  overlapping  activity  in 
response  to  TNF-(x  (Tanaka  and  Samuel,  1994).  The  recognition  of  PKR  importance  in 
the  antiviral  response  promoted  by  IFN-y  came  from  studies  using  a  model  of 
encephalomyocarditis  virus  (ECMV)  infection  in  mice.  Following  treatment  with  IFN-y, 
normal  mice  had  a  prolonged  survival  to  the  virus,  when  compared  with  PKR-deficient 
mice  (Yang  et  al,  1995). 
-  (2'-5')  oligoadenylate  synthetase  is  also  constitutively  expressed  in  several  cell 
types  and  is  induced  by  type  I  IFNs  and  less  potently  by  IFN-y.  When  activated,  the 
enzyme  polymerises  ATP  into  a  series  of  2'-5'  linked  oligomers  [  ppp(A2'p)n  -  with  four 
isoforms  (n=l  to  n=4)],  which  in  turn  activate  the  latent  cellular  endoribonuclease  (Rnase 
L)  which  is  responsible  for  antiviral  activity  through  single  stranded  RNA  degradation. 
However,  degradation  is  not  limited  to  viral  RNA  as  cellular  ribosomal  and  mRNA  are 
also  degraded  in  the  process  (reviewed  in  Hovanessian,  1991;  De  Maeyer  and  De 
Maeyer-Guinard,  1998). 
-  dsRNA  specific  adenosine  deaminase  (dsRDA)  is  an  enzyme  that  catalyses  the 
dearnination  of  adenosine  into  inosine  using  dsRNA  as  substrate,  producing  so  called 
edited  mRNAs  whose  translation  does  not  lead  to  functional  proteins.  Exposure  of  cells 
to  both  IFN-(x  and  IFN-y  significantly  increases  transcription  of  dsRDA  (Patterson  et  al, 
1995). 
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The  second  set  of  mechanisms  governing  recovery  from  viral  infection  is  mediated  by 
immune  responses  largely  orchestrated  by  IFN-y.  Among  the  actions  that  skew  the 
immune  response  towards  a  cell  mediated  state  are,  as  described  below,  activation  of  NK 
cells  and  macrophages,  antibody  class  switching  from  IgGl/IgE  to  IgG2/IgG3,  promotion 
of  Thl  over  Th2  type  responses,  maturation  of  CTLs  and  upregulation  of  MHC  class  I 
and  Il  presentation  pathways.  Because  NK  cells  and  T  cells  produce  IFN-y,  a  positive 
feedback  loop  is  created  that  amplifies  local  cell  killing.  Paradoxically  IFN-y  appears  to'. 
at  least  in  vitro,  render  target  cells  refractory  to  NK  cell  activity  although  retaining 
susceptibility  to  CTL  killing  (Wallach,  1983).  These  observations  lead  to  the  assumption 
that  IFN-y  might  increase  the  development  of  specific  immune  responses  elicited  by 
CTLs  in  detriment  of  the  unspecific  cell  killing  mediated  by  NK  cells,  as  the 
immunological  process  progresses  (Reiter  et  al,  199  1). 
Striking  evidence  of  the  relevance  of  IFN-y  expression  as  a  defence  mechanism  against 
viral  infections  comes  from  observations  that  some  viruses  evolving  under 
immunological  pressure  have  acquired  genetic  codes,  by  recombination  with  host  DNA, 
that  specifically  evade  IFN-y  activity.  Examples  of  these  are  the  expression  of  soluble 
receptors  for  IFN-y  encoded  by  poxviruses  that  serve  as  a  decoy  for  IFN-y  binding 
(Alcani  and  Smith,  1995)  and  the  production  of  IL-  1  O-like  protein,  a  potent  antagonist  of 
IFN-y  activity,  encoded  by  the  human  herpes  virus,  Epstein-Barr  (Sairenji  et  al,  1998). 
Antigen  presentation 
The  recognition  of  foreign  antigens  is  a  critical  step  in  the  development  of  specific 
immune  responses.  Because  T  cells  are  unable  to  recognize  antigens  in  free  or  soluble 
form,  these  have  to  be  presented  to  them  as  portions  of  protein  antigens  (peptides)  that  are 
associated,  non-covalently,  with  major  histocompatibity  complex  (MHQ  molecules.  The 
MHC  is  a  large  genetic  region  of  human  chromosome  6,  coding  for  both  class  I  and  class 
II  determinants,  as  well  as  other  proteins  involved  in  processing  and  transport  of  antigens. 
Both  classes  of  MHC  are  structurally  similar  with  a  highly  polymorphic  extracellular 
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peptide  binding  domain,  an  extracellular  Ig-like  domain,  transmembrane  and  cytoplasmic 
domains.  The  size  of  the  binding  domains,  in  both  classes,  restrict  the  size  of  the  peptides 
that  can  be  presented  (9  to  II  residues  in  the  case  of  class  I  and  up  to  30  amino  acids  in 
class  II),  meaning  that  foreign  proteins  have  to  be  processed  prior  to  loading  and 
presentation  on  the  cell  surface.  MHC  molecules  bind  only  one  peptide  at  a  time  and 
although  this  association  is  one  of  low  affinity,  the  complexes  once  formed  persist  for 
sufficiently  long  time  to  be  recognized  by  T  cells  (reviewed  in  Germain,  1994;  Abbas'  et 
al,  1997).  In  table  1.7  are  presented  some  differential  features  of  Class  I  and  II  antigen 
processing  and  presentation  pathways. 
Table  1.7  Comparative  features  of  MHC  class  I  and  II  presentation  pathways  (Abbas'  et 
al,  1997). 
Feature  MHC  class  I  MHC  class  11 
Composition  of  MHC  polymorphic  a-chain,  13,  polymorphic  cc  and  P  chains, 
complex  microglobul  n,  peptide  peptide 
mononuclear  phagocytes,  B 
Type  of  APC's  all  nucleated  cells  lymphocytes,  dendritic  cells, 
endothelial  cells,  thymic 
epithelium 
Source  of  protein  antigens  mostly  synthesized  on  mostly  of  extracellular  origin 
polyribosomes  in  the  cell 
Site  of  peptide  generation  cytosolic  proteasome  endosome/lysosome 
specialized 
Site  of  MHC  peptide  loading  ER  endosomal/lysosomal 
compartment 
Associated  proteins  prior  to  Calnexin,  BiP,  TAP  Calnexin,  invariant  chain 
loading 
Peptide  transport  for  loading  TAP  not  necessary 
Transport  to  cell  surface  secretory  pathway  ?  secretory  pathway  ? 
Responsive  T  cells 
1 
CD8'  T  cells  (CTL's)  CD4*  T  cells  (mostly  T  helper 
- 
cells) 
APC,  antigen  presenting  cell;  ER,  endoplasmic  reticulum;  BiP,  binding  protein;  TAP,  transporter 
associated  with  antigen  processing;  CTL,  cytotoxic  T  lymphocyte. 
The  upregulation  of  MHC  molecules  was  one  of  the  first  biological  effects  attributed  to 
IFNs.  IFN-y  not  only  shares  the  ability  of  regulating  expression  of  MHC  class  I  with  type 
I  IFNs,  but  it  also  regulates  elevation  of  MHC  class  II  presentation  (Rosa  et  al,  1986). 
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This  process  involves  the  activation  of  multiple  genes,  whose  products  contribute  in 
distinct  ways  to  antigen  presentation. 
CLASS  I  ANTIGEN  PRESENTATION 
MHC  Class  I  molecules  contain  two  separate  polypeptide  chains:  (x  or  heavy  chain  and  a 
non  MHC  encoded  P  chain  (P2  microglobulin).  Expression  of  class  I  molecules  on  the 
cell  surface  depends  on  the  post-translational  association  of  cc  and  P  chains  (reviewed  in 
York  and  Rock,  1996).  MHC  Class  I  is  constitutively  expressed  in  most  tissues  with  a 
relatively  high  expression  in  lymphomyeloid  cells.  Although  all  IFNs  are  able  to 
upregulate  class  I  expression,  IFN-y  is  generally  more  active  than  IFN-cc  or  P.  In  vivo 
administration  of  IFN-y  results  in  a  disseminated  increase  of  class  I  expression  on  many 
tissues  (Watine  et  al,  1990).  The  responsiveness  to  IFNs  is  mediated  mainly  by  an  ISRE 
motif  present  in  the  promoter  region  of  class  I  heavy  chain  genes.  Although  induction  of 
IRF-I  by  IFN-y  with  binding  to  ISRE  is  an  important  factor  in  transcription,  it  appears 
that  other  mediators  are  needed  for  efficient  gene  activation.  Among  these  is  the  TNF--a 
induction  of  NFrB  and  consequent  binding  to  an  enhancer,  adjacent  to  the  ISRE  that 
contains  three  NFKB  binding  sites  (enhancer  A).  The  enhancer  A  element,  plays  a  central 
role  in  inducible  expression  of  class  I  genes  and  is  the  basis  of  the  strong  synergism 
between  IFN  and  TNF--a  in  the  regulation  of  MHC  class  I  (Johnson  and  Pober,  1990). 
Similarly  IFNs  increase  expression  of  P2-microglobulin  in  synergism  with  TNF--a.  IFN-y 
also  upregulates  the  expression  of  other  proteins  involved  in  processing  of  antigens  for 
presentation  in  the  cell  surface  (Anderson  et  al,  1994;  Rotem-Yehudar  et  al,  1996).  These 
include:  the  proteasome,  a  multiple  subunit  endopeptidase  responsible  for  the  generation 
of  peptides  from  foreign  proteins;  the  TAP  family  of  proteins,  involved  in  the  transport  of 
peptides  to  the  ER  for  loading  and  gp96,  a  stress  protein  present  in  the  lumen  of  the  ER 
and  involved  in  the  protection  of  peptides  from  degradation  or  default  secretion  (reviewed 
in  York  and  Rock,  1996). 
CLASS  11  ANTIGEN  PRESENTATION 
The  MHC  class  II  presentation  pathway  is  constitutively  active  only  in  professional 
antigen  presenting  cells  (e.  g.  macrophages,  dendritic  cells,  B  cells)  and  is  strongly 
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upregulated  by  IFN-y  (Mach  et  al,  1996).  Paradoxically  while  IFN-y  acts  to  increase  class 
II  expression  in  most  cell  types  it  inhibits  this  antigen  presentation  pathway  in  B  cells 
(Mond  et  al,  1986).  IFN-y  can  also  induce  de  novo  expression  of  class  II  molecules  in 
most  cell  types,  converting  the  responding  cells  into  non  professional  antigen  presenting 
cells.  These  cells,  being  unable  to  express  costimulatory  signals  (e.  g.  B7,  ICAM-1)  are 
thought  to  play  an  important  role  in  the  induction  of  T  cell  anergy  as  a  mechanism  of 
immunological  tolerance  (Lenschow,  1996).  B7  and  ICAM-1  expression  is  also  enhanced 
by  IFN-y  (Freedman  et  al,  1991).  All  the  key  genes  required  for  normal  expression  of 
MHC  class  11  at  the  cell  surface  are  regulated  by  IFN-y.  These  include,  (x  and  P  chains 
that  form  the  class  II  molecule;  the  ER  chaperone  Ii,  proteins  responsible  for  peptide 
loading  (DMA  and  DMB)  and  lysosomal  cathepsins.  IFN-y  induction  of  MHC-11  is 
orchestrated  by  a  single  transcription  factor,  the  class  II  transactivator  (CIITA)  in  a  highly 
specialised  process  that  is  a  paradigm  of  non  redundant  cytokine  activity.  Although, 
because  CIITA  itself  has  no  DNA  binding  activity,  is  thought  to  activate  genes  through 
the  interaction  with  multiple  nuclear  transcription  factors  (e.  g.  RFX).  The  CIITA  gene 
promoter  contains  a  GAS  element  and  is  therefore  directly  activated  by  IFN-y  (reviewed 
in  Chang  and  Flavell,  1995  and  Mach  et  al,  1996). 
Immunomodulatory  activities 
EFFECTS  ON  MACROPHAGES  AND  NK  CELLS 
The  activation  of  macrophages  as  a  mechanism  of  non-specific  cell  mediated  host 
defence  is  a  well  established  phenomenon  that  constitutes  one  of  the  major  manifestations 
of  cellular  response  to  IFN-y.  This  activity,  firstly  demonstrated  in  vitro  in  response  to 
supernatants  from  stimulated  T  lymphocytes,  was  given  the  name  of  macrophage 
activating  factor  and  was  ultimately  shown  to  be  largely  accounted  for  by  IFN-y  (Nathan 
et  al,  1983).  Macrophage  activation  by  IFN-y  entails  an  increase  in  the  phagocytosis  and 
endocytocis  capability  of  these  cells.  Phagocytosis  is  ftirther  enhanced  by  IFN-y  induced 
expression  of  the  high  affinity  receptor  FcyRI  that  binds  to  specific  IgG  molecules  on  the 
surface  of  opsonised  bacteria.  Once  inside  macrophages,  microorganisms  are  killed  by 
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toxic  molecules,  namely  reactive  oxygen  and  nitric  oxide  whose  production  is  also 
primarily  upregulated  by  IFN-y  (Nathan,  1992).  IFN-y  is  therefore  sufficient  to  fully 
activate  macrophages  for  killing  of  microorganisms.  Similarly,  in  NK  cells,  IFN-y 
upregulates  the  expression  of  the  low  affinity  receptor  FCYRIII  and  promotes  an  increase 
in  cytolitic  activity  (Farrar  and  Schreiber,  1993).  The  upregulation  of  FcyRI,  in 
macrophages,  and  FcyRIII  inNK  cells  increases  the  capability  of  these  cells  to  kill 
neoplasic  and  virus  infected  cells  by  means  of  antibody  dependent  cell  cytotoxicity 
(ADCQ  (Ravetch  and  Kinet,  1991).  Expression  of  cytokines  (e.  g.  IL-12,  TNF-a)  by 
macrophages  and  NK  cells  in  response  to  IFN-y  leads  to  implementation  of  synergism 
and  local  activation  positive  feedbacks,  contributing  for  clearance  of  infection. 
Additionally,  by  upregulating  the  expression  of  co-stimulatory  adhesion  molecules  (e.  g. 
ICAM-1)  in  target  cells  and  their  ligands  (e.  g.  Mac-1)  in  macrophages  and  NK  cells,  IFN- 
y  intensifies  the  killing  of  virus  infected  and  tumour  cells  (Bevilacqua,  1993). 
EFFECTS  ON  T  LYMPHOCYTES 
IFN-y  stimulates  proliferation  of  mitogen-triggered  primary  T  cells  and  mixed 
lymphocyte  populations  and  of  a  variety  of  T  cell  lines  in  contrast  to  the  antiproliferative 
effect  that  it  exerts  in  most  other  cell  types.  This  apparently  paradoxical  situation  is 
thought  to  be  due  to  upregulation  of  both  IL-2  and  IL-2  receptor  in  responsive  T 
lymphocytes  by  IFN-y  (Landolfo  et  al,  1988).  IFN-y  also  increases  the  development  of 
CTL  activity  in  antigen-stimulated  lymphocyte  cultures  (Siegel,  1988).  This  effect  results 
from  stimulatory  *cffects  on  mononuclear  phagocytes,  T  helper  cells  or  CD8+  precursors 
or  alternatively  from  inhibitory  effects  on  suppressor  T  cells.  Additionally,  IFN-y  both 
accelerates  and  enhances  IL-12  determined  Thl  phenotype  development,  possibly  by 
upregulating  IL-12  receptor  expression  on  naive  CD4+  T  cells,  in  synergism  with  TCR 
cross-linking  (Wenner  et  al,  1996). 
EFFEM  ON  B  LYMPHOC=S 
Cytokines  regulate  the  switching  of  heavy  chain  class  in  antibody  secreting  B  cells  from 
IgM  to  other  downstream  isotypes  (e.  g.  IgG,  IgE)  by  activation  of  transcription  of  the 
target  isotype  genes.  IFN-y  is  the  main  switch  regulating  IgG2a  and,  to  a  lesser  scale, 
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IgG3  switching  in  the  mouse.  IFN-y  also  strongly  antagonises  IL-4  dependent  switching 
to  IgGI  and  IgE  heavy  chain  classes.  Confirmation  of  this  phenomenon  was  obtained 
when  treatment  of  mice  with  neutralising  antibodies  to  IFN-y  followed  by  vaccination 
with  influenza  virus  antigens,  resulted  in  increased  levels  of  antigen  specific  IgGI  and 
ýgE  and  reduced  levels  of  IgG2  and  IgG3  (Dobber  et  al,  1995).  This  effect,  exerted 
directly  on  B  cells  through  activation  of  STAT  I,  is  dependent  on  B  cell  activation  and  IL- 
2  stimulation  and  is  enhanced  by  IL-1  (Snapper  et  al,  1996).  There  are  also  reports, 
although  somewhat  contradictory,  linking  IFN-y  with  B  cell  maturation  from  resting 
splenic  B  cells  and  apoptosis  of  differentiated  B  cell  lines  (Sidman  et  al,  1984;  Trubiani 
et  al,  1994). 
CYTOKINE  NETWO 
IFN  regulates  the  expression  of  a  number  of  cytokines  and  growth  factors  or  their 
receptors  (see  table  1.8)  including  its  own  expression  and  that  of  its  receptor  (Farrar  and 
Schreiber,  1993).  Receptor  autoregulation  is  an  aberrant  phenomenon  only  observed  in 
CD4+  T  cells.  It  entails  the  induction  or  repression  of  IFN-yR  P-chain  synthesis  in  Th2 
and  Thl  cells,  respectively  (Bach  et  al,  1995).  As  mentioned  before,  although  P-chains  do 
not  take  part  in  IFN-y  binding,  they  do  intervene  in  signal  transduction. 
Although  several  cytokines  can  reinforce  the  production  and/or  activity  of  IFN-y  (e.  g.  IL- 
12,  IL-18,  type  I  interferons,  IL-1,  IL-2),  IFN-y  synergises  mainly  with  TNF-oc.  This 
synergism  is  often  additive  and  is  observed  both  in  vitro  (e.  g.  induction  of  expression  of 
cell  surface  molecules,  microbicidal  activity  of  macrophages,  cytotoxicity  of  tumour 
cells)  and  in  vivo  (e.  g.  antitumour  effects,  induction  of  cytokines,  systemic  toxicity).  The 
synergism  between  IFN-y  and  TNF--a  is  largely  mediated  by  overlapping  of  the  signal 
transduction  pathways  involving  IRF-  I  and  NFkB,  respectively  (Drew  et  al,  1995)  and  is 
supported  by  the  strong  upregulation  of  both  TNF-a  protein  and  receptor  by  IFN-y  (see 
table  1.8). 
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Several  cytokines  have,  conversely,  an  antagonistic  effect  towards  IFN-y  activity  and 
production,  representing  mechanisms  that  prevent  deleterious  effects  of  continuous  IFN-y 
production.  IL-4,  produced  mainly  by  B  cells  and  T  helper  type  2  cells,  is  the  main 
antagonist  of  IFN-y,  countering  the  majority  of  its  biological  activities.  Examples  of 
opposing  effects  of  IL-4  on  IFN-y  activity  are  the  inhibition  of  macrophage  activation  and 
microbicidal  activity  and  antiviral  activity,  the  induction  of  cytokines  and  thymocyte 
proliferation  and  the  antibody  class  switching  favouring  IgGI  and  IgE  isotypes  (Paul, 
1991).  Nevertheless,  the  single  most  emphatic  way  by  which  IL-4  antagonises  IFN-y  is 
the  skewing  of  T  helper  responses  towards  the  Th2  phenotype,  therefore  directly 
inhibiting  IFN-y  production  (reviewed  in  1.4). 
Other  cytokines  with  antagonistic  effects  over  IFN-y  include: 
-  TGF-Pl,  secreted  by  a  variety  of  cells  (e.  g.  platelets,  fibroblasts,  lymphocytes, 
macrophages),  antagonises  IFN-y  by  inhibiting  T  lymphocyte  proliferation  and 
generation  of  CTLs,  IFN-y  driven  MHC  II  expression  and  generation  of  nitric 
oxide  by  activated  macrophages  (Chantry  et  al,  1989); 
-  IL-  10,  produced  by  Th2,  monocytic  and  B  cells,  directly  inhibits  the  synthesis  of 
IFN-y  in  all  cell  types.  Since  this  antagonism  is  reciprocal,  the  balance  between 
IL-10  and  IFN-y  appears  to  be  important  in  the  regulation  of  the  course  of  an 
immune  response  (Moore  et  al,  1993); 
-  IL-13,  synthesised  mainly  by  Th2  cells,  is  structurally  related  to  IL-4,  sharing 
some  of  its  biological  activities,  including  inhibition  of  IFN-y  driven  macrophage 
activation  and  microbicidal  activity  (Zurawski  and  De  Vries,  1994). 
IMMUNE  SUPPRESSION 
IFN-y  has  been  involved  in  the  induction  of  "suppressor"  (or  regulatory)  T  cells.  These 
cells  produce  mainly  TGF-01  and  IL-10  and  are  responsible  for  the  inhibition  of  the 
activation  phase  of  immune  responses  with  a  consequent  decrease  in  lymphocyte 
proliferation  capability.  The  T  regulatory  cell  population  is  characteristically  expanded  in 
graft-versus-host  disease  following  bone  marrow  transplantation  (Bloom  et  al,  1992). 
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This  process  was  found  to  be,  at  least  in  part,  regulated  by  IFN-y,  since  treatment  of  hosts 
with  anti-IFN-y  antibodies  relieves  symptoms  (Wall  et  al,  1988). 
The  requirement  of  IFN-y  for  appropriate  modulation  of  immune  responses  is  highlighted 
by  the  use  of  IFN-y  or  IFN-yR  gene  knockout  mice.  These  mice  show  increased 
susceptibility  to  infections  by  intracellular  pathogens  due  to  deficient  macrophage 
activation,  reduced  production  of  NO  and  expression  of  MHC  II  by  macrophages, 
reduced  seruin  levels  of  IgG2a  and  IgG3  antibodies  and  defective  NK  cell  function 
(Abbas'et  al,  1997). 
Effects  on  Turnour  cells 
Type  I  IFNs  show  an  important  anti-tumour  activity  and  are  currently  used  as  therapeutic 
agents  for  patients  with  a  number  of  different  carcinomas.  IFN-y  also  shows  some  direct 
anti-tumoural  activity  through  the  production  of  NO  that  inhibits  tumour  growth  and  the 
activation  of  interferon-inducible  protein-10  (IP-10)  that  inhibits  angiogenesis  and 
therefore  tumour  mass  growth  (Yu  et  al,  1996).  IFN-y  also  activates  indirect  effector 
mechanisms  including  MHC  antigen  expression,  macrophage  activation,  stimulation  of 
CTL  and  NK  cell  activity  (reviewed  in  De  Maeyer  an  De  Maeyer-Guignard,  1998)  and 
has  a  role  in  the  elicitation  of  specific  turnour-associated  antigens  (Murray  et  al,  1988). 
Additionally,  IFN-y  exerts  a  mild  antiproliferative  effect  on  most  cell  types  (with  the 
exception  of  some  populations  of  activated  T  cells).  Moreover,  IFN-y  has  been  shown  to 
bind  and  activate  signal  transduction  on  several  neoplasic  cell  lines  and  is  thought  that  the 
downregulation  of  oncogene  (myc)  expression  might  be  involved  (Kurzrock,  1992). 
Role  of  IFN-y  in  infection 
Equipped  with  the  information  provided  in  the  previous  paragraphs  we  can  now  draw  a 
general  scheme  of  IFN-y  mediated  activity  in  response  to  infection.  Some  pathogens, 
including  bacteria'(e.  g.  Listeria,  Salmonella,  Mycobacterium)  and  parasites  (e.  g. 
Protozoa,  Clamydia,  Fungi)  use  the  intracellular  environment  as  a  means  to  escape  host 
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defence  mechanisms  (e.  g.  elicitation  of  microbicidal  antibodies,  activation  of 
complement).  Therefore,  clearance  of  these  infections  is  dependent  on  cell  mediated 
immune  responses.  Early  in  infection,  IFN-y  produced  mainly  by  NK  cells  is  responsible 
for  monocyte/macrophage  activation  and  increased  phagocytosis  capability.  IFN-y  also 
promotes  induction  of  cell  surface  presentation  of  pathogen  antigens  in  the  context  of 
MHC  class  II,  which  leads  to  activation  of  CD4+  Thl  lymphocytes  through  TCR  cross 
linking.  Thl  cells  produce  increased  levels  of  IFN-y  that  optimises  phagocytosis  of 
opsonised  pathogens  (mediated  by  FcyRI  upregulation)  and  induces  microbicidal 
mechanisms  (e.  g.  reactive  oxygen  and  nitric  oxide)  of  infected  phagocytes.  A  positive 
feedback  loop  of  cell  activation  is  maintained  between  macrophages  (producing  IL-12 
and  IL-18)  and  Thl  cells  (producing  IFN-y  )  that  leads  to  the  eventual  clearance  of 
infection.  This  cytokine  dependent  pathway  is  nonetheless"complemented  by  cytotoxic  T 
cell  activity  that  specifically  kills  phagocytes  or  other  infected  cells,  presenting  pathogen 
peptides  in  the  context  of  MHC  class  I.  As  described  previously,  both  CTL  activation  and 
MHC  class  I  expression  are  actively  induced  by  IFN-y. 
IFN-y  is  instrumental  in  host  defence  against  viral  infection,  with  functions  both  in  the 
elimination  of  virus  following  primary  infection  and  in  the  establishment  of  appropriate 
immunity  against  reinfection.  Whether  the  in  vivo  antiviral  effects  of  IFN-y  are  due  to  its 
direct  induction  of  antiviral  proteins  (e.  g.  PKR,  dsRDA)  or  to  its  immunomodulatory 
activities  (e.  g.  activation  of  NK  cells  and  ADCC,  maturation  of  CTLs,  regulation  of  Thl 
in  detriment  of  Th2  type  responses)  is  a  subject  still  in  debate. 
The  role  of  IFN-y  in  host  defence  is  emphasised  when  murine  IFN-y  or  IFN-yR  gene 
knockout  models  are  challenged  with  infectious  organisms.  These  mice  show  several 
failures  in  immune  function  that  result  in  increased  susceptibility  to  intracellular 
pathogens  such  as  Leishmania  major,  Listeria  monocytogenes,  Mycobacteria  and 
vaccinia  virus  (reviewed  in  Farrar  and  Schreiber,  1993).  Nevertheless  IFN-y  is  not  always 
beneficial  for  the  resolution'Of  infectious  diseases  and  can  also  act  to  the  detriment  of  the 
host.  Examples  of  detrimental  activity  of  IFN-y  include:  the  onset  of  cerebral  malaria;  the 
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conversion  of  an  inapparent  to  an  aggressive  infection  in  response  to  lymphocytic 
choriomeningitis  virus;  the  stimulation  of  HIV  replication  in  monocytic  cells  and  the 
contribution  to  the  progression  of  endotoxin  triggered  septic  shock  pathology,  either 
directly  or  indirectly,  through  the  induction  of  TNF--a  production  (reviewed  in  De 
Maeyer  and  De  Maeyer-Guignard,  1992;  Farrar  and  Shreiber,  1993). 
1.8  Background  to  the  project 
Due  to  the  low  level  of  cytokine  cross-reactivity  between  species,  investigation  of 
cytokine  biology  is  often  dependent  on  the  development  of  species-specific  reagents  such 
as  recombinant  cytokines  and  monoclonal  and  polyclonal  antibodies  to  those  cytokines. 
Advances  in  the  standardisation  of  molecular  biological  and  immunological  techniques 
have  prompted  the  cloning  of  a  number  of  equine  cytokines  following  the  lead  of  human 
immunology  and  that  of  rodent  models. 
Table  1.9  Equine  cytokines  cloned  to  date 
Equine  cytokine  Accession 
number 
Reference 
IFN-a  1/2/3/4  M14540/MI4541 
M14542  M14543  Hinimler  et  al,  1986 
IFN-P  M14546  Himmler  et  al,  1986 
IFN-,  y  D28520  Cur-ran  et  al,  1994;  Grunig  et  at,  1994 
IFN-(o  1/2  M  14544  M  14545  Himmler  et  al,  1986 
IL-Icc  D42146  Kato  et  al,  1995 
IL-lp  D42147  Kato  et  al,  1995 
IL-  IRA  (receptor  antagonist)  D83714  Kato  et  al,  1997 
IL-2  L06009  Vandergriffl  and  Horohov,  1993 
IL-4  L06010  Vandergrifft  et  al,  1994 
IL-5  U91947  Vandergrifft  and  Horohov,  1997  (unpublished 
IL-6  AF041975  Lai,  1998  (unpublished) 
IL-10  U38200  Swiderski,  et  al,  1995  (unpublished) 
IL-  12  p4O  /  p35  YI  1129  /  YI  1130  Nicolson  et  al,  1999  (in  press) 
IL-  18  (IGIF)  YI  1131  Nicolson  et  al,  1999  (in  press) 
TGFCý-  I  X99438  Penha  Goncalves  et  al,  1997 
TNF-(x  M64087  Su  et  al,  1993  (unpublished) 
Accession  number-  for  access  to  the  nucleotide  sequence  and  putative  amino  acid  sequence  of  genes  or 
cDNAs  in  GeneBank. 
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However,  when  this  project  was  initiated  very  few  equine  cytokine  genes  had  been 
sequenced  and  equine  IFN--f  cDNA  had  just  been  cloned.  The  cloning  of  equine  Thl 
cytokines  was  therefore  an  essential  step  in  the  fulfilment  of  the  aims  of  this  project  that 
were  to  characterise  recombinant  equine  IFN-y  and  to  determine  whether  this  cytokine, 
and  cytokines  inducing  IFN-y  expression,  had  application  as  viral  vaccine  adjuvants. 
Following  the  trend  in  modem  medicine  for  the  application  of  cytokine  and  anti-cytokine 
therapies  (e.  g.  soluble  cytokine  receptors,  anti-cytokine  antibodies)  so  too  the  production 
of  recombinant  equine  cytokines  and  their  receptors  will  facilitate  their  use  in 
therapeutical  or  prophylactic  regimens  as  well  as  in  vaccine  adjuvancy  (Nicolson  et  al, 
1993).  For  the  sake  of  completeness  an  up  to  date  list  of  equine  cytokines  sequences  is 
presented  in  table  1.9. 
jp 
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MATERULS  AND  METHODS Mat  &  meth 
The  contents  of  this  chapter  will  be  referred  to  as  "mat&meth'  'in  the  remaining  of  this 
thesis.  In  the  present  chapter  will  only  be  enumerated  materials  and  methods  of 
general  use.  Specific  procedures  and  corresponding  reagents  and  equipment  will  be 
detailed  in  the  appropriate  section  of  each  chapter. 
2.1  Materials 
2.1.1  Major  equipment 
-  Automated  Processor  Kodak  X-omat  processor  ME-3  (Eastman  Kodak  Co.,  USA). 
-  Automatic  Sequencing  Apparatus  and  appliances:  Licor  4000,  Licor  Inc.,  USA. 
-  Cell  freezer:  Model  Kryo  10  series  II  (Planer  Products  Ltd.,  UK) 
CENTRIFUGES: 
-  Microfuge  5415C  (Eppendorf  GMBH,  Germany). 
-  Benchtop  ccntrifugc  GS-6R  (Beclanan  Instnmcnts  Inc.,  USA).  - 
-  Ultracentrifuge  J2-21(Beclcman  Instnments  Inc.,  USA) 
-  Flurescence  Assisted  Cell  Sorter  (FACS):  Epics  Elite  (Coulter  corporation,  USA). 
-  Get  Documentation  System:  (Ultra  Violet  Products  Inc.,  USA). 
-  Gel  drier:  Model  583  Gel  Dryer  (Bio-Rad,  USA) 
-  Incubators  for  tissue  culture  (Heraeus  Sepatech  and  Leec  Ltd.,  UK). 
-  Pipetteman  (P20,  PIOO,  P200,  P1000):  (Gilson  Medical  Electronics,  France). 
-  Spectrophotometer  Model  DU640,  Beckman. 
-  Thermal  Cycler:  GeneAmp  9600  (The  Perkin  Elmer  Corporation,  USA). 
-  Vacuum  dessicator:  Hetovac,  Heto  Laboratory  Equipment,  Denmark. 
-  Water  baths  (Grant  Instruments  Ltd.,  UK). 
2.1.2  Consumables 
Acrodisc  syringe  filters  0.22  and  0.4  gm  (Gelman  Sciences,  USA). 
Bottle  top  filters  0.22ýtrn  pore  size  (Sigma,  UK). 
Cell  scrapers  (Greiner  Labortechnik  Ltd,  UK) 
Disposable,  sterile  scalpels  (Swann-Morton,  UK). 
46 Mat&  ittelh 
-  Falcon  Tubes  15  and  50ml  (Becton  Dickinson  labware,  UK).  ' 
-  Filter  tip  pipette  tips  30  ýtl  and  200  gl  (Rainin  Instrument  Co.  ',  USA). 
-  Flat  ended  gel  loading  tips  (Sorenson  Bioscience  Ltd.,  Denmark). 
-  Cryo-tubes  (2ml)  Nunc  (Nalge  Nunc  International,  Denmark) 
-  PCR  tubes  (The  Perkin  Elmer  Corporation,  USA). 
-  Petri  dishes,  bijoux  and  universals  (Greiner). 
-  Pipette  tips  yellow  (200gl)  and  blue  (10001A)  (Sarstedt). 
-  Screw  top  and  flip  top  1.5  ml  eppendorf  and  0.5  ml  tubes  (Treff  AG,  Switzerland). 
-  Syringes  of  2,5,10,20  and  50  ml  (Becton  Dickinson  labware,  UK) 
-  Tissue  culture  disposables:  Costar  Flasks,  Multiwell  plates,  Pipettes  (Coming  Inc., 
USA). 
2.1.3  Chemicals 
All  general  chemicals  used  were  of  analytical  (Analar)  or  ultra  pure  grade  and  were 
supplied  by  Sigma  Chemical  Company  (Dorset,  UK)  or  BDH  Ltd.  (Poole,  UK)  unless 
otherwise  stated.  - 
Radiochemicals:  (a"P)-dCTP  Redivue  (specific  activity  300OCi/mmol)  and  methyl- 
'H  Thymidine  (specific  activity  74  GBq/mmol)  were  supplied  by  Amersham  Life 
Science  (Bucks,  UK). 
2.1.4  Complete  kits 
-  ELISA  Starter  Kitsupplied  by  Pierce  &  War-riner  (Chester,  UK)  for  evaluation  of 
antipeptide  equine  serum. 
-  Gene  Amp  PCR  Core  Reagents  (Roche  Molecular  Systems  Inc.,  USA)  supplied  by 
Applied  Biosystems  Ltd. 
-  Mammalian  Transfection  Kit  supplied  by  Stratagene  (Amsterdam,  The  Netherlands) 
for  the  transient  transfection  of  COS  7  cells. 
-  High  Prime  DNA  Labelling  Kit  (random  primed)  supplied  by  Boehringer  Manheim. 
for  the  labelling  of  cDNA  probes  to  use  in  northem  blots. 
-  PCR-Script  Cloning  Kit  supplied  by  Stratagene  (Amsterdam,  The  Netherlands)  for 
the  cloning  of  blunt  end  PCR  products  generated  by  Pfu  polymerase. 
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-  Qiaprep  Miniprep  System  including  vacuum  manifold  supplied  by  Qiagen  (West 
Sussex,  UK)  for  the  isolation  of  up  to  20ýtg  of  high-purity  plasmid  DNA  from 
bacteria. 
-  Qiagen  Plasmid  Mega  Kit  supplied  by  Qiagen  (West  Sussex,  UK)  for  the  isolation  of 
up  to  2.5mg  of  high-purity  plasmid  DNA  from  bacteria.  - 
-  QuickPrep  mRNA  purification  Kit  supplied  by  Pharmacia  Biotech  (Herts,  UK). 
First  Strand  cDNA  Synthesis  Kit  supplied  by  Pharmacia  Biotech  (Herts,  UK). 
-  Rneasy  Total  RNA  system  supplied  by  Qiagen  (West  Sussex,  UK)  for  the  isolation 
of  total  RNA  from  transfected  cells. 
-  TA  Cloning  Kit,  supplied  by  Invitrogen  (Groningen,  The  Netherlands)  for  the 
cloning  of  PCR  products  with  A  overhangs,  generated  by  Taq  polymerase. 
-  Thermo  Sequenase  Cycle  Sequencing  Kit  supplied  by  Amersham  Life  Science 
(Bucks,  UK)  for  the  automated  sequencing  of  dsDNA. 
-  Wizard  PCR  Prep  DNA  Purification  System  supplied  by  Promega  (Madinson,  USA) 
for  the  purification  of  DNA  fragments  from  agarose  gels. 
2.1.5  Molecular  size  standards 
DNA:  lkb  DNA  Ladder  (size  range  500bp  to  12  kb)  and  ýX174  RF  DNA/Hae  III 
fragments  (size  range  72  to  1353  bp)  supplied  by  Gibco  BRL  (Paisley,  UK). 
Protein:  Kaleidoscope  Prestained  Markers  wide  range  (6.7-205  kDa)  supplied  by  Bio- 
Rad  (Herts,  UK). 
2.1.6  Other  specialist  reagents 
Bio-Rad  Protein  Assay  Reagent  supplied  by  Bio-Rad,  for  measuring  protein 
concentration  by  the  Bradford  procedure.  - 
ECL  Western  Blotting  Reagents  supplied  by  Amersham  Life  Science. 
Lipofectin  Reagent  supplied  by  Gibco  BRL,  for  the  co-transfection  of  insect  cells  with 
baculovirus. 
ENZYMES: 
-  Restriction  enzymes  and  respective  buffers  were  supplied  by  New  England 
Biolabs  (Herts,  UK)  or  Gibco  BRL. 
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-  DNAse  I  supplied  by  Gibco  BRL,  for  removing  DNA  from  RNA 
preparations. 
-  Murine  Moloney  Virus  Reverse  Transcriptase  Enzyme  supplied  as  part  of  the 
cDNA  synthesis  kit  by  Pharmacia. 
-  Pfu  DNA  polymerase  was  supplied  by  Stratagene. 
-  RNAse  A  supplied  by  Gibco  BRL,  for  removal  of  RNA  contaminants  from 
crudely  purified  DNA 
-  T4  DNA  Ligase  supplied  by  Gibco  BRI,  (or  Invitrogen  and  Stratagene  as  a 
component  of  the  cloning  kits). 
-  Taq  DNA  polymerase  as  part  of  the  Gene  Amp  PCR  kit. 
-  Thermo  Sequenase  DNA  polymerase  supplied  as  a  component  of  the  cycle 
sequencing  kit  by  Amersham  Life  Science. 
2.1.7  Oligonucleotides 
All  oligonucleotides  were  synthesised  by  the  departmental  contractor  MWG-Biotech 
and  supplied  in  dH20  suspension.  Sequencing  primers  were  modified  by  IRD800 
labelling.  Sequences  of  the  primers  are  detailed  in  the  appropriate  chapters. 
2.1.8  DNA  Plasmid  vectors 
-  pCDNA3.1  Vector  supplied  by  Invitrogen.  Designed  for  transient  or  selectable 
constitutive  gene  expression  in  mammalian  cells  expressing  the  SV40  large  T  antigen 
(e.  g.  COS-7  cells). 
-  pCI-neo  Mammalian  Expression  Vector  supplied  by  Promega.  Designed  for 
mammalian  expression  as  above. 
-  pCRII  TA  Cloning  Vector  purchased  from  Invitrogen  as  part  of  the  TA  cloning  kit. 
Supplied  as  linearised  DNA  with  3'  T  overhangs. 
-  pCR-Script  Cloning  Vector  purchased  from  Stratagene.  Supplied  as  blunt  end 
linearised  DNA. 
-  pGEX-4T-1  Vector  supplied  by  Pharmacia  Biotech.  Designed  for  inducible  intra- 
cellular  expression  in  E.  coli  of  genes  as  fusion  proteins  with  Schistosoma 
japonicum  glutathione-S-transferase. 
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2.1.9  Bacterial  strains 
-  E.  coli  DH5a  cells  (Gibco  BRL):  F'  ý801acZAM15  A(IacZYA-argF)Ul69  deoR 
recAl  endAI  hsdR17(rý,  Mk')  supE44  ý:  thi-l  gyrA96  relAl. 
-  E.  coli  INVaF  cells  (Invitrogen):  F'  endAI  recAl  hsdR17(rý,  Mk")  supE44  thi-I 
gyrA96  reIAI  ý801acZAM15  A(IacZYA-argF)Ul69  deoR'%-. 
-  E.  coli  JM  105  cells  (Pharmacia  Biotech):  thi  rpsL  endA  sbcB  15  hsdR4  SupE  A(lac- 
proAB)IF  [traD36  roAB'  LacF  LacZAM15].  Host  restriction  minus,  modification 
plus. 
-  E.  coli  MAX  Efficiency  DH10B'  (Gibco  BRQ:  FmcrA  A(mrr-hsdRMS-mcrBQ 
ý801acZAM15  AlacX74  deoR  recAl  endAI  araD139  A(ara,  leu)7697  ga[U  gaIK  X: 
rpsL  nupG. 
-  E.  coli  BL21  [DE3]  (Stratagene):  BF  dcm  ompT  hsdS(rB-  mBý)  gal  X  [DE3]. 
The  BL21  bacterial  cells  are  deficient  in  Lon  and  OmpT  proteases  and  are  therefore 
ideal  for  supporting  protein  expression  (discussed  in  chapter  3). 
The  genotypes  endAI  and  hsdR17  give  improved  quality  of  miniprep  DNA;  recAl 
denotes  recombination  deficiency,  recommended  for  stable  episomal  replication  of 
high  copy  number  plasmids.  The  ý  801acZAM  15  marker,  enables  blue-white  screening 
by  cc-complementation  of  P-galactosidase  (X-Gal)  encoded  by  the  plasmid  DNA. 
2.1.10  Eukaryotic  cells 
PRIMARY  CUMURES 
-  Equine  Peripheral  Blood  Lymphocytes  (equine  PBLs).  Isolated  from  complete  blood 
by  Ficoll  centrifugation  gradient  (detailed  in  chapter  3). 
-  Equine  enriched  T  cells.  Isolated  from  equine  PBLs  by  negative  selection  using  a 
nylon  wool  column  (detailed  in  chapter  3). 
-  Equine  enriched  lung  macrophages.  Tissue  culture  flask-adherent  cells  from  lung 
washes  (detailed  in  chapter  4). 
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CELL  LINES 
-  Insect  cell  lines  (SF-9  and  SF-21)  purchased  from  Invitrogen.  Support  optimal 
replication  (SF-9)  and  optimal  protein  expression  (SF-21)  when  infected  with 
recombinant  AcMNPV  baculovirus  (Vaughn  et  al,  1977)  as  detailed  in  chapter  3. 
-COS-7  cell  line,  supplied  by  European  Collection  of  Cell  Cultures  (ECACC). 
Derived  from  African  green  monkey  kidney  cells  transformed  with  the  SV40  large  T 
antigen  and  has  a  fibroblast  morphology  (Gluzman,  1981) 
-  Equine  Embryonic  Kidney  cell  line,  kindly  supplied  by  Dr  Jay  Patel  of  Intervet  UK 
(The  Elms,  Cambridge).  This  cell  line  has  an  epithelial-like  morphology  (Edington  et 
al,  1984). 
-  Madin-Darby  Bovine  Kidney  (MDBK)  cell  line.  Supplied  by  ECACC  and  has  an 
epithelial-like  morphology  (Nanni  et  al,  1986). 
2.1.11  Media  and  suppIernents 
FOR BACTERIA 
-  Luria-Bertani  (LB)  medium:  1%  (w/v)  tryptone,  0.5%  (w/v)  yeast  extract,  1%  (w/v) 
sodium  chloride  in  ddH20  autoclaved  and  stored  at  room  temperature. 
-  LB-agar:  LB  medium  containing  1.5%  (w/v)  agar. 
-  SOC  Medium:  2%  tryptone,  0.5%  yeast  extract,  10  mM  NaCl,  2.5  mM  KCI,  10  mm 
MgCI29  10  mM  MgSO,,  20  mM  glucose. 
-2X  YT:  Bacto-tryptone,  bacto-yeast  extract,  NaCI  (GibcoBRL).  31g  made  up  in 
I  litre  of  ddH20,  autoclaved  and  stored  at  4'C. 
-  Ampicillin:  100mg/ml  in  dH20 
.  Filtered  through  a  0.22pm  filter,  aliquotted  and 
stored  at  -20'C.  Used  at  a  final  concentration  of  100pg/nil. 
FOR  EUCARYOTIC  CELLS 
All  media  and  supplements  were  puichased  from  Gibco  BRL. 
-  Dulbecco's  Modified  Eagle's  Medium  (DMEM):  with  1000mg/L  D-glucose, 
Sodium  Pyruvate  and  Pyridoxine. 
-  Minimum  Essential  Medium  with  Earl's  salts  (EMEM):,  without  L-glutarnine. 
-  RPMI  1640  medium:  without  L-glutamine. 
-  TC  100  Insect  medium:  with  L-glutarnine,  without  Sodium  bicarbonate. 
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-  Foetal  Calf  Serum  (FCS),  TCS  Biologicals  Ltd.,  (Buckingham,  UK):  virus  screened, 
mycoplasma  screened.  Heat  inactivated. 
-  Gentamicin:  supplied  as  gentamicin  sulphate  50mg/ml  in  dH,  O  and  used  at  10ýLg/xnl. 
-  L-glutamine:  supplied  as  200mM  (I  OOX)  stock  solution. 
-  MEM  Non  Essential  Amino  Acids  (NEAA):  supplied  as  100  x  solution  containing 
L-alanine  (890  mg/L),  L-asparagine  (1320  mg/L),  L-aspartic  acid  (1330  mg/L),  L- 
glutamic  acid  (1470  mg/L),  glycine  (750  mg/L),  L-proline  (1150  mg/L)  and  L-serine 
(1050  mg/L). 
-  Penicillin/streptomycin:  supplied  as  a  IOOX  stock  solution  of  10,000  units  penicillin 
and  10,000gg  streptomycin  per  millilitre.  Used  at  a  final  concentration  of  100  units 
penicillin  and  I  OOgg  streptomycin  per  ml  (I  X  Penicillin/Strptomycin). 
-  Trypsin-EDTA:  supplied  as  I  OX  liquid,  stored  at  -20  *C.  This  was  diluted  1:  10  in 
sterile  PBS  prior  to  use  and  stored  at+4*C. 
-  P-Mercaptoethanol  (2-ME):  supplied  as  50mM  solution  in  Dulbecco's  PBS. 
2.1.12  Reagents  and  solutions 
The  following  list  represents  only  the  most  commonly  used  solutions.  Other,  more 
specific  reagents,  will  be  listed  in  the  appropriate  methods  section  of  each  chapter. 
WATER 
Tissue  culture  grade  distilled  water  was  supplied  by  Gibco  BRL.  Ultrapure  water  (for 
procedures  involving  recombinant  DNA  and  protein  methods  was  provided  by  a 
Millipore  Q50  water  purification  system  (Millipore  (UK)  Ltd.,  Watford,  UK).  Water 
for  preparation  of  general  solutions  and  media  was  purified  using  a  Millipore  ROIO 
system.  For  all  procedure  involving  RNA  was  used  DEPC  treated  water  (ddH20  was 
treated  with  0.05%  diethyl  pyrocarbonate  (DEPQ  overnight  at  room  temperature.  To 
remove  any  trace  of  DEPC,  the  DEPC-H20  was  autoclaved  for  30  minutes  at  120*C. 
GEL  LOADING  BUFFERS 
-  DNA:  50%  glycerol,  0.5%  bromophenol  blue,  0.5%  xylene  cyanol,  IOOmM 
EDTA  in  ddH20.  Stored  at  room  temperature  and  used  at  a  1:  10  dilution. 
-  RNA:  50%  formamide,  2.2M  fonnaldehyde,  IX  MOPS,  in  ddH20. 
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-Protein:  62.5  mM  Tris-HCI,  pH  6.8,20%  glycerol,  2%  SDS,  5%  P- 
mercaptoethanol.  dH20  3.0  ml,  0.5M  Tris-HCI,,  pH  6.8  1.0  ml,  glycerol, 
1.6ml,  10%  SDS  1.6  ml,  P-mercaptoethanol  0.4  ml,  0.5%  (w/v)  bromophenol 
blue  (in  dH20)  0.4  ml,  stored  at  4*C.  Sample  diluted  at  least  1:  4  with  buffer 
and  heated  at  I  OO'C  for  5  minutes  prior  to  loading  gel. 
-  Denhardt's  solution  (50X):  1%  bovine  Serum  Albumin  (BSA),  1%  Ficol,  1% 
polyvinyl  pyrollidone  in  ddH20.  Aliquoted  and  stored  at  -20*C. 
-  Ethidium  bromide:  10mg/ml  stock  in  ddH20,  working  solution  at  3mg/ml  with 
dH20* 
-  MOPS  buffer  (IOX):  200mM  MOPS  pH7.0,5OmM*  potassium  acetate,  10mm 
EDTA.  Stored  at  4'C  in  the  dark. 
-Ix  PBS:  140  mM  NaCl,  2.7  mM  KCI,  10  mM  Na2HPO4  J.  8  r"M  KH2P04  (pH  7.3). 
-  10  x  SDS-PAGE  RunningBuffer:  tris  base  60  g,  glycine  288  g,  SDS  20  g.  Made  up 
to  2L  by  addition  of  dH20. 
-  Polyacrylamide  solution:  Acrylamide/Bis  acrylamide  stock  solution.  30%  (w/v) 
acrylamide,  1.579%  (w/v)  bis  acrylamide,  ratio  19:  1.  Severn  Biotech  Ltd.,  stored  in 
the  dark  at  4'C. 
-  Phosphate  buffered  saline  (PBS):  100mM  NaCl,  80mM  di-sodium  hydrogen 
orthophosphate,  20mM  sodium  di-hydrogen  orthophosphate,  adjusted  to  pH7.5. 
Autoclaved  and  stored  at  40C. 
-  Pre-hybridisation  buffer  Northern  blots:  50%  deionised  formamide,  4X  Denhardt's 
solution,  4X  SSC,  1.6  X  Gene  Screen,  0.1%  SDS,  8%  Dextran  Sulphate  and  30mg/ml 
heat  denatured,  sheared  salmon  sperm  DNA. 
I-  Red  blood  cells  lysis  buffer:  1.650g  ammonium  chloride,  0.20g  potassium 
bicarbonate,  0.0074g  EDTA  (tetra)  adding  dH20  to  a  volume  of  200ml. 
-  RNase  A:  Prepared  as  a  10mg/ml  stock  in  I  OmM  Tris-HCI  pH7.5  and  I  5MM  NaCl. 
Boiled  for  15  minutes  and  cooled  slowly.  Stored  at  -20*C. 
-  SDS-PAGE  Protein  Gel  Fix-Stain  Solution:  dH20  45  ml,  methanol  45  ml,  HAc  10 
ml,  Coomassie  Brilliant  Blue  R250  0.25g.  Filtered  through  Whatman  No.  I  filter 
paper. 
-  SDS-PAGE  Protein  Des-Stain  Solution:  dH20  85  ml,  methanol  5  ml,  HAc  10  ml. 
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-  10  x  Semi  Dry  Transfer  Buffer  (Towbin):  Tris  base  (48mM)  58  g,  glycine  (39mM) 
29  g,  SDS  (0.01%)  1  g.  dH.  O  to  I  L.  Working  stock  was  prepared  prior  to  use  by  the 
addition  of  100  ml  10  x  stock  to  200  ml  methanol  and  700  ml  dH20, 
-  SSC  (20X):  3M  NaCl,  0.3M  Sodium  Citrate  in  dH.  O  and  adjusted  to  pH7.0.  Stored 
at  room  temperature. 
-  STET:  8%  sucrose,  50mM  Tris-HCI  pH8,50mM  EDTA  pH8,5%  triton  XIOO  made 
up  in  ddH20,  filtered  (0.22  mm).  Stored  at  room  temperature. 
-  TAE  (50X):  2M  Tris-HCI  pH8.15,1.5M  NaOAc,  IM  NaCl,  O.  lM  EDTA. 
-TBE(IOX):  0.9MTris-HCI,  0.9M  Boric  acid,  25mM  EDTApH8.3. 
-  TE:  I  OmM  Tris-HCI,  I  mM  EDTA  adjusted  to  pH8.0.  Autoclaved. 
-  10  x  Tris  Buffered  Saline  (TBS):  Tris  base  24.2  g,  NaCl  80.0  g,  HCI  38.0  ml.  pH 
7.6.  dH20  to  I  L. 
-  IM  Tris  HCI:  l2lg  Tris  base,  800ml  dH20.  Adjusted  to  desired  pH  with 
concentrated  HCI  and  made  up  to  I  L. 
-  X-gal  solution:  prepared  as  40  mg/ml  stock  in  dimethylforrnarnide,  stored  at  -20'C. 
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2.2  Methods 
2.2.1  Eukaryotic  cell  culture  I 
This  section  will  only  refer  to  established  cell  lines,  as  primary  cell  cultures  were  of 
short  term  (chapters  3  and  4). 
MAINTENANCE  OF CELLS  - 
COS-7  cells  were  maintained  in  DMEM,  10%  FCS,  2mM  L-glutamine  and  IX 
penicillin/Streptomycin.  EEK  cells  in  EMEM,  10%  FBS,  2mM  glutamine,  IX 
Pen/Strep.  MDBK  cells  in  EMEM,  5%  FBS,  2mM  glutamine,  IX  Non  essential 
amino  acids,  IX  Pen/Strep-  These  mammalian  cell  lines  were  grown  in  monolayers 
and  maintained  in  plastic  tissue  culture  flasks  (75cm'  with  20ml  of  medium  or  135cm' 
with  35  ml)  in  a  37"C  atmosphere  with  5%  CO,  Cells  were  subcultured  every  I  to  2 
times  a  week  depending  on  rate  of  bulking  (reflected  in  the  seeding  density).  The 
subculture  routine  was  performed  by  removing  the  culture  medium,  washing  the  cells 
once  with  PBS  (equilibrated  at  371C)  followed  by  the  addition  of  2ml  (small  flasks)  or 
4ml  (large  flasks)  of  trypsin-EDTA  and  incubation  at  for  37*C  15  to  20min.  Two 
volumes  of  medium  are  added  to  the  flasks  and  the  cells  are  removed  and  washed  by 
vigorous  resuspension  and  centrifuged  at  10OOg  for  5  min.  Cells  are  resuspended  in 
fresh  medium  to  the  required  density,  distributed  by  the  required  number  of  flasks  and 
incubated  as  before. 
Insect  cells  were  maintained  in  TC-100  medium,  10%  FCS  and  1011g/ml  gentamycin 
at  27*C.  Cells  were  subcultured  2  to  3  times  a  week  (as  they  grew  rapidly  and  showed 
contact  inhibition)  by  removing  the  culture  medium,  adding  10  ml  of  fresh  medium 
and  scrape  cells  off  using  a  disposable  cell  scraper.  The  cells  were  then  diluted  to 
desired  density  and  incubated  as  before. 
STOFJNG  AND  REVIVING  CELLS 
For  long  term  storage  cells  were  treated  as  follows.  Mammalian  cell  lines  after 
trypsinisation  were  washed,  counted  and  resuspended  at  IXIO'  cells/ml  in  90%  FCS 
and  10%  dimethyl  sulphoxide  (DMSO-  Analar,  BDH  Ltd).  They  were  then  aliquoted 
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(Iml)  in  cryo-tubes  and  stored  overnight  in  the  first  shelf  of  a  liquid  nitrogen  storing 
rack  (the  tubes  were  above  the  liquid  level  allowing  the  cells  to  freeze  slower).  Next 
day  cells  were  transferred  to  the  bottom  shelfs.  When  required  cells  were  quickly 
thawed  by  immersion  of  the  in  warm  dH20  and  the  contents  of  a  full  aliquot 
transferred  to  a  135CM2  flask  containing  complete  medium  pre  warmed  to  37*C,  cells 
were  then  maintained  as  before. 
For  insect  cells  the  procedure  was  the  same  except  that  the  freezing  medium  was 
composed  of  60%  of  TC-100  medium  30%  of  FCS  and  10%  of  DMSO.  Also,  when 
recovering  cells  from  frozen,  the  full  contents  of  one  aliquot  were  transferred  to  a 
small  (25cm')  flask  containing  4  ml  of  medium  at  room  temperature.  They  were  left  to 
incubate  for  I  hour  after  which  the  medium  was  carefully  removed  and  fresh  medium 
added.  After  24  hours  of  incubation  the  medium  was  changed  once  more. 
COUNTING  CELLS 
Cells  were  counted  by  trypan  blue  exclusion  of  dead  cells.  A  small  volume  of  cell 
suspension  (e.  g.  20ýtl)  was  dilute  with  an  equal  volume  of  0.4%  trypan  blue  (Gibco 
BRL)  and  101il  were  loaded  to  a  haemocytometer  with  cover  slip.  Under  the  IOX 
objective  of  an  inverted  microscope,  5  of  the  9  central  fields  are  counted.  The  sum  of 
the  counted  cells  is  multiplied  by  4000  to  assign  the  number  of  cells  per  ml. 
2.2.2  MolecuIar  bioIogy  techniques 
Detailed  protocols  of  most  of  the  techniques  outlined  below  can  be  found,  in 
Sambrook  et  al  (1989)  and  Ausubel  et  al  (1996). 
Growth  of  bacteria 
Bacteria  were  used  both  for  maintenance  and  replication  of  plasmid  DNA  and  in  one 
instance,  also  for  production  of  recombinant  protein  (chapter  3).  Because  all  the 
plasmids  used  contained  an  ampicillin  resistance  gene,  the  addition  of  ampicillin  to  all 
bacterial  media,  to  a  final  concentration  of  100ýtg/ml  (unless  otherwise  stated),  leads 
to  the  selective  growth  of  bacteria  containing  plasmid. 
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Bacterial  cells  were  stored  in  glycerol  stocks.  Bacteria  to  be  revived  were  streaked  on 
to  an  LB-agar  plate  (e.  g.  I  Omm  petri  dish  containing  approximately  20ml  of  LB-agar) 
using  a  platinum  wire  sterilised  by  naked  flame.  Plates  were  incubated  overnight  in  a 
designated  oven  at  37"C.  Single  colonies  were  picked  using  a  pipette  tip  and  dispersed 
in  3ml  of  LB  medium  (LB  broth)  in  a  sterile  universal.  The  inoculated  broth  was 
incubated  at  37'C  overnight  in  an  orbital  incubator.  Confirmation  of  the  presence  of 
the  desired  plasmid  was  attained  by  DNA  minipreparation  and  restriction  analysis  (see 
below).  The  culture  could  them  be  scaled  up  by  dilution  in  excess  of  1/1000  in  LB 
medium  and  overnight  growth.  Glycerol  stocks  were  prepared  by  addition  of  200PI  of 
80%  glycerol  to  Iml  of  freshly  prepared  culture.  The  mixture  was  aliquoted  (Iml 
aliquots)  and  stored  at  -10"C 
Purification  of  plasmid  DNA  from  bacteria 
SMALL  SCALE  PREPARATIONS  - 
Minipreparations  of  DNA  were  used  for  identification  of  recombinant  plasmids  by 
restriction  digestion,  following  generation  of  each  new  construct  and  also  to  assess 
maintenance  of  the  plasmid  of  interest  in  recovered  bacterial  stocks.  'Miniprep'  DNA 
was  isolated  by  the  STET  method.  Briefly,  1.5ml  of  an  exponentially  growing 
overnight  culture  was  pelleted  and  resuspended  in  100ptl  STET  containing  3mg/ml 
lysozyme  and  100gg/ml  Lysozyme.  The  samples  were  boiled  for  45  sec  and 
centrifuged  at  140OOrpm  for  15  min  in  a  microfuge.  The  DNA  was  precipitated  with 
100gl  propan-2-ol,  pelleted  by  centrifugation,  washed  in  70%  ethanol,  dried  and 
resuspended  in  20gl  of  dH,  O.  DNA  was  stored  at  -20'C. 
High  quality  small  scale  plasmid  DNA  preparations  were  obtained  using  the  Qiaprep 
Miniprep,  System  (Qiagen)  according  to  the  manufacturers  instructions.  The  DNA 
obtained  in  this  fashion  was  used  mainly  in  sequencing  reactions  but  also  in 
intermediate  cloning  steps  of  complex  cloning  strategies.  This  system  of  DNA 
purification  is  a  modification  of  the  classical  alkali  lysis  procedure  followed  by 
recovery  using  a  plasmid  DNA  binding  resin.  The  DNA  eluted  from  the  column  is 
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precipitated  in  an  equal  volume  of  propan-2-ol  by  centrifugation  as  before,  dried  and 
resuspended  in  50ýtl  of 
dH20. 
LARGE  SCALE  PREPARATIONS 
Preparation  of  up  to  2.5mg  high  purity  plasmid  DNA  was  accomplished  using  the 
Qiagen  Plasmid  Mega  Kit  in  a  procedure  that  is  a  scale  up  of  the  above.  DNA 
recovered  by  this  method  was  mainly  used  for  transfection  of  mammalian  cells  with 
expression  vector  chimeras. 
Quantitation  of  nucleic  acid  concentration 
BY  SPECTROPHOTOMETRY 
For  quantitation  the  sample  was  diluted  1:  100  to  a  total  volume  of  500gl  in  dH20. 
The  optical  density  was  measured  at  260  nm  and  280  run,  in  comparison  to  a  blank  of 
dH20.  The  concentration  of  nucleic  acid  (N.  A.  )  in  the  sample  was  calculated  using  the 
formula: 
[N.  A.  ]  /gl  = 
OD260 
x  NAF  x  DF  /  1000, 
where  NAF  (nucleic  acid  factor)  is  20  for  oligonucleotides,  40  for  RNA  and  50  for 
DNA  and  DF  (dilution  factor),  generally  100  (Sambrook  et  al,  1989).  The  ratio  of  the 
OD  readings  at  260  run  and  280  run  (OD2aOD280)  was  used  to  estimate  the  purity  of 
the  nucleic  acid.  Pure  preparations  of  DNA  and  RNA  have  an  OD2.  /OD280  of  1.8  and 
2.0,  respectively;  a  lower  value  suggests  possible  protein  contamination. 
BY  GEL  ELECTROPHORESIS 
In  cases  where  it  was  desired  to  verify  the  purity  of  DNA  fragments  of  a  certain  size, 
the  concentration  of  dsDNA  was  determined  by  running  the  sample  on  a 
polyacrylamide  or  agarose  gel  (see  below)  and  comparing  the  intensity  of  the 
fluorescence  of  the  unknown  DNA  to  that  of  a  known  quantity  of  the  appropriate  size 
marker  (ýX174  RF  DNA/Hae  III  fragments  or  Ikb  DNA  ladder),  following  staining 
with  ethidium  bromide  and  visualisation  by  UV  transillumination. 
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Digestion  of  DNA  with  restriction  enzymes 
Restriction  endonucleases  were  used  to  digest  DNA  for  analysis  and  cloning 
procedures.  Typically,  1-2jig  of  DNA  was  digested  in  a  20pl  reaction  mix  containing 
the  appropriate  buffer  and  5  to  10  units  of  the  desired  restriction  enzyme.  The 
reactions  were  incubated  at  37*C  for  a  minimum  of  one  hour.  Where  the  isolation  of 
restriction  fragments  was  required,  larger  quantities  of  DNA,  generally  5  to  20  gg, 
were  digested,  with  the  reaction  volume  and  components  being  increased 
proportionally.  When  digesting  plasmid  DNA  prepared  by  the  small  scale  procedure, 
likely  to  contain  significant  RNA  contamination,  10  [tg  of  RNAse  A  was  added  to  the 
digestion  reaction. 
DNA  electrophoresis 
Depending  on  the  size  of  the  DNA  molecules  to  be  separated,  gels  containing  0.6  to 
2%  agarose  can  be  used  for  electrophoresis.  In  this  project  most  of  the  gels  contained 
1.2%  agarose,  giving  good  separation  of  DNA  molecules  with  sizes  between  500  and 
2000bp.  50  ml  to  200ml  of  gels  made  in  IX  TAE  or  IX  TBE  were  poured  in  perspex 
trays  and  wells  cast  with  appropriate  combs.  Ethidiurn  bromide  was  added  to  a  final 
concentration  of  0.25pLg/ml  and  gels  were  left  at  room  temperature  until  set, 
transferred  to  perspex  tanks,  a  sufficient  appropriate  buffer  (IXTAE  or  TBE)  was 
added  to  submerge  the  gel  and  the  comb  was  removed.  An  appropriate  volume  of 
DNA  gel  loading  buffer  was  added  to  samples  and  samples  were  loaded  along  with 
molecular  size  DNA  standards.  Gels  were  ran  at  50  to  90  volts  from  30  to  90  min. 
Gels  were  visualised  in  a  short  wave  UV  transilluminator  and  photographed  using  a 
gel  documentation  system. 
Purification  of  DNA  fragments  from  geIs 
Following  electrophoresis  the  DNA  fragment  was  excised  using  a  sterile  scalpel, 
under  UV  illumination.  Purification  of  DNA  from  the  gel  slice  was  accomplished 
using  the  Wizard  PCR  Prep  DNA  Purification  System  (Promega)  and  according  to 
instructions  supplied.  DNA  was  eluted  in  50ýd  of  dH20. 
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Ligation  of  DNA  fragments 
Vector  and  insert  DNA  were  mixed  at  a  molar  ratio  of  1:  5  to  1:  10  (typically  using  50 
to  100  ng  vector  DNA),  with  an  appropriate  volume  of  5X  ligation  buffer  and  4  units 
DNA  ligase,  in  a  volume  of  10  to  20  pl.  Reactions  were  allowed  to  proceed  overnight 
at  14  to  15*C  and  stored  thereafter  at  -20"C  if  not  used  immediately.  A  control 
ligation,  omitting  insert  DNA  was  generally  set  up  in  parallel  to  the  above,  in  order  to 
check  for  'background'  when  performing  subsequent  bacterial  transformations. 
Ligation  of  inserts  into  the  plasmids  pCR-II  (Invitrogen)  and  pCR-Script  (Stratagene) 
was  performed  according  to  the  manufacturer  instructions. 
Transformation  of  bacteria 
The  ligation  reaction  was  diluted  1:  5  and  1  to  2ýtl  was  added  to  50pLI  of  competent  E. 
coli  cells  (see  materials),  or  IpLI  of  TA  cloned  DNA  was  added  to  50gl  of  INVaF 
competent  cells  (Invitrogen)  along  with  2gl  of  P-mercaptoethanol.  In  all  cases  the 
mixtures  were  then  incubated  on  ice  for  30  min.  Cells  were  subsequently  heat- 
shocked  at  42'C  for  45  seconds  and  returned  to  ice  for  2  min.  450111  of  SOC  medium 
was  then  added  and  incubated  with  shaking  for  60  min.  Volumes  of  50  and  200til  of 
each  transformation  were  then  plated  onto  LB-agar  plates  containing  100[ig/ml 
ampicillin  (and  80ýLg/ml  X-gal  if  plasmids  contained  lacZ  gene  or  equivalent  for 
blue/white  selection).  The  plates  were  incubated  overnight  at  37C.  The  next  day 
individual  (white)  colonies  were  picked  and  expanded  by  culture  as  described  before. 
Preparation  of  RNA 
For  the  preparation  and  all  subsequent  manipulations  of  RNA,  all  plasticware  and 
solutions  were  treated  or  made  in  DEPC  treated  water.  Total  RNA  and  mRNA  were 
prepared  directly  from  cell  pellets  using  Rneasy  Total  RNA  System  (Qiagen)  and 
QuickPrep  mRNA  Purification  Kit  (Pharmacia  Biotech),  respectively  according  to  the 
manufacturers  instructions. 
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First  strand  DNA  synthesis 
mRNA  to  be  amplified  by  PCR  was  reverse  transcribed  using  the  First-strand  cDNA 
synthesis  kit  Pharmacia  Biotech.  The  kit  contains  all  components  required  for  first 
strand  cDNA  synthesis,  including  a  preassembled  reaction  mix  containing  Moloney 
Murine  Leukaemia  Virus  (M-MuLV)  reverse  transcriptase,  RNAguard  (an  RNAse 
inhibitor),  RNAse/DNAse  free  BSA,  and  dNTPs  in  an  aqueous  buffer.  An  oligo-dT 
primer  (Not  I-d(T),,  primer)  supplied  with  the  kit  was  used  to  prime  cDNA  synthesis; 
sequence  as  follows:  5'-d[AAC  TGG  AAG  AAT  TCG  CGG  CCG  CAG  GAA  T,,  ]-3'.  Oligo-dT 
primers  bind  to  the  polyA  tail  of  mRNAs  permiting  synthesis  of  complementary 
strands  by  the  reverse-transcriptase.  Typically  from  500ng  to  Igg  of  mRNA  was 
reverse  transcribed  in  a  single  reaction,  at  37*C,  following  manufacturers  instructions 
and  maintaining  proportional  reaction  volumes. 
Polymerase  chain  reaction  (PCR) 
PCR  is  a  powerful  technique  that  allows  specific  amplification  of  DNA  sequences, 
facilitated  by  gene  specific  primers.  It  enables  the  amplification  of  unknown  DNA 
sequences  as  long  as  the  primers  flanking  the  sequence  are  specific  enough.  In  the 
present  project  PCR  was  used  either  for  the  modification  of  cloned  DNA  sequences, 
for  example  by  deletion  of  unwanted  sequences  or  inclusion  of  particular  restriction 
sites  to  the  ends  of  the  molecules  to  facilitate  subcloning,  but  also  for  the  isolation  of 
previously  unknown  sequences  by  using  primers  derived  from  homologous  gene 
sequences  of  other  animal  species.  A  recent  review  on  PCF,  its  applications  and 
corresponding  protocols  can  be  found  in  Dieffenbach  and  Dveksler,  1995. 
PRIMER  DESIGN 
For  the  design  of  PCR  primers  the  following  guidelines  were  observed.  Primers  were 
generally  18  to  28  nucleotides  in  length,  with  a  G+C  composition  of  50  to  60%  where 
possible.  For  a  given  primer  pair,  the  annealing  temperatures  (T.  ),  were  balanced  and 
complementary  regions  between  and  within  primers  were  avoided,  minimising  the 
production  of  primer-dimers.  Also,  target  sequences  in  the  gene  with  secondary 
structure  (high  G+C  content)  were  not  selected  for  priming  sites. 
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MASTE  MIXES 
Master  mixes  are  the  reaction  components  (enzyme,  buffer  and  dNTPs)  excluding 
specific  primers  and  DNA  template.  The  relative  proportion  of  components  in  a 
reaction  mix  is  subject  to  optimisation  in  order  to  achieve  a  balance  between 
specificity  and  quantity  of  amplified  product.  As  a  general  rule  decreasing  the  dNTP, 
primer  and/or  Magnesium  content  of  a  reaction  mix  increases  the  specificity  of 
amplification  accompanied,  however  by  a  decrease  in  product  yeld.  All  master  mixes 
were  set  up  in  a  departmental  designated  "PCR  clean  area!  '  taking  precautions  to 
avoid  PCR  contamination  such  as  the  use  of  filter  pipette  tips.  PCR  was  performed 
using  either  Taq  polymerase  (isolated  from  Thermus  aquaticus)  contained  in  the  kits 
Gene  Amp  PCR  Core  (Perkin  Elmer)  or  Pfu  polymerase  (from  Pyrococcusfuriosus) 
supplied  by  Stratagene.  Care  was  taken  to  use  the  full  contents  of  one  kit  at  one 
meeting,  avoiding  freeze-thaw  cycles.  All  the  reagents  were  mixed  at  appropriate 
concentrations  in  an  eppendorf  tube,  aliquoted  in  500ul  Perkin  Elmer  DNAse  free 
reaction  tubes  and  stored  at  -20C  until  used.  The  composition  of  individual  reaction 
mixes  as  well  as  specific  cycling  conditions  are  detailed  in  each  chapter. 
Sequencing 
Cycle  sequencing  reactions  were  carried  out  using  IRD800-labeled  primers  (MWG- 
Biotech)  and  the  ThermoSequenase  Fluorescent  Labeled  Primer  Cycle  Sequencing  Kit 
with  7-deaza-dGTP  (Amersharn  Life  Science).  Cycle  sequencing  is  based  on  the 
dideoxynucleoside  triphosphate  chain  termination  method  (Sanger,  1977)  using  a 
thermostable  DNA  polymerase  that  allows  multiple  rounds  of  high  temperature  DNA 
synthesis.  Briefly,  400ng  of  plasmid  DNA,  Ipmol  of  IRD800  labelled  primer  and  21il 
of  reaction  mix  which  contains  45mM  each  of  dGTP,  dATP,  dTTP  and  dCTP, 
reaction  buffer  and  thermostable  DNA  polymerase,  were  mixed  in  a  0.5ml  reaction 
tube,  to  a  total  volume  of  8pl.  Cycling  conditions  were:  95"C  for  5  min  followed  by 
25  cycles  of  95'C  for  30  seconds,  50  to  60*C  for  30  seconds  and  72*C  for  30  seconds. 
The  annealing  temperature  was  generally  2'C  below  the  melting  temperature  of  the 
primer  used  (details  in  individual  chapters).  Formamide  loading  buffer  (4PI  ), 
supplied  with  the  kit,  was  added  and  the  reactions  separated  on  denaturing  gels, 
Sequagel  XR  ultra  pure  concentrate  (National  Diagnostics).  Data  recording  was 
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performed  on  a  Li-Cor  model  4000  DNA  sequencer  (MWG-Biotech).  Typically  500 
to  700bp  of  good  sequence  was  generated  from  one  ran. 
DNA  sequence  data  was  analysed  using  the  GCG  package  (Wisconsin  Package 
Version  9.1,  Genetics  Computer  Group  (GCG),  Madison,  Wisconsin). 
RNA  hybridisation  analysis 
NORTHE  BLOT  TRANSFE  OF  RNA 
15[ig  of  total  cellular  RNA  was  Iyophylised  (VR-1  Hetovac,  Heto),  resuspended  in 
20pl  of  RNA  loading  buffer  and  denatured  for  15  min  at  65*C.  Subsequently,  3  to 
5ýtl  of  RNA  loading  buffer  was  added  and  the  samples  electrophoresed  for  3  hours  at 
100V  in  200ml  of  a  1%  agarose  gel  containing  IX  MOPS  and  2.2M  formaldehyde. 
The  gel  running  buffer  contained  IX  MOPS  buffer  and  was  continually  recirculated. 
Following  electrophoresis  the  gel  was  washed  twice  in  ddH20  for  20  min  to  remove 
formaldehyde,  then  equilibrated  in  10  X  SSC  and  transferred  overnight  onto  Hybond- 
N  (Amersham  Life  Science)  in  10  X  SSC.  The  membrane  was  removed  and  rinsed 
briefly  in  2X  SSC  and  the  RNA  crosslinked  to  the  membrane  (Spectrolinker  XL-  1500 
UV  Crosslinker,  Spectronics  Corporation).  All  northern  blots  were  probed  with  a  rat 
gapdh  probe  to  control  for  RNA  loading  and  integrity.  The  GAPDH  probe,  kindly 
supplied  by  Dr  E.  Baxter  (Department  Veterinary  Pathology,  Glasgow),  is  a  750bp 
EcoRI  fragment  purified  from  the  plasmid  pGapdh. 
PREPARATION  OF  RADIOLABELED  DNA  PROBES 
PCR  or  restriction  fragment  DNA  probes  were  gel-purified  and  radioactively  labelled 
using  a  random  primed  DNA  labeling  kit  (High  Prime,  Boehringer  Mannheim),  and 
cc("P)  dCTP,  specific  activity  3000Ci/mmol  (Amersham).  Generally,  20-50ng  of  heat 
denatured  DNA  was  radiolabeled  using  5OmCi  (1.85Mbq)  of  (x("P)  dCTP  and  4ýil  of 
High  Prime  in  a  final  volume  of  20ýtl,  following  the  manufacturer's  instructions. 
Unincorporated  nucleotides  were  removed  by  gel-filtration  through  Sephadex-G50 
beads  (Nick  Columns,  Pharmacia  biotech)  and  labelled  fragments  were  cluted  in 
400ýfl  of  TE  buffer. 
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HYBRIDISATION  AND  FILM  EXPOSURE 
Standard  high  stringency  conditions  for  the  hybridisation  of  specific  radiolabeled 
probes  on  nucleic  acids  immobilised  on  nylon  membranes  were  as  follows. 
Membranes  pre-wetted  in  2X  SSC,  were  rolled  into  Hybaid  hybridisation  bottles  and 
pre-hybridised  in  20ml  of  RNA  pre-hybridisation  buffer  (see  section  2.1.12)  at  42T 
for  at  least  2  hours  in  a  Hybaid  oven  with  continual  rotation.  Freshly  boiled  DNA 
probe  (100pl)  was  added  to  the  pre-hybridisation  solution  and  the  filters  were 
hybridised  overnight  as  above.  After  rinsing  briefly  with  2X  SSC,  the  membrane  was 
%-ýashed  for  20  min  and  with  three  changes  of  O.  IX  SSC,  0.5%  SDS  at  60T. 
Membranes  were  then  sealed  in  polythene  and  exposed  to  X-ray  film  (Kodak)  and 
following  overnight  exposure  films  were  developed  (Kodak  X-omat  processor  ME-3). 
Protein  methods 
ESTIMATION  OF PROTEIN  CONCENTRATIONS 
In  order  to  estimate  protein  yields  a  modified  Bradford  assay  was  used.  This  assay 
utilises  the  fact  that  the  absorbance  maximum  for  an  acidic  solution  of  Coomassie 
Brilliant  Blue  G-250  shifts  from  465  run  to  595  mn  following  binding  to  protein.  This 
shift  in  absorbance  is  linear  over  a  relatively  broad  range  of  protein  concentrations  so 
allows  accurate  protein  quantification  within  a  sample. 
A  protein  standard  (bovine  serum  albumin  or  bovine  gamma  globulin)  was  diluted 
with  dH20  toconcentrations  ranging  from  0.1  to  1.5  mg/mI  to  enable  the  production 
of  a  standard  curve  each  time  the  assay  was  performed.  Into  individual  wells  of  a  flat- 
bottom  96  well  plate  was  added  I  OpLI  of  each  test  sample,  10ýd  of  PBS  (blank  control) 
and  10ýd  of  each  dilution  of  the  BSA  standard  curve.  200ýd  of  Bradford  dye  reagent 
(Bio-rad)  was  added  to  each  well  and  mixed  thoroughly.  The  dye  reagent  was 
prepared  by  addition  of  4  volumes  oTdH20  to  I  volume  of  dye  and  filtration  through  a 
0.4  prn  syringe  filter  (Gelman  Sciences).  The  plate  was  incubated  incubated  at  room 
temperature  for  30  min  to  I  hour,  and  the  OD.  95  subsequently  measured  against  the 
reagent  blank.  The  absorbance  of  the  protein  standards  was  used  to  construct  a 
standard  curve  from  which  an  approximate  concentration  of  the  unknown  samples 
cuald  be  read. 
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SDS  -  POLYACRYLAMIDE  GEL  ELECTROPHORESTS  OF  PRQTEINS 
The  separation  and  analysis  of  proteins  was  facilitated  by  one  dimensional  denaturing 
discontinuous  gel  electrophoresis.  Proteins  were  denatured  by  boiling  in  the  presence 
of  SDS  and  P-mercaptoethanol.  The  sample  is  then  loaded  onto  a  discontinuous  gel 
consisting  of  a  stacking  buffer  which  concentrates  the  loaded  protein  sample  into  a 
narrow  band  and  a  separating  gel  which  separates  proteins  on  the  basis  of  molecular 
size. 
Minigels  (8.0  x  7.3  cm)  were  produced  and  run  using  the  Mini-PROTEAN  11 
electrophoresis  system  (Biorad,  Herts,  UK)  as  recommended  by  the  manufacturer. 
Glass  plates  were  assembled  with  0.75  mm  spacers  in  a  casting  stand.  The  separating 
gel  (12  to  15%)  was  poured  to  a  depth  of  approximately  5  cm.  Gel  constituents  and 
concentrations  can  be  found  in  Sambrook  et  al,  1989  (page  18.52).  This  was  overlaid 
with  tris-saturated  butanol  and  allowed  to  polymerise.  The  butanol  was  then  poured 
off,  the  surface  of  the  separating  gel  rinsed  with  dH2O  and  the  stacking  gel  poured.  A 
10  well  comb  was  inserted  and  the  gel  allowed  to  polymerise.  The  gel  was  then 
transferred  to  the  electrophoresis  tank,  both  buffer  tanks  filled  with  running  buffer,  the 
comb  removed  and  the  wells  flushed.  Protein  samples  (typically  5-  20  jig  of  protein 
in  5-  25  jil)  were  prepared  by  addition  of  an  appropriate  volume  of  6x  protein  sample 
loading  buffer,  followed  by  heating  to  100*C  for  five  minutes.  Samples  were  then 
loaded  onto  the  gel  using  0.2  mm  flat  ended  gel  loading  tips.  A  protein  molecular 
weight  standard  (5  -10  pl)  was  loaded  in  one  or  both  outer  wells  to  allow  estimation 
of  the  size  of  sample  proteins. 
Gels  were  electrophoresed  at  140V  for  60  to  80  minutes  until  the  bromophenol  blue 
dye  reached  the  bottom  of  the  separating  gel.  The  gel  was  then  removed  from  the 
glass  plates,  the  stacking  gel  discarded,.  and  the  protein  bands  detected  either  by 
staining  with  Coomassie  blue  or  by  immunodetection. 
GE  STAINING 
Visualisation  of  protein  bands  with  Coomassie  blue  involved  staining  for  two  hours  in 
four  to  five  gel  volumes  of  protein  fix-stain  solution,  followed  by  destaining  for 
approximately  12  -  16  hours  in  destain  solution.  Gels  were  then  removed  and 
65 Mat  &  ineth 
preserved  by  drying  for  two  to  six  hours,  sandwiched  between  pre-wetted  cellulose 
film,  in  a  gel  drying  apparatus  (Bio-Rad)  for  2  hours  at  80"C. 
DETEMON  OF  PROTEINS  BY  IMMUNOBLOTTING 
The  detection  of  proteins  by  immunoblotting  (western  blotting)  is  aý  rapid  and 
sensitive  technique  that  exploits  the  inherent  specificity  of  antigen  recognition  by 
antibodies.  Proteins  were  transferred  to  PVDF  membrane  by  electroblotting, 
following  electrophoretic  separation  and  detected  using  ECL  reagents  (Amersham 
Life  Science).  This  detection  system  is  based  on  the  emission  of  light  following  the 
oxidation  of  luminol  by  horseradish  peroxidase  W"  labelled  antibodies),  in  the 
presence  of  chemical  enhancers  such  as  phenols.  The  light  emitted  can  be  detected  by 
a  short  exposure  to  blue-light  sensitive  fihn  (Hyperfihn  ECL,  Amersham). 
Following  SDS-PAGE,  the  gel  was  removed  from  the  glass  plates  and  rinsed  in  TBS. 
Hybond-ECL  membrane  was  pre-wetted  in  100%  methanol  for  15  seconds  and  then 
allowed  to  equilibrate  with  transfer  buffer  for  10  minutes  prior  to  blotting.  Proteins 
were  transferred  to  the  membrane  using  a  semi-dry  electroblotting  system  (Transblot 
SD  -  Biorad).  The  gel  and  membrane  were  sandwiched  in  close  apposition  between 
two  sheets  of  extra  thick  filter  paper  (Biorad)  pre-soaked  in  transfer  buffer,  and 
transferred  at  10  V  for  45  minutes. 
The  membrane  was  rinsed  in  TBS  and  non-specific  binding  sites  blocked  by 
immersing  the  membrane  for  30  minutes  in  10%  low  fat  dried  milk  (Marvel  -  Premier 
Beverages,  Stafford,  UK)  TBS-T  (0.1%  Tween  in  tris  buffered  saline)  solution  at 
room  temperature  on  an  orbital  shaker.  The  membrane  was  rinsed  briefly  with  TBS-T, 
washed  once  for  15  minutes  then  twice  for  five  minutes,  with  shaking  at  room 
temperature.  The  membrane  was  then  incubated  with  the  primary  antibody,  at  a  pre- 
determined  dilution  (generally  1/10000)  in  5%  low  fat  dried  milk,  TBS-T,  for  I  hour 
at  room  temperature,  with  shaking.  The  membrane  was  then  washed  as  detailed 
above  prior  to  incubating  with  the  secondary  antibody  (HRP  labelled),  appropriately 
diluted  (115000)  in  5%  low  fat  dried  milk,  TBS-T,  for  45  min  to  I  hour,  at  room 
temperature,  with  shaking. 
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The  membrane  was  washed  before  detection  by  the  ECL  method,  which  was  carried 
out  in  a  darkroom,  following  manufacturers  instructions.  The  membrane  was  placed, 
protein  side  up,  in  a  film  cassette  and  a  sheet  of  autoradiography  film  (Hyperfilm- 
ECL)  placed  on  top,  in  the  dark.  The  cassette  was  closed  and  the  film  exposed  for  15 
to  30  seconds,  before  developing  in  an  automated  processor.  A  second  sheet  of  film 
was  then  exposed,  generally  for  2  to  20  minutes,  the  time  being  estimated  from  the 
appearance  of  the  first  autoradiograph. 
In  order  to  confirm  that  the  bands  seen  on  Western  blots  were  not  due  to  non-specific 
binding  of  the  secondary  antibody,  the  blots  were  'stripped'  by  soaking  in  10  ml 
stripping  buffer  (6.25  mM  Tris-HCI  (pH  6.8),  2%  SDS,  100  mM  2-ME)  for  30 
minutes,  at  50*C,  with  -agitation.  The  membrane  was  then  reprobed,  as  above, 
however  the  primary  antibody  labelling  step  was  omitted.  Any  non-specific  binding 
of  the  secondary  antibody  was  then  detected  by  the  ECL  method,  as  outlined  above. 
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EXPRESSION  AND  BIOACTIVITY  OF 
EQUINE  INTERFERON  GAMMA IFjV-Y 
3.1  Introduction 
A  comprehensive  review  on  the  structure  and  biology  of  IFN-y  can  be  found  in  chapter  1. 
The  present  chapter  is  focused  on  the  practical  aspects  of  the  expression  and  assessment 
of  biological  activity  of  equine  IFN-y. 
Since  the  cloning  of  human  IFN-y  was  attained  (Gray  et  al,  1982),  IFN-7  cDNAs  from 
a  number  of  species  have  been  cloned,  including:  murine  (Gray  and  Goeddel,  1983); 
bovine  (Cerretti  et  al,  1986);  porcine  (Dijkmans  et  al,  1990);  canine  (Zucker  et  al,  1992) 
and  feline  (Argyle  et  at,  1995).  Many  of  these  groups  went  on  to  produce  recombinant 
IFN-y  and  to  reproduce  the  results  pioneered  from  murine  and  human  studies  in  the 
assessment  of  its  biological  activity  in  vitro  and  in  vivo.  The  main  body  of  evidence 
related  to  the  biological  activity  of  natural  and  recombinant  IFN-,  y  was  gathered  in  the 
murine  model.  Nevertheless,  the  development  of  in  vitro  studies  has  facilitated  the 
establishment  of  important  parallels  for  the  biological  activity  of  IFN--y  in  humans  and 
other  species  with  that  observed  in  rt-&e.  IFN--y  was  shown  to  stimulate  an  array  of 
cellular  responses  in  vitro  that  have  been  explored  to  assess  the  presence  of  biologically 
active  IFN--y  in  recombinant  protein  preparations  and  in  clinical  samples  of  a  number  of 
species  (reviewed  in  De  Maeyer  and  De  Maeyer-Guignard,  1998).  These  activities  are 
generally  species  specific  and  include:  antiviral  activity;  anti-proliferative  activity  over 
tumour  cells;  induction  of  MEC  class  I  and  class  II  antigens;  activation  of  macrophages 
for  tumour  cell  and  intracellular  parasite  killing;  enhancement  of  NK  cell  activity; 
induction  of  B  cells  for  antibody  secretion. 
The  protocols  used  in  this  chapter  are  therefore  adaptations  of  techniques  developed  for 
the  study  of  IFN-y  in  humans  and  mice,  but  successively  applied  in  other  animal  models. 
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3.1.1  Equine  Interferon  Gamma 
The  cDNA  for  equine  IFN-y  (eqlFN-y)  was  onginally  cloned  in  the  Department  of 
Veterinary  Pathology,  Glasgow  by  Curran  et  al  (1994).  The  cloning  procedure  entailed, 
in  summary,  the  recovery  of  mRNA  from  mitogen  stimulated  penpheral  blood 
lymphocytes  and  its  amplification  by  RT-PCR  using  pnmers  denved  from  conserved 
regions  of  the  IFN--t  coding  sequence  of  a  number  of  species.  The  amplified  cDNA  was 
then  cloned  into  a  Bluescript  plasmid  and  sequenced. 
1  ATGAAATATACAAGTTTTATCTTGýGCTTTTCAGCTGTGTGCGATTTTGGGTTCTTCTACC  60 
(20) 
61  TATTACTGCCAGG4CCGCGTTTTTTAAAGAAATAGAAAACCTAAAG4GAATATTTTAACGCA  120 
IQAAFFKEIENLKEYFNA  (40) 
121  AGTAACCCAGATGTAGGGGATGGTGGGCCTCTTTTCCTGGATATCTTGAAGAACTGGAAA  180 
SNPDVGDGGPLFLDILKNWK  (60) 
181  GAGGATAGTGACAAAAAAATAATTCAGAGCCAAATCGTCTCCTTCTACTTCAAACTCTTT  240 
EDSDKKIIQSQIVSFYFKLF  (80) 
241  GAAAACTTGAAAGATAACCAGGTCATTCAA.  AAGAGCATGGACACCATCAAGGAGGACCTG  300 
ENLKDNQVIQKSMDTIKEDL  (100) 
301  TTCGTTAAGTTCTTTAACAGCAGCACCAGCAAGCTGGAAGACTTCCAAAAGCTGATTCAG  360 
FVKFFNSSTSKLEDFQKLIQ  (120) 
361  ATTCCGGTAAATGATCTGAAGGTCCAGCGCAAAGCAATAAGTGAACTCATCAAAGTGATG  420 
IPVNDLKVQRKAISELIKVM  (140) 
421  AATGATCTGTCGCCCAAAGCTAACCTGAGGAAGCG<3AAGAGGAGTCAGAATCCGTTTCGA  480 
NDLSPKANLRKRKRSQNPFR  (160) 
481  GGCCGGAGAGCGTTGCAATAGTGGTCATCCTGCCTGCAATA  521 
GRRALQ*  (166) 
Figure  3.1  EqIFN-y  nucleotide  sequence  and  corresponding  predicted  amino 
acid  sequence.  Signal  peptide  is  shadowed  and  potential  N-linked  glycosylation  sites 
underlined.  The  stop  codon  is  marked  by  (-).  Numbers  correspond  to  nucleotide 
positions.  Amino  acid  residues  are  numbered  in  brackets. 
Analysis  of  the  eqlFN-y  coding  sequence  revealed  a  498  nucleotide  long  open  reading 
frame  with  a  homology  of  66,78  and  83%  towards  the  munne,  human  and  bovine 
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counterparts,  respectively.  At  the  amino  acid  level  these  homologies  were  of  45.5,67.5 
and  78%,  respectively  (figures  3.1  and  3.2).  The  predicted  protein  product  is  a  166  amino 
acid  polypeptide  featuring  two  potential  N-linked  glycosylation  sites  at  residue  positions 
39  and  106.  The  sequence  features  a  potential  signal  peptide  sequence  of  23  residues,  by 
comparison  to  what  was  established  in  relation  to  human  IFN-y.  Additionally  the  equine 
sequence  150RKRKRSQ  156  is  similar  to  the  munne  RKRKRSR,  recently  reported  to  be 
necessary  and  sufficient  for  nuclear  translocation  of  IFN-y  (Subramaniam  P.  et  al,  1999). 
1  50 
EquineIFN-y  MKYTSFILAF  QLCAILGSST  YYCQAAFFKE  IENLKEYFNA  SNPDVGDGGP 
BovineIFN-y  -----  YF--L  L--GL--F-G  S-G-GQ--R  -  ----------  -S  ---  AK--- 
HumanIFN-y  -----  Y  ----  ---  IV  ---  LG  C---DPYV--  A  ----  K  ----  GHS--A-NGT 
MurineIFN-y  -NA-HC  ---  L  --*FLMAV-G  C--HGTVIES  L-S-NN  ---  S  -GI--EEKS* 
51  100 
EquineIFN-y  LFLDILKNWK  EDSDKKIIQS  QIVSFYFKLF  ENLKDNQVIQ  KSMDTIKEDL 
BovineIFN-y  --SE  ------  DE  --------  ----------  ----------  R---  I--Q-M 
HumanIFN-y  ---  G  ------  -  E--R--M  --  ----------  K-F--D-S--  --VE  -----  M 
MurineIFN-y  -----  WR--Q  K-G-M--L--  --I  ---  LR--  -V  -----  AIS  NNISV-ESH- 
101  150 
EquineIFN-y  FVKFFNSSTS  KLEDFQKLIQ  IPVNDLKVQR  KAISELIKVM  NDLSPKANLR 
BovineIFN-y  -Q--L-G-SE  -----  K  ----  ---  D--QI--  ---N  ------  ------  S--- 
HumanIFN-y  N  ------  NKK  -RD--E--TN  YS-T--N  ---  ---  H  ---  Q--  AE  ---  A-KTG 
MurineIFN-y  ITT--SN-KA  -KDA-MSIAK  FE--NPQ  ---  Q-FN  ---  R-V  HQ-L-ESS-- 
151  166 
EquineIFN-y  KRKRSQNPFR  GRRALQ 
BovineIFN-y  -------  L  --  ----  ST  78.0%. 
HumanIFN-y  ------  ML  --  ----  S-  68.1%. 
MurineIFN-y  -----  RC  45.5%. 
Figure3.2  Comparison  of  the  eqlFN-y  predicted  amino  acid  sequence  to  that  of 
other  species.  The  percentage  of  homology  to  the  equine  protein  is  shown.  Shadowed  box 
corresponds  to  the  putative  signal  peptide  sequence.  (*)  represents  missing  residues  in  the 
munne  sequence.  Numbers  correspond  to  amino  acid  positions. 
This  conservation  of  features  and  the  degree  of  homology  suggest  a  similar  role  for 
eqIFN-y  to  that  observed  in  other  mammalian  species. 
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3.1.2  Expression  of  eqlFN'  y 
3.1.2.1  Systems  for  heterologous  gene  expression 
Recombinant  proteins  are  proteins  produced  in  heterologous  gene  expression  systems 
through  the  introduction  of  the  gene  of  interest  carried  by  a  vector  (e.  g.  plasmid,  virus) 
into  living  cells.  The  vector,  containing  an  appropriate  promoter,  directs  expression  of  the 
gene  utilising,  or  even  taking  over,  the  machinery  of  the  cells  responsible  for  protein 
synthesis  (Brent,  1994).  The  expression  systems  more  commonly  used  are  based  on 
prokaryotic  (e.  g.  E.  coli,  B.  subtilis)  or  eukaryotic  (e.  g.  yeast,  insect,  mammalian)  cells. 
In  selecting  a'system  of  expression  the  unique  advantages  of  each  system  as  well  as  the 
intended  use  of  the  expressed  protein  must  be  carefully  considered,  along  with  other 
factors  such  as  cost  and  degree  of  expertise  required  (Goeddel,  1991).  The  general 
advantages  of  the  prokaryotic  systems  of  expression  are  its  low  cost  and  the  considerable 
knowledge  accumulated  in  the  genetics  and  physiology  of  these  organisms  translated  in  a 
range  of  strategies  for  initiating  and  optimising  the  expression  of  proteins.  The  expression 
in  E.  coli  is  discussed  in  detail  below.  Expression  in  B.  subtilis  has  the  added  advantage 
(in  relation  to  E.  coli)  of  efficient  secretion  of  the  proteins  produced  to  the  culture 
medium.  Nevertheless,  this  is  accompanied  by  secretion  of  several  proteases  with  the 
potential  to  degrade  the  nascent  recombinant  protein  (reviewed  in  Henner,  199  1). 
The  main  advantage  of  eukaryotic  cell  systems  is  their  ability  to  express  eukaryotic 
proteins  in  their  native  (or  near-native)  form  due  to  efficient  post-translational 
modification  and  secretion  of  the  produced  protein.  The  characteristics  of  the  baculovirus 
and  mammalian  systems  of  expression  are  outlined  below.  Expression  in  yeast  is  based 
on  the  Saccharomyces  cerevisiae  strain,  which  can  be  propagated  to  very  high  cell 
densities  and  therefore  produce  large  amounts  of  the  protein  of  interest.  However,  high 
amounts  of  endo  and  exoproteinases:  gain  access  to  the  proteins  in  the  yeast  cytoplasm 
which  results  in  extensive  proteolysis  of  the  recombinant  proteins  (reviewed  in  Erm, 
1991). 
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3.1.2.2  Systems  for  expression  of  eqlFN-y 
Production  of  recombinant  eqIFN-y  was  accomplished  using  different  systems  of 
heterologous  gene  expression,  namely,  procaryotic,  baculovirus  and  mammalian.  The 
intrinsic  properties  of  each  individual  expression  system  were  explored  to  fulfil  different 
end  uses  of  the  expressed  protein.  Thus,  bacterial  expression  was  used  as  a  high  yield 
source  of  IFN-y  of  which  crudely  purified  preparations  could  be  easily  obtained  for 
inoculation  and  resulting  production  of  antibodies.  The  baculovirus  expression  system 
was  used  for  large  scale  production  of  biologically  active  IFN-y  and  transient  expression 
in  mammalian  cells  was  used  as  a  verification  system  for  the  screening  of  constructs  to  be 
used  in  a  DNA  vaccination  trial. 
Expression  in  Escherichia  coU 
The  expression  of  mammalian  proteins  in  prokaryotes  is  a  well  established  molecular 
biology  tool,  especially  in  the  case  of  Escherichia  coli  (reviewed  in  Brent,  1994). 
Virtually  any  protein  can  be  relatively  fast  and  inexpensively  produced  in  E.  coU,  as  long 
as  it  is  not  too  small,  too  large,  too  hydrophobic,  too  glycosylated  or  susceptible  to 
proteolytic  degradation.  A'number  of  expression  systems  based  on  E.  coU  have  been 
developed  and  refined  for  the  production  of  foreign  proteins  in  high  yields.  A  large 
amount  of  plasmid  based  systems  of  expression  are  currently  available  for  introduction  of 
foreign  DNA  into  E.  coli,  efficiently  orchestrating  the  expression  of  encoded  proteins. 
Features  shared  by  most  of  these  systems  include:  a  high  copy  number  plasmid;  a  strong 
inducible  promoter  (e.  g.  lac,  tac,  trp);  a  potent  translation  initiation  domain;  a  selectable 
marker  (e.  g.  ampicillin  resistance)  that  ensures  maintenance  of  the  vector  and  a  multiple 
cloning  site  for  insertion  of  the  gene  of  interest  (Goeddel,  1991). 
A  growing  number  of  expression  systems  make  use  of  fusion  protein  strategies  (either  N 
or  C  terminal)  to  increase  the  efficiency  of  expression.  Reasons  for  the  use  of  a  fusion 
protein  are:  ensuring  a  good  translation  initiation;  overcoming  instability  problems 
(especially  of  small  peptides),  increasing  the  solubility  of  the  expressed  protein  and 
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reducing  proteolytic  degradation.  A  finther  reason  for  using  fusion  partners  is  often  the 
ability  to  purify  the  expressed  protein  by  affinity  of  the  tags  [  e.  g.  histidine  (His),  trpE, 
glutathione  S-transferase  (GST)  ]  to  specific  substances  (e.  g.  metals,  antibodies  or 
substrates,  respectively)  (reviewed  in  Riggs,  1994) 
The  main  disadvantage  of  the  system  resides  in  the  fact  that  expressed  proteins  do  not 
undergo  post-translational  processing  including:  glycosylation,  phosphorylation, 
myristylation,  signal  peptide  cleavage,  etc.  This  can  be  overcome  in  some  measure  by  the 
use  of  special  host  strains  and  intricate  cloning  strategies,  but  often  these  are  time 
consuming  and  of  limited  success  (Gold,  1991) 
For  the  expression  of  eqIFN-y  in  bacteria  the  glutathione  S-transferase  (GST)  gene  fusion 
system  (Smith  and  Johnson,  1988)  was  chosen.  This  utilises  a  series  of  pGEX  plasmids 
(Pharmacia,  Biotech)  featuring  a  tac  promoter  for  isopropyl-l-thio-o-D-galactoside 
(IPTG)  inducible  high  level  expression  and  a  lac  P  gene  that  enables  its  use  in  any  E.  coli 
host.  Heterologous  proteins  are  expressed  as  C-terminal  fusions  of  Schistosoma 
japonicum  GST.  The  translation  of  protein  in  pGEX-4T-  I  begins  at  the  ATG  codon  of  the 
GST  tag  and  fragments  to  be  expressed  are  inserted  in  the  polylinker  downstream  of 
GST.  Therefore,  care  has  to  be  taken  in  the  preparation  of  inserts  for  cloning,  as  the 
reading  frame  has  to  be  maintained. 
Crude  purification  of  fusion  proteins  is  achieved  by  affinity  chromatography  and  relies  on 
the  avidity  of  the  GST  tag  to  glutathione  bound  to  a  sepharose  matrix.  Recovery  of  GST 
tagged  proteins  is  attained  by  the  use  of  reduced  glutathione  under  mild  eIution 
conditions,  thus  minimising  procedural  effects  on  the  antigenicity  and  functional  activity 
of  eluted  proteins.  The  plasmids  also  contain  a  thrombin  recognition  site  (Gly-Pro-Arg) 
that  allows  cleavage  of  the  protein  of  interest  from  the  GST  tag. 
The  host  strain  selected  was  BL21[DE3]  (Stratagene)  for  increased  protein  expression 
and  to  minimize  degradation  of  the  expressed  protein  by  E.  coU  proteases.  BL21  strains 
are  deficient  in  Lon  and  ompT  proteases.  Lon  is  a  major  ATP-dependent  protease, 
73 responsible  for  the  degradation  of  naturally  unstable  or  abnormal  proteins  (Gottesman, 
1989).  OmpT,  localized  in  the  outer  membrane,  is  very  active  in  E.  coli  extracts  and  cuts 
specifically  at  paired  basic  residues  (Sugimura  and  Nishihara,  1988).  The  DE3  derivative 
contains  the  T7  RNA  polymerase  gene,  controlled  by  the  lacUV5  promoter  for  high  level 
expression  induced  by  EPTG. 
Expression  in  Baculovirus 
Expression  in  the  baculovirus  system  entails  the  substitution  of  a  non-essential  gene  of 
the  virus  by  the  gene  of  interest,  followed  by  propagation  of  the  recombinant  virus  in 
susceptible  insect  cells. 
Baculoviruses  that  have  been  developed  as  expression  vectors  were  originally  isolated 
from  the  alfalfa  caterpillar  (Autographa  californica)  and  belong  to  the  Baculoviridae 
family  of  viruses  that  infect  arthropods.  Their  large,  double  stranded,  circular  DNA 
genome  is  enclosed  in  a  nucleocapsid,  which  is  further  packaged  in  a  lipoprotein 
envelope  to  form  the  virus  particle.  Multiple  nucleocapsids  are  occluded  in  a  crystalline 
matrix  (polyhedron),  consisting  largely  of  polyhedrin,  hence  the  name  (AcMNPV) 
Autographa  californica  multiple  nuclear  polyhedrosis  viruses  (King  and  Possee,  1992). 
In  the  natural  virus  life  cycle,  polyhedrin  protects  viral  particles  from  proteolytic 
digestion  as  the  host  decomposes,  although  it  is  not  required  for  production  of  infectious 
virus  particles  in  cell  culture.  It  is  expressed  in  extremely  large  quantities  at  a  very  late 
stage  of  the  replication  cycle,  making  its  promoter  an  ideal  candidate  to  drive  expression 
of  foreign  genes  (Luckow  and  Summers,  1988). 
- 
The  cell  lines  most  commonly  used  for  the  replication  of  AcMNPV  in  vitro  (Sf-9,  Sf-21) 
were  derived  from  pupal  ovarian  tissue  of  the  "fall  army  worm"  -  Spodopterafrugiperda 
(Vaughn  et  at,  1977).  When  cells  are  exposed  to  infectious  virus,  two  structurally  distinct 
forms  of  virus  are  produced.  The  first,  extracellular  virus  (ECV),  responsible  for  the 
infection  of  neighbouring  cells,  begins  to  bud  at  12  hours  post-infection  (p.  i.  )  and  features 
a  glycoprotein  (gp67)  responsible  for  the  attachment  of  virus  to  susceptible  cells.  The 
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inf6cted  cells  after  18  hours  p.  i.,  accumulating  until  released  by  cell  lysis,  up  to  5  days 
p.  i.  The  ECV  is  1000  fold  more  infectious  than  the  occluded  form  of  virus  (Volkman  et 
at,  1986),  whereas  the  occluded  form  produces  larger  amounts  of  polyhedrin,  and 
therefore  of  foreign  protein. 
The  advantages  of  the  baculovirus  system  are  that  the  genome  can  accommodate  large 
amounts  of  foreign  DNA  without  affecting  normal  replication  and  a  high  level  of 
expression  can  be  achieved  using  the  strong  polyhedrin  promoter.  Furthermore,  the 
expression  of  very  late  gene  promoters  occurs  in  maturing  infectious  particles,  which 
constitutes  an  advantage  when  expressing  cytotoxic  proteins,  as  they  will  not  affect  virus 
replication  (Luckow  and  Summers,  1988).  Also,  the  insect  cells  are  able  to  perform  most 
of  the  post-translational  modifications  required  for  biological  activity  of  heterologous 
proteins.  These  include:  glycosylation;  phosphorylation;  myristylation;  palmitylation; 
proteolytic  processing  (including  signal  peptide  cleavage)  and  secretion  or  cellular 
targeting.  In  the  case  of  N-linked  glycosylation,  although  being  performed  at  the  correct 
site  (Asn-X-SerfIlir)  this  is  not  done  to  the  same  extent  as  to  that  of  mammalian  cells. 
Recombinant  glycoproteins  expressed  in  insect  cells  are  high  in  mannose  but  lack  or  have 
low  levels  of  fucose,  galactose  and  sialic  acid  residues  (reviewed  in  King  and  Possee, 
1992). 
The  system  used  is  composed  of  a  polyhedrin  deficient  AcMNPV  (BAK-PAK6)  and  a 
transfer  vector.  The  viral  DNA,  has  been  modified  to  include  the  E.  coli  P-galactosidase 
(lacZ)  gene  downstream  of  the  polyhedrin  promoter,  in  substitution  of  the  polyhedrin 
gene.  A  unique  Bsu361  enzyme  recognition  site  was  engineered  within  the  lacZ  gene 
(Possee  el  al,  1991)  for  the  generation  of  linearized  virus,  following  observations  that  this 
greatly  increases  the  recombination  efficiency  (Kitts  et  al,  1990).  The  transfer  vector 
(pAcC129.1)  consists  of  a  bacterial  plasmid  containing  the  polyhedrin  gene  promoterAnd 
transcription  termination  elements  flanked  by  AcMNPV  sequences.  It  also  features  a 
polylinker  sequence,  downstream  of  the  promoter,  for  insertion  of  foreign  DNA 
(Livingstone  and  Jones,  1989).  Co-transfection  of  insect  cells  with  linearized  infectious 
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viral  DNA  (AcMNPV-IacZ)  and  transfer  vector  containing  the  -gene  of  interest,  allows 
homologous  recombination  to  occur,  with  consequent  generation  of  recombinant  virus. 
Recombinants  are  identified  by  blue/white  selection  in  the  presence  of  X-gal  in  a  standard 
plaque  assay.  The  blue  plaques  correspond  to  P-gal  expressing  parental  virus,  while  white 
plaques  correspond  to  recombinant  virus  in  which  the  lacZ  gene  has  been  substituted  by 
foreign  DNA. 
Expression  in  Mammalian  cells 
The  broad  advantages  of  using  mammalian  cells  to  express  proteins  from  higher 
eukaryotes  stem  from  the  fact  that  the  signals  for  synthesis,  processing,  and  secretion  of 
these  proteins  are  usually  correctly  recognised.  This  authenticity  of  modifications  reduces 
the  risk  of  the  expressed  protein  having  altered  biological  activity,  pharmacokinetics,  or 
immunogenicity,  which  are  factors  of  particular  relevance  when  in  vivo  administration  is 
planned.  (Levinson,  1991;  Brent,  1994). 
There  are  two  general  methods  of  introducing  genetic  information  to  be  expressed  into 
mammalian  cells.  The  first  method  is  mediated  by  virus  infection  and  has  the  advantage 
of  efficiently  targeting  (near  100%)  susceptible  cells  by  exploiting  the  infectious 
capability  of  the  virus.  Nevertheless,  a  draw  back  to  this  strategy  is  the  difficulty  inherent 
in  the  engineering  of  the  virus  to  express  a  foreign  gene  without  compromising  its 
replication  and  infection  ability  (Levinson,  1991).  The  second  method  is  mediated  by 
direct  DNA  transfection  and  utilises  plasmid  DNA  as  a  vector  of  transfer.  An  advantage 
to  this  system  is  the  commercial  availability  of  a  great  variety  of  expression  vectors 
constructed  around  known  promoter  (e.  g.  Roux  Sarcoma  Virus,  Cytomegalovirus)  and 
RNA  processing  signal  sequences  and  containing  polylinker  cassettes  for  trouble  free 
insertion  of  foreign  cDNA  Its  biggest  disadvantage  is  the  poor  efficiency  of  DNA 
transfer,  with  only  5  to  50%  of  the  cells  acquiring  and  transiently  expressing  DNA. 
Although  this  may  be  circumvented  by  the  laborious  and  time  consuming  procedure  of 
isolating  and  characterising  stably  transfected  cell  lines  (Kaufinan,  1991). 
76 IF,  V-y 
The  system  used  for  mammalian  expression  of  eqIFN-y  is  based  on  the  pCI-neo  vector 
(Promega)  for  constitutive  expression  of  genes  in  mammalian  cells.  The  system  can  be 
used  both  for  transient  expression  and  for  stable  expression  when  transfected  cells  are 
selected  with  the  neomycin  analogue  geneticin  (G  418).  The  pCI-neo  vector  features:  the 
human  cytomegalovirus  (CMV)  immediate-early  enhancer/promoter  region  for 
constitutive  expression;  the  bacterial  neomycin  phosphotransferase  gene  allowing  for 
selection  of  stably  transfected  cells;  the  SV40  origin  of  replication  for  transient  high  copy 
number  episomal  replication  in  cells  expressing  the  SV40  large  T  antigen;  a  chimeric 
intron  for  increased  expression  levels,  composed  of  the  5'  splicing  element  from  the  P- 
globin  intron  and  the  Y-splice  site  from  an  IgG  intron;  the  SV40  late  polyadenylation 
signal  for  efficient  RNA  processing  and  a  multiple  cloning  site  for  insertion  of  foreign 
DNA. 
The  Cos7  cell  line  (Gluzman,  1981)  was  used  for  transfection.  These  cells  are  derived 
from  African  green  monkey  kidney  cultures  that  were  transformed  with  SV40  virus 
carrying  a  defective  origin  of  replication  and  are  therefore  unable  to  produce  viral 
particles.  The  cells  produce  large  amounts  of  the  viral  protein,  SV40  large  tumour  (T) 
antigen  which  directs  in  trans,  high  level  amplification  (10,000  to  100,000  copies  per 
cell)  of  vectors  containing  the  SV40  origin  of  replication.  Consequently,  plasmids 
containing  a  cDNA  encoding  a  desired  protein,  under  the  control  of  an  appropriate 
promoter,  express  large  amounts  of  the  protein  in  a  short  period  of  time.  Typically  protein 
production  starts  24  hours  post-transfection  and  lasts  for  up  to  a  week,  after  which  the 
cells  either  die  or  lose  the  plasmid  (reviewed  in  Aruffo,  1994). 
3.1.3  Biological  activity  of  recombinant  eqIFN-y 
3.1.3.1  Assays  for  cytokine  detection 
Existing  methods  for  the  in  vitro  detection  and  measurement  of  cytokines  can  be 
classified  in  two  groups.  The  first  group,  immunoassays,  although  useful  as  a  specific  and 
sensitive  way  to  quantitate  cytokines,  do  not  provide  information  on  the  bioactivity  of  the 
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detected  cytokine  as  they  also  detect  biologically  inactive  molecules.  Immunoassays  are 
based  in  the  immunoreactivity  of  cytokines  to  specific  antibodies  (e.  g.  enzyme-linked 
immunosorbent  assay-ELISA,  radioimmunoassay-  RIA)  and  can  therefore  be  easily 
performed  (Thorpe  et  al,  1992)  .  The  second  group,  bioassays,  are  the  only  methods  of 
cytokine  detection  that  enable  an  estimation  of  the  biological  potency  of  the  cytokines 
present  in  the  test  samples.  Bioassays  make  use  of  cellular  systems  (cell  lines  or  primary 
cultures)  that  require  a  certain  cytokine  for  optimal  growth  (factor-dependent  cell  lines) 
or,  more  commonly,  exploit  different  cellular  functions  dependent  or  enhanced  by 
cytokine  stimulation  (Mire-:  Sluis  et  al,  1998).  These  ffinctions  include  cell  proliferation 
and  the  production  of  particular  molecules  that  might  be  secreted  (e.  g.  further  cytokines 
and  other  intercellular  mediators)  or  expressed  in  the  surface  of  the  cell  (e.  g.  cytokine 
receptors,  adhesion  molecules,  MHQ.  The  suitability  of  a  given  cell  line  for  assaying  a 
particular  cytokine  depends  on  factors  such  as  the  ease  of  production  and  maintenance 
and  sensitivity  of  response  to  the  cytokine  to  be  tested  (Wadhwa  and  Thorpe,  1998;  Mire- 
Sluis  and  Thorpe,  1998). 
3.1.3.2  Biological  assays  for  recombinant  eqIFN-y 
Theoretically,  every  measurable  function  of  IFN-y  can  be  considered  for  use  as  proof  of 
biological  activity.  One  has  to  attend,  however,  to  more  practical  aspects  like  feasibility, 
availability  of  resources,  time  consumption  and  cost,  when  deciding  which  assay  to  use. 
The  original  and  relatively  simple  assays  based  on  the  antiviral  activity  of  IFN-y  in 
fibroblastic  /  epithelial  cell  lines  have  recently  evolved  to  more  complex  and  sensitive 
assays  (e.  g  labelling  of  MHC  upregulated  molecules,  intracellular  staining  of  induced 
cytokines,  measurement  of  nitric  oxide  production).  This  evolution  is  linked  to 
continuous  addition  to  the  never  ending  list  of  intra  and  intercellular  mediators  and  cell 
markers  that  can  be  up  or  downregulated  by  IFN-y  and  to  the  development  of  powerful 
biological  resources  (e.  g.  monoclonal  antibodies,  transgenic  mice). 
The  assays  employed  for  investigation  of  biological  activity  of  the  eqIFN-y  preparations 
in  vitro  were  chosen  to  reflect  various  aspects  of  IFN-y  activity. 
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EqIFN-y  cytopathic  effect  (CPE)  reduction  assay 
This  assay  is  based  on  the  antiviral  activity  that  IFN-y  shares  with  type  I  IFNs,  albeit  to  a 
lesser  extent.  It  relies  on  the  cellular  response  to  interferon  and  consequent  inhibition  of 
replication  of  an  infecting  virus,  which  can  be  measured  in  terms  of  reduction  of 
cytopathic  effect  (CPE)  in  comparison  to  cells  not  treated  with  IFN,  hence  the  name  CPE 
reduction  assay  (reviewed  in  Meager,  1987). 
The  degree  of  protection  conferred  by  the  IFN  preparation  correlates  with  its  potency  and 
can  therefore  be  used  to  titre  individual  preparations  in  terms  of  protective  units.  A  unit  is 
defted  as  the  reciprocal  of  the  dilution  at  which  50%  protection  against  virus  infection  is 
obtained.  The  accuracy  of  the  unit  determination  depends  on  the  dilution  increments  and 
number  of  replicates.  These  are  designated  laboratory  units  and  are  extremely  arbitrary, 
varying  with  virus  stocks,  cell  lines,  media,  cell  culture  conditions  and  even  operator. 
When  uniformity  of  preparations  is  an  absolute  requirement,  titrations  should  be 
calibrated  to  international  reference  standards  provided  by  the  World  Health  Organisation 
(reviewed  in  Lewis,  1987). 
In  deciding  on  the  format  of  the  assay,  care  has  to  be  taken  in  the  selection  of  a  cell  line 
sensitive  to  both  the  virus  and  responsive  to  IFN-y  and  of  a  virus  sensitive  to  the  antiviral 
state  of  the  cells.  The  virus  chosen  was  the  Vesicular  Stomatitis  Virus  (VSV).  Two  cell 
lines  were  used:  initially  Equine  Embryonic  Kidney  (EEK)  and  at  a  later  stage  Madin 
Darby  Bovine  Kidney  (MIDBK),  both  of  epithelial-like  phenotype. 
VSV  is  a  rhabdovirus  that  infects  cattle,  horses  pigs  and  humans  of  which  three  serotypes 
have  been  isolated  to  date  (VSV-New  Jersey  the  most  common  ,  Indiana  and  Alagoas).  In 
cattle  VSV  causes  a  disease  clinically  indistinguishable  from  Foot  and  Mouth  disease 
with  typical  vesicles  following  scarification  of  the  tongue  and  footpads.  Occasional 
human  infections  with  VSV  have  been  reported,  mostly  from  close  contact  with  infected 
cattle  or  from  laboratory  exposures.  In  humans  the  disease  is  subclinical  or  mild  and 
flulike  (Dietzschold  et  al,  1996).  The  virus  used  in  the  CPE  reduction  assay  is  a 
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temperature  sensitive  mutant  (VSVtsE2)  of  the  New  Jersey  strain,  containing  two 
independent  mutations  in  the  NS  gene  (Rae  and  Elliott,  1986).  The  ideal  growth 
temperature  is  31  *C  and  this  strain  is  therefore  unable  to  produce  disease  in  livestock,  or 
indeed  to  sustain  a  transmission  cycle  between  animals. 
SAFETY  ASPECTS 
In  Scotland,  the  use  of  VSV  is  restricted  to  laboratories  with  category  II  status  or 
superior,  being  additionally  dependent  on  licence  and  report  of  periodical  inspections  by 
the  Scottish  Office,  Agriculture  and  Fisheries  Department.  The  departmental Code  of 
Practice  recommends:  avoiding  the  use  of  sharps  or  blades;  avoiding  forming  aerosols; 
before  leaving  the  designated  laboratory,  all  working  surfaces  are  to  be  swabbed  with  2% 
Virkon  followed  by  70%  ethanol  and  all  non-sterile  material  autoclaved  immediately. 
Proliferation  assay  for  EqIFN-y 
This  assay  is  based  on  the  proliferation  activity  that  IFN-y  exerts  over  T  cell  and  B  cell 
lines  particularly  when  triggered  by  mitogens  (Landolfo  et  al,  1988). 
In  the  present  assay,  equine  PBLs  primed  with  IL-2  and  concanavalin  A  (ConA)  are 
stimulated  with  preparations  of  EFN-y  with  or  without  basal  amounts  of  ConA.  The  basal 
concentration  of  ConA  is  one  that  alone  does  not  lead  to  proliferation.  The  measurement 
of  proliferation  relies  in  the  incorporation  of  radioactive  thymidine  (H'-Thymidine)  by 
the  newly  synthesised  DNA  in  multiplying  cells.  The  radioactivity  retained  by  the  cells  is 
proportional  to  the  level  of  proliferation  and  can  be  measured  in  a  scintillation  counter  by 
the  addition  of  a  scintillation  fluid  to  the  cells. 
MHC-11  Upregulation  by  EqIFN-y 
This  assay  is  based  on  the  fact  that  IFN-y  can  upregulate  the  expression  of  Major 
Histocompatibility  Complex  class  11  (MHC  II)  molecules  in  the  surface  of  activated 
antigen  presenting  cells  such  as  macrophages  and  dendritic  cells  (Wong  et  at,  1984). 
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While  in  most  species  MHC  Il  epitopes  are  exclusively  expressed  by  antigen  presenting 
cells,  in  the  case  of  the-horse,  circulating  T  cells  also  express  significant  amounts  of 
equine  MHC  II  (Crepaldi  et  al,  1986).  Additionally,  a  large  subset  of  circulating  T 
lymphocytes  (up  to  95%)  in  the  adult  horse  express  MHC  11,  whereas  in  one  day  old  foals 
expression  of  MHC  11  could  not  be  detected  (Lunn  et  al,  1993).  This  is  comparable  to  the 
situation  observed  in  humans  in  relation  to  the  generation  of  CD45RO'  T  cells  that 
precedes  T  cell  differentiation  to  a  effector/memory  phenotype  (reviewed  in  Altin  and 
Sloan,  1997).  The  constitutive  expression  of  equine  MEC  II  in  T  cells  was  therefore 
associated  with  the  activation  and/or  development  of  memory  of  T  cells  in  the  horse 
(Lanzavecchia,  1990).  Cells  expressing  MHC  Il  are  labelled  with  a  monoclonal  antibody 
against  equine  MHC  class  11  and  a  secondary  anti-mouse  antibody  conjugated  with 
fluorescein.  Quantitative  and  qualitative  variations  of  MHC  II  expression  by  the  cell 
population  can  then  be  assessed  using  a  fluorescence-activated  cell  sorter  (FACS). 
Below  is  a  description  of  the  techniques  used  for  the  expression,  detection  and  assay  of 
biological  activities  in  vitro  of  eqEFN-y  and  the  results  obtained. 
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3.2  -  Materials  and  Methods 
3.2.1  Expression  in  E.  coU 
Cloning  of  eqIFN-y  into  pGEX  expression  vectors 
For  the  production  of  recombinant  eqIFN-y  protein  in  E.  coli,  cDNA's  encoding  a  full 
length  protein  and  a  truncated  version  lacking  the  signal  peptide  sequence  were  cloned 
(figure  3.1).  The  predicted  mature  version  was  prepared  due  to  fears  that  the  high  content 
in  hydrophobic  residues  of  the  leader  sequence  would  reduce  solubility  of  the  expressed 
protein  and  therefore  decrease  its  yield  following  purification. 
PREPARATION  OF  Eg  CDNA  INSERTS 
Full  length  eqlFN-y  cDNA  was  recovered  from  pBlueScript  (pBS)  plasmid  as  follows. 
I  Oýtg  of  pBS-eqIFN-y  was  digested  in  a'  50ýil  volume  using  20  units  of  EcoRl  and  5pl  of 
EcoRl  buffer  at  37*C  for  four  hours.  The  reaction  was  stopped  by  the  addition  of  6ýil  of 
I  OX  DNA  loading  buffer  (mat&meth).  The  sample  was  loaded  onto  a  1.2%  TAE  agarose 
minigel,  stained  with  ethidium.  bromide,  and  electrophoresed  at  90  volts  for  I  hour.  Upon 
LJV  visualisation,  a  band  of  approximately  500bp  in  length,  as  determined  by  comparison 
to  a  DNA  molecular  weight  standard  (OX174  RF  DNA/Hae  III  fragments),  was  excised 
and  the  DNA  extracted  using  Wizard  PCR  Prep  (Promega)  and  eluted  in  50ýd  of  dH20 
(Figure  3.3-  A).  The  truncated  version  of  eqIFN-y  (IFNtr)  was  obtained  by  PCR 
amplification  for  which  the  following  primers  were  designed: 
Primer  Sequence  Tm 
5'  Primer  5'-CTG  CCA  GGC  CGC  GTT  T77  TA-3'  62*C 
3'  Primer  5'-GGC  AGG  ATC  ACC  ACT  ATT  GC-3'  62*C 
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Figure  3.3  -  Schematic  showing  cloning  of  eqlFN-y  in  pGEX-4T-1  and  major 
steps  in  the  production  and  purification  of  recombinant  eqlFN-y  in  bacteria. 
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For  PCR  amplification,  the  primers  were  used  at  a  concentration  of  0.511M  (2.5111  of  each 
primer)  in  a  501A  reaction  volume  containing  2.5  units  (0.5gl)  of  Taq  polymerase,  5gl  of 
IOX  PCR  buffer,  5gl  of  dNTP  mix  (1.25  mM  each)  and  24.51A  of  dH20.  The  template 
consisted  of  50ng  of  pBS-eqIFN-y  M  101A  of  dH20.  Cycling  parameters  were:  94"C  for  5 
min.;  followed  by  30  cycles  of  94*C  for  30  sec.,  55*C  for  45  sec.  and  72"C  for  I  min.; 
followed  by  a  final  extension  step  of  721C  for  7  min.  and  by  chilling  at  4"C.  PCR 
amplification  was  assessed  by  running  lOul  of  product  in  a  ethidium  bromide  stained 
1.2%  TAE  agarose  minigel  and  visualisation  under  UV  light  of  a  band  with  an 
approximate  size  of  450bp.  This  PCR  product  was  ligated  into  a  TA  cloning  vector 
(Invitrogen)  following  -manufacturers  instructions,  followed  by  transformation  and 
selection  of  InvccF'  bacteria  in  LB  agar  containing  ampicilin  (100gg/ml).  Screening  of 
recombinant  clones  was  accomplished  by  restriction  analysis  of  DNA  minipreparations 
(Qiagen)  using  EcoRL 
Ten  micrograms  of  TA-  IFNtr  DNA  (as  estimated  by  spectrophotometry)  were  digested 
in  a  50ul  volume  using  20  units  of  EcoRl  and  5ýtl  of  EcoRI  buffer  at  37*C  for  four  hours. 
The  reaction  was  stopped  by  the  addition  of  61il  of  I  OX  DNA  loading  buffer.  The  sample 
was  loaded  onto  a  1.2%  TAE  agarose  minigel  and  electrophoresed  at  90  volts  for  I  hour. 
Upon  ethidium  bromide  staining  and  UV  visualisation,  a  band  of  approximately  450bp  in 
length,  was  excised  and  the  DNA  extracted  using  Wizard  PCR  Prep  (Promega)  and  eluted 
in  50pLI  of  dH.  O  (Figure  3.3-13). 
PREPARATION  OF  12GEX4T-  I  DNA 
One  aliquot  of  competent  E.  coli  JM105  was  transformed  with  lOng  of  plasmid  DNA 
and,  following  selection  by  ampicillin  (50lig/ml)  on  LB  agar  plates,  a  single  colony  was 
grown  in  large  scale  for  preparation  of  DNA  by  Qiagen  plasmid  mega  kit.  Ten 
micrograms  were  digested  with  EcoRI,  and  the  linearised  plasmid  was  gel  purified  as 
described  above. 
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LIGATION  OF  VECTO  TO  INSERTS  AND  TRANSFORMATI  OF  BACTERIA 
Prior  to  ligation  the  DNA  concentration  of  the  linearised  vector  and  both  the  inserts  was 
estimated  by  spectrophotometry.  To  obtain  a  insert  :  vector  molar  ratio  of  approximately 
5:  1,50ng  of  each  insert  was  combined  with  100ng  of  vector  in  a  total  volume  of  20ý11, 
containing  I  ptl  (I  units)  of  T4  DNA  ligase  (Gibco,  Brl)  and  41A  of  5X  ligase  buffer.  The 
reaction  was  incubated  overnight  at  15'C.  A  control  ligation  containing  only  linearised 
vector  was  also  performed. 
Competent  E.  coli  JM105  were  transformed  with  lOul  of  each  ligation  reaction. 
Following  overnight  selection  on  LB  agar  with  ampicillin  (5011g/ml)  colonies  were 
picked  and  DNA  minipreparations  (Qiagen)  were  made  and  the  DNA  was  submited  to 
restriction  enzyme  digestion  followed  by  gel  electrophoresis  The  use  of  EcoRV  enabled 
the  screening  of  recombinants  in  the  correct  orientation  by  the  release  of  a  bands  of 
approximatrely  1700  and  1750  bp  for  pGEX-IFNtr  and  pGEX-eqlFN-y  respectively. 
SEQUENCING  OF  RECONMINANTS 
Two  clones  containing  each  of  the  recombinant  plasn-ýids  were  sequenced  using  "rhermo- 
Sequenase  Cycle  Sequencing  Kit"  (Amersham)  and  the  following  IRD800  labelled 
primers  (kindly  supplied  by  Dr.  S.  Dunham,  Department  of  Veterinary  Pathology, 
Glasgow): 
Primer  Sequence  Tm 
5'  pGEX  primer  5'-GGG  CTG  GCA  AGC  CAC  GTr  TGG  TG-3'  76"C 
3'  pGEX  primer  5'-CCG  GGA  GCT  GCA  TGT  GTC  AGA  GG-3'  76C 
Cycle  sequencing  was  performed  in  a  Perkin  Elmer  9600  thermal-cycler.  Cycling 
conditions  were:  94'C  for  5  min  followed  by  25  cycles  of  95T  for  30  sec;  55T  for  30 
sec.  and  extension  at  72'C  for  40  sec;  followed  by  chilling  at  4C.  Sequencing  reactions 
were  run  in  a  DNA  automated  sequencer  (Li-Cor  4000L)  using  gel  running  conditions, 
solutions  and  buffers  specified  in  the  accompanying  protocols  (mat&meth).  One  clone  of 
each  recombinant,  showing  100%  identity  with  published  equine  IFN-y  sequence  (Curran 
et  al,  1994),  was  taken  Uhrough  protein  expression  procedures. 
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Expression  of  eqlFN--y  fusion  proteins 
For  this  purpose,  competent  BL21  [DE3]  cells  were  transformed  with  recombinant 
plasmids,  selected  as  detailed  above  and  single  colonies  were  picked  for  protein 
production.  Cells  were  also  transformed  with  parental  plasmid  for  use  as  a  control  of  the 
purification  procedure. 
SCREENING  BY  SMALL  SCALE  PROTE  EXPRESSIO 
At  this  point  the  recombinant  bacteria  were  screened  for  the  production'of  detectable 
amounts  of  fusion  proteins  to  investigate  if  the  level  of  expression  was  sufficient  to 
justify  large  scale  purification  procedures.  Thus,  3ml  cultures  of  the  each  construct  were 
grown  overnight  in  LB  (with  lOOpg/mI  of  ampicillin  and  IgIlitre  glucose)  at  37*C  with 
shaking.  Cultures  were  diluted  1:  10  into  5ml  of  the  same  medium  and  re-grown  under  the 
same  conditions  for  2.5  hours.  The  5  ml  cultures  were  divided  in  two  fractions  and  to  one 
of  the  fractions  IPTG  was  added  to  a  final  concentration  of  0.4mM.  Both  fractions  of 
cells  (induced  and  not  induced)  were  incubated  for  another  2.5  hours.  Cell  extracts  were 
prepared  by  pelleting  1.5ml  of  each  fraction  of  the  cultures  and  resuspending  the  pellet  in 
200ýd  of  IX  Protein  loading  buffer  (mat&meth).  Samples  were  then  boiled  for  5  min.  and 
spun  in  a  microcentrifuge  for  10  min.  An  101A  aliquot  of  each  sample  was  loaded  in  a 
sodium  dodecyl  sulphate  polyacrylamide  electrophoresis  (SDS-PAGE)  gel  and  analysed 
by  Coomassie  blue  staining  (mat&meth). 
PREPARATION  OF  LARGE  SCALE  BACTERIAL  SONICATES 
A  single  colony  of  each  recombinant  and  one  colony  containing  empty  plasmid  were  used 
to  inoculate  20ml  of  2YT  medium  rpontaining  100ýtg/ml  ampicillin  and  grown  overnight 
at  37"C  with  vigorous  shaking.  The  cultures  were  diluted  1:  50  into  a  total  of  400ml  of 
pre-warmed  2YTA  medium  and  grown  with  agitation  at  301C  until  the  optical  density 
reached  approximately  1.0  at  A...  Cultures  were  induced  with  IPTG  to  a  final 
concentration  of  0.1  mM  and  incubated  for  a  finther  4  hours. 
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The  cultures  were  transferred  to  500ml  centrifuge  bottles  (Beckman)  and  centrifuged  at 
80OOrpm  for  10  min.  in  a  JA-10  rotor  to  pellet  the  cells.  The  supernatants  were  discarded 
and  the  pellets  drained  and  resuspended  in  20ml  of  ice  cold  PBS  containing  the  protease 
inhibitor  AEBSF  [4-2-(aminoethyl)-benzenesulfonyI  fluoride  hydrochloride]  at  Imm. 
AEBSF  is  commercially  available  as  Pefabloc  SC  (Boehringer  Mannheim)  and  is  a  non- 
toxic  water  soluble  alternative  to  the  commonly  used  PMSF  (Phenylmethylsulfonyl 
fluoride).  Using  a  sonicator  (XL  2020  -  Heat  Systems  Inc.  )  equipped  with  an  appropriate 
probe,  the  bacterial  suspensions  were  sonicated  on  ice  in  three  bursts  of  20  sec.  separated 
by  I  min.  Care  was  taken  to  avoid  frothing  which  is  a  known  cause  of  protein 
denaturation.  The  degree  of  cell  disruption  was  evaluated  by  darkening  and  decreasing  of 
the  suspension  viscosity.  To  aid  solubilisation  of  the  fiision  protein,  20%  Triton  X-100 
was  added  to  a  final  concentration  of  1%  and  mixed  gently  at  4*C  for  30  min.  The 
suspension  was  transferred  to  polypropylene  tubes  and  centriffiged  at  18000  rpm  for  10 
min.  in  a  Beckman  JA-20  rotor.  The  supernatant  was  harvested  to  a  clean  tube  and  stored 
at  -20'C  until  purification. 
AFFINrrY  CHROMATOGRAPHY  PURIFICATION  OF  FUSION  PROTEINS 
Prior  to  purification,  266ýil  of  sepharose  Q  slurry  (Pharmacia  Biotech)  was  applied  to 
each  disposable  chromatography  column  and  equilibrated  with  PBS.  For  the  calculation 
of  the  amount  of  matrix  needed  the  following  figures  were  observed:  Sepharose  4B  is 
supplied  as  75%  slurry  in  20%  ethanol  and  in  accordance  with  the  manufacturers 
instructions  1.33ml  of  slurry  is  needed  to  produce  one  millilitre  of  bed  volume;  also 
200pil  of  bed  volume  is  needed  for  the  purification  of  a  sonicate  derived  from  a  400ml 
culture.  After  equilibration  a  50%  slurry  is  obtained.  The  20ml  sonicates  were  added  to 
the  columns  and  allowed  to  flow  through.  The  matrix  is  washed  by  the  addition  of  10  bed 
volumes  of  ice  cold  PBS  and  drainage.  The  wash  step  is  repeated  twice  more  for  a  total  of 
3  washes.  At  the  end  of  the  wash  the  O.  D.  at  A280  of  the  flow  through  should  be  zero 
when  compared  to  a  blank  of  PBS.  For  elution  of  fusion  proteins  0.5ml  of  elution  buffer  [ 
I  OmM  glutathione,  50mM  Tris-HCI  (pH  8.0)  ]  was  added  to  the  matrix  and  incubated  for 
15  min.  at  room  temperature  before  collection  of  eluate.  The  elution  step  was  repeated 
twice  and  the  three  eluates  were  pooled  and  dialysed. 
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TMOMBIN  CLEAVAGE  QF  FUSIO  PROTEINS 
Cleavage  by  thrombin  releases  the  GST  tag  from  the  fusion  protein.  This  is  best  done 
while  fusion  protein  is  still  bound  to  the  matrix,  as  cleavage  releases  the  protein  of 
interest  for  collection,  whereas  the  GST  tag  remains  attached  to  the  matrix.  To  this  effect 
the  above  protocol  was  followed  until  completion  of  the  wash  step.  The  column  was 
sealed  and  20ýtl  of  thrombin  solution  and  980pl  of  PBS  was  added  to  the  washed  matrix. 
The  thrombin  solution  consists  of  thrombin  at  lunit/lil  in  PBS  and  the  manufacturer 
recommends  the  use  of  50  units  of  thrombin  per  millilitre  of  bed  volume  The  matrix  was 
then  dislodged  by  tapping  the  column  and  incubated  overnight  with  gentle  rocking.  Upon 
completion  of  incubation  the  column  was  centrifuged  in  a  bench  top  centrifuge  at  500rpm 
for  a  few  seconds  to  sediment  matrix.  The  bottom  cap  of  the  column  was  removed  for 
collection  of  the  eluate  containing  eqIFN-y.  The  eluates  were  then  dialysed. 
DIALYSIS 
Eluted  proteins  were  dialysed  against  PBS  to  remove  free  glutathione  and  to  equilibrate 
samples.  Each  eluate  was  loaded  in  a  pre-soaked  3ml  Slide-a-lyzer  (Pierce  )  with  a  10 
kDa  molecular  weight  cut  off  dialysis  membrane.  Dialysis  was  performed  against  PBS  (I 
litre  per  1.5ml  sample),  for  approximately  20  hours,  at  4*C,  with  3  changes  of  buffer. 
Dialysed  samples  were  collected  and  stored  at  -70T  until  further  use. 
IDENTIFICATTO  OF RECOMBINANT  EgIFN-Y  PREPARATIONS 
Following  crude  purification  and  dialysis,  recombinant  proteins  were  analysed  by 
Coomassie  blue  staining  of  SDS-PAGE  gels.  (mat&meth).  Gels  were  assembled  on  a  gel 
drier  (Biorad)  and  dried  at  80'C  for  2  hours. 
3.2.2  Expression  in  baculovirus 
Production  of  Baculovirus-eqlFN-y  recombinants 
A  diagram  outlining  the  major  steps  in  the  generation  of  recombinant  Baculovirus- 
eqIFN-y  is  shown  in  figure  3.4. 
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Figure  3.4  Schematic  pinpointing  major  steps  in  the  generation  of  recombinant 
Baculo-eqlFN-y  virus 
CLONING  eqIFN-  IN  pAcCL29.1 
Full  length  eqIFN-y  cDNA  was  recovered  from  pBlueScript  (pBS)  plasmid  as  follows. 
10ýig  of  pBS-eqlFN-y  was  digested  in  a  50pl  volume  using  20  units  of  Sall  and  5p]  of 
Sall  buffer  at  37'C  for  four  hours.  The  reaction  was  stopped  by  the  addition  of  6ý11  of 
IOX  DNA  loading  buffer  (math&meth).  The  sample  was  loaded  onto  a  1.2%  TAE 
agarose  minigel,  stained  with  ethidium  bromide,  and  electrophoresed  at  90  volts  for  I 
hour.  Upon  UV  visualisation,  a  band  of  approximately  500bp  in  length,  as  compared  to  a 
DNA  molecular  weight  standard  (ýX  174  RF  DNA/Hae  III  fragments),  was  excised  and 
89 IFN-j' 
the  DNA  extracted  using  Wizard  PCR  Prep  (Promega)  and  eluted  in  501il  of  (U-120' 
Similarly,  10ýLg  of  pAcCI29.1  DNA  (kindly  supplied  by  Dr  Mark  Harris,  Department  of 
Veterinary  Pathology,  Glasgow)  was  digested  with  Sall  and  gel  purified. 
LIGATION  AND  TRANSFORMATIO  OF  BACTERIA 
Prior  to  ligation  the  DNA  concentration  of  both  the  linearised  vector  and  the  insert  was 
estimated  by  spectrophotometry.  To  obtain  a  insert  :  vector  molar  ratio  of  approximately 
10:  1,20ng  of  insert  was  combined  with  300ng  of  vector  in  a  total  volume  of  20ý11, 
containing  I  pl  (I  unit)  of  T4  DNA  ligase  (Gibco,  Brl)  and  4ýfl  of  5X  ligase  buffer.  The 
reaction  was  incubated  overnight  at  15"C.  A  control  ligation  containing  only  linearised 
vector  was  also  performed. 
Competent  E.  coli  Max  Efficiency  DHIOB  were  transformed  with  lOul  of  ligation 
reaction  (math&meth).  Following  overnight  selection  on  LB  agar  with  ampicillin 
(50tig/ml)  colonies  were  picked  and  DNA  minipreparations  (Qiagen)  were  made.  The 
DNA  was  submited  to  restriction  enzyme  digestion  using  XbaI/Bsu36I  followed  by  gel 
electrophoresis  This  enabled  the  screening  of  recombinants  in  the  correct  orientation  by 
the  release  of  a  band  of  approximately  450  bp.  One  positive  clone  was  grown  and  a  stock 
of  pAcC129.1-eqlFN-y  was  prepared  using  'Tlasmid  Mega  Kit"  (Qiagen).  Resulting 
DNA  was  analysed  by  ethidiurn  bromide  stained  agarose  gel  and  quantified  by 
spectrophotometry 
PREPARATIO  OF  VIRAL  DNA- 
One  microgram  of  AcMNPV  DNA  (provided  by  Dr  Mark  Harris)  was  digested  in  a  50PI 
volume  using  10  units  (1ýtl)  of  Bsu361  and  5ýtl  of  buffer  III,  at  37'C  for  2  hours, 
followed  by  inactivation  of  the  enzyme  by  heating  at  65*C  for  10min.  Completion  of 
digestion  was  verified  by  loading  5ýd  of  the  reaction  in  a  1.2%  TAE  agarose  minigel, 
stained  with  ethidium.  bromide,  and  comparing  it  with  uncut  DNA.  The  remaining  of  the 
digested  DNA  was  made  up  to  2001il  with  dH20  and  extracted  with  an  equal  volume 
phenol  /  chloroform  /  isoamyl  alcohol  [  25:  24:  1  (v/v)  ],  precipitated  in  10%  3M  Sodium 
acetate  (v/v)  and  2.5  volumes  of  100%  ethanol.  The  DNA  was  pelleted  by  centrifugation 
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in  a  microfuge  at  13000  rpm,  washed  with  ice  cold  70%  ethanol  (v/v)  and  freeze-dried. 
Resulting  pellet  was  resuspended  in  50ýfl  of  dH20  and  DNA  concentration  assessed  by 
spectrophotometry. 
CO-TRANSFEMON  OF  INSECT  CELLS 
Prior  to  transfection,  SF-9  cells  (kindly  provided  by  Dr.  Mark  Harris)  were  grown  and 
maintained  (mat&meth)  in  log  phase,  characterised  by  doubling  times  of  approximately 
48  hours  and  viability  over  90%  between  passages.  Co-transfections  were  performed  in 
triplicate.  For  each  transfection  a  35mm  tissue  culture  dish  was  seeded  with  10"  SF-9 
cells  in  2ml  of  complete  medium  [  TCIOO  (Gibco,  Brl),  10%  Foetal  bovine  serum  (FBS), 
10ýLg/ml  gentamycin  ]  and  incubated  at  28*C  overnight.  In  an  eppendorf  tube  200ng  of 
viral  DNA  and  I  ýtg  of  recombinant  transfer  vector  were  mixed  in  a  total  volume  of  20111. 
Lipofectin  (Gibco,  Brl)  was  diluted  2:  1  (lipofectin  :  dH20)  and  20pil  combined  with  the 
DNA  mixture  and  incubated  for  20min.  at  room  temperature.  Meanwhile  the  cells  were 
gently  washed  twice  with  2ml  of  TCIOO  medium  (without  FBS  or  antibiotics)  and  left  in 
Iml  of  this  medium.  The  liposome-DNA  mixture  was  then  added  to  the  cells  and  after  5 
hours  of  incubation  at  28*C,  Iml  of  complete  medium  was  applied  and  the  cells  incubated 
overnight.  The  medium  was  removed  and  substituted  by  2ml  of  fresh  complete  medium 
and  incubation  was  resumed  until  48  hours  post-transfection. 
HARVES  AND  PLAQUE  PMFICATION  aF  RECOMBINANT  VIRUS 
The  cells  were  resuspended  by  vigorous  pipetting  and  the  suspension  transferred  to  sterile 
eppendorf  tubes  and  centrifuged  in  a  microfuge  at  13000  rpm  for  5min.  The  supernatant 
containing  a  mixture  of  parental  and  recombinant  virus  was  then  harvested  and  filtered 
through  a  0.45ýLrn  filter  for  plaque  purification.  The  virus  suspension  obtained  was  added 
both  neat  and  at  a  10'  dilution  in  a,  ý61ume  of  1001A  to  35min  tissue  culture  dishes  seeded 
with  10"  Sf-9  cells  and  incubated  for  I  hour  at  room  temperature.  Meanwhile  sufficient 
3%  low  melting  point  Seaplaque  agarose  (Flowgen)  in  dH,  O  was  melted  and  equilibrated 
at  45*C.  The  inoculum  was  removed  and  discarded  and  2ml  of  3%  agarose  mixed  1:  1 
with  complete  TC  100  medium  (at  room  temperature)  was  added  to  the  cells  and  allowed 
to  set.  The  solid  agarose  overlay  was  covered  with  1.5ml  of  complete  medium  and  the 
91 plates  incubated  at  27*C  for  3  to  4  days.  A  viable  cell  stain  was  prepared  containing  0.1% 
neutral  red  (w/v)  and  X-gal  (0.4mg/ml)  in  dH20.  The  stain  was  added  to  the  overlayed 
cells  (O.  5ml  per  dish)  and  incubated  for  1  hour  at  27*C.  The  supernatant  was  removed  and 
the  dishes  were  inverted  and  left  to  stand  overnight  in  the  dark  and  at  room  temperature. 
A  total  of  nine  white  plaques  (three  per  co-transfection)  were  picked  using  sterile  plastic 
Pasteur  pipettes  and  resuspended  into  bijoux  containing  2ml  of  complete  medium.  The 
bijoux  were  vortexed  and  stored  at  4"C  until  further  use.  The  resuspended  virus  passed 
through  two  more  rounds  of  plaque  purification.  Three  blue  plaques  (of  parental  virus) 
were  also  picked  to  serve  as  negative  control  in  downstream  procedures. 
Screening  for  recombinant  Baculo-eqlFN-y  virus 
After  each  of  the  three  rounds  of  plaque  purification  the  resuspended  plaques  were 
screened  for  the  presence  of  eqIFN--y  by  PCR.  A  negative  control  consisting  of  a  parental 
virus  plaque  suspension  was  used.  Viral  templates  tG  be  used  in  PCR  amplification  were 
prepared  simply  by  boiling  plaque  suspension  aliquots  for  10min,  centrifugation  in  a 
microfuge  at  13000  rpm,  and  transferring  supernatants  to  fresh  tubes. 
Primer  Sequence  Tm 
5'  Primer  5'-  GCG  TCC  ACC  ATG  AAT  TAT  AC-3'  580C 
3'Primer  5'-  GGA  TAC  TGT  ATT  GCA  GGC  AG-3'  600C 
The  primers  above  were  used  at  a  concentration  of  0.5gM  (2.5gl  of  each  primer)  in  a 
50ptl  reaction  volume  containing  2.5  units  (0.5gl)  of  Taq  polymerase,  5gl  of  IOX  PCR 
buffer,  5gl  of  dNTP  mix  (1.25  mM  each)  and  24.5ýtl  of  dH20.  The  template  consisted  of 
l[tl  of  boiled  viral  supernatants  in  9ýd  of  dH20.  Cycling  parameters  were:  94'C  for  5 
min.;  followed  by  30  cycles  of  94"C  for  30  sec.,  55T  for  45  sec.  And  72*C  for  I  min.; 
followed  by  a  final  extension  step  of  72'C  for  7  min.  and  by  chilling  at  4T.  PCR 
amplification  was  assessed  by  running  lOul  of  product  in  a  ethidium  bromide  stained 
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1.2%  TAE  agarose  minigel  and  visualisation  under  UV  light  of  a  band  with  an 
approximate  size  of  500bp. 
Propagation  and  titration  of  Baculo-eqIFN-y  virus 
Two  recombinants  (1.3.1  and  3.5.1)  were  selected  for  propagation  and  "large  scale" 
production  of  recombinant  eqIFN-y.  To  this  effect,  100[il  of  each  selected  plaque 
suspension  (from  the  third  round  of  purification)  was  used  to  infect  a  75cm'  tissue  culture 
flask  seeded  with  5xlO`  SF-9  cells.  After  1  hour  of  incubation  at  room  temperature  the 
cells  were  overlayed  with  15ml  of  complete  medium  and  incubated  for  7  days  at  271C. 
The  medium  was  harvested,  freed  of  cell  debris  by  centrifugation  filtered  through  a 
0.22ýLrn  filter  and  stored  at  4"C.  Titration  was  performed  using  the  standard  plaque  assay 
described  above.  Dilutions  of  the  virus  were  made  (10-ý  10',  10'  and  10-7  )  and  plated  in 
duplicate.  To  determine  the  virus  titre  the  monolayers  were  stained  and  the  plaques  were 
counted  in  the  dilution  that  enabled  clear  distinction  of  the  plaques  (dishes  containing 
from  5  to  30  plaques).  The  titre  is  given  in  plaque  forming  units  per  millilitre  (pfu/ml) 
and  is  calculated  by  the  average  number  of  plaques  between  the  two  dishes  of  the  same 
virus  dilution,  multiplied  by  the  dilution  factor  (10',  10',  etc.  )  and  by  10  (as  only  0.1  ml  of 
virus  dilution  was  applied  to  each  dish).  Propagation  of  baculuvirus  constructs  was 
accomplished  by  infecting  SF9  cells  with  a  multiplicity  of  0.1  to  0.2  pfu/cell.  After  one 
hour  incubation  and  harvesting  of  the  inoculum,  cells  were  replenished  with  fresh 
medium  and  incubated  at  27*C  for  6  to  7  days.  After  three  rounds  of  infection,  the  titres 
obtained  for  individual  baculovirus  constructs  were:  R107  pfti/ml  for  Baculo.  eqIFN-Y 
(1.3.1);  4.8xl  07  pftL/ml  for  Baculo.  eqIFN-y  (3.5.1);  and  LR107  pfu/ml  for  Baculovirus 
wild  type. 
Large  scale  production  of  eqIFN-y  in  bacuIovirus 
For  production  of  baculovirus  derived  eqIFN-y,  healthy  SF21  cells  were  infected  as 
before  with  a  multiplicity  of  10  p.  f.  u  /  cell.  Cells  were  incubated  at  2'17"C  for  3  and  4  days. 
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Incubation  times  were  based  on  optimisation  of  expression  of  feline  IFN-y  in  baculovirus 
(Dr  D.  Argyle  personal  communication).  The  medium  was  then  harvested  by 
centrifugation,  dialysed  against  PBS  (I  litre  per  ml  of  supernatant,  changed  four  times), 
using  a  30ml  lOkDa  molecular  weight  cut  off  slide-a-lyser  (Pierce),  filtered  through  a 
0.22ýtm  filter,  aliquoted  and  stored  at  -70C. 
3.2.3  Expression  in  mammalian  cells 
Cloning  eqIFN-y  into  pCI-neo 
Full  length  eqIFN-y  cDNA  was  recovered  from  pBlueScript  (pBS)  plasmid  as  follows 
(see  figure  3.5).  10ýig  of  pBS-EqIFN-y  was  added  to  20  units  of  Xhol  and  20  units  of 
Notl  in  aI  00ýil  volume  and  digested  at  3  7'C  for  four  hours.  The  reaction  was  stopped  by 
the  addition  of  12ýtl  of  I  OX  DNA  loading  buffer  (mat&meth). 
pBS-EqIFNy 
E-RI 
HmdW 
Xhol,  'Notl 
y 
d1l, 
pCIneo-Eq[FNy 
Tmnsfection 
/ 
.................. 
Cclls  and  SupematanLs  24  h  48  h  72  h 
Nh  .1 
xh"l 
SIAXI 
Figure  3.5  Schematic  depicting  the  expression  of  eqIFN-7  in  mammalian  cells. 
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The  sample  was  loaded  onto  a  1.2%  TAE  agarose  minigel,  stained  with  ethidium 
bromide,  and  electrophoresed  at  90  volts  for  I  hour.  Upon  UV  visualisation,  a  band  of 
approximately  500bp  in  length,  as  compared  to  a  DNA  molecular  weight  standard 
(ýX174  RF  DNA/Hae  III  fragments),  was  excised  and  the  DNA  extracted  using  Wizard 
PCR  Prep  (Promega)  and  eluted  in  50ýfl  of  dH20.  Similarly,  1011g  of  pCI-neo  DNA 
(Promega)  was  digested  with  XhoI/NotI  and  gel  purified.  Ligation  of  the  fragments  was 
then  performed  (as  described  before). 
The  E.  coli  strain  Max  Efficiency  DHIOB  was  transformed  and  recombinant  clones  were 
screened  by  restriction  analysis  of  minipreped  DNA,  using  YhoI/NotI  enzymes  followed 
by  agarose  gel  electrophoresis,  producing  a  band  of  approximately  500  bp.  Two  clones 
containing  the  correct  size  insert  were  sequenced  by  automated  sequencing  (mat&meth) 
using  the  following  primers: 
Primer  Sequence  Tm  Target 
T3 
T7 
5'-  CAT  TAA  CCC  TCA  CTA  AAG  GG  -3' 
5'-  TTA  ATA  CGA  CTC  ACT  ATA  GG  -31 
58"C 
54"C 
Vector 
Vector 
DNA  from  one  clone  showing  100%  identity  with  published  equine  IFN--y  sequence 
(Curran  et  al,  1994)  was  large  scale  purified  and  taken  through  to  the  next  stage. 
Transfection  of  mammalian  cells  and  RNA  analysis 
To  investigate  if  the  cloned  gene  was  functional,  the  COS-7  cell  line  was  used  for 
transient  expression  of  eqlFN-y.  Cells  were  transfected  using  the  Calcium-phosphate 
based  "Mammalian  Transfection  Kif'  (Stratagene)  according  to  the  manufacturer 
guidelines.  As  a  negative  control  cells  were  also  transfected  with  empty  pCI-Neo 
plasmid.  The  medium  was  then  harvested  at  24,48  and  72  hours  by  centrifugation, 
filtered  through  a  0.22ýtrn  filter,  dialysed  against  PBS  (as  described  before)  using  a  30ml 
I  OkDa  molecular  weight  cut  off  slide-a-lyser  (Pierce),  aliquoted  and  stored  at  -70'C. 
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Detection  of  eqlFN-y  expression 
Transfected  cells  were  collected  by  trypsinisation  and  centrifugation  at  24,48  and  72 
hour  time  points.  Total  RNA  was  extracted  from  cells  using  "Rneasy  Midi  Kit"  (Qiagen) 
and  contaminating  DNA  was  removed  by  incubating  the  samples  with  I  unit  of  DNAse  I 
(Gibco  BRL)  per  pg  of  RNA  for  20  min  at  37C  followed  by  enzyme  inactivation  at  65*C 
for  5  min.  and  by  phenol/chloroforin  extraction  of  the  resulting  RNA.  The  purified  RNA 
was  quantified  by  spectrophotometry  and  analysed  by  northern  blot  (mat&meth)  using  a 
gene  specific  radiolabelled  probe.  The  probe,  consisting  of  a  fragment  eqIFN-y, 
generated  by  EcoRI  digestion  of  Bluescript-eqlFN--y  plasmid  DNA,  was  labelled  with  [a- 
32  P]dCTP  (Amersham)  making  use  of  the  "Oligolabelling  Kit"(Pharmacia).  A  probe  for 
the  house-keeping  enzyme  GAPDH  (mat&meth)  was  used  for  quality  control  of  the  RNA 
preparations. 
3.2.4  Immunological  detection  of  eqlFN-y 
The  detection  of  eqIFN-y  derived  from  the  various  heterologous  expression  systems, 
confirming  the  identity  of  the  expressed  products,  was  accomplishedby  means  of  specific 
antibodies  against  eqIFN-y.  In  an  attempt  to  explore  the  possibility  of  benefiting  from 
commercially  available  antibodies  for  the  detection  of  eqIFN--y,  a  panel  of  monoclonal 
antibodies  to  human  and  murine  EFN-y  expressed  in  bacteria  was  used  in  western  blots 
but  no  cross-reactivity  was  observed. 
Antibody  tested  Antibody  type  Supplier  Catalogue  No. 
anti-human  IFN-y 
anti-mouse  IFN-y 
mouse  monoclonal 
rat  monoclonal 
Serotec 
Serotec 
MCA1533B 
MCA  1394 
anti-human  IFN-y  mouse  monoclonal  R&D  MAB  285 
anti-human  IFN-y  mouse  monoclonal  Chernicon  MAB408 
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The  rationale  of  testing  monoclonal  antibodies  rather  then  polyclonal  serum  was  the 
possibility  monoclonals  brought  of  developing  a  capture  ELISA  suitable  for  quantitation 
of  recombinant  and  natural  equine  IFN-y  preparations. 
3.2.4.1  Antibodies  to  eqlFN-y  peptides 
Antibodies  specific  to  eqlFN--y  in  the  form  of  polyclonal  rabbit  sera  were  obtained  using 
two  strategies.  The  first  involved  the  immunisation  of  rabbits  with  synthetic  peptides  and 
the  second  made  use  of  GST-eqlFN-y  fusion  protein  for  immunisation. 
Design  and  Synthesis  of  eqlFN-y  peptides 
I 
To  increase  the  probability  of  a  peptide  being  immunogenic,  a  few  simple  guidelines  are 
to  be  followed:  peptides  are  ideally  10  to  20  residues  in  length,  hydrophilic  and/or 
flexible  amino  acids  are  more  likely  to  be  exposed  in  the  surface  of  molecules  therefore 
forming  epitopes;  the  amino  and  carboxy  termini  are  also  generally  exposed  (reviewed  in 
Harlow  and  Lane,  1988).  To  facilitate  the  design  of  peptides  the  nucleotide  sequence  of 
equine  IFN--y  cDNA  (Curran  et  al,  1994)  was  analysed  using  GCG  software.  The 
predicted  amino  acid  sequence  was  analysed  using  the  programs  'Teptidestructure"  and 
'Tlotstructure"  to  display  graphically  (figure  3.6)  the  antigenic  index  as  predicted  by  the 
Jameson  and  Wolf  index  (Wolf  et  al,  1987).  The  calculation  of  the  antigenic  index  takes 
into  consideration  various  predicted  parameters,  such  as:  N-linked  glycosylation; 
hydrophilicity  (according  to  Kyte  and  Doolitle);  surface  probability  (Emini);  chain 
flexibility  (Karplus-Schulz);  secondary  structure  (according  to  Chou-Fasman  and 
Gamier-Osguthorpe-Robson). 
Two  regions  of  the  molecule,  with  20  amino  acids  in  length  and  scoring  a  high  antigenic 
index,  were  chosen  to  serve  as  immunogens: 
Peptide  35  NH2-  AFFKEIENLKEYFNASNPDV-  COOH  (residues  26  to  45) 
Peptide  36  NH2-  DLSPKANLRKRKRSQNPFR-  COOH  (residues  142  to  161) 
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Figure  3.6  Analysis  of  eqIFN-y  predicted  amino  acid  sequence  using  GCG  software, 
showing  predicted  antigenic  structure  of  the  molecule  (Wolf  et  al,  1987). 
Both  peptides  correspond  to  regions  of  the  human  IFN-,  y  molecule  thought  to  be  involved 
in  receptor  biding,  and  are  for  that  reason  flexible  structures,  constituting  therefore, 
potentially  good  immunogens  (reviewed  in  3.1.1). 
so 
MKYTSFILAF  QLCAILGSST  YYCQAAFFKE  IENLKEYFNA,  SNPDVGDGGP 
51  100 
LFLDILKNWK  EDSDKKIIQS  QIVSFYFKLF  ENLKDNQVIQ  KSMDTIKEDL 
101  150 
FVKFFNSSTS  KLEDFQKLIQ  IPVNDLKVQR  KAISELIKVM  NDLSPKANLR 
151 
. 
166 
KRKRSQNPFR  GRRALQ 
Figure  3.7  Amino  acid  sequence  of  eqIFN-y  showing  peptide  sequences  selected  for  use 
as  immunogens. 
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Pcptides  were  synthesiscd  using  a  multiple  antigen  peptide  (MAP)  system  (Tam,  1988) 
consisting  of  a  small  inner  core  of  branched  lysine  residues,  to  which  multiple  copies  of 
the  peptide  antigen  can  be  attached.  The  immunogenicity  of  peptides  synthesised  in  this 
fashion  is  greatly  increased  due  to  the  mobility  conferred  by  the  branching  conformation 
of  MAP.  This  system,  when  compared  with  the  linear  conjugation  of  peptides  to  carrier 
proteins  (such  as  bovine  serum  albumin),  has  the  additional  advantages  of  not  altering  the 
folding  of  the  peptides  and  because  the  carrier  is  internal  it  does  not  constitute  an 
immunogen  per  se,  therefore  not  contributing  significantly  to  the  total  antibody  response 
(Tam  and  Shao,  1993).  Synthesis  was  performed  in  a  432A  Peptide  Synthesiser  (Applied 
Biosystems)  operated  by  Mr  Tom  Dunsford  (Department  of  Veterinary  Pathology, 
Glasgow) 
.  Peptide  35  and  36  were  synthesised  as  multiple  antigen  peptides,  in  a4 
branched  lysine  synthesis  column  using  the  Fast-moc  procedure  as  detailed  in  the 
manufacturer  instructions.  Both  peptides,  obtained  as  freeze-dried  preparations,  were 
reconstituted  in  dH20  to  I  mg/ml,  aliquoted  and  stored  at  -70*C 
Preparation  of  immunogen  and  immunisation  of  rabbits 
Immunogens  were  prepared  by  the  combination  of  peptides  with  Freund's  adjuvant  (FA) 
that  consists  of  non-metabolisable  oils.  The  addition  of  the  aqueous  peptide  solution 
produces  a  water  in  oil  emulsion  which  prevents  dispersion  of  the  immunogen  and 
generates  a  strong  and  durable  non-specific  immune  response.  For  primary 
immunisations  the  peptides  were  combined  with  complete  Freund's  adjuvant  (CFA) 
prepared  by  the  addition  of  inactivated  Mycobacterium  tuberculosis  vaccine  (Bacillus 
Calmette-Guerin-  BCG).  Booster  immunisations  consisted  of  peptide  combined  with 
incomplete  Freund's  adjuvant  (IFA)  to  prevent  adverse  side  effects  associated  with 
repetitive  inoculation  of  CFA,  such  as  ulcerative  and  granulornatous  lesions  (reviewed  in 
Harlow  and  Lane,  1988).  To  prepare  CFA,  O.  Iml  of  BCG  vaccine  (Evans  Medical  Ltd.  ) 
was  added  to  0.9ml  of  aqueous  peptide  solution.  This  mix  was  then  combined  with  2ml 
of  non-ulcerative  FA  (NUFA  -  Guildhay  Ltd.  )  to  produce  a  water  in  oil  emulsion.  The 
procedure  for  preparation  of  IFA  simply  excludes  the  addition  of  BCG. 
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Four  adult  New  Zealand  white  rabbits  (two  per  peptide),  were  selected  and  prior  to 
immunisation  15ml  of  blood,  from  each  rabbit,  was  collected  from  the  marginal  ear  vein 
into  sterile  glass  universals.  The  blood  was  left  at  room  temperature  for  a  few  hours  and 
then  left  to  clot  overnight  at  4*C.  Senun  was  harvested  and  transferred  to  clean  universals 
and  residual  red  blood  cells  pelleted  by  centrifugation  at  3000  rpm  for  10  min.  in  a  bench 
top  centrifuge.  The  serum  was  then  aliquoted  (I  ml  aliquots)  and  stored  at  -20*C.  The  pre- 
immune  serum  derived  from  this  blood  was  to  be  used  as  a  negative  serum  control.  The 
immunisation  using  a  standard  protocol  is  outlined  below.  Each  inoculation  consisted  of  a 
total  volume  of  I  ml,  administered  subcutaneously,  divided  between  four  sites: 
Rabbit  V579  V693  V566  V606 
Peptide  35  35  36  36 
I"  Immunisation 
(CFA) 
looýLg  looýtg  loogg  loogg 
4  WEEKS 
Booster  (EFA)  loogg  loogg  100ýtg  loogg 
14  DAYS 
Serum  Collection  V579  V693  V566  V606 
Ten  to  fifteen  millifitres  of  blood  was  collected  14  days  post-immunisation,  and 
respective  serum  prepared  as  before.  All  immunisations  and  bleedings  were  performed  by 
Home  Office  Licence  holder  Dr  David  Argyle  (Department  of  Veterinary  Pathology, 
Glasgow). 
Indirect  antibody  ELISA 
An  indirect  antibody  enzyme  linked  immunosorbent  assay  (ELISA)  was  performed  to 
verify  the  specificity  and  sensitivity  of  the  sera  in  the  detection  of  the  respective  peptides 
and  to  assess  cross  reactivity  between  sera  and  peptides.  For  this  purpose  an  ELISA 
starter  kit  (Pierce  &  Warriner)  which  consists  of  coating  and  washing  buffers;  goat  anti- 
rabbit  IgG  (H+L)  antibody,  conjugated  with  -horseradish  peroxidase  and  the  enzyme 
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substrate  [2,2'-azinobis(3-ethylbenzothiazoline-6-sulphonic  acid)  diammonium.  salt 
(ABTS)  ]  was  used.  Initially  each  antiserurn  was  assayed  in  a  bi-dimensional  titration 
procedure,  where  both  the  primary  and  secondaryý  antibodies  were  serially  diluted  in 
checker  board  fashion  (see  diagram  below).  To  this  effect  peptides  35  or  36  were  diluted 
to  5gg/ml  in  coating  buffer  (carbonate-bicarbonate  buffer  -  BupH'),  100  jil  was  added  to 
each  well  of  a  96  well  ELISA  plate  and  the  plates  were  incubated  at  room  temperature  for 
I  hour.  After  incubation  the  plates  were  washed  by  addition  of  I  00gl  per  well  of  wash 
buffer  (modified  Dulbecco's  phosphate  buffered  saline  with  tween  20  and  bovine  serum 
albumin).  The  wash  was  repeated  twice  more  for  a  total  of  three  washes. 
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The  plates  were  then  blocked,  for  30  min  at  room  temperature,  with  I  00ml  per  well  of  1% 
BSA  in  wash  buffer.  To  titrate  the  primary  antibody,  100ýtl  of  wash  buffer  was  added  to 
each  well  of  rows  B  to  G  and  190pl  to  row  A.  Then  I  Optl  of  serum  to  be  tested  was  added 
to  each  well  of  row  A  (to  give  a  1/20  dilution).  The  antibody  was  serially  diluted  1/2  (by 
pipetting  100pl)  from  row  A  to  G.  To  row  H  was  added  a  1/20  dilution  of  pre-immune 
serum  (P.  I.  S.  )  in  wash  buffer,  as  a  negative  control.  Plates  were  incubated  for  I  hour  at 
room  temperature  and  washed  three  times  as  before.  The  secondary  antibody  is  titrated  in 
the  same  fashion,  but  this  time  starting  in  column  I  and  with  a  1/100  dilution.  Column  12 
is  left  without  secondary  antibody  as  a  negative  control.  Plates  were  incubated  for  30  min. 
at  room  temperature,  washed  three  times  and  100ýtl  of  the  enzyme  substrate  (ABTS)  was 
added  to  each  well.  After  30  min  of  incubation  plates  were  read  at  an  absorbance  of 
405nm  using  an  ELISA  plate  reader  model  EL312  (Bio-tek  Instruments  Inc.  ). 
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A  further  ELISA  assay  was  devised  to  investigate  if  each  sera  had  unique  specificity  for 
the  peptide  used  as  immunogen  or  if,  on  the  other  hand,  they  were  cross  reactive.  This 
time,  though,  information  collected  in  the  previous  assay  led  to  optimisation  of  the 
dilutions  of  primary  and  secondary  antibodies  used  (see  diagram  below).  Thus,  rows  A  to 
D  were  coated  with  peptide  36,  rows  E  to  G  with  peptide  35  and  row  H  was  left 
uncoated.  Columns  I  to  9  contained  the  primary  antibody  serially  diluted  twofold  from 
1/200  through  to  1/51200.  To  column  10  no  primary  antibody  was  added  and  columns  II 
and  12  contained  a  1/200  and  a  1/800  dilution  of  pre-immune  serum,  respectively.  Rows 
A  and  E;  B  and  F;  C  and  G,  contained  secondary  antibody  in  decreasing  concentrations 
(1/2500;  115000;  1/10000,  respectively).  Row  D  was  negative  control  for  the  secondary 
antibody.  Incubation  times  and  washes  were  as  before. 
Coat.  No 
2  nd  lst  P.  1  serum 
Pep 
36, 
'I  , 
Pep 
3[ 
No 
Pep 
Detection  of  GST-eqlFN-y  by  anti-peptide  sera 
A  series  of  ELISA  assays  were  performed  to  ascertain  if  anti-peptide  antibodies  would 
recognise  mature  eqIFN-y.  The  assay  was  similar  to  the  one  described  previously.  In 
summary,  each  well  of  a  96  well  plate  was  coated  with  100  jil  of  GST-eqIFN-y  at 
l0gg/ml  (as  assessed  by  Bradford).  Two  sera  were  tested  per  plate  and  were  twofold 
serially  diluted  (1/200  through  to  1/51200).  Secondary  antibody  was  used  at  different 
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concentrations  (1/2500,115000,1/10000)  as  before.  Sufficient  wells  were  allocated  for 
pre-immune  antibody  control  and  absence  of  secondary  antibody. 
3.2.4.2  Antibodies  to  GST-eqlFN-,  y 
Crudely  purified  GST-eqIFN-y  fusion  protein  (as  described  above,  3.2.1.1)  was  used  to 
immunise  rabbits  and  consequently  raise  polyclonal  serum.  The  option  of  using  the 
tagged  protein  (as  opposed  to  the  cleaved  eqlFN-y  molecule)  was  justified  by  the 
reported  highly  immunogenic  character  of  the  GST  tag  (Campbell  et  al,  1995).  Two  adult 
New  Zealand  white  rabbits  (82  and  95)  were  selected  for  immunisation.  The  protocol  for 
preparation  of  the  immunogen,  as  well  as  the  dose  and  route  of  administration  were  the 
same  as  used  for  the  production  of  anti-eqlFN-peptide  serum  using  100pg  of  GST- 
eqIFN-y  per  inoculation.  Significantly  the  immunisation  procedure  for  rabbit  82 
consisted  of  a  primary  immunisation  of  GST-eqIFN  combined  with  CFA,  followed  by 
three  boosts  (combined  with  IFA)  at  six  weeks  intervals.  In  the  case  of  rabbit  95  only  one 
boost  was  made,  with  thrombin  cleaved  eqIFN-y.  Bleeds  were  made  two  weeks  after 
each  immunisation.  This  work  was  executed  in  collaboration  with  Dr  Jay  Patel  at  Intervet 
UK  (The  Elms.  -  Cambridge).  On  receipt,  sera  were  labelled  82-A,  82-B,  82-C  and  95-A. 
Sodium  Azide,  to  a  final  concentration  of  0.01%  (w/v),  was  added  to  the  sera,  followed 
by  aliquoting  in  500pl  aliquots;  and  freezing  at  -70*C. 
3.2.4.3  Detection  of  expressed  products 
For  the  immunological  detection  of  eqlFN-y  produced  in  different  expression  systems, 
typically  10ýd  of  each  sample  to  be  analysed  was  combined  with  2ýfl  of  IOX  protein 
loading  buffer  and  ran  on  SDS-PAGE  (mat&meth).  Following  transfer  to  a  PVDF 
membrane  and  blocking,  the  polyclonal  serum  to  GSTeqlFN-y  was  used  as  primary 
antibody  at  a  dilution  of  1/10000.  The  secondary  antibody  was  an  anti-rabbit  IgG 
peroxidase  conjugate  (Sigma  A-6154)  diluted  to  115000.  ECL  reagents  (Amersham)  were 
used  to  develop  blots.  The  full  protocol  for  western  blot  is  described  in  mat&meth. 
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Potency  of  signal  after  ECL  detection,  proportional  to  the  quantity  of  eqIFN-y,  was  the 
main  selection  criterion  for  samples  to  be  tested  in  in  vitro  bioactivity  experiments. 
Additionally,  within  samples  with  equivalent  amounts  of  recombinant  protein,  were 
selected  those  derived  from  shorter  time  point  infections  or  transfections,  in  order  to 
minimise  degradation  and  loss  of  activity  of  secreted  recombinant  IFN-y  exposed  to 
temperatures  over  25*C.  Also,  as  detailed  before,  samples  were  dialysed  against  PBS  (pH 
7.0),  as  pH  values  higher  than  9.0  and  lower  than  5.0  lead  to  rapid  loss  of  IFN--y  activity 
(Farrar  and  Schreiber,  1993).  Particularly  for  baculovirus  derived  eqIFN-y,  the  choice  of 
samples  was  also  influenced  by  fmdings  obtained  in  the  case  of  feline  interferon  gamma 
in  this  department  (Dr  D.  Argyle  personal  communication). 
Samples  taken  through  assessment  of  biological  activities  were: 
Baculovirus.  eqlFN--y(3.5.1)  72  hours  infection  supernatant  BaclFN72 
Baculovims.  eqIFN-y  (3.5.1)  96  hours  infection  supernatant  BacIFN96  TEST 
PciNeo.  eqEFN-y*  24  hours  transfection  supernatant  PciIFN24  SAMPLES 
PciNeo.  eqlFN-y*  48  hours  transfection  supernatant  PciIFN48 
Baculovirus  wild  r  ype  72  hours  infection  supernatant  Bacwt  NEG. 
Pci-neo*  48  hours  transfection  supernatant  Pcineo  CONTROLS 
(*)  Mammalian  expression  constructs  were  assayed  at  one  instance  only,  in  the 
cytopathic  effect  reduction  assay. 
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3.2.5  Bioactivity  in  vitro  of  EqIFN-y 
3.2.5.1  Cytopathic  effect  reduction  assay 
The  assay  is  loosely  based  in  that  described  by  Familletti  et  al  (198  1). 
PREPARATORY  PROCEDURES 
A  stock  of  VSV,  originally  adapted  to  feline  embryonic  fibroblasts  (FEA)  was  kindly 
provided  by  Dr.  David  Argyle  (Department  of  Veterinary  Pathology).  The  virus  was 
adapted  to  EEK  and  MBDK  cell  lines  by  consecutive  passages  of  virus  at  a  multiplicity 
of  infection  of  0.2  TCID50/cell,  until  a  high  titre  was  obtained,  as  assessed  by  TCIDSO. 
Cell  growth  experiments  were  made  and  the  number  of  cells  per  well  necessary  for  the 
production  of  a  monolayer  in  36h  was  2x  10"  for  EEK  and  1.5x  1  04  MBDK- 
VIRUS  TrrRATIO 
TCID50  was  performed  by  adding  the  above  amount  of  cells  per  well  of  a  96  well  plate 
and  incubate  for  20  h  at  37*C  and  5%  C02..  Logarithmic  dilutions  of  the  virus  were  made 
in  complete  cell.  medium  (EMEM,  10%  FBS, 
- 
2mM  glutamine,  IX 
Penicillin/Streptomycin  for  EEK  and  MEM,  5%  FBS,  2mM  glutamine,  IX  Non  essential 
amino  acids,  IX  Penicillin/Streptomycin  for  MDBK)  and  incubation  at  31*C  for  72  h. 
Plates  were  scored  by  inverted  microscopy  at  IOX  magnification.  The  virus  had  a  final 
titre  of  1.5xlO'  TCID5WMl  in  EEK  and  IxIO'  TClD5O  /ml  in  MBDK,  as  calculated  by  the 
formula: 
Log  TCID50  =D-x  (S  -  0.5  ) 
where:  D=  log  of  the  lowest  dilution  showing  100%  CPE 
x=  difference  between  successive  dilutions 
S=  sum  of  proportional  mortalities  (sum  of  the  percentual  score  of 
mortality  in  successive  dilutions  from  100%  to  0%  CPE) 
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The  time  necessary  for  development  of  100%  CPE  in  the  dilution  corresponding  to  100 
TCID,,,  was  also  noted  (48  h). 
ASSAY  CONDITIONS 
Twofold  dilutions  of  the  samples  (BacIFN72/96  and  PciIFN24/48)  or  of  negative  control 
samples  (Bacwt  and  Pcineo)  were  performed  in  sufficient  96  well  plates.  Each  sample 
was  analysed  in  a  different  plate  and  wells  were  left  without  interferon  to  serve  as  cell 
and  virus  controls.  Each  well  was  then  seeded  with  2xlO"  (EEK)  or  1.5xlw  (MBDK) 
cells.  Cells  were  incubated  at  37C  for  20  hours.  After  incubation  the  supernatants 
containing  interferon  were  removed  and  cells  were  gently  washed  twice  with  PBS,  and 
fresh  medium  added  to  the  cells.  VSV  virus  was  diluted  and  100ýfl  of  each  dilution  was 
added  to  the  plates  as  follows:  IOOTCID,,,  were  added  in  fourfold  to  wells  corresponding 
to  each  interferon  dilution;  in  the  same  fashion  I  OTCID50  were  added  to  threefold  wells;  a 
back  titration  of  the  virus  was  also  performed  in  each  plate;  some  wells  were  left  free  of 
virus  to  serve  as  cell  controls  (figure  3.8). 
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Figure  3.8  Cytopathic  effect  reduction  assay  setup. 
Plates  were  incubated  at  31"C  until  100%  CPE  was  observed  in  the  virus  control  wells 
(48  h).  The  medium  was  removed  from  the  wells  and  the  cells  stained  /  fixed  by  adding 
50ýil  of  0.5%  crystal  violet  in  70%  methanol  to  each  well  and  incubating  5  min  at  room 
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temperature.  The  excess  stain  was  decanted  and  the  plates  rinsed  thoroughly  with  tap 
water  and  air-diied  at  room  temperature.  Interferon  laboratory  titre'of  the  samples  was 
calculated  as  the  reciprocal  of  the  dilution  of  interferon  that  protected  50%  of  the  wells 
from  the  CPE  of  the  virus. 
3.2.5.2  Proliferation  assay  for  Equine  IFN-y 
PREPARATION  OF  EQUINE  PERIPHERAL  BLOOD  LYMPHOCYTES  (PBLS) 
Whole  horse  blood  (SAPU  Lanarks,  UK)  supplied  1:  1  in  Alsever's  solution,  was  diluted 
with  an  equal  volume  of  ice  cold  PBS  (mat&meth)  and  layered  onto  a  Ficoll  gradient 
(Ficoll-Paque  Plus,  Pharmacia  Biotech)  in  50ml  Falcon  tubes  and  centrifuged  at  1500g  at 
4*C  in  excess  of  30  min.  Cells  in  the  interface  were  carefully  aspirated,  washed  in  an 
equal  volume  of  PBS  (by  centrifugation  at  1000g)  and  resuspended  in  Iml  of  PBS  per 
10ml  of  original  volume  of  blood.  An  equal  volume  of  freshly  prepared  red  blood  cell 
lysis  buffer  (mat&meth)  equilibrated  at  37"C  was  added  to  the  cell  suspension  and 
incubated  with  rocking  movement  at  37*C  for  under  4  min.  The  cells  were  then  recovered 
by  centrifugation  as  before  and  washed  twice  in  complete  lymphocyte  medium  (RPMI 
1640  with  2%  FCS,  100  IU/mI  of  penicillin/streptomycin,  I  OmM  Hepes,  2mM  Glutamine 
and  5xI0-'M  P-mercaptoethanol).  Cells  were  then  counted,  resuspended,  in  freezing 
medium  (90%  FCS,  10%  dimethyl-sulfoxide)  to  IxIO'  cells/ml.  aliquoted  in  cryo-tubes 
(Iml  aliquots)  and  frozen  using  a  programmable  cell  freezer  (Planer  KryolO)  and  a 
standard  protocol  for  lymphocytes.  On  completion  of  the  freezing  cycle,  cells  were 
transferred  to  liquid  nitrogen  and  stored  until  needed. 
ASSAY  CONDITIONS 
The  following  protocol  was  modified  from  one  used  for  the  detection  of  murine  IL-12 
bioactivity  in  phytohaemagglutinin  stimulated  lymphoblasts  (Schoenhaut  et  al,  1992). 
PBLs  retrieved  from  liquid  nitrogen  were  quickly  thawed  at  37*C,  diluted  in  complete 
lymphocyte  medium  and  incubated  for  2  hours  at  371C  and  5%  CO..  Cells  were  then 
recovered  by  centrifugation,  counted  and  cultured  at  a  density  of  IxIO'  cells/ml  in 
complete  lymphocyte  medium  contairling  rhIL-2  and  5jig/ml  of  Concanavalin  A  (ConA) 
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(Sigma)  and  incubated  at  37C  for  48  hours.  Recombinant  human  IL-2  (rhIL-2)  obtained 
as  a  supernatant  of  stably  transfected  LTK7  cells  (T.  Hattori  et  ao,  kindly  supplied  by  Dr. 
Margaret  Hosie  (Department  of  Veterinary  Pathology,  Glasgow)  was  used  for 
proliferation  purposes  at  a  1150  dilution  (as  suggested  by  Dr.  Hosie). 
The  cells  were  harvested,  washed  twice  in  PBS,  counted  and  resuspended  at  lxlO" 
cells/ml.  Cells  were  then  plated  in  sufficient  96  well  plates  at  50ýtl/well.  Serial  twofold 
dilutions  of  eqIFN-y  preparations  BacIFN72  and  BacIFN96  or  negative  control  (Bacwt) 
were  made  in  complete  medium  and  50ýtl  added  to  each  well  in  triplicate,  in  conjugation 
or  not  with  0.3ptg/ml  of  ConA.  This  concentration  of  ConA  was  previously  observed  not 
to  cause  PBL  proliferation. 
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Figure  3.9  Equine  PBL  proliferation  assay  setup. 
A  ConA  standard  curve,  consisting  of  twofold  dilutions  varying  'from  SýLg/ml  to 
0.16ýLg/ml  added  to  dedicated  wells  of  each  plate  in  50  ýd  volumes,  was  also  performed  to 
serve  as  an  intra-assay  positive  control.  Additional  negative  controls  consisting  of  wells 
with  cells  or  medium  only  were  also  made.  Plates  were  incubated  for  48  hours  at  37T. 
0.5ptCi  [H']  methyl-thymidine  (Amersham)  in  50ýtl  of  complete  medium  was  added  to 
each  well  and  the  cells  were  pulsed  by  incubation  for  18  hours  at  37"C.  The  cells  were 
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then  harvested  into  filters  and  washed  four  times,  using  a  cell  harvester  (Packard  Filter- 
mate  196)  and  oven  dried  at  60'C  for  I  hour.  25ýtl  of  Microscint-0  (Packard)  scintillation 
fluid  was  added  to  each  well.  'The  amount  of  'H-thymidine  incorporated  was  assessed 
using  a  scintillation  counter  (Packard  model  A9904V). 
3.2.5.3  MHC-11  Upregulation  by  EqIFN-y 
For  the  purpose  of  the  assay,  an  enriched  population  of  T  lymphocytes  was  stimulated 
with  eqIFN-y  preparations  and  appropriate  negative  controls.  The  cells  were  then  stained 
and  analysed  by  flow  cytometry  for  the  presence  of  MHC  II.  The  assay  was  based  on  the 
one  described  for  recombinant  canine  IFN-y  (Zucker  et  al,  1993). 
PREPARATION  OF T  CELLS 
T  cells  were  enriched  by  negative  selection  using  a  nylon  wool  column.  For  the 
preparation  of  columns,  ready  to  use  nylon  wool  (Polysciences)  was  teased  apart  to 
remove  clumps  using  sterile  technique.  The  wool  was  then  packed  into  a  syringe  barrel 
(1.2g  for  a  10  ml  syringe  or  2.4g  for  a  20ml  syringe),  sealed  in  a  autoclave  bag  and 
autoclaved  (1201C  for  a  minimum  of  20  minutes). 
Enough  aliquots  of  PBVs  (see  above)  stored  in  liquid  nitrogen  were  quickly  thawed  at 
37'C,  diluted  in  complete  medium  (RPMI  1640,2%  FBS,  100ýLg/ml  penicillin/ 
streptomycin,  2mM  glutamine,  5xlO-'M  B-mercaptoethanol)  and  incubated  for  2  hours  at 
37'C  and  5%  C02.  Cells  were  then  centrihged  as  before,  resuspended  in  an  appropriate 
volume  of  complete  medium  and  counted  as  before  and  a  single  cell  suspension  at  Ix  10' 
cells/ml  in  complete  medium  was  prepared.  The  column  was  attached  to  a  stand  in  a 
tissue  culture  hood  and  on  the  column  outlet  was  placed  a3  way  stopcock  (BDH,  Merck) 
and  a  23-gauge  needle.  A  minimum  of  3  volumes  of  complete  medium  was  run  through 
the  column  removing  any  air  bubbles  and  the  column  was  equilibrated  for  I  hour  at  37*C. 
The  column  was  then  flushed  with  additional  complete  medium  and  the  cell  suspension 
loaded  (10ml  column  for  up  to  1.5x!  O"  cells  and  20ml  column  for  up  to  3.  OxIO'  cells)  and 
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the  cells  allowed  to  drain  into  the  column.  A  fin-ther  I  to  3ml  of  complete  medium  was 
added  and  allowed  to  drain  into  the  column  after  which  the  stopcock  was  closed  and  the 
cells  (in  the  column)  incubated  for  1  hour  at  37*C.  The  stopcock  was  opened  and  slowly 
(rate  =1  drop/3secs)  the  cells  were  eluted  in  a  minimum  of  2  volumes  of  complete 
medium.  The  cells  were  collected  in  a  50ml  Falcon  tube,  spun,  washed  once  with 
complete  medium  and  counted  and  resuspended  at  2xlO"  cells/ml. 
ASSAY  CONDITIONS 
1 
A  volume  of  2501il  of  cells  (5xlO'  cells)  was  dispensed  in  each  well  of  a  48  well  tissue 
culture  plate.  Serial  logarithmic  dilutions  of  the  BacIFN72  preparation  and  appropriate 
control  Bacwt  were  made  in  complete  medium  and  a  250pl  volume  of  the  dilutions  was 
added  to  consecutive  wells  and  the  plates  incubated  at  37"C  with  5%CO2  for  24  hours. 
Some  wells  were  inoculated  with  complete  medium  only,  as  a  cell  control.  In  a  separate 
experiment  the  same  dilutions  of  BacIFN72  and  negative  controls  were  co-incubated  with 
rhIL-2  at  a  dilution  of  1150  as  described  previously. 
AýMBODIES 
Cells  were  stained  by  indirect  staining,  using  as  primary  antibody  mouse  IgGI  anti- 
equine  MHC  11  monoclonal  antibody  (Kydd  et  al,  1991)  commercially  available  with  the 
designation  CVS  20  (Serotec)  and  as  secondary  antibody  the  F(ab')2  fragment  of  sheep 
anti-mouse  IgG  (whole  molecule)  conjugated  to  fluorescein  isothiocyanate  (FITC) 
(Sigma).  Primary  antibodies  oflen  bind,  through  the  Fc  portion,  to  cells  expressing  FcR, 
resulting  in  an  overestimation  of  the  percentage  of  positive  epitopes  in  the  labelled  cells. 
To  investigate  if  this  overestimation  was  significant,  an  isotype  control,  termed 
"irrelevant  antibody",  with  no  epitope  specificity  but  with  same  isotype  and  subclass  as 
the  primary  antibody  (and  therefore  containing  the  same  Fc  determinant)  was  used.  The 
irrelevant  antibody,  used  in  substitution  of  the  primary  antibody,  as  a  negative  control, 
was  a  mouse  IgGI  anti-FIV  p24  mAb  (kindly  supplied  by  Dr  A.  Muller,  Dept.  of  Vet. 
Pathology,  Glasgow).  Also  as  negative  controls,  cells  were  stained  in  the  absence  of 
either  primary  or  secondary  antibody. 
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To  determine'the  relative  amounts  of  lymphocyte  subsets  in  the  cell  population  and 
therefore  the  purity  of  the  T  cells,  the  following  antibodies  were  used:  mouse  IgGI  anti- 
equine  CD5  mAb  (Serotec)  for  staining  of  T  cells;  mouse  IgGI  anti-equine  CD4  mAb 
(Serotec)  for  T  helper  cells  and  mouse  IgG2b  anti-equine  B  cell  mAb  (Serotec)  for  B 
lymphocytes.  A  pre-assay  was  performed  to  verify  if  the  cells  could  be  stained  with  the 
selected  antibodies  and  to'make  a  rough  titration  of  the  antibodies  to  optimise  the 
concentration  of  mAb  to  be  used,  minimising  waste.  For  this  purpose  unstimulated  cells 
were  stained  (as  described  below)  with  different  amounts  of  primary  mAb  (30,15,  and 
7.5gl)  and  combined  with  various  amounts  of  secondary  antibody  (20,10,  and  5gl)  in 
checker  board  fashion.  Cells  were  then  analysed  by  flow  cytometry  and  the  minimum 
amount  of  both  antibodies  that  gave  rise  to  an  optimum  fluorescence  was  noted. 
STAINING  PROCEDURE 
Prior  to  staining,  Facs  buffer  [  PBS  with  1%  (w/v)  bovine  serum  albumine  (BSA)  and 
0.1  %  (w/v)  Sodium  azide  ]  was  prepared  and  stored  at  4'C.  The  complete  content  of  each 
well  of  the  48  well  plates  (500gl  with  5xlO'  cells)  was  transferred  to  individual  labelled 
Falcon  2054  tubes  and  washed  twice.  Washing  procedure  consisted  of  addition  of  4ml  of 
Facs  buffer,  centrifugation  at  10OOrpm  for  5min,  quick  inversion  of  the  tubes  to  decant 
the  supernatant  and  gentle  resuspention  (after  inversion  of  the  tubes,  a  volume  of 
approximately  200ýtl  of  supernatant,  containing  the  cell  pellet  remains  in  the  tube). 
Following  the  second  wash,  20ýil  of  primary  antibody  was  added  to  each  cell  pellet.  The 
cells  were  gently  resuspended  in  the  remaining  supernatant  and  incubated  on  crushed  ice 
for  30min.  Cells  were  washed  twice  in  Facs  buffer  as  before.  Secondary  antibody  (10ýfl) 
was  added,  and  the  cells  were  resuspended  as  before  and  incubated  on  crushed  ice  for 
20min.  Following  incubation  the  cells  were  washed  twice  as  before  and  analysed  by  flow 
cytometty. 
FLOW  CYTOMETRY  PARAMETERS 
Fluorescence-activated  cell  sorting  (FACS)  is  the  name  given  to  the  physical  separation 
of  cells  based  on  the  presence  of  a  cell  marker  specifically  labelled  with  fluorescein,  that 
is  detected  by  a  laser  bean  focused  on  the  cells  flowing  as  a  single  cell  stream.  Flow 
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cytometry  is  the  analysis  of  subpopulations  of  cells  based  on  fluorescence  emission  (as 
above)  but  without  actual  physical  separation  of  the  cells.  A  pre-set  number  of  cells 
(acquired  events)  are  analysed  one  by  one  and  the  intensity  of  fluorescence  emitted  by 
them  is  measured.  The  measurements  are  then  plotted  in  a  chart  format  (histogram)  with 
the  number  of  cells  in  the  Y  axis  and  respective  level  of  fluorescence  (measured  by  the 
photomultiplier  tube  2-  PMT2)  in  the  X  axis.  Prior  to  the  analysis  of  samples,  the  cells 
are  gated  and  the  interval  of  fluorescence  acquisition  is  set.  Gating  is  the  selection  of 
subpopulations  of  cells  in  the  sample,  based  on  cell  measurements  such  as  cell  size 
(measured  by  the  forward  scatter)  and  granularity  (by  the  side  scatter).  Because  virtually 
all  cells  in  the  samples  were  lymphocytes,  the  gating  was  directed  to  live  cells.  As  a 
general  rule,  dead  cells  are  smaller  and  more  granular  then  live  cells.  The  interval  for 
measuring  fluorescence  was  set  by  subtraction  of  the  maximum  level  of  fluorescence 
emitted  by  unstained  cells  and  by  cells  labelled  with  an  irrelevant  primary  antibody  and  a 
FITC-conjugated  secondary  antibody.  The  departmental  FACS  machine  (Epics  Elite) 
operated  by  Dr  Linda  Andrew  was  used  to  analyse  samples. 
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3.3  Results 
3.3.1  Evidence  of  expression  of  recombinant  eqlFN-y 
Expression  in  bacteria 
A  modified  Bradford  assay  (mat&meth)  was  used  to  estimate  the  recombinant  protein 
recovery.  Typical  recovery  yields,  for  400  ml  bacterial  cultures,  were  approximately 
between  1.5  and  2mg  for  GST,  from  lmg  to  1.5mg  to  GSTeqlFN-y  and  around  0.75mg 
for  cleaved  eqIFN-y. 
Cell  lysates  of  bacteria  expressing  GST-IFN-y  fusion  protein,  following  affinity 
chromatography  were  analysed  on  a  SDS-PAGE  gel.  Coomassie  blue  staining  of  the  gels 
(figure  3.10)  reveals  that  each  sample  shows  only  one  major  protein  product.  The 
products,  of  approximately  28  and  43  kDa,  when  compared  to  a  suitable  protein  size 
marker,  correspond  to  the  expected  sizes  of  GST  protein  and  GST-eqlFN-y  fusion 
protein,  respectively.  The  smaller  products  in  the  lane  containing  GST-eqlFN-y  are 
possibly  due  to  premature  termination  of  protein  synthesis  or  to  slight  proteolytic 
degradation  of  the  fusion  protein  by  E.  coli  proteases.  This  fusion  protein  product 
corresponds  to  the  truncated  version  of  eqIFN-y  (lacking  signal  peptide).  The  expression 
of  full  length  eqIFN-y  protein  in  this  system  led  to  poor  and  inconsistent  protein  yelds 
following  purification  (results  not  shown).  Thrombin  cleavage  of  the  filsion  protein 
reveals  a  major  product  of  approximately  15  kDa,  consisting  of  mature  eqIFN-y.  In  this 
lane  can  also  be  seen  some  larger  products  that  correspond  to  GST  tag  protein  not 
completely  removed  following  cleavage  and  affinity  purification. 
Expression  in  baculovirus 
Confirmation  of  expression  of  IFN-y  in  the  baculovirus  system  was  obtained  by  plaque 
assay  and  PCR  amplification  of  plaque  viral  DNA.  Because  wild  type  virus  encodes  the 
gene  for  P-galactosi4ase  that  is  disrupted  by  the  insertion  of  foreign  genes,  after  X-gal 
staining,  plaques  corresponding  to  parental  virus  are  blue,  while  plaques  containing 
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baculo.  eqIFN-y  are  white.  Figure  3.11  (A)  shows  a  typical  plaque  assay  of  P-gal 
expressing  parental  virus.  Figure  3.11  (B)  depicts  the  PCR  amplification  of  white  plaques 
following  one  of  three  rounds  of  plaque  purification.  Plaque  assays  for  eqIFN-y 
recombinant  virus  are  not  shown. 
Mammalian  expression 
Expression  of  eqIFN-y  in  cos7  cells  was  assessed  by  northern  blot  analysis  of  total  RNA 
preparations  recovered  from  transfected  cells  harvested  at  different  time  points.  A 
negative  control  consisting  of  total  RNA  derived  from  cells  transfected  with  parental 
plasmid  is  also  used  (figure  3.12-A).  Probing  with  IFN-y  cDNA  (derived  from  restriction 
digestion  of  plasmid  DNA)  led  to  the  detection  of  transcripts  of  approximately  500b  in 
length,  consistent  with  the  expected  size  for  eqIFN-y  mRNA  molecules.  The  size  of  the 
transcripts  was  calculated  by  the  relative  electrophoretic  distance  to  ribosomal  RNA 
molecules  (28S  corresponding  to  4718  bases  and  18S  to  1874)  of  total  RNA  stained  with 
ethidum-bromide  prior  to  blotting.  A  probe  for  the  house  keeping  enzyme  GAPDH  was 
also  used  to  probe  RNA  derived  from  transfections  with  both  chimeric  (figure  3.12-B) 
and  parental  plasmid  (figure  3.12-C)  as  a  measure  of  the  quality  of  the  RNA  samples. 
3.3.2  Immunodetection  of  recombinant  eqlFN-y 
Commercially  available  antibodies  to  human  and  murine  IFN-g  were  used  for  the 
detection  of  eqlFN-y  by  western  blot  but  no  cross-reactivity  was  observed  (see  table 
below). 
Antibody  Type  Supplier  Catalogue  No.  Cross  reactivity  to: 
GST-eqIFN-g  CleavedeqIFN-g 
cc-hum  IFN-y  mAb  Serotec  MCA1533B  no  no 
cc-mse  IFN-y  mAb  Serotec  MCA  1394  no  no 
a-humIFN-y  mAb  R&D  MAB  285  no  no 
a-humWN-y  mAb  Chemicon  MA13408  no 
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This  result  is  hardly  surprising  in  light  of  the  fact  that  the  eqIFN-y  amino  acid  sequence 
as  an  homology  of  68%  towards  its  human  counterpart  and  as  low  as  45%  when 
compared  to  the  murine  equivalent. 
Antipeptide  sera 
An  example  of  the  estimation  of  antipeptide  sera  sensitivity  to  bind  corresponding 
immunogenic  peptides  is  shown  in  table  3.1,  in  a  typical  bidimensional  serial  dilution  of 
antipeptide  serum  against  secondary  antibody.  In  the  case  shown,  serum  V606  binds 
strongly  to  peptide  36  (adsorbed  to  the  plate)  with  an  endpoint  of  detection  observed  to 
correspond  to  a  1/320  dilution  of  the  peptide  serum  for  a  116400  dilution  of  secondary 
antibody.  Higher  dilutions  of  the  secondary  antibody  did  not  allow  an  endpoint  to  be 
reached.  The  endpoint  is  calculated  as  half  of  the  maximum  optical  density  reading,  in 
this  case,  at  405nm. 
In  the  second  type  of  ELISAS  the  specificity  of  the  serum  was  tested  by  assessment  of  its 
reactivity  with  peptides  35  and  36.  Additionally  the  results  of  the  first  round  of  ELISA 
are  used  for  further  optimisation  of  sera  and  secondary  antibody  concentrations. 
Assessment  of  serum  specificity  showed  that  sera  V566  and  V606  (raised  against  peptide 
36)  exhibit  strong  positivity  in  binding  to  peptide  36  and  negligible  cross  reactivity  with 
peptide  35.  In  the  case  of  serum  V606  (table  3.2)  the  endpoint  was  1/400  at  a  secondary 
antibody  dilution  of  1/10000,  confirming  the  results  of  the  previous  test  and  indicating 
optimal  antibody  concentrations  of  between  1/300  and  1/400  for  primary  antibody  and 
around  1/10000  for  secondary  antibody.  Comparable  results  were  observed  for  serum 
V566  (results  not  shown).  Additionally,  pre-immune  sera  from  both  rabbits  V566  and 
V606  showed  negligible  peptide  binding.  Sera  raised  against  peptide  35  (V579  and  V693) 
showed  insignificant  antipeptide  antibody  titre,  demonstrating  that  peptide  35  has  poor 
immunogenic  potential,  at  least  when  compared  with  peptide  36.  Sera  V606  bound  very 
poorly  to  GSTeqIFN-y  and  to  cleaved  eqlFN-y  and  failed  to  detect  these  proteins  in 
western  blots  (results  not  shown). 
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Identification  of  expressed  products 
Anti-GSTeqlFN-y  polyclonal  serurn  recognises  not  only  GST  and  GSTeqIFN-y  fusion 
protein,  but  also  thrombin  cleaved  eqIFN-y  in  western  blot  (figure  3.13).  Additionally, 
anti  GSTeqIFN-y  was  found  to  bind,  in  western  blots,  to  both  in  house  produced  feline 
IFN-y  and  commercially  available  human  IFN-y.  These  cross-reactivity  studies  were 
performed  by  L.  McMonagle,  Dept.  Veterinary  Pathology  (results  not  shown). 
Figures  3.14  and  3.15  show  the  specific  detection  of  recombinant  equine  IFN-y 
expressed  in  the  baculovirus  and  mammalian  expression  backgrounds,  respectively.  The 
use  of  a  positive  control,  consisting  of  cleaved  GSTeqIFN-y  fusion  protein,  revealed  that 
the  baculovirus  and  mammalian  derived  eqIFN-y  have  a  greater  molecular  weight 
(between  20  and  30  kDa)  than  the  E.  coli  derived  eqIFN-y. 
3.3.3  Biological  activity  of  eqIFN-y 
Cytopathic  effect  reduction  assay 
Results  shown  in  figure  3.16  show  typical  assays  for  the  determination  of  the  level  of 
protection  conferred  by  recombinant  eqIFN-y  to  the  challenge  of  MDBK  cells  with  VSV 
virus.  The  eqIFN-y  antiviral  potency  was  calculated  as  the  reciprocal  of  the  dilution  that 
gives  rise  to  protection  of  50%  of  the  wells,  which  is  the  potency  in  laboratory  units  of 
the  sample  (in  this  case  100pl).  For  calculation  of  the  potency  per  millilitre,  the  result  is 
multiplied  by  the  dilution  factor  (in  this  case  10).  The  titres  of  the  individual  IFN-y 
preparations  (table  3.3),  expressed  in  laboratory  units  (U),  are  as  follows:  640U  for 
BacIFN72;  no  protection  for  BacIFN96;  2560U  for  PciIFN24;  640U  for  PciIFN48  and  no 
protection  for  Bacwt  and  Pcineo. 
'e- 
Earlier  experiments  that  made  use  of  an  equine  cell  line  (EEK)  in  this  assay  system 
showed  that,  baculovirus  derived  eqlFN-y,  protected  cells  from  challenge  virus  (at 
IOOTCID50)  up  to  a  dilution  of  10',  corresponding  to  100000  laboratory  units  of  eqIFN-y 
per  ml  (results  not  shown). 
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PBL  proliferation  assay 
Equine  peripheral  blood  lymphocytes  were  stimulated  with  mitogen,  eqIFN-y  or  both  and 
their  proliferative  response  was  assessed  by  the  relative  amount  of  tritiated  thymidine 
incorporated  as  the  cells  divide.  Experiments  were  conducted  in  triplicate  and  the  average 
'H-thymidine  incorporation,  measured  in  counts  per  minute  (cpm),  and  standard  deviation 
was  calculated. 
As  a  means  to  investigate  if  equine  peripheral  blood  lymphocytes  would  proliferate  in 
response  to  mitogen,  varying  concentrations  of  concanavalin  A  (ConA  standard  curve), 
were  used  to  stimulate  the  cells.  Decreasing  quantities  of  ConA  corresponded  to  a 
decrease  in  the  average  'H-thyrnidine  incorporation  in  a  linear,  dose  dependent  manner. 
Incorporation  varied  from  13480  cpm,  corresponding  to  5Ag/ml  of  ConA,  to  a  value  of 
2488  cpm,  for  0.16Aglml.  Also,  background  levels  of  incorporation  in  wells  containing 
unstimulated  cells  were  1984  cpm  and  in  wells  with  no  cells  30  cpm  (table  3.4  and  figure 
3.17). 
Cells  stimulated  with  BaclFN72  alone,  exhibited  a  mild  dose  response  pattern  of 
incorporation,  varying  from  a  maximum  of  6541  cpm,  for  a  V2  dilution  of  IFN-Y,  to  a 
minimum  of  2813  cpm,  corresponding  to  a  1/256  dilution,  and  comparable  to  the  basal 
incorporation  observed  in,  cells  stimulated  with  the  negative  control  (Bacwt)  of 
approximately  2200  cpm  (table  3.5  and  figure  3.18). 
When  cells  treated  with  BacIFN72  were  co-stimulated  with  0.3Pg/mI  of  ConA,  a 
maximum  incorporation  of  64896  cpm  decreased  linearly  to  a  minimum  of  2863  cpm  in 
the  same  dilution  interval.  Significantly,  the  basal  incorporation  in  response  to  Bacwt 
plus  0.3mg/mI  of  ConA  suffered  little  or  no  effect,  remaining  at  the  low  level  of 
approximately  2800  cpm  (table  3.6  and  figure  3.19).  The  difference  in  proliferation 
between  cells  stimulated  with  eqIFN-y  alone  or  cqlFN-y  plus  mitogen  represents  a 
striking  ten  fold  increase  in  the  level  of  'H-  thymidine  incorporation.  A  comparison  of 
incorporation  levels  between  the  different  samples  is  shown  in  figure  3.20. 
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Supernatants  corresponding  to  BacIFN96  were  also  tested  using  this  assay  system  but  no 
correlation  between  dilution  of  the  sample  and  cell  proliferation  could  be  extrapolated. 
MHC  class  11  upregulation 
Unstimulated  equine  "r  cells"  were  labelled  with  antibodies  for  a  number  of  cell  surface 
molecules  and  analysed  by  flow  cytometry  to  investigate  the  relative  frequency  of 
lymphocyte  subsets  in  the  cell  preparation.  The  results  obtained  are  within  the  typical 
ranges  described  by  other  groups  (Kydd  et  al,  1991;  Lunn  et  al,  1997),  where  anti-B  cells 
antibody  (an  homologue  of  CD19)  bound  to  3.5%  of  the  cells;  anti-CD5  bound  to  85.5% 
and  anti-CD4  to  60%  (figure  3.2  1). 
Two  experiments  were  designed  to  investigate  if  recombinant  eqIFN-y  would  upregulate 
MHC  class  II  molecules  on  the  surface  of  the  "r  cells".  In  the  first,  cells  were  stimulated 
with  eqIFN-y  preparations  alone  and  in  the  second  cells  were  co-stimulated  with  human 
recombinant  IL-2. 
In  the  first  set  of  experiments,  following  incubation,  there  was  a  great  number  of  dead 
cells,  on  both  stimulated  and  unstimulated  samples,  as  assessed  by  size  and  granularity 
(figure  3.22  A  and  Q.  Also,  staining  with  a-MHC  II  (figure  3.22  D)  revealed  a  bimodal 
pattern  of  fluorescence  where  some  T  cells  stain  brighter  while  others  stain  dimmer, 
depending  principally  in  their  activation  state.  Within  the  bright  population  is  possibly 
the  entire  population  of  B  cells  (Rideout  et  al,  1990).  This  pattern  was  maintained  in  all 
samples.  However,  increasing  concentrations  of  eqIFN-y  in  this  experiment,  led  to  an 
increase  in  the  number  of  dim  cells  expressing  MHC  class  II  molecules  while  the  brighter 
population  of  cells  remained  largely  unaltered  (figure  3.23  A  to  D).  A  total  of  three 
experiments  were  performed  with  similar  results. 
In  the  second  set  of  experiments,  cells  were  incubated  with  eqIFN-y  and  co-stimulated 
with  recombinant  human  IL-2.  In  this  case,  the  number  of  dead  cells  was  much  smaller 
(figure  3.24  A  and*C).  More  importantly,  although  the  bimodal  curve  of  MHC  II  staining 
was  maintained,  it  was  the  brighter  cells  that  responded  to  the  presence  of  IFN-y  with  an 
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increased  expression  of  the  surface  molecule  with  the  dim  cells  remaining  mostly 
unaltered  (figure  3.25  A  to  E).  Once  again  three  independent  experiments  were  performed 
with  similar  results. 
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Figure  3.10  Expression  of  equine  IFN-y  in  E.  coli. 
Affinity  purified  protein  products  of  bacteria  expressing  GST  and  GSTeqlFN-y,  were 
analysed  by  SDS-PAGE  and  stained  with  Coomassie  blue.  Cleaved  GSTeqlFNy  was 
also  analysed.  Approximately  10ýtg  of  each  protein  preparation  was  loaded  on  a  15% 
gel  as  follows:  Lanel-  GST;  Lane2-  GSTeqlFN-y  fusion;  lane3-  cleaved  eqIFN-y.  On 
lane  4  was  loaded  I  Oýil  of  protein  standard. Virus  dilutions:  10-3  104  10-5 
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Figure  3.11  A-  Typical  plaque  assay  of  baculovirus  wild  type. 
10-5  v  us  Cells  were  stained  with  X-gal  for  blue  plaque  development.  At  the  ir 
dflution,  9  plaques  can  clearly  be  counted. 
B-  PCR  amplification  of  Baculo.  eqlFN-y  plaque  picks. 
Plaque  DNA  amplified  with  equine  IFN-y  specific  primers,  was  loaded  on  a  1.2% 
TAE  agarose  gel  as  follows:  Lanes-  1,2  and  3,  were  loaded  with  I  Ojil  of  individual 
PCR  products;  Lane  4-1  ýLg  of  ýX  174  RF  DNA/Haelll  fragments;  Lane  5-1  jig  of 
I  Kb  DNA  ladder.  A  band  of  approximately  500bp  was  obtained  for  positive  clones 
(  lanes  2  and  3). 456 
eqlFN-y 
C 
Figure  3.12  Expression  of  equine  IFN-y  in  mammalian  cells. 
A-  RNA  derived  from  transfected  cos7  cells  was  probed  with  an  IFN-y  gene  specific 
probe.  RNA  (I  5pg/lane  )  was  loaded  as  follows:  Lanes  1,2  and  3  pCI-eqlFN-y  at  24, 
48  and  72  hours  post-transfection,  respectively;  Lanes  4,5  and  6-  pCI-neo  parental 
plasn-ýd  at  24,48  and  72  hours  post-transtection,  respectively. 
B  and  C-  The  same  samples  as  in  gel  A,  loaded  in  the  same  order,  were  probed  with  a 
GAPDH  probe.  Gels  B  and  C  were  sized  to  fit  gel  A  aligm-nent. 
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Figure  3.13  Specificity  of  anti-GSTeqlFN-y  serum. 
Samples  were  loaded  in  a  12%  SDS-PAGE  gel  as  follows:  Lanel  -  GSTeqI  FN-7  (5pg); 
lane2-  cleaved  GSTeqlFN-y  (5pg):  lane3-  GST  (2pg). 
Protein  quantities  were  assessed  by  Bradford  assay.  Detection  using  primary  antibody 
(antFGSTeqlFN-7)  at  a  1/10000  dilution  followed  by  secondary  antibody  (HRP 
conjugated  goat  anti-rabbit  IgG  polyclonal  antibody)  diluted  115000.  Blot  developed 
using  ECL  reagents.  Film  exposed  for  15  seconds. <  20  kDa  No- 
15  kDa  lot- 
Figure  3.14  Identification  of  eqlFN-y  expressed  in  baculovirus. 
Samples  were  loaded  in  a  15%  SDS-PAGE  gel  as  follows:  lanel-  cleaved  GSTeqlFN-Y 
positive  control  (2ltg).  lane2-  72  hours  baculoeqlFN-y  infection  supernatant  (IOPI). 
lane3-  72  hours  baculoeqlFN-y  infection  cell  lysate(lOpl);  lane4-  96  hours  baculoeqIFN- 
y  infection  supematant(IOpl);  lane5-  96  hours  baculoeqlFN-y  infection  cell 
lysate(  I  0[d).  Detection  using  primary  antibody  (anti-GSTeqlFN-y)  at  a  1/10000  dilution 
followed  by  secondary  antibody  (HRP  conjugated  goat  anti-rabbit  IgG  polyclonal 
antibody)  diluted  115000.  Blot  developed  using  ECL  reagents.  Film  exposed  for  I 
minute. Figure  3.15  Identification  of  eqlFN-y  expressed  in  mammalian  cells  (cos7). 
Samples  (10ktl  each)  were  loaded  in  a  12%  SDS-PAGE  gel  as  follows:  Lane] 
. 
2,3  pCl- 
neo.  eqlFN-y  transfection  supernatant  of  24,48  and  72  hours,  respectively,  lane4- 
cleaved  GSTeqlFN-7  positive  control  (2  ptg).  Detection  using  primary  antibody  (anti- 
GSTeqlFNy)  at  I/  10000  dilution  followed  by  secondary  antibody  (HRP  conjugated  goat 
anti-rabbit  IgG  polyclonal  antibody)  diluted  115000.  Blot  developed  using  FCL 
reagents.  Film  exposed  for  5  minutes. A-  BacIFN72 
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Figure  3.16  Cytopathic  effect  reduction  assay. 
MDBK  (1.5XI04  cells  per  well)  were  stimulated  with  twofold  dilutions  of 
eqlFN-y  preparations  or  parental  vector  controls  and  challenged  with  VSV.  Each 
sample  was  tested  in  an  individual  plate.  Plate  A-  bacIFN72;  Plate  B-  PcilFN24; 
Plate  C  -columns  I  to  5  contain  twofold  dilutions  of  BacWT  and  columns  6  to  9 
Pcineo.  Conditions  are  detailed  on  correspondent  charts. TabIe  3.3  Summary  of  CPE  reduction  assay  results 
EqIFN-y  preparation  Dilution  %  Protection  Titre 
1/32  100% 
BacIFN72  1/64  50%  640U/ml 
1/128  0 
BacIFN96  All  0 
Bacwt  All  0 
1/64  100% 
PcilFN24  1/128  75%  256OU/ml 
1/256  50% 
1/512  0 
1/32  100% 
PciIFN48  1/64  50%  640U/ml 
1/128  0 
Pcineo  All  0 
1/10000  100% 
BacIFN  1.2.1  1/100000  50%  IOIU/mi 
1/1000000  0 
1/10000  100% 
BacIFN  1.3.1  1/100000  25%  -5xlO5U/ml 
1  1000000  0 
Bacwt  All  0 
Virus  challenge  was  I  OOTCID50  per  well  with  development  of  full  CPE,  in  control  wells, 
within  48  hours.  BacIFN  1.2.1  and  1.3.1  are  two  further  baculovirus  expressing  eqlFN-y 
developed  early  in  the  project  and  shown,  at  the  time,  to  have  a  potent  antiviral  effect. Table  3.4  Proliferation  of  equine  PBLs  in  response  to  ConA,  measured  by  'H- 
thymidine  incorporation.  Values  represent  scintillation  counts  per  minute 
(cpm).  The  average  and  standard  deviation  (ST.  Dev.  )  corresponding  to  each 
dilution  are  also  shown 
ConA  standard  curve 
Dilutions  Counts  per  minute  (CPM)  X3  Average  ST.  Dev. 
5mg/ml  13264.9  14237.5  12938.5  13480.3  675.8 
2.5mg/ml  8307.3  7676.3  7372.2  7785.3  477.0 
1.25mg/ml  5432.3  5075.2  4918.9  5142.1  263.2 
0.62m-q/ml  3575.3  3645.4  3930.4  3717.0  188.1 
0.31mg/ml  2636.9  3069.9  3146.8  2951.2  274.9 
0.16mg/ml  2694.7  2484.8  2284.4  2487.9  205.2 
0  2119.7  2108.1 
1 
1724.2  1984.0  225.7 
No  cells  22.0  46.2  22.3  30.2  13.9 
ConA  standard  curve 
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Figure  3.17  Graphical  representation  of  averages  depicted  in  table  3.4. Table  3.5  Proliferation  of  equine  PBLs  in  response  to  BacIFN72,  measured  by 
3  H-thymidine  incorporation  as  before. 
BaculoIFN 
Dilutions  Counts  r  minute  (  PM)  X3  I  Average  ST.  Dev. 
1/2  6265.8  6950.1  6409.8  6541.9  360.7 
1/4  5968.9  6084.6  6295.2  6116.2  165.4 
1/8  5231.5  5127.1  5371.4  5243.3  122.6 
1/16  1  4792.0  4273.7  4471.4  4512.4  261.6 
1/32  3724.9  4094.0  3918.3  3912.4  184.6 
1/64  3410.0  3864.2  3718.1  3664.1  231.9 
1/128  2646.9  2767.8  3026.6  2813.7  1  193.9 
1/256  2503.2  3112.5  2736.7  2784.1  1  307.4 
Baculo  WT 
Dilutions  Counts  er  minute  PM)  X3  I  Average  ST.  Dev. 
1/2  2962.2  2925.2  2749.3  2878.9  113.7 
1/4  1800.3  2239.8  1797.8  1946.0  254.5 
1/8  2494.4  2118.7  1945.6  2186.3  280.6 
1/16  2022.9  2064.8  2347.2  2144.9  176.4 
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Figure  3.18  Graphical  representation  of  averages  depicted  in  table  3.5. Table  3.6  Protiferation  of  equine  PBLs  in  response  to  BacIFN72  +  ConA, 
measured  by  3  H-thymidine  incorporation  as  before. 
BaculolFN  +  ConA  a  0.3  g/ml 
Dilutions  Counts  er  minute  (CPM)  X3  Average  ST.  Dev. 
1/2  64184.2  66218.1  1  64287.3  64896.5  1145.7 
1/4  47233.0  45519.6  44204.9  45652.5  1518.4 
1/8  21596.2  20952.0  21704.1  21417.4  406.7 
1/16  10187.2  12306.8  14057.6  12183.9  1938.1 
1/32  6308.1  6382.1  6410.2  6366.8  52.7 
1/64  4128.5  4244.7  3815.4  4062.9  222.0 
1/128  3472.9  3548.8  3117.4  3379.7  230.3 
1/256  2940.6  1  2941.9  1  2706.6  2863.0  1  135.5 
Baculo  WT  +  ConA  Q  0.  pg/!  Dl 
Dilutions  Counts  er  minute  (CPM)  X3  Averaqe  ST.  Dev. 
1/2  3086.7  2847.0  1  2771.9  2901.9  190.1 
1/4  3462.8  3191.0  3069.7  3241.2  201.3 
1/8  2671.6  2803.6  2472.9  2649.4  166.5 
1/16  2937.0  2644.0  2734.1  2771.7  150.1_j 
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Figure  3.19  Graphical  representation  of  averages  depicted  in  table  3.6. 70000  - 
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Figure  3.20  Comparison  of  results  shown  in  figures  3.17,3.18,3.19. A 
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Figure  3.21  Frequency  of  lymphocyte  subpopulations  in  enriched  equine  T  cell 
preparations.  Cells  were  labelled  with  the  prhnary  antibody:  a-equine  Bcell  (A);  a- 
equine  CD5  (B)  and  cc-equine  CD4  (C)  and  with  a-mouse:  FITC  as  secondary  antibody. 
Gating  was  set  for  live  cells,  based  on  cell  granularity. 
10  lop  I*'  I*, ssý 
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Figure  3.22  Flow  cytometry  analysis  setup  (experiment  1). 
Gating  of  lymphocytes  using  forward  and  side  scater  (A  and  C)  and  setting  of 
fluorescence  acquisition  interval  using  orthogonal  seater  and  PMT2  (B  and  D). 
A  and  B  are  unstimulated  cells  labelled  with  isotypic  antibody  (  U.  -gq24  /  CC- 
mouse:  FITC  )  and  C  and  D  are  unstimulated  cells  labelled  with  (x-MHCII  /  (x- 
mouse:  FITC IDý  ol 
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Figure  3.23-  EqIFN-y  upregulation  of  MHC  11  (  experiment  1) 
Enriched  T  cells  were  incubated  for  24  hours  with  dilutions  of  bacIFN72  or 
parental  virus  preparations  and  stained  with  (x-MHCll/a-rnouse:  FITC.  Figures 
A  to  D  show  increasing  dilutions  of  IFN-y  (10-'  to  10-4 
,  respectively)  and 
figure  E  corresponds  to  a  10-'  dilution  of  parental  vector  negative  control. 
*N.  B.  -  Experiments  were  performed  with  blood  from  two  individual  animals 
with  similar  results. A 
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Figure  3.24  Flow  cytometry  analysis  setup  (experiment  2). 
Gating  of  lymphocytes  and  setting  FITC  aquisition  interval  as  before  for  cells 
stimulated  with  rhIL-2  for  24  hours.  A  and  B  represent  cells  stained  with  (X- 
gp24  /a-  mouse:  FITC;  C  and  D  cells  stained  with  a,  -MHC  11  /ct-niouse:  FITC ABC 
FITC  FITC  FITC 
DE 
F 
FITC  FITC 
I  R, 
Figure  3.25  EqIFN-y  upregulation  of  MHC  11  (experiment  2)  *. 
Enriched  T  cells  incubated  24  hours  with  rhIL-2  and  dilutions  of  BaclFN72  or 
Bacwt  control  preparations,  were  stained  with  a-MHCll/(x-rnouse:  FlTC. 
Figures  A  to  E  show  increasing  dilutions  of  IFN-y  (  10-'  to  10-',  respectively 
and  figure  F  corresponds  to  a  10-'  dilution  of  negative  control. 
*  N.  B.  -  Experiments  were  performed  with  blood  frorn  two  individual  animals 
with  similar  results. Table  3.7  Upregulation  of  MHC  class  II  expression  by  enriched 
equineT  cells  in  response  to  baculovirus  derived  recombinant 
equine  IFN-y. 
%  of  cells  positive  to  MHC  11  staining 
EqIFN-y  T  cells  +  T  cells  + 
dilution  EqIFN-y  EqIFN-y  +  rhIL-2 
10-1  85.9  94.2 
10-2  80.1  93.2 
10-1  70.2  91.5 
10-4  69.9  90.4 
10--,  N.  D.  86.8 
Parental  virus  69.0  82.5 
Unstim.  cells  70.8  81.3 IF,  V-y 
3.4  Discussion 
Equine  IFN-y  was  successfidly  produced  in  bacterial,  baculovirus  -and  mammalian 
expression  systems.  The  identity  of  the  expressed  products  was  confirmed  both  by 
westem-blot  and  by  alternative  methods  (SDS-PAGE,  PCR  and  northern,  blot 
analysis,  respectively). 
Antipeptide  antibodies  showed  poor  or  no  affinity  for  protein  expressed  in  bacteria. 
This  was  possibly  due  to  misrepresentation  of  the  actual  protein  epitopes  by  the 
immunising  peptides.  Alternatively,  folding  of  the  mature  protein  conceals  the 
specific  epitopes  represented  by  the  peptides,  making  them  unavailable  for  binding  to 
the  antibodies.  Although  the  gels  were  run  under  denaturing  conditions  it  is  possible 
that  this  was  not  enough  to  completely  unfold  the  protein. 
The  alternative  strategy  for  antibody  production  resulted  in  the  generation  of  a 
polyclonal  antibody  preparation  able  to  strongly  recognise  not  only  its  GSTeqIFN-y 
immunogen,  but  also  recombinant  IFN-y  derived  from  baculovirus  and  mammalian 
expression  systems.  Additionally  the  antibody  is  cross  reactive  to  human  and  feline 
species  of  IFN--y. 
Both  baculovirus  and  mammalian  expressed  eqIFN-y  revealed  a  higher  molecular 
weight,  when  compared  with  the  GST  derived  protein  control.  This  result  is  consistent 
with  post-translational  glycosylation  of  IFN-y  in  eukaryotic  expression  systems.  Still 
to  prove,  remains  the  usefulness  of  this  polyclonal  preparation  in  the  detection  of 
natural  eqlFN-y,  as  a  tool  for  the  dissection  of  immunological  functions  and 
pathology  of  the  horse. 
The  low  level  of  protection  (640  to  2560  U/ml)  exerted  by  eqlFN-y  against  VSV  in 
bovine  kidney  cells  (MBDK),  when  compared  to  that  reported  for  bovine  IFN-y,  is 
possibly  a  consequence  of  the  species  specific.  character  of  IFN-y  activity,  although 
cross  reactivity  between  bovine  and  ovine  species  of  IFN--y  as  been  documented 
(Martin  et  A  1996  in  Pastoret  et  al,  1998).  Nevertheless,  the  bioactivity  of 
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recombinant  eqIFN--y  was  confirmed  by  early  experiments  with  the  same  assay 
system  but  using  an  equine  cell  line  (EEK).  In  EEKs,  baculovirus  derived  eqIFN-y 
showed  an  activity  corresponding  to  105  laboratory  units  of  IFN-y  per  ml.  This  value 
matches  those  obtained  by  Zucker  et  al,  (1993)  for  canine  IFN-y  and  of  Argyle  et  al 
(1998)  for  the  feline  species.  Unfortunately,  we  have  lately  been  unable  repeat  these 
results.  A  plausible  explanation  would  be  the  loss  of  sensitivity  to  of  the  cells  (EEK) 
to  eqlFN-y,  caused  by  increasing  passage  number.  A  similar  observation  was  reported 
in  the  case  of  WISH  cells  in  response  to  human  IFN-y  (Lewis,  1987). 
In  the  proliferation  assay,  response  to  eqIFN-,  y  alone  was  characterised  by  a  mild 
incorporation  of  tritiated  thymidine.  However,  when  IFN-y  treated  cells  were  spiked 
with  mitogen  (ConA),  the  proliferative  response  represented  almost  a  tenfold  increase. 
These  results  are  consistent  with  observations  that  IFN-y  expands  mitogen  induced 
proliferation  of  lymphocytes  (Landolfo  et  al,  1988).  Another  significant  observation  is 
that  responses  to  both  IFN--f  alone  or  IFN--f  plus  ConA  are  characterised  by  linear, 
dose  dependent,  cell  growth  curves,  which  correlates  with  unequivocal  proliferative 
activity  of  the  samples  testedL  However  these  results  need  Way  to  be  confirmed 
since,  due  to  time  constraints,  the  assay  was  performed  in  only  one  batch  of 
recombinant  eqIFN-j. 
In  the  case  of  MHC  class  11  regulation  on  enriched  T  cells,  was  observed  a  dose 
dependent  variation  in  the  percentage  of  cells  expressing  MHC  II  upon  stimulation 
with  eqlFN-y.  Nevertheless,  the  small  interval  between  basal  and  maximal  expression 
of  MHC  Il  and  the  non  linearity  of  the  increments  make  difficult  the  interpretation  of 
the  results  obtained  in  absolute  values.  More  importantly,  though,  when  in  co- 
stimulation  with  rhIL-2,  the  pattern  of  M111C  upregulation  by  eqIFN-y  shifted  from 
the  dim  to  the  bright  population.  As  discussed  before,  resting  T  cells  constitutively 
express  low  levels  of  MHC  class  11  molecules,  but  can  nevertheless  be  induced  to 
increase  the  expression  level.  Activated  T  cells,  on  the  other  hand,  not  only  are  able  to 
express  larger  amounts  of  MHC  11  but  do  it  in  a  very  specific  and  inducibIC  way, 
possibly  by  reduction  of  the  threshold  for  MHC  11  induction  in  response  to  antigens 
and  particularly  to  IFN-y.  This  fact  is  the  basis  of  the  association  of  increased 
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capacity  in  expressing  MEC  IL  with  equine  T  cell  activation  and  development  into  an 
effector/memory  state  (Lanzavecchia,  1990;  Altin  and  Sloan,  1997).  Because  IL-2  is  a 
competent  activator  of  T  cells  (originally  named  T  cell  growth  factor)  its  plausible 
that,  in  the  present  system,  IL-2  increased  the  susceptibility  of  T  cells  to  IFN-y 
activity. 
Still,  the  heterogeneity  of  the  cell  population,  precludes  a  definitive  correlation 
between  eqIFN-y  dose  and  the  upregulation  of  MEC  H  molecules.  This  problem 
could  be  addressed  by  the  use  of  an  inducible  cell  line  with  negligible  basal 
expression  of  MHC  II.  In  such  cell  lines  (e.  g.  B  cell  lymphoma)  addition  of  IFN--y 
leads  to  a  major  shift  in  the  pattern  of  MHC  H  expression  with  an  increase  of  mean 
fluorescence  of  up  100  fold.  Unfortunately  we  were  not  able  to  secure  such  a  cell  line 
for  the  horse.  This  was  in  fact  the  reason  for  enrichment  of  the  PBL  population  in  T 
cells,  in  an  attempt  to  increase  cellular  uniformity. 
Another  approach  to  the  problem  would  be  the  simultaneous  (double)  labelling  of 
MHC  class  II  molecules  and  of  lymphocyte  subset  markers  (e.  g.  CD3  for  T  cells; 
CD19  for  B  cells).  This  enables  the  tracking  of  discrete  populations  of  cells  and  the 
observation  of  small  variations  in  MEC  11  expression  by  those  cells.  However,  this 
technique  requires  antibodies  with  different  fluorochromes  (e.  g.  FITC,  PE)  and,  more 
importantly,  at  least  one  of  the  antibodies  to  be  directly  conjugated  with 
fluorochrome.  There  are  no  commercially  available,  directly  conjugated  antibodies 
against  equine  antigens,  and  this  approach  was  not  applied. 
In  view  of  the  inconsistent  and  subtle  biological  activity  demonstrated  by  the  eqIFN-y 
preparations  tested,  much  work  remains  to  be  done  not  only  in  the  optimisation  of  the 
assays  but  also,  and  perhaps  more  importantly,  in  the  production  of  purer  protein 
preparations.  Significantly,  the  biological  potency  of  the  preparations  does  not 
correlate  with  the  amount  of  recombinant  protein  detected  by  western  blot.  There  are 
two  main  explanations  for  this  observation.  Firstly,  that  recombinant  eqIFN-y  is  being 
Produced  largely  in  an  inactive  form  and  in  this  case  the  preparations  would  probably 
benefit  of  more  refined  methods  of  protein  purification  methods  (e.  g.  HPLC;  FPLQ. 
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Secondly,  we  could  postulate  that  IFN--y  is  not  as  active  in  the  horse  as  in  other 
species,  which  would  in  part  be  settled  if  sufficiently  pure  preparations  of  natural 
equine  IFN-j  were  obtained,  that  could  be  tested  in  the  present  assay  systems. 
Nevertheless  the  second  does  not  seem  to  apply  in  view  of  preliminary  results 
obtained  with  the  CPE  reduction  assay  in  EEKs  and  with  the  proliferation  of  T  cells 
costimulated  with  mitogen. 
Finally,  attempts  were  also  made,  in  the  CPE  reduction  assay,  to  neutralise  the 
biological  activity  observed  by  means  of  the  existing  polyclonal  antibody,  although 
without  success  (results  not  shown).  This  was  probably  due  to  the  inability  of  the 
polyclonal  to  bind  to  the  receptor  binding  domains  of  equine  IFN-Y  and  therefore  to 
specifically  neutralise  its  activity.  Steps  are  now  being  taken,  both  through 
collaborations  and  within  the  department,  for  the  development  of  monoclonal 
antibodies  against  eqIFN-y  that  will  prove  invaluable  in  the  optimisation  of  the 
present  assays. 
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CLONING  OF  EQUINE  IL-12  AND  IL-18 IL-121IL-18 
4.1  Introduction 
4.1.1  Interleukin-12  (11,42 
4.1.1.1  Molecular  structure  and  production  of  IL-12 
Interleukin-12,  the  only  heterodimeric  cytokine  isolated  to  date,  was  originally 
identified  independently  by  two  groups  investigating  the  activity  of  a  novel  factor  in 
lymphocytes  and  NK  cells.  The  first  group  (Kobayashi  et  al,  1989)  described  a  factor 
that  could  stimulate  NK  cell  functions,  NK  cell  stimulatory  factor  (NKSF).  The 
second  group  (Stem  et  al,  1990)  identified  a  molecule  that  activated  cytolytic 
lymphocyte  activities  and  was  named  accordingly,  cytotoxic  lymphocyte  maturation 
factor  (CLMF).  It  was  only  when  both  this  factors  were  cloned  (Wolf  et  al,  1991  and 
Gubler  et  al,  1991,  respectively)  that  it  became  clear  that  this  was  in  fact  one  molecule 
and  the  name  IL-12  was  proposed. 
IL-12  is  composed  of  two  polypeptide  chains,  p35  and  p40,  covalently  linked  by  a 
disulfide  bond  (figure  4.1).  The  p35  gene  was  mapped  to  human  chromosome  3 
(3pl2-3ql35.2)  and  to  murine  chromosome  3.  The  human  p35  gene  encodes  a  253 
amino  acid  polypeptide  with  two  potential  translation  initiation  codons  (residues  I 
and  35).  Translation  from  the  second  methionine  gives  rise  to  a  typical  hydrophobic 
signal  peptide  (22  residues  long)  followed  by  a  mature  protein  of  197  amino  acids 
(with  a  predicted  molecular  weight  of  27.5kDa)  containing  seven  cysteine  residues 
and  three  consensus  N-linked  glycosylation  sites.  Differential  glycosylation  leads  to 
molecular  heterogeneity  of  natural  IL-12  p35,  ranging  from  30kDa  to  over  35kDa,  as 
observed  under  denaturing  conditions.  Similarly,  p40  is  encoded  by  a  gene  mapped  to 
human  chromosome  5  (5q3l-q33)  and  to  murine  chromosome  11.  Human  p40  is 
composed  of  eight  exons  and  seven  introns  and  encodes  for  an  open  reading  frame  of 
328  amino  acids  in  length  that  includes  a  N-terminal  22  amino  acid  long  hydrophobic 
leader  sequence.  The  mature  protein,  with  a  predicted  molecular  weight  of  34.7  kDa, 
features  ten  cyifeine  residues,  four  possible  N-linked  glycosylation  sites  and  a 
consensus  heparin  binding  site.  Natural  IL-12  p40,  has  a  molecular  weight 
heterogeneity  from  36  to  over  40  kDa,  under  denaturing  conditions,  depending  on  the 
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extent  of  glycosylation  (Wolf  et  al,  1991;  Gubler  et  al,  1991,  reviewed  in  Trinchieri, 
1995). 
The  p40  and  p35  subunits  of  the  mouse  IL-12  share,  respectively,  70%  and  60% 
amino  acid  sequence  identity  to  their  human  counterparts. 
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Figure  4.1  Structure  of  the  human  IL-12  heterodimer  (Trinchieri,  1998). 
Showing  intra  and  inter-chain  disulfide  bonds.  Cys74  of  the  p35  subunit  and 
Cys,  77  of  p40  are  involved  in  interchain  covalent  linking.  All  other  cysteine 
residues  in  both  molecules  are  involved  in  intra-chain  bonds  except  for  CYS252 
of  p40  that  is  cysteinylated  with  thioglycolate  (TGA)  and  therefore  not 
available  for  disulphide  bridging. 
While  there  is  no  sequence  homology  between  IL-12  p35  and  p40  subunits,  p35 
shares  significant  homology  with  IL-6  and  G-CSF  and  has,  similarly  to  several  other 
cytokines,  an  cc-helix-rich  structure  (Merberg  et  al,  1992).  On  the  other  hand,  p40  is 
not  homologous  to  other  cytokines,  but  belongs  to  the  hemopoietin  receptor  family, 
resembling  the  extracellular  domain  of  IL-6  receptor  (Gearing  et  al,  1991).  It  is 
therefore  possible  that  a  primordial  cytokine  (the  p35  equivalent)  by  binding  to  its 
soluble  receptor  (  the  p40  equivalent)  gave  rise  to  the  heterodimeric  IL-12  during 
evolution.  This  notion  is  supported  by  observations  that  other  cytokines  (e.  g.  IL-6,  IL- 
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11)  can  bind  their  soluble  receptors  without  compromising  cellular  receptor  binding 
and  signal  fi-ansduction  (Trinchieri,  1998). 
Although  originally  identified  in  supernatants  of  B  cell  lines  transformed  with 
Epstein-Barr  virus  (Kobayashi  et  al,  1989),  it  is  now  known  that  the  main  sources  of 
IL-12,  in  vivo,  are  activated  macrophages  and  dendritic  cells,  mainly  in  response  to 
intracellular  parasites,  bacteria  and  their  products  (reviewed  in  Trinchieri,  1995). 
Other  cellular  producers  of  IL-12  include  neutrophils,  Langerhans  cells,  keratinocytes, 
microglia  and  astrocytes  (  reviewed  in  Storkus  et  al,  1998). 
The  production  of  EL-12  is  complex,  as  simultaneous  expression  of  p35  and  p40  is 
required  for  secretion  of  bioactive  heterodimer.  Although  most  somatic  cells 
constitutively  express  low  levels  of  p35  transcripts,  p35  protein  has  not  been  detected, 
suggesting  that  this  chain  is  efficiently  secreted  only  when  associated  with  p40. 
Furthermore,  the  expression  of  p40  is  highly  regulated  and  restricted  to  cells  able  to 
produce  bioactive  IL-12.  It  has  been  reported  that  stimulated  macrophages  produce  a 
large  excess  of  p40  relatively  to  IL-12  heterodimer,  and  that  p40  possesses  an 
antagonistic  effect  over  IL-  12.  Also  p40  homodimer  was  found  to  bind  IL-  12  receptor 
without  mediating  biological  responses.  Taken  together  these  observations  suggest 
that  p40  expression  plays  an  important  regulatory  role  in  IL-12  production  and 
activity  (reviewed  in  Stem  et  al,  1997;  Trinchieri,  1998). 
4.1.1.2  IL-12  receptor  and  signalling 
IL-12  receptor  (IL-12R)  is  primarily  expressed  on  activated  T  and  NK  cells  (Desai  et 
al,  1992).  It  is  composed  of  two  subunits  designated  IL-12RPI  (of  lOOkDa)  and  P2 
(of  130kDa).  Both  subunits  are  type  I  tran  smembrane  glycoproteins  and  belong  to  the 
gpl30  subgroup  of  the  cytokine  receptor  superfamily  (figure  4.2).  Radiolabelled 
ligand  and  expression  studies  revealed  the  presence  of  both  high  and  low  affinity  IL- 
12  binding  sites  in  activated  lymphoblasts.  These  studies  also  suggest  that  the  PI 
subunit  provides  most  of  the  binding  energy,  whereas  the  P2  subunit  is  the  primary 
signal  transducing  element  (reviewed  in  Presky  et  al,  1996).  Control  of  IL-12RP2 
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expression  constitutes  a  critical  mechanism  for  regulating  IL-12  responsiveness.  This 
is  well  illustrated  by  the  increased  response  to  IL-12  of  developing  TH  I  cells  through 
IFNy  driven  upregulation  of  IL-12RP2  and  the  loss  of  response  to  IL-12  observed  in 
TH2  cells  mediated  by  IL-4,  IL-10  and  TGF-P  downregulation  of  the  P2  receptor 
subunit  (Gollob  et  al,  1997). 
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Figure  4.2  Structure  of  the  human  IL-12  receptor  (modified  from  Stem  et  al, 
1997;  Trinchien,  1998).  Functionally  important  residues  include  the  characteristic 
cytokine  receptor  superfamily  motifs  (C/CXW  and  WSXWS)  within  the  cytokine 
receptor  homology  (CRH)  domain,  responsible  for  ligand  binding,  and  the  P2  chain 
cytoplasmic  tyrosine  residues  (Y)  involved  in  signal  transduction. 
The  transduction  of  signal  by  IL-12  is  still  not  completely  understood.  Initial  reports 
described  IL-12  induced  phosphorylation  of  mitogen  activated  protein  kinase 
(MAPK)  in  T  cells  (Pignata  et  al,  1994)  and  of  p56LCK  in  NK  cells  (Pignata  et  al, 
1995).  Nevertheless,  it  is  now  thought  that  the  JAK/STAT  pathway  is  the  main 
mechanism  involved  in  mediating  IL-12  biological  activities.  This  assumption  is 
supported  by  evidence  that  treatment  of  T  and  NK  cells  with  IL-12  induces  rapid 
phosphorylation  of  both  JAK2  and  Tyk2  kinases  followed  by  activation  of  members 
of  the  STAT  family  of  tanscription  factors  (Yu  et  al,  1996).  Three  components  of  the 
STAT  family  (STATI,  STAT3  and  STAT4)  are  phosphorylated  and  associate  as 
homo  or  heterodimers  in  response  to  IL-12  before  translocation  to  the  nucleus  and 
activation  of  gene  transcription.  The  relative  importance  of  each  of  the  STAT  proteins 
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has  not  yet  been  established  -although  STAT4  has  so  far  only  been  found  to  be 
activated  in  response  to  IL-12  and  IFNct,  contrary  to  the  involvement  of  STAT  I  and 
STAT3  in  the  activity  of  many  cytokincs  (Cho  et  al,  1996).  The  importance  of  STAT4 
in  IL-12  signalling  was  further  emphasised  when  STAT4  knockout  mice  were 
observed  to  have  a  phenotype  equivalent  to  that  of  IL-12  or  IL-12R  knockout  mice. 
Additionally  T  and  NK  cells  from  STAT4  knockouts  do  not  produce  IFN-y  in 
response  to  IL-12,  suggesting  a  direct  involvement  of  STAT4  in  IFN-y  gene 
transcription  (Thierfelder  et  al,  1996;  Kaplan  et  al,  1996). 
4.1.1.3  Biological  activities  of  11.42 
Altli6llgh  firstly  identified  by  its  ability  to  stimulate  both  NK  and  CTL  activity  and 
IFN-y  production,  the  main  functional  feature  of  IL-12  is  its  absolute  requirement  for 
driving  Thl  development  from  a  naYve  CD4+  cell  population,  both  in  mice  (Hsieh  et 
al,  1993)  and  in  human  (Sieling  et  al,  1994).  Thl  responses  trigger  profound 
modulatory  effects  on  both  cellular  and  humoral  immunity  that  are  largely  mediated 
by  IFN-y  (discussed  in  chapter  1). 
Other  activities  of  IL-12  (reviewed  in  Ma  et  al,  1997;  Gately  et  al,  1998;  Storkus  et  al, 
1998;  Trinchieri,  1998)  include: 
-production  of  other  cytokines,  including  TNF-cc,  GM-CSF,  IL-8,  IL-3  from  T 
and  NK  cells  when  these  cells  are  co-induced  by  other  stimuli  like  anti-CD3, 
anti-CD16,  anti-CD28  or  phorbol  diesters.  Inhibitory  effect  over  the 
production  of  IL-4  and  IL-10; 
-enhanced  proliferation  of  NK  and  T  cells  upon  pre-activation  (by  antigen),  or 
costimulation.  In  T  cells  the  proliferation  effect  of  IL-12  is  observed  on  both 
CD4'  and  CD8'  and  is  not  mediated  by  endogenous  IL-2.  In  this  activity  IL-12 
synergises  with  IL-  18  and  IFN-y  and  is  antagonised  mainly  by  IL-4,  IL-  10  and 
TGF-P  (by  downregulation  of  the  IL-  I  2R); 
-synergism  with  IL-2  in  the  generation  of  lymphokine-activated  killer  (LAK) 
cell  activity  against  sensitive  target  cells  (e.  g.  tumour  cells,  virus  infected 
cells).  LAK  cells  are  cytotoxic  cells  compris:  LAA,  -,  NK  cells  and  non-MHC 
restricted  CIL&  The  ability  of  IL-12  to  enhance  cytotoxic  activity  is  due  both 
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to  the  induction  of  expression  of  granule  associated  proteins  (e.  g.  perforin, 
granzyme)  and  to  the  direct  cell  proliferation  activity  of  IL-12  that  leads  to 
expansion  of  cytolytic  effector  cells; 
-IL-12  is  chemotactic  for  human  NK  cells  in  vitro  and  stimulates  their 
interaction  with  vascular  endothelium,  via  the  LFA-  I  /ICAM-  I  pathway; 
-synergises  with  stem  cell  factor  in  the  differentiation  of  lymphohematopoietic 
precursors  and  with  IL-3  in  the  production  of  granulocyte  macrophage  colony 
forming  unit  from  hematopoietic  progenitors. 
IL-12  appears  to  have  a  direct  role  in  preventing  the  occurrence  of  spontaneous 
tumours.  Indeed,  tumour  transplantation  studies  in  mice  have  shown  that 
administration  of  IL-12  dramatically  reduced  tumour  growth  and  metastasis 
formation.  These  studies  have  also  shown  that  the  anti-tumour  effect  of  IL-12  is 
mainly  due  to  the  stimulation  of  CTL  activity  and  independent  of  NK  cells  (Brunda  et 
al,  1993). 
A.  variety  of  studies  employing  murine  models  of  infection  have  confirmed  an 
important  role  for  IL-12  in  the  resistance  to  a  variety  of  intracellular  parasites 
including  bacteria,  fungi,  protozoans  and  viruses,  mediated,  in  part,  if  not  totally  by 
IFN-y  (Gately  et  al,  1998).  The  requirement  for  IL-12  appears  to  be  an  early  event  in 
infection  as  mice  infected  with  Toxoplasma  gondii  succumb  to  infection  if  treated 
with  anti-IL-12  antibodies  during  the  acute  phase  of  infection  but  not  if  the  treatment 
is  applied  when  the  process  has  evolved  to  chronicity  (Gazzinelli  et  al,  1992).  The 
importance  of  IFN-y  production  in  response  to  IL-12  was  highlighted  in  experimental 
viral  infection  studies.  It  was  found  that  mice  receiving  inactivated  pseudorabies  virus 
in  conjunction  with  IL-12  were  resistant  to  lethal  virus  challenge  whereas  IFN-YR 
knock-out  mice  succumbed  to  challenge  (Schijns  et  al,  1995).  Likewise,  the 
piýotection  conferred  by  IL-12  to  infection  with  murine  cytomegalovirus  was 
abrogated  by  using  anti-IFN-y  antibodies  or  depletion  of  NK  cells  (Orange  et  al, 
1995). 
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In  conclusion,  by  being  rapidly  produced  in  response  to  infection,  IL-12  contributes  to 
an  'early  innate  response  by  activation  of  NK  cells  which,  through  increased 
production  of  IFN-y,  mediate  activation  of  macrophages  and  inflammatory  responses. 
At  the  same  time  it  sets  the  stage  for  an  antigen-specific  cell  mediated  response  by 
skewing  Th  and  CTLs  to  type  I  (MI  and  TCI,  respectively)  effector  responses 
complemented  by  the  development  of  an  appropriate  immunological  memory  (Gately 
et  al,  'I  998;  Trinchieri,  1998). 
4.1.2  Interleukin-18  (  IL-18) 
4.1.2.1  Molecular  structure  and  production  of  IL-18 
IL-  18  was  first  identified  in  the  senim  (Nakamura  et  al,  1989)  and  purified  from  liver 
extracts  of  mice  (Nakamura  et  al,  1993),  primed  with  Propionibacterium  acnes  and 
challenged  with  LPS,  as  a  factor  involved  in  the  onset  of  endotoxic  shock  through  the 
induction  of  IFN-y  production.  Consequently  the  name  interferon-gamma-inducing 
factor  (IGIF)  was  proposed  (Okamura'  et  al,  1995).  Primers  designed  from  the 
purified  protein  were  used  to  probe  liver  cDNA  libraries  of  this  murine  model,  leading 
to  the  isolation  and  cloning  of  a  full  length  cDNA  product  (Okamura2  et  al,  1995). 
Subsequently,  the  murine  probes  were  also  used  clone  the  human  equivalent  from  the 
erythroleukernic  cell  line  K  562  (Ushio  et  al,  1996).  The  cloned  murine  and  human 
IL-18  encode  precursor  polypeptides  of  192  and  193  aa.,  respectively,  with  an 
apparent  molecular  weight  of  24kDa  as  assessed  by  electrophoresis  under  denaturing 
conditions.  Human  and  murine  IL-18  have  65%  homology  at  the  protein  level. 
Features  of  the  protein  sequence  (figure  4.3)  include  an  unusual  non-hydrophobic 
signal  peptide  sequence,  the  absence  of  N-glycosylation  sites,  the  (F_Y.  (12)-F-X-S_Y,  (6)_ 
F-L)  IL-1  signature-like  sequence  (reviewed  in  Kohno  and  Kurimoto,  1998)  and  an 
overall  P-trefoil  structure  ',  comprising  12  P-sheets,  resembling  that  of  the  IL-I  family 
of  proteins  (Bazan  et  al  1996). 
IL-18'  is  produced  as  an  inactive  precursor  polypeptide  (proIL-18)  that  requires 
cleavage,  at  the  Asp-X  processing  site,  by  the  extracellular  protease  interleukin-IP- 
converting  enzyme  (ICE),  for  the  generation  of  the  biologically  active  mature  IL-18 
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with  l8kDa  (figure  4.3).  The  importance  of  ICE  in  the  generation  of  bloactive  IL-18 
was  elucidated  when  mice  deficient  in  ICE  were  found  to  have  circulating  levels  of 
IFN-y  matching  those  detected  in  IL-  18  "knock-out"  mice,  under  the  same  stimulation 
conditions  (Ghayur  et  al,  1997).  ICE  belongs  to  the  caspase  family  of  proteins  and 
another  member  of  this  family  (caspase-3)  was  found  to  cleave  IL-18,  although 
generating  biologically  inactive  fragments  (reviewed  in  Fantuzzi  and  Dinarello, 
1999). 
Figure  4.3  Polypeptide  structure  and  processing  of  IL-18  (modified  from 
Okarnura  et  al,  1998;  Fantuzzi  and  Dinarello,  1999). 
IL-  18  is  expressed  primarily  by  monocytes/macrophages,  but  also  by  other  cell  types 
including  keratinocytes  (Stoll  et  al,  1997),  osteoblasts  (Udagawa  et  al,  1997)  and 
epithelial  cells  of  the  intestine  (Takeuchi  et  al,  1997)  and  adrenal  cortex  (Conti  et  al, 
1997).  Nevertheless,  due  to  its  requirement  for  post-translational  processing,  the 
detection  of  IL-  18  RNA  transcnpts  does  not  mean  that  the  cells  produce  active  IL-  18. 
In  fact,  although  RNA  message  can  be  readily  detected  in  unstimulated  liver 
macrophages  (Kupffer  cells),  only  after  LPS  stimulation  do  these  cells  produce 
bioactive  IL-  18  (Okamura  et  al,  1998). 
4.1.2.2  IL-18  receptor  and  signalling 
The  IL-  18  receptor  (IL-  I  8R)  complex  appears  to  be  formed,  like  that  of  IL-  1,  by  an  cc 
chain  (IL-18Ra),  responsible  for  binding  and  a  P-chain  (IL-18RP)  which  is  mainly 
involved  in  signalling.  The  IL-  I  8R(x  was  found  to  be  the  molecule  previously  known 
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as  IL-  IR  related  protein  (Tongoe  et  al,  1997)  but  so  far  without  a  ligand  as  it  did  not 
bind  any  of  the  IL-1  family  of  proteins  (Parriet  et  al,  1996).  IL-18RP  is  structurally 
and  functionally  similar  to  the  IL-1  R  accessory  protein  (IL-IR-AcP)  having  initially 
been  named  accessory  protein  like  (AcPL)  (Born  et  al,  1998).  Cells  can  express  both 
low  affinity  receptors  formed  by  IL-Rcc  alone  and  high  affinity  receptors  that  are 
complexes  of  the  two  chains.  A  third  protein  with  IL-18  binding  activity  (IL-18BP) 
has  recently  been  isolated  from  human  unne  and  is  thought  to  be  the  soluble  form  of 
the  extracellular  portion  of  IL-18R(x,  serving  as  a  decoy  receptor  for  IL-18  (Novick  et 
al,  1999). 
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Figure  4.4  Signal  transcluction  by  IL-18  (modified  from  Fantuzzi  and 
Dinarello,  1999). 
Following  IL-18  binding  to  its  receptor,  oligmerisation  of  the  receptor  complex 
initiates  the  signalling  cascade  responsible  for  the  transcnption  of  responsive  genes 
(figure  4.4).  The  intracellular  domain  of  receptor  P-chain  phosphorylates  the  IL-1 
receptor  associated  kinase  (IRAK)  possibly  with  the  mediation  of  an  adapter  molecule 
named  MyD88,  that  allows  docking  of  IRAK  to  the  receptor.  Once  phosphorylated 
IRAK  dissociates  from  the  receptor  complex  and  phosphorylates  the  TNF  receptor 
associated  factor-6  (TRAF-6).  The  nuclear  factor-KB  (T"!  FKB),  in  its  resting  form,  is 
bound  to  an  inhibitory  protein  named  lKB.  Phosphorylation  Of  IKB  by  TRAF-6  leads 
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to  its  degradation  by  ubiquitin.  with  release  of  the  p5O  and  p65  components  of  NFY.  B. 
Activated  NFxB  translocates  to  the  nucleus  activating  gene  transcription  (Reviewed  in 
May-  and  Ghosh,  1998;  Fantuzzi  and  Dinarello,  1999).  In  addition,  p56LCK  and 
p42MAPK  were  also  found  to  be  activated  and  associate  following  IL-  18  induction, 
but  their  function  as  signalling  components  of  IL-18  is  still  not  understood  (Tsuji- 
Takayama,  et  al,  1997).  Also  obscure  is  the  process  by  which  IL-18  binding  to  its 
receptor  leads  to  activation  of  AP-1,  found  to  be  the  major  DNA  binding  protein 
associating  with  the  IFN-y  gene  promoter  following  IL-18  stimulation  of  T  cells 
(Barbulescu  et  al,  1998). 
4.1.2.3  Biological  activities  of  IL-18 
Functionally  the  most  important  characteristic  of  IL-  18,  suggested  by  its  former  name 
(IGIF),  is  the  induction  of  IFN-y  production  from  both  T  and  NK  cells  (described 
below).  Nevertheless  IL-  18  promotes  many  pleiotropic  activities  that  are  not  mediated 
by  IFN-y.  These  activities  are  reviewed  in  Kohno  and  Kurimoto  (1998),  Okamura  et 
al  (1998)  and  Dinarello  (1999)  and  include: 
-  induction  of  IL-2,  GM-CSF,  and  TNF-cc  and  suppression  of  IL-10  production 
by  T  cells; 
-  synergism  with  IL-12  in  the  development  and  proliferation  of  Th  I  cells; 
-  enhancement  of  cytoltoxic  activity  of  both  CTLs  and  NK  cells  not  only  by 
the  increased  release  of  cytolytic  substances  (e.  g.  perforin,  granzyme  A)  but 
also  by  increasing  Fas-ligand  expression  leading  to  Fas  mediated  apoptosis  of 
target  cells; 
-ý- 
induction  of  chemokine  production  (e.  g.  IL-8)  by  monocytes  and  NK  cells  in 
,  synergism  with  TNF-a; 
.-  enhancement  nitric  oxide  production  and  that  of  proinflamatory  cytokines 
I-ý,  (e.  g.  IL-6,  IL-  10)  by  macrophages; 
role  in  bone  remodelling  by  suppression  of  osteoclast  differentiation 
mediated  by  GM-CSF. 
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IL-18  promotes  increased  resistance  to  viral  infection  through  the  enhancement  of 
cytotoxic  activity.  Nevertheless,  addition  of  IL-18  to  human  lymphoma  cells  (U937) 
inficted  with  HIV-1,  was  found  to  increase  production  of  virus  linked  to  an  increase 
in  nitric  oxide  synthase  activity  (Okamura  et  al,  1998).  IL-18,  administered  to  mice, 
had  a  significant  antitumour  effect  and  induced  specific  immunity  to  the  tumour.  This 
effect  was  found  to  be  promoted  by  the  activation  of  NK  cells  independently  but  in 
synergism  with  IL-12  and  IFN-y  (Osaki  et  al,  1998).  The  role  of  IL-18  in  bacterial 
infection  is  controversial  appearing  to  be  dependent  on  the  infection  model  used.  In 
Salmonella  infection  the  protection  afforded  by  IL-18  administration  is  mediated  by 
whereas  in  the  case  of  Y  IFN-  ersinia  infection,  IL-18  promotes  resistance 
independently  of  IFN-y  (Dinarello,  1999). 
4.1.3  Induction  of  IFN-y  by  IL-12  and  IL-18 
The  single  most  important  activity  of  both  IL-12  and  IL-18  is  their  potent  synergistic 
induction  of  IFN-y  production  primarily  from  T  and  NK  cells  but  also  from  B  cells 
(Yoshimoto  et  al,  1997)  and  macrophages  (Munder  et  al,  1998).  Results  obtained  in 
vitro,  with  various  cell  types  revealed  that,  in  every  case,  the  combination  of  IL-12 
and  IL-18  was  far  more  effective  in  inducing  IFN-y  than  either  cytokine  alone. 
Furthermore,  the  synergism  is  observed  even  with  saturating  concentrations  of  both 
molecules  (Kohno  and  Kurimoto,  1998).  This  suggests  that  they  act  through  different 
signalling  pathways,  leading  to  transcription  through  activation  of  different  enhancer 
elements  of  the  gene  promoter  with  a  rapid  accumulation  of  IFN-y  mRNA.  Indeed,  in 
freshly  isolated  human  T  cells,  IL-18  was  reported  to  cause  high  IFN-y  gene  promoter 
activity  via  its  AP-1  site,  whereas  binding  of  STAT  4  to  the  IFN-y  promoter  following 
IL-12  stimulation  resulted  in  low  level  of  gene  transcription.  However  when  IL-12 
was  added  in  combination  with  anti-CD3  and  anti-CD28  antibodies  (therefore 
mimicking  full  T  cell  activation)  both  STAT  4  and  AP-I  sites  of  the  IFN-y  promoter 
were  activated,  resulting  in  high  level  of  transcription  (Barbulescu  et  al,  1998).  A 
further  explanation  for  the  synergism  between  this  two  cytokines  is  offered  by  the 
observation  that  IL-12  is  able  to  directly  upregulate  the  exprussion  of  IL-18R  (Ahn  et 
al  1997)  while  IL-  18,  at  least  indirectly  through  IFN-y  production,  is  able  to  have  the 
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same  effect  over  the  expression  of  IL-12R  P-chain  (Dinarello,  1999).  As  yet 
unpublished  data  suggests  that  IL-18  is  also  able  to  directly  upregulate  expression  of 
IL-  I  2R  (A.  O'Garra  personal  communication). 
Inflammatory  responses 
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Figure  4.5  Integration  of  IL-12,  IL-18  and  IFN-y  activities  in  a  Thl  context. 
Showing  positive  feed-back  loops  in  the  production  of  IFN-y  (solid  lines)  and 
IL-  12/IL-  18  (dashed  lines).  (modified  from  Dinarello,  1999). 
The  reciprocal  receptor  transmodulation,  in  addition  to  the  fact  that  IL-12  and  IL-18 
have  essentially  the  same  cellular  targets,  is  reflected  in  their  cooperation  in  a 
significant  number  of  activities  that  bridge  innate  and  antigen-specific  immune 
responses  as  well  as  inflammatory  responses  and  that  have  IFN-y  production  as  a 
common  denominator  (figure  4.5).  These  include:  optimal  development  of  a  CD4+ 
Th  I  phenotype;  proliferation  and  enhancement  of  cytolytic  activity  of  T  and  NK  cells; 
activation  of  macrophages  and  induction  of  activated  B  cells  to  shift  antibody 
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production  from  neutralising  (IgE  and  IgGl)  to  cytotoxic  and  complement-fixing 
(IgG2a/b  and  IgG3)  subclasses  in  mice  (Trinchieri,  1998;  Dinarello,  1999). 
The'-potent  induction  of  IFN-y  production,  associated  with  the  other  synergistical 
activities  of  IL-12  and  IL-18  in  host  protection  against  intracellular  pathogens, 
motivated  us'to  isolate  these  cytokines  in  the  horse.  At  the  time  the  only  sequences 
published  for  IL-12  were  those  corresponding  to  human  (Wolf  et  al,  1991;  Gubler  et 
at-al,  1991),  murine  (Schocnhaut  et  al,  1992)  and  bovine  (Zarlcnga  et  al,  1995) 
species.  Despite  the'level  of  homology  these  molecules  have  (table  4.1),  cross 
reactivity  studies  of  IL-12  between  mouse  and  human  showed  that  although  mouse 
IL-'12  has  some  biological  activity  over  human  lymphocytes,  human  IL-12  is  not 
active  in  murine  cells  (Trinchieri,  1998).  Furthermore,  recombinant  human  IL-12 
administered  to  non-human  primates,  gives  rise  to  anti-human  IL-12  antibodies 
(Sarmiento  et  al,  1994). 
Table  4.1  Cross-species  homology  of  IL-12  p40  and  p35  peptides. 
11,12  p40  Human  p4O  Murine  p4O  Bovine  0 0 
Human  p4O  -  66.7%  84.2%. 
Murine  p4O  66.7%  -  65.8% 
2 
Bovine  p4O  84.2%  65.8%  - 
11,12  p35  Human  p35  Murine  p35  -  Bovine  p35 
Human  p35  -  58.9%  81.5% 
Murine  p35  58.9%  -  57.9% 
Bovine  p35  81.5%  57.9%  - 
in  the  case  of  IL-  18,  the  only  two  sequences  available  were  the  human  (Ushio  et  al, 
1996)  and  the  murine  (Okamur2  et  al,  1995)  with  an  homology  of  65%  at  the  protein 
level.  Again,  although  some  bioactivity  was  detected  by  using  murine  recombinant 
protein  in  human  cells  this  was  100-fold  less  active  than  recombinant  human  IL-18 
under  the  same  conditions  (Konishi  et  al,  1997),  highlighting  once  more  the 
requirement  for  species-specific  cytokines. 
Previous  experience  obtained  by  the  cloning  of  equine  TGF-P  (Penha-Goncalves  et  al, 
1997-Appendix  1)  indicated  that  the  cross-species  homology  of  both  IL-12  and  IL-18 
was  sufficient  to  derive  oligonucleotides  from  conserved  regions  of  the  molecules. 
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This  would  then  enable  the  amplification  of  transcribed  equine  mRNA  molecules,  by 
RT-PCF,  from  suitable  equine  cells  and  under  appropriate  stimulation  conditions. 
Below  is  a  description  of  the  methods  used  in  the  amplification  of  equine  IL-  12  (eqlL- 
12)  and  IL-  18  (eqIL-  18)  coding  sequences  as  well  as  their  cloning  in  plasmids  to  be 
co-administered.  in  a  DNA  vaccination  trial  against  equine  influenza  virus  (chapter  6). 
The  collaboration  of  the  following  co-workers  in  this  part  of  the  project  is 
acknowledged:  Ms  J.  L.  Keanie  in  the  cloning  of  IL-12  and  IL-18;  Miss  N.  Logan  in 
the  generation  of  full  length  IL-12  p35  and  p40  cDNAs;  Mrs  L.  McMonagle  and 
summer  students  Claire  Brown  and  Spencer  French  in  the  generation  of  expression 
constructs  and  Mrs  Dorothy  Reid  in  the  preliminary  expression  of  IL-12  and  IL-18. 
Most  of  the  results  of  the  present  chapter  were  submitted  for  publication  (Nicolson  et 
al,  1999  -  Apendix  I). 
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4.2  Materials  and  methods 
Because  the  main  producers  of  IL-12  and  IL-18  are  macrophagic  cells,  isolation  of 
eqlL-12  and  eqIL-18  was  attempted  from  primary  cell  cultures  enriched  in  alveolar 
macrophages,  derived  from  lung  washes. 
4.2.1  Preparation  of  enriched  alveolar  macrophages 
Lung  washes  were  performed  in  the  post-mortem.  room  of  the  veterinary  school, 
blasgow.  After  euthanasia  and  careful  removal  of  lungs  from  horses,  the  lungs  were 
cleaned  from  excess  blood  and  a  sterile  plastic  funnel  was  introduced  in  the  trachea. 
The  lungs  were  then  filled,  with  up  to  one  litre  of  ice  cold  Hank's  Buffered  Saline 
(HBSS),  and  gently  massaged.  Liquid  was  decanted  directly  to  centrifuge  bottles 
avoiding  blood  contamination.  The  lung  wash  was  repeated  twice  more  for  a  total  of 
three  times.  Resulting  wash  fluid  was  pooled  in  centriffige  bottles,  transferred  to  the 
laboratory  in  crushed  ice  and  centrifuged  at  1800g  (4500  rpm  in  a  J14  rotor)  for  10 
min  at  4C.  After  centrifugation  the  froth  was  removed,  the  supernatant  discarded  and 
the  cells  resuspended  in  HBSS.  Cells  were  pooled  and  washed  once  more  in  HBSS  by 
centrifugation  as  before.  The  supernatant  was  discarded  and  the  cells  were  washed 
twice  in  RPMI  1640  with  10%  FCS,  resuspended  in  5  to  I  Oml  of  RPMI  and  counted 
by  Trypan  blue  exclusion.  Cells  were  diluted  to  2x  I  0'/mI  in  complete  medium  (RPMI 
1640  with  5%  FCS,  100  IIJ/ml  of  penicillin/streptomycin,  IOmM  Hepes,  2mm 
Glutamine  and  5xIO-'M  P-mercaptoethanol),  and  distributed  into  162cm'  flasks  (50ml 
per  flask  with  IO'cells),  followed  by  overnight  incubation  at  37*C  with  5%  C02.  The 
supernatant  was  removed  and  adherent  cells  were  washed  two  times  with  complete 
medium.  40ml  of  complete  medium  containing  LPS  at  10ýtg/ml  was  added  to  each 
flask  followed  by  incubation  for  6  hours  as  before.  The  supernatant  was  removed  and 
using  a  cell  scraper  the  cells  were  detached,  resuspended  in  50ml  of  complete 
medium  and  pelleted  at  1200  rpm  for  5min  in  a  bench  top  centrifuge.  The  pellet 
resultant  from  each  flask  was  resuspended  in  50ml  of  complete  medium  and  divided 
in  two  tubes  and  the  cells  centrifuged  as  before.  The  supernatant  was  discarded  and 
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the  pellets  were  snap-frozen  in  dry-ice  with  100%  ethanol.  Frozen  pellets  were  stored 
at  -70"C  until  ready  to  perform  mRNA  extraction. 
4.2.2  Amplification  of  equine  IL-12  and  IL-18  cDNAs 
Preparation  of  cDNA 
All  the  reagents  used  in  the  preparation  of  mRNA  and  cDNA  were  prepared  in  DEPC 
treated  dH.  O  (mat&meth)  and  all  tubes  and  tips  were  RNAse  free. 
Extraction  of  mRNA  from  stimulated  equine  "macrophages"  was  performed  using  the 
Quick  Prep  mRNA  Isolation  Kit  (Pharmacia)  observing  the  manufacturers 
instructions.  Resulting  mRNA  yeld  and  purity  was  assessed  by  spectrophotometry  and 
treated  with  methylmercury  hydroxide  as  follows.  Up  to  I  ýLg  of  mRNA  was  diluted  in 
DEPC  treated  dH20  to  a  volume  of  20  til  and  incubated  at  650C  for  10  min  and 
transferred  to  crushed  ice.  Methyl  mercury  hydroxide  (2  pl  of  a  100mM  solution)  was 
added  to  the  tubes  and  incubated  at  room  temperature  for  I  min.  P-mercaptoethanol 
(4pl  of  a  700mM  solution)  was  added  and  the  tubes  incubated  at  room  temperature  for 
a  further  5  min.  The  mRNA  was  reverse  transcribed  using  the  First  Strand  cDNA 
Synthesis  Kit  (Pharmacia)  with  an  oligo-dT  as  primer,  following  the  manufacturers 
instructions.  The  cDNA  synthesis  reaction  was  incubated  at  37*C  for  I  hour  and  the 
reaction  was  stopped  by  denaturation  of  the  enzyme  at  940C  for  5  min,  and  frozen  at  - 
700C  when  not  used  immediately. 
Primer  design 
Primers  for  PCR  (table  4.2)  were  designed  by  aligning  published  nucleotide 
sequences  of  IL-  12  and  IL-  18  from  other  species  (figure  4.6).  For  IL-  12  the  sequences 
of  human  (Wolf  et  al,  199  1;  Gubler  et  al,  199  1),  murine  (Schoenhaut  et  al,  1992)  and 
bovine  (Zarlenga  et  al,  1995)  species  were  used.  For  IL-18  were  used  the  human 
(Ushio  et  al,  1996)  -and  murine  (Oka=2  et  al,  1995)  sequences. 
160 IL-121IL-18 
P40 
-16  21 
TCCTGCCCAGAGCAAGATOTGTC4CCAGCAGTTGGTC  Human 
Primer  1  ATGCACCCTCAGCAGTTGGTC  Bovine 
CTCGCAGCAAAGCAAGATGTGTCCTCAGAAGCTAACC  Murine 
978  1014 
GCCCTGCAGTTAGGTTCTGATCCAGGATGAAAATTTG  Human 
Primer  2  GTCCTGCAGTTAGGTTCTAACCTCAGTATGAAACCTC  Bovine 
TCCCTGCAGGGGTCCGATCCTAGGATGCAACGTTGGA  Murine 
p35 
-20  16 
Primer  1  CCCTGCAGTGCCGGCTCAGCATGTGTCCAGCGCGCA  Human 
ATGTGCCCGCTTCGCA  Bovine 
CCTCTCAGTGCCGGTCCAGCATGTGTCAATCACGCT  Murine 
650  686 
GAGTGACGAGCTATCTGAATGCTTCCTAAAAAGC.  GA  Human 
Primer  2  GAATGATGAGcTýx,;  cT(*a7qTTc=jýGA4TqqrGA  Bovine 
GGGTGATGGGCTATCTGAGCTCCGCCTGAAAGCTCAA  Murine 
282  319 
TTGGAATTAACCAAGAATGAGAGTTGCCTAAATTCCAG  Human 
Primer  3  CTGGAATTAGCCACOAATGAGAPTTGCCTGGCTTCCAG  Bovine 
CTGGAACTACACAAGAACGAGAGTTGCCTGGCTACTAG  Murine 
544  581 
Primer  4  CAAAAATCCTý:  CCTTGAAGAACCGGATTTTTATAAAAC  Human 
CAGAAACCCTCCCTGAAAGAACTGGATTTTTACAAGAC  Bovine 
CAGAAACCTCCTGTGGGAGAAGCAGACCCTTACAGAGT  Murine 
IL-18 
160  191 
Primer  A 
,, 
PTGCTGAACC  TTTGTCGCAGAPA4TWqý6TQG  Human 
CCTCTTGGCCCAGGAACAATGGCTGCCATGTC  Murine 
750  784 
primer  B  CGAAGACTAGCTATTAAAATTTCATGCCGGGCGCA  Human 
CTTACATCAAAGTTAGGTGGGGAGGGTTTGTGTTC  Murine 
229  260 
Primer  C  TTTATTGACAATACGCTTTACTTTATAGCTGA  Human 
=ATTGACAACACGC=AC=ATACCTGA  Murine 
725  259 
primer  D  GATCTATAATGTTCACTGTTCAAAACGAAGACTAG  Human 
AATCTGTAATGTTCACTCTCACTAACTTACATCAA  Murine 
Figure  4.6  Derivation  of  primers  from  published  IL-12  and  IL-18  sequences. 
In  the  case  of  p40  and  p35  the  numbers  relate  to  nucleotide  positions  in  the 
bovine  sequence  and  for  IL-I  8  in  the  human  sequence. 
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For  amplification  of  equine  p35  all  the  primer  sequences  were  derived  from  a 
consensus  of  the  human  and  bovine  equivalents.  In  the  case  of  p40,  primers  1,3  and  4 
are  derived  from  human  sequence  whereas  primer  2  was  derived  from  the  bovine 
sequence.  Primers  3  and  4  were  a  gift  from  Dr.  Mary  B.  Tompkins  (details  in  Rottman 
et  al,  1995).  Table  4.2  shows  the  sequences  of  primers  designed  and  figure  4.7  their 
relative  position  in  the  respective  genes. 
Table4.2  Primers  for  PCR  amplification  of  equine  IL-12  and  IL-18. 
Target  gene  Name  Orientation  Sequence  (  5'-  Y)  Tm 
p4O.  l  sense  CAGAGCAAGATGTGTCACCAG  64"C 
11,12  p40  p4O.  2  antisense  CATACTGAGGTFAGAACC  52*C 
p4O.  3  sense  AGATGCTGGCCAGTACACCT  62*C 
p4O.  4  antisense  GGGAGAAGTAGGAATGTGGAG  64*C 
p35.1  sense  CAGTGCCGGCTCAGCATGTG  66*C 
IL-12  p35  p35.2  antisense  GCT=AGGAAGCATrCAGATAGC  70'C 
p35.3  sense  CACGAATGAGAGTrGCCT  54'C 
p35.4  antisense  GAAGTATGCAGAGCTTGA  52C 
A  sense  GCAGGAATAAAGATGGCTGC  60'C 
IL-18  B  antisense  GGCATGAAATTTTAATAGCTA  56"C 
c  sense  GACAATACG=A=AT  52*C 
D  antisense  GCG=GAACAGTGAACAT  54*C 
p40.  l  p40.3  1049 
p40 
0  p40.4  p40.2 
p35.1  p3  5.3  669 
p35 
-m  -1 
i 
0  p35.4  p35.2 
Ac  582 
IL-18  ------ 
0DB 
Figure  4.7  Relative  positions  of  PCR  primers  in  respective  target  sequences. 
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The  primers  were  ordered  for  synthesis  at  MWG-biotech  (Germany)  and  the 
corresponding  melting  temperatures  (Tm)  were  calculated  using  the  formula  Tm= 
4x(G+Q  +  2x(A+T). 
Cycling  conditions 
For  PCR  amplification  of  eqIL-  12  and  eqIL-  18  Perkin  Elmer  PCR  core  reagents  were 
used.  All  primers  were  used  at  a  final  concentration  of  I  ýM  (2.5  til  per  reaction  of 
each  primer  at  20  pmoles/lil)  in  a  50gl  reaction  volume  with  2.5  units  (0.5gl)  of  Taq 
polymerase,  5gl  of  I  OX  PCR  buffer,  200  gM  dNTP  mix  (51il  of  a  solution  containing 
1.25  mM  each  dNTP)  and  24.5  [d  of  dH20.  The  template  consisting  of  10111  of  cDNA 
per  reaction  was  added  just  prior  to  PCR  cycling.  In  the  case  of  IL-  18  secondary  PCR 
reactions  were  also  performed,  using  as  template  11il  of  the  primary  PCR  reaction 
product.  PCR  reactions  were  performed  in  a  Perkin  Elmer  9600  thennal  cycler  with 
the  following  conditions.  For  both  p35  and  p40,94*C  for  5  min.,  followed  by  30 
cycles  of  94*C  for  Imin.,  55*C  for  1.5  min.  and  72"C  for  2  min.,  terminating  with  a 
single  cycle  of  72T  for  7  min.  For  IL-18  primary  PCRs  conditions  were  94*C  for  5 
min  with  30  cycles  of  94C  for  45sec,  450C  I  min  and  720C  for  1.5  min  terminating 
with  72"C  for  7  min  and  for  secondary  PCRs  30  cycles  of  94"C  for  45sec,  45"'C  I  min 
and  72"C  for  2  min.  In  the  case  eqlL-12,  two  fragments  of  p40  were  obtained  by  using 
primers  p40.1  and  p40.4  (5'  fragment  )  and  primers  p40.3  and  p40.2  (3'  fragment)  and 
p35  was  also  obtained  in  two  fragments  using  p35.1  with  p35.4  (5'  fragment)  and 
p35.3  with  p35.2  (3'  fragment).  To  obtain  eqIL-18  in  a  single  fragment  an  equine 
specific  primer  was  design  based  on  the  PCR  product  sequence  generated  by  primers 
A+D  and  C+B,  this  new  primer,  termed  G(  51-GCTAGTrCTGG=GAACA-3' 
successfully  amplified  the  full  length  IL-  18  cDNA  in  combination  with  primer  A. 
4.2.3  Cloning  and  sequencing  of  eqlL-12  and  eqIL-18 
PCR  products  were  cloned  into  pCR-II  TA  cloning  vector  (Invitrogen)  following  the 
manufacturer  instructions.  Plasmid  DNA  was  amplified  by  transformation  and  growth 
of  the  InvaF'  strain  of  E.  coli  (mat  &meth).  Recombinants  were  screened  by 
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restriction  enzyme  digestion  of  minipreparations  of  plasmid  DNA  (mat  &  meth)  using 
the  enzymes  SpeI  and  NotI.  Double  digestion  using  these  enzymes,  followed  by 
electrophoresis  in  a  1.2%  agarose  gel  stained  with  ethidium  bromide  (math  &  meth) 
generated  the  following  band  pattern:  for  p40  (5'  fragment  -  800  bp  and  3'  fragment 
-750  bp);  for  p35  (5'  fragment  --600bp  and  3'  fragment  -400bp)  and  for  IL-18  a 
unique  fragment  of  -600  bp. 
Fifteen  p40  clones,  15  p35  clones  and  10  IL-18  clones  were  subcultured  by  overnight 
growth  in  LB  medium  containing  100ýtglml  of  ampicillin  at  37'C.  Sequencing  quality 
DNA  was  recovered  using  QIAprep  Miniprep  kit  (Qiagen),  observing  the 
manufacturer  instructions,  analysed  by  ethidium  bromide  stained  agarose 
electrophoresis  and  quantified  by  spectrophotometry.  Sequencing  reactions  were 
prepared  using  the  ThermoSequenase  Cycle  Sequencing  Kit  (Amersham)  with  vector 
derived  M13  forward  and  reverse  primers,  modified  by  5'  labelling  with  the  IRD-800 
fluorochrome  (MWG-Biotech).  Sequencing  reactions  were  run  in  a  LICOR400 
automated  sequencer  (math  &  meth).  Sequences  generated  for  the  clones  across  both 
strands  were  analysed  by  GCG  software  and  consensus  sequences  for  eqp40,  eqp35 
and  eqIL-  18  were  generated. 
4.2.4  Generation  of  full  length  eqIL-12  p40  and  p35 
Full  length  p35  and  p40  cDNAs  were  obtained  by  cloning  strategies  that  took 
advantage  of  unique  restriction  sites  in  the  overlapping  regions  of  both  molecules, 
surnmarised  in  figures  4.8  and  4.9  for  p40  and  p35,  respectively.  The  full  length  open 
reading  frames  obtained  in  this  fashion  were  re-sequenced  and  found  to  be  100% 
conserved  to  the  respective  consensus  sequences. 
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Figure  4.8  Generation  of  full  length  equine  p40. 
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Figure  4.9  Generation  of  full  length  equine  p35. 
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4.2.5  Cloning  of  eqIL-12  and  eqll.  -18  in  mammalian  expression  vectors 
The  generation  of  constructs  containing  eqIL-12  and  IL-18  for  DNA  vaccination 
utilised  a  plasmid  suitable  for  driving  the  expression  of  these  cytokines  in  mammalian 
cell  systems.  The  plasmid  chosen  was  the  pCI-Neo,  (Promega)  and  the  reasons  for  its 
selection  are  reviewed  in  chapter  6. 
The  secretion  of  bioactive  recombinant  IL-12  is  only  achieved  by  simultaneous 
expression  of  subunits  p40  and  p35  in  the  same  cell.  To  ensure  that  both  subunits 
would  be  delivered  (by  transfection)  to  individual  cells,  equine  p40  and  p35  were 
cloned  into  a  single  vector  with  dedicated  gene  promoters  and  polyadenylation  signals 
driving  expression  of  both  mRNA  species  (figure  4.10).  Additionally,  in  this  system 
p40  expression  is  driven  by  a  weaker  promoter  (lacking  intronic  sequence)  than  that 
regulating  p35  expression,  favouring  secretion  of  heterodimeric  IL-12  rather  then 
monomeric  p40,  known  to  have  receptor  binding  capability  and  therefore  a 
competitive  inhibitory  effect  over  IL-12  activity. 
Table  4.3  Nucleotide  sequences  used  in  the  construction  of  eqIL-12  and  eqlL-18 
Tm 
IL12p4O 
51primer  5'-GCX 
MIUI 
GAGCAAGATOTG-3'  72*C 
3'primer  5'-GCýdXdkWATCCCTAACTGC-3'  68"C 
Xbal 
IL12p35  Mlul 
,  51primer  5'-  GCACGCGTTCGGCTTGGATATG  -3'  700C 
3'primer  5'-  GCTrTAGACGGCTTGCTTMAGG-3'  720C 
Xbal 
11,48  Bst  11071 
5'primer  5'-  GCACCATGGTATACTTTGGCAG-3,660C 
31primer  5'-GCTAGTTCrGGTTTTGAACA-3'  560C 
Linker*  5'-CTAGCATTTAAATATG-Ig  leader  sequence-GTTCCACTGGTOATATCATTTAAATG-3' 
Nhel  EcoRV  Sall 
*  Sequence  derived  from  the  plasmid  pSecTag2  (Invitrogen). 
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Figure  4.10  Strategy  for  construction  of  plasmid  driving  the  expression  of 
both  p3  5  and  p40  subunits  of  eq]L-  12. 
In  summary  equine  p40  and  p35  specific  primers,  tagged  with  restriction  enzyme 
recognition  sites  (table  4.3)  were  used  to  amplify  full  length  p4o  and  p35  from 
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plasmid  template.  Using  the  engineered  enzyme  sites  (MluI  and  XbaI)  p40  and  p35 
were  cloned  into  the  multiple  cloning  site  of  pCDNA3.1  (Invitrogen)  and  pCI-Neo, 
respectively.  The  p40  cDNA  together  with  the  pCDNA3.1  CMV  promoter  and 
polyadenylation  signal  was  then  removed  from  pCDNA3.1  using  the  enzymes  BsshII 
and  AflIII  and  slotted  into  the  pCI-Neo  vector  using  a  BamHI  site  just  downstream  of 
the  expression  cassette  CMV  promoter-intron-eqp35-polyadenylation  sequence. 
In  the  case  of  eqIL-18,  an  expression  plasmid  was  constructed  by  cloning  equine 
mature  IL-18  (mIL18)  downstream  of  an  artificial  signal  peptide  sequence.  Because 
this  signal  pcptide  is  efficiently  processed  in  transfected  cells,  it  eliminates  the  need 
for  the  presence  of  ICE  in  the  cells  transfected  by  in  vivo  administration  of  DNA,  that 
would  otherwise  be  required  for  processing  IL-  18  precursor  (proIL-  18)  with  secretion 
of  biologically  active  equine  mIL-  18. 
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Figure  4.11  Strategy  for  construction  of  plasmid  driving  eqIL-18  expression 
linked  to  an  artificial  leader  sequence. 
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Briefly,  a  linker  sequence  (table  4.3)  containing  an  artificial  signal  peptide  derived 
from  the  V-J2-C  region  of  the  mouse  Ig  kappa-chain,  was  synthesised  and  cloned  into 
the  NheI  and  Sall  enzyme  sites  of  pCI-Neo  (pCI-Sig).  Also,  eqIL-18  specific  primers 
(table  4.3)  were  used  to  amplify  the  mature  portion  of  the  molecule  from  plasmd  DNA 
template.  The  5'  primer  contained  a  BstI107I  enzyme  site.  The  PCR  product  was 
cloned  into  a  PCR-11  TA  cloning  vector  and  excised  from  this  plasmid  using  the 
Bstl  1071  site  and  an  EcoRV  site  provided  by  the  vector.  The  fragment  generated  was 
cloned  into  the  EcoRV  site  of  the  artificial  signal  peptide  generating  the  chimera  pCI- 
sig-mIL18. 
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4.3  Results 
Equine  IL-12 
As  mentioned  in  the  description  of  methods,  both  p35  and  p40  were  obtained  in  two 
overlapping  fragments  each  (results  not  shown).  To  obtain  the  sequence  data,  15 
clones  of  p35  and  15  clones  of  p40  were  sequenced  across  both  strands  and  the 
resulting  data  was  analysed  to  derive  consensus  sequences  for  the  respective  open 
reading  frames. 
Regarding  the  p40  subunit  of  equine  IL-12,  analysis  of  the  sequence  data  revealed  an 
open  reading  of  990  bp  encoding  a  precursor  polypeptide  of  329  aminoacids  (figure 
4.12).  The  predicted  peptide  sequence  has  an  identity  of  86%  towards  human  and 
bovine  and  66%  towards  the  corresponding  murine  sequence.  Comparison  of  the 
equine  p40  predicted  protein  with  the  human  sequence  revealed  conservation  of 
features  such  as  3  of  the  4  consensus  N-linked  glycosylation  sites,  9  of  the  10  cysteine 
residues  and  the  sequence320WSEWAS325  similar  to  the  consensus  WSXWS  typical  of 
the  hemopoietin  receptor  family  (figure  4.13).  Further  analysis  of  the  antigenic 
structure  of  equine  p40  (figure  4.18-A)  disclosed  the  hydrophobic  nature  of  the  N- 
terminal  region  of  the  protein,  typical  of  many  cytokines,  suggesting  it  has  the  same 
post-translational  role  in  the  efficient  cellular  trafficking  and  secretion  of  the 
molecule. 
The  equine  p35  open  reading  frame  is  669  bp  in  length  and  codes  for  a  polypeptide  of 
222  aminoacids  (figure  4.14).  Equine  p35  peptide  shows  a  reasonable  degree  of 
homologY  to  correspondent  mammalian  proteins  with  identities  of  82,80  and  59%  to 
human,  bovine  and  murine  peptides,  respectively.  When  compared  to  the  human 
molecule  shows  a  notable  conservation  of  features,  including  all  3  predicted  N-linked 
glycosylation  sites  and  all  7  cysteine  residues  and  three  leucine  zipper  motifs  thought 
to  be  involved  in  protein-protein  interactions  (figure  4.15).  Again,  antigenic  analysis 
of  the  molecule,  r6vealed  a  typical  hydrophobic  leader  sequence  (figure  4.18-13). 
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Equine  IL-18 
In  relation  to  equine  IL-  18,  the  cloned  gene  fragment  contains  a  full  size  open  reading 
frame  of  582  bp  that  codes  for  a  193  residue  equine  proIL-18  (figure  4.16).  Sequence 
homology  studies  (figure  4.17)  revealed  that  features  in  common  with  human  IL-18 
include  the  ICE  processing  site  (ASP36-Tyr37)  and  those  of  caspase-3  (ASP71-Ser72  and 
ASP76-Asn77)  and  the  IL-1-like  signature  sequence  (F-X, 
2-F-X-S-X6-F-L-) 
in  residues 
138  to  161.  As  in  the  case  of  mouse  and  human  IL-18,  the  equine  peptide  is  deprived 
of  N-linked  glycosylation  sites.  The  overall  identity  of  equine  IL-18  peptide  to  the 
mouse  and  human  representatives  is  of  67  and  79%,  respectively.  Analysis  of  the 
sequence  antigenic  structure  (figure  4.18-C)  revealed  a  non-hydrophobic  and  therefore 
unusual  leader  sequence  typical  of  IL-18  and  of  the  IL-  I  family  of  proteins. 
171 1  ATGTGTCACCAGTGGTTGGTCCTCTCCTGGTTTTCCCTGGTTTTGCTGGCGTCTCCCCTC  60 
MCHQWLVLSWFSLVLLASPL  (20) 
ATGGCCATATGGGAACTGGAGAAAGATGTGTATGTTGTAGAATTGGATTGGTACCCTGAT  120 
MAIWELEKDVYVVELDWYPD  (40) 
GCCCCTGGAGAAATGGTGGTCCTCACCTGCAATACCCCTGAAGAAGAAGGCATCACCTGG  180 
APGEMVVLTCNTPEEEGITW  (60) 
ACCTCGGCCCAGAGCAATGAGGTCTTAGGCTCTGGCAAAACCTTGACCATCCAAGTCAAA  240 
TSAQSNEVLGSGKTLTIQVK  (80) 
GAGTTTGGAGATGCTGGCTGGTACACCTGTCACAAAGGAGGCGAGGTTCTGAGCCATTCT  300 
EFGDAGWYTCHKGGEVLSHS  (100) 
CACCTGCTGCTTCACAAGAAGGAAGATGGAATTTGGTCCACTGACATTTTAAAAGACCAG  360 
HLLLHKKEDGIWSTDILKDQ  (120) 
AAAGAATCCAAAAATAAGACCTTTCTAAAATGTGAGGCAAAGAATTATTCCGGACGTTTC  420 
KESKNKTFLKCEAKNYSGRF  (140) 
ACATGCTGGTGGCTGACAGCAATCAGTACTGATTTGAAATTCAGTGTCAAAAGCAGCAGA  480 
TCWWLTAISTDLKFSVKSSR  (160) 
GGTTCCTCTGACCCCCGAGGGGTGACGTGTGGAGCAGCGACACTCTCCGCAGAGAGGGTC  540 
GSSDPRGVTCGAATLSAERV  (180) 
AGCGTGGACGACAGGGAGTATAAGAAGTACACGGTGGAGTGTCAGGAGGGCAGTGCCTGC  600 
SVDDREYKKYTVECQEGSAC  (200) 
CCGGCCGCCGAGGAGAGCCTGCCCATTGAGATCGTGGTGGATGCTGTTCACAAGCTCAAG  660 
PAAEESLPIEIVVDAVHKLK  (220) 
G 
TATGAAAACTACACCAGCGGCTTCTTCATCAGGGACATCATCAAACCAGACCCACCCAAG  720 
YENYTSGFFIRDIIKPDPPK  (240) 
AACCTGCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTCAGCTGGGAGTACCCC  780 
NLQLKPLKNSRQVEVSWEYP  (260) 
GAGACCTGGAGCACCCCACATTCCTACTTCTCCCTGACATTCTCTATTCAGGTCCAGGGC  840 
ETWSTPHSYFSLTFSIQVQG  (280) 
AAGAACAAGAAGGAAAGGAAAGACAGACTCTTCATGGATGAGACTTCAGCCACAGTCACA  900 
KNKKERKDRLFMDETSATVT  (300) 
TGCCACAAGGATGGCCAGATCCGTGTCCAAGCCAGGGACCGCTACTACAGCTCATCCTGG  960 
CHKDGQIRVQARDRYYSSSW  (320) 
AGCGAATGGGCATCCGTATCCTGCAGTTAGGGATGCAGACTCAGGCAGCCCAGGCCAGAC  1020 
SEWASVSCS*  (329) 
CTGAACACTCAGTGTACCCAGGTTCTAACCTCAGTATG  1058 
Figure  4.12  Equine  IL-12  p4O  subunit  nucleotide  sequence  and  predicted  a.  a. 
sequence.  Nucleotides  are  numbered  in  bold  type  and  a.  a.  in  brackets.  Primer 
determined  sequence  is  underlined.  The  restriction  site  for  the  enzyme  BspEl, 
used  for  recovery  of  full  length  p4O,  is  shadowed.  An  allefic  difference  (A  or  G) 
observed  at  base  714,  that  does  not  incur  in  substitution  of  the  coded  amino 
acid  (D-aspartic  acid)  is  also  shadowed. 50 
Equine  p4O  IWELEKDV  YVVELDWYPD  APGEMVVLTC 
Bovine  p4O  -HP-Q--V  --  ---------  I  V-M  -----  N-  ----------  ----  T  ----- 
Human  p4O  ----  Q--I  --  ----  F  -----  V  -----  K  ---  ----------  ---------- 
Murine  p4O  --P-K-TI--  -AI  ---  V  ---  --  M  -------  ----  V--T  --  ----  T-N  --- 
51  100 
Fquinep4O  NTPEEEGITW  TSAQSNEVLG  SGKTLTIQVK  EFGDAGWYTC  HKGGEVLSHS 
Bovine  p4O  D  ----  D  ----  --  D--S  ----  ----------  ------  Q  ---  -----  A--R- 
Humanp4O  D  ----  D  ----  -  LD--S  ----  ----------  ------  Q  ---  ---------- 
Murine  p4O  D  ----  DD  ---  --  D-RHG  ---  -------  T--  --L  ---  Q  ---  -----  T  ---- 
101  150 
Equinep4O  HLLLHKKEDG  IWSTDILKDQ  KESKNKTFLK  CEAKNYSGRF  TCWWLTAIST 
Bovine  p4O  L  ---------  ----------  --  P-A-S  ---  ----  D  ---  H-  ---------- 
Human  p4O  L  ---------  ----------  --  P  ------  R  ----------  ------  T  --- 
Murine  p4O  --------  N-  ----E  ---  NF  ***  -------  ---  P  ------  --  S--VQRNM 
151  200 
EquineP40  DLKFSVKSSR  GSSDPRGVTC  GAATLSAERV  SVDDREYKKY  TVECQEGSAC 
Bovine  p4O  ----------  ----------  ---  L  ----  K-  -LEH  ---  N  --  ---------- 
Human  p4O  --T  -------  -----  Q  ----  ----------  RG-NK--*E-  S  -----  D  --- 
Murine  p4O  ----  NI  ---  S  S-P-S-A---  -M-S  ----  K-  TL-Q-D-E--  S-S  ---  DVT- 
201  250 
Equinep4O  PAAEESLPIE  IVVDAVHKLK  YENYTSGFFI  RDIIKPDPPK  NLQLKPLKNS 
Bovine  p4O  -------  L--  V--E  ------  ------  s  ---  ----------  ----  R  ----- 
Hwnan  p4O  ----------  Vm  --------  ------  s  ---  ----------  ---------- 
Murine  p4O  -T  ---  T  ----  LALE-RQQN-  ----STS  ---  ----------  ---  M  ------ 
251  292 
Equinep4O  RQVEVSWEYP  ETWSTPHSYF  SLTFSIQVQG  KNKKER****  ****KDRLFM 
Bovine  p4O  ----------  D  ---------  ----  CV  ----  ---  R-K  ----  -----  **  --- 
Human  p4O  ----------  D  ---------  ----  CV----  -S-R-K  ----  -------  V-T 
Murine  p4O  *  ---------  DS  --------  --  KFFVRI-R  -KE-MKETEE  GCNQ-GAFLV 
293  329 
Equinep4O  DETSATVTCH  KDGQIRVQAR  DRYYSSSWSZ  WASVSCS 
Bovinep4O  -QT--K  ----  --  ANV  -----  ------  F  ---  -------  86% 
Humanp4O  -K  -----  I-R  -NAS-S-R-Q  ----------  ----  P--  86% 
Murinep4O  EK--TE-Q-*  -G-NVC  ---  Q  ----  N--C-K  --C-P-RVRS  66.1% 
Figure  4.13  Sequence  comparison  between  equine  p4O  subunit  of  IL-12  and 
other  published  mammalian  species,  highlighting  aa  substitutions.  Homology 
percentages  in  relation  to  the  equine  sequence  are  shown.  Numbers  correspond  to 
a.  a.  positions  of  equine  sequence.  The  predicted  signal  peptide  sequence  is 
shaded  blue.  Conserved  N-linked  glycosylation  sites  are  underlined  and  the 
haernopoietin  receptor  related  sequence  is  in  bold  type.  (.  )  represent  absent 
residues. 1  ATGTGCCCGCCGCGCGGCCTCCTCCTTGTGGCCATCCTGGTCCTCCTAAACCACCTGGAC  60 
MCPPRGLLLVAILVLLNHLD  (20) 
CACCTCAGTTTGGCCAGGAACCTCCCCACAGCCACACCAGGCCCAGGAATGTTCCAGTGC  120 
HLSLARNLPTATPGPGMFQC  (40) 
CTCAACCACTCCCAAAACCTGCTGAGGACCGTCAGCAACACGCTTCAGAAGGCCAGGCAA  180 
LNHSQNLLRTVSNTLQKARQ  (60) 
ACCCTAGAATTCTACTCCTGCACTTCTGAAGAGATCGATCATGAGGATATCACAAAAGAC  240 
TLEFYSCTSEEIDHEDITKD  (BO) 
AAGAGCAGCACCGTGGCGGCCTGCCTCCCCCTGGAACTCGCCCCGAACGAGAGTTGCCTG  300 
KSSTVAACLPLELAPNESCL  (100) 
GCTTCCAGAGAGATCTCTTTCATAACTAATGGGAGTTGCCTGACCCCCGGAAAGGCCTCT  360 
ASREISFITNGSCLTPGKAS  (120) 
TCTATGATGACGCTGTGCCTTAGCAGCATCTATGAGGACTTGAAGATGTACCAGGTGGAG  420 
SMMTLCLSSIYEDLKMYQVE  (140) 
TTCAAGGCCATGAATGCCAAGCTGTTGATAGATCCTCAGAGGCAGATCTTTCTGGATGAG  480 
FKAMNAKLLIDPQRQIFLDE  (160) 
AACATGCTGACAGCCATTGACAAGCTGATGCAGGCCCTGAACTTCAACAGTGAGACTGTG  540 
NMLTAIDKLMQALNFNSETV  (180) 
CCACAAAAGCCCTCCCTTGAAGGACTGGATTTTTATAAAACTAAAGTCAAGCTCTGCATC  600 
PQKPSLEGLDFYKTKVKLC1  (200) 
CTTCTTCATGCCTTCAGAATCCGCGCAGTGACCATCAACAGGATGATGGGCTATCTGAAT  660 
LLHAFRIRAVTINRMMGYLN  (220) 
GCTTCCTAA  669 
AS*  (222) 
Figure  4.14  Nucleotide  and  derived  a.  a.  sequence  for  equine  IL-12  p35 
subunit.  Numbers  in  bold  type  for  nucleotide  and  in  brackets  for  a.  a. 
positions.  Primer  determined  sequence  is  underlined.  The  recognition  site  for 
Stul,  used  to  produced  full  length  p35  is  shadowed. -34  16 
Equine  p35 
Bovine  p35  ---  L-S  ---  IST---- 
Hurnanp35  MWPPGSASQP  PPSPAAATGL  HPAARPVSLQ  CRLS  ---  A-S  -----  TL--* 
Murine  p35  --QS-Y  --FLAT-A-- 
17  66 
Equine  p35  ý  SLAR  NLPTATPGPG  MFQCLNHSQN  LLRTVSNTLQ  KARQTLEFYS 
Bovine  p35  H--P  ----  G-  S  ---  T-AS--  R*S--DY  ---  ---  A  ------  ---------- 
Human  p35  **  --------  ---  V  ---  D--  --P--H  ----  ---  A  ---  M  --  ---------  P 
Murinep35  -***  ------  VI-VS****G  PARC-SQ-R-  --K-TDDMVK  T--EK-KH-- 
67  116 
Equinep35  CTSEEIDHED  ITKDKSSTVA  ACLPLELAPN  ESCLASREIS  FITNGscLTP 
Bovine  p35  ----------  -----  T  ---  E  --------  T-  --------  T-  -----  H--AS 
Human  p35  ----------  -----  T  ---  E  -------  TK-  ----N  -----  --------  AS 
Murine  p35  --A-D  -----  --  R-QT-T  --  ----------  -----  T--T-  ST-R  ----  P- 
117  166 
Equinep35  GKASSMMTLC  LSSIYEDLKM  YQVEFKAMNA  KLLIDPQRQI  FLDENMLTAI 
Bovine  p35  --T-F-T---  -R  --------  -H  ---  Q  ----  ---  M--K  ---  ---  Q  ---  A-- 
Human  p35  R-T-F--A  --  ----------  ------  T  ---  ---  M--K  ---  ---  Q  ---  AV- 
Murine  p35  Q-T-L  -----  -G  --------  --  T--Q-I--  A-QNHNHQ--  I--KG--V-- 
167  216 
Equinep35  DKLMQALNFN  SETVPQKPSL  EGLDFYKTKV  KLCILLHAFR  IRAVTINRMM 
Bovine  p35  AE  -------  D  ----------  KE  --------  ----------  ------  D--- 
Human  p35  -E  --------  -------  S--  -EP  ------  I  ----------  ------  D-V- 
Murine  p35  -E  ---  S--H-  G--LR  ---  PV  GEA-P-RV-M  ---------  S  T-V  -----  V- 
222 
Equine  p35  GYLNAS 
Bovinep35  s--ss-  80.2% 
Human  p35  s  -----  82.4% 
Murine  p35  ---  SSA  58.6% 
Figure  4.15  Comparison  of  the  predicted  a.  a.  sequence  of  equine  IL-12  p35 
subunit  with  its  counterpart  of  other  animal  species,  showing  the  percentage  of 
homology  to  the  equine  molecule.  Numbers  relate  to  a.  a.  positions  in  the  equine 
sequence.  Conserved  cysteine  residues  (shadowed),  N-linked  glycosylation  sites 
(underlined)  and  leucine  zipper  motifs  (overlined)  are  shown.  The  typical 
hydrophobic  leader  sequence  is  shaded  blue.  Translation  of  the  human  molecule 
from  the  upstream  initiation  site  results  in  the  addition  of  N-tern-tinal  residues 
(positions  -34  to  1) I  LTGGCTGCTGGACCAGTAGAAGACAATTGCATTAGCTTGGTGGAAATGAAATTTATTGAC  60 
MAAGPVEDNCISLVEMKFID  (20) 
AACACACTTTACTTTGTAGCTGAAAACGATGAAAACCTGGAATCAGATTACTTTGGCAGG  120 
NTLYFVAENDENLESDYFGR  (40) 
CTTGAACCTAAACTCTCAATCATACGAAATTTGAACGACCAAGTTCTCTTCATTAACCAG  180 
LEPKLSIIRNLNDQVLFIN0  (60) 
GGAAATCAACCTGTGTTTGAGGATATGCCTGATTCTGATTGTACAGACAACGCACCCCAG  240 
GNQPVFEDMPDSDCTDNAP0  (80) 
ACCGTATTTATCATATATATGTATAAAGATAGCCTCACTAGAGGTCTAGCGGTAACCATC  300 
TVFIIYMYKDSLTRGLAVT1  (100) 
TCTGTGAAGTGTGAGAAAACGTCTACTCTCTCCTGTAAGAACAAAATTATTTCCTTTAAG  360 
SVKCEKTSTLSCKNKIISFK  (120) 
GAAATGAGTCCTCCTGAGAATATCAATGATGAAGGAAATGACATCATATTCTTTCAGAGA  420 
EMSPPENINDEGNDIIFFQR  (140) 
AGTGTTCCAGGACATGATGATAAGATACAGTTTGAGTCTTCACTGTATAAAGGATACTTT  480 
SVPGHDDKIQFESSLYKGYF  (160) 
CTAGCTTGTGAAAAAGAGAATGATCTTTTCAAACTCATTTTGAAAGAAAAGGATGAAAAT  540 
LACEKENDLFKLILKEKDEN  (180) 
GGGGATAAATCTGTAATGTTCACTGTTCAAAACCAGAACTAG  582 
GDKSVMFTV0N0N*  (193) 
Figure  4.16  Equine  IL-  18  nucleotide  sequence  and  predicted  a.  a.  sequence. 
Numbers  in  bold  correspond  to  nucleotide  positions  and  a.  a.  are  numbered  in 
brackets.  Primer  determined  sequence  is  underlined. 14  50 
EquineILI8  MAAGPVEDNC  ISLVEMKFID  NTLYFVAEND  ENLESDYFGR  LEPKLSIIRN 
HumanIL18  ---  E  ------  -  NF-A  -----  -----  I--D  -  ---------  K  --S  ---  V  --- 
Murine  ILI  8  M--MS*EDS-  VNFK--M  ---  -----  IP-EN  GD  ----  N---  -HCTTAV  --- 
51  44  100 
Equinell,  18  LNDQVLFINQ  GNQPVFEDMP  DSDCTDNAPQ  TVFIIYMYKD  SLTRGLAVTI 
HumanIL18  --------  D-  --RPL  ----  T  ----  R  ----  R  -I  ---  S----  -QP--M  ---- 
Murine  IL18  I  ------  VDK  *R  -------  T  -I-QSASE--  -RL  -------  -  EV  ------  L 
101  150 
Equine  ELI  8  SVKCEKTSTL  SCKNKIISFK  EMSPPENIND  EGNDIIFFQR  SVPGHDDKIQ 
Human  ELI  8  ------  I  ---  --  E  -------  --  N--D--K-  TKS  -------  ------  N-M- 
Murine  ILI  8  ---  DS-M  ---  ---------  E  --D  -----  D-  IQS-L  ----  KR  ----  *N-ME 
151  193 
Equine  ELI  8  FESSLYKGYF  LACEKENDLF  KLILKEKDEN  GDKSVMFTVQ  NQN 
Human  ILI  8  ----  S-E  ---  ------  R  ---  -----  KE--L  --RSI  -----  -  ED  79% 
Murine  ELI  8  ------  E-H-  ---Q--D-A  -  -----  K  ----  --------  LT  -HQs  67% 
Figure  4.17  Comparison  of  the  predicted  amino  acid  sequence  of  eqIL-18 
with  other  known  IL-18  sequences,  showing  the  percentage  of  homology  to 
the  equine  protein  and  non-conserved  residues.  Proteolytic  processing  sites  for 
I--  (V)  and  caspase-3  e)  ard  indicated  and  the  IL-  I  -like  signature  sequence 
is  shadowed.  Numbers  correspond  to  aa.  positions. - 
S.  P. 
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4.4  Discussion 
IL-12111,18 
The  aim  of  this  part  of  the  project  was  to  clone  the  cDNAs  of  equine  IL-12  and  IL-18, 
to  facilitate  the  investigation  of  their  potential  to  drive  antiviral  responses  in  vivo 
through  induction  of  EFN-y  production.  The  conservation  of  features  observed  in  the 
nucleotide  sequence  and  predicted  amino  acid  sequence  of  both  molecules,  when 
compared  to  their  counterparts  of  other  mammalian  species,  allows  for  the  conclusion 
that  equine  IL-  12  and  IL-  18  were  successively  cloned. 
The  cloning  of  the  cDNAs  for  equine  IL-12  and  IL-18  also  facilitates  their  use  in  the 
production  of  the  corresponding  recombinant  proteins.  The  expression  of  these 
proteins  in  vitro  will  permit  the  generation  of  bioactive  molecules  and  antibodies 
against  them,  which  are  vital  tools  to  attempt  the  dissection  of  the  biology  of  these 
cytokines  in  the  horse  model,  keeping  in  line  with  recent  developments  in  basic 
immunology. 
Preliminary  work  on  expression  of  these  cytokines  has  been  carried  out  mainly  as  a 
means  to  verify  the  functionality  of  constructs  to  be  used  in  the  vaccine  trial.  So  far 
transient  expression  of  IL-12  (in  single  plasmid)  has  been  accomplished  and  the 
expression  efficiency  assessed  by  northern  blot.  A  mature  (truncated)  form  of  IL-18 
has  been  expressed  in  E.  coli  and  used  as  an  immunogen  for  polyclonal  antibody 
production.  These  antibodies  were  found  to  recognise  eqlL-18  in  cell  lysates  of 
transiently  transfected  mammalian  cells,  by  westem  blot,  and  to  cross-react  with 
canine  and  feline  IL-18. 
Attempts  arc  also  being  made  to  assess  biological  activity  of  these  cytokines. 
Concerning  IL-12  an  assay  to  measure  IL-12-induced  proliferation  of  equine  PBLs  is 
presently  in  development,  following  success  obtained  with  a  similar  assay  for  IFN-y 
(chapter  3)  and  an  encouraging  report  that  eqIL-12  expressed  in  baculovirus  was  able 
to  promote  proliferation  of  phytohaemagglutinin  (PHA)  stimulated  equine  PBLs  (Dr. 
Virgil  E.  Schijns,  personal  communication).  In  regard  to  IL-18,  a  first  attempt  was 
made  to  detect  biological  activitry  as  measured  by  the  upregulation  of  IFN-Y 
production.  The  assay,  described  by  Konishi  et  al  (1997),  makes  use  of  a  human 
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myelomonocytic  cell  line  that,  in  response  to  human  IL-18,  produces  IFN-7  in  a  dose 
dependent  manner.  The  authors  also  found  the  cell  line  to  be  responsive  to  murine  IL- 
18,  although  acknowledging  that  the  later  was  near  100-fold  less  potent.  While  we 
were  able  to  repeat  the  author's  results  in  regard  to  commercially  available 
recombinant  human  IL-  18  (R&D  Systems)  we  were  unable  to  detect  specific  activity 
of  eqIL-18.  We  could  also  not  detect  eqIL-18  protein  (by  western  blot)  in  the 
supernatants  of  transfected  cells.  Failure  to  detect  eqIL-18  bioactivity  could  therefore 
be  due  to  the  presence  of  low  amounts  of  bioactive  IL-18  in  the  supernatants  tested, 
low  cross-reactivity  of  equine  IL-18  in  the  human  cell  system  and/or  deficient 
processing  and  secretion  of  active  mature  IL-18  mediated  by  the  artificial  signal 
peptide.  The  latest  is  reinforced  by  reports  that  IL-18  is  rendered  active  only  after 
processing  by  ICE  (Okamura  et  al,  1998).  Taking  this  into  consideration  we  have 
cloned  the  equine  ICE  cDNA  (Wardlow  et  al,  1999  -  Appendix  I)  and  its  role  in 
processing  the  eqIL-  18  precursor  (equine  proIL-  18)  is  currently  being  assessed. 
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CLONING  AND  EXPRESSION  OF 
EQUINE  INFLUENZA  VIRUS  GENES Influenza  Virus 
5.1  Introduction 
Influenza  viruses  cause  the  contagious  and  acute  respiratory  illness  known  as  influenza. 
Epidemic  and  pandemic  outbreaks  in  humans  are  documented  as  far  back  as  412  B.  C. 
(Hippocrates)  and  have  occurred  at  irregular  intervals  varying  in  severity.  Major  human 
pandemics  include  the  1889  Asiatic  influenza,  with  a  further  outbreak  in  1900  and  the 
1918  Spanish  influenza  that  resulted  in  over  20  million  deaths  worldwide.  The  isolation 
of  the  first  influenza  virus  from  pigs  in  1931,  followed  by  human  influenza  virus  in  1933 
allowed  the  close  monitoring  of  outbreaks  and  seroepidemiological  studies  that  followed 
suggest  that  epidemics  are  caused  by  two  main  mechanisms:  the  introduction  of  new 
viral  variants  into  human  populations,  usually  from  reservoir  species  (e.  g.  ducks)  as 
happened  in  the  epidemic  of  1968  and  the  recirculation  of  viral  strains  thought  to  have 
been  cleared  from  human  populations  as  in  1957  and  1977  (Webster  et  al,  1983;  Assad  et 
al,  1983). 
Influenza  viruses  belong  to  the  family  Orthomyxoviridae  which  is  divided  into  three  main 
genus  (or  types)  on  the  basis  of  antigenic  differences  between  major  internal  proteins,  the 
nucleocapsid  and  matrix  proteins.  These  viral  types  are  organised  into:  influenza  A,  B  and 
C,  (Russell  and  Edington,  1985).  Type  A  viruses  are  widely  distributed,  naturally 
infecting  humans  and  other  mammals  including  swine,  horses  and  seals  and  a  great 
variety  of  domestic  and  wild  birds.  Type  B  and  C  viruses  infect  predominantly  humans 
although  type  C has  been  isolated  from  pigs  in  China  (Guo  et  al,  1983).  A  further  type,  D, 
of  tickbome  viruses  was  described  as  being  genetically  and  structurally  similar  to  the 
other  types  (reviewed  in  Lamb  and  Krug,  1996).  Within  a  viral  type,  strains  are  grouped 
according  to  the  antigenic  nature  of  the  surface  glycoproteins,  haernagglutinin  and 
neuraminidase. 
A  precise  nomenclature  system,  last  revised  in  1980  (Hinshaw  et  al,  1983),  has  been 
devised  by  the  World  Health  Organisation  to  facilitate  close  monitoring  of  outbreaks. 
Strains  are  defined  by  type  (A  to  Q,  host,  geographical  origin,  strain  or  laboratory 
reference  number  and  year  of  isolation.  The  subtyping  based  on  the  nature  of 
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haernagglutinin  and  neuraminidase  is  given  in  brackets  [e.  g.,  A/Swine/Wisconsin/5/76 
(HINI)]. 
Influenza  viruses  are  subjected  to  a  constant  selective  pressure  to  overcome  rising 
immunocompetence  in  human  and  animal  host  populations  (  Killbourne,  1983  ).  It  is 
therefore  hardly  surprising  that  a  wealth  of  subtypes  of  virus  has  been  isolated  from 
different  host  species,  since  the  immunological  pressure,  in  the  shape  of  neutralizing 
antibodies,  is  mainly  directed  to  the  surface  haernagglutinin  and  neuraminidase  proteins, 
Smith  and  Palese,  1989  ) 
5.1.1  The  virus 
Figure  5.1  Infuenza  A  virus.  (A)  negati  .  ve  staining  electron  microscopy  (X27  000) 
and  (B)  detail  (X300  000)  showing  vinon  components:  spikes,  viral  membrane  and 
internal  RNA-protein  elements  (Oxford  and  Hockley,  1987). 
Virion  structure 
The  vinon  of  influenza  A  has  a  regular  spherical  appearance  (figure  5.1)  with  80  to  120 
run  in  diameter,  comprising  the  following  structures  (figure  5.2).  A  lipid  envelope 
(derived  from  the  host  cell  plasma  membrane)  from  which  radiate  surface  projections 
(spikes)  formed  by  trimers  of  haernagglutinin  (rod-shaped)  and  tetramers  of  neurami- 
nidase  (mushroom-shaped).  A  third  transmembrane  protein  (M2)  forins  a  functional  pore. 
Underlining  the  lipid  bilayer  is  the  viral  matrix  formed  by  M,  and  NS2  proteins.  InsidIc 
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the  virus  are  the  RNP  structures  containing  eight  segments  of  RNA  of  different  sizes 
(table  5.1).  These  structures  consist  of  RNA  and  protein  complexes  where  nucleocapsid 
protein  is  predominant.  Also  associated  with  RNP  are  the  three  polymerase  proteins  (PB,, 
PB,  and  PA). 
vm 
Figure  5.2  Diagram  of  influenza  virus  showing  tridimensional  relationships 
between  the  viral  membrane  and  the  spikes  (HA  and  NA)  forming  the  viral  envelope, 
while  M  protein  and  RNP  associate  to  form  the  viral  core  (Oxford  and  Hockley,  1987). 
Genome 
The  Influenza  A  virus  genome  is  composed  of  eight  segments  (table  5.1)  of  single 
negative  stranded  RNA  [RNA(-)].  Transcription  of  the  RNA(-)  gives  rise  to  mRNAs  (by 
definition  mRNAs  are  positive  stranded)  required  for  the  synthesis  of  viral  proteins.  In 
addition,  synthesis  of  antigenome,  RNA(+),  is  a  prerequisite  for  the  replication  of  the 
virus  as  the  RNA(+)  will  serve  as  template  for  further  copies  of  genomic  RNA(-). 
Transcription  and  replication  are  performed  by  RNA-dependent  RNA  polymerases 
encoded  and  packaged  by  the  virus,  and  take  place  in  the  nucleus  of  infected  cells. 
Mechanisms  such  as  overlapping  reading  frames,  bicistronic  mRNAs  and  coupled 
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translation  of  tandem  cistrons  are  used  as  a  means  of  maximising  the  coding  capacity  of 
the  compact  genome  (reviewed  in  Lamb  and  Krug,  1996). 
Table  5.1  Influenza  A  genome  and  encoded  proteins. 
RNA  segment  Gene  length 
(in  nucleotides) 
Encoded  protein  Protein  length 
(in  a.  a.  ) 
1  2341  PB2  759 
2  2341  PBI  757 
3  2233  PA  716 
4  1778  HA  566 
5  1565  NP  498 
6  1413  NA  454 
7  1027  Ml/M2  252/97 
8  890  NSIINS2  230/121 
Note:  a.  a.  -  amino  acids 
Viral  proteins 
a)  RNA  segments  1,2  and  3  are  the  largest  in  the  influenza  genomes  and  encode 
the  three  polymerases:  PB1,  PB2  and  PA  so  called  by  their  migration  pattern  in 
isoclectric  focusing  gels  (PB  I  and  PB2  are  basic  and  PA  is  acidic). 
The  P  proteins  are  synthesised  in  the  cytoplasm  of  the  infected  cell  and  then  translocated 
to  the  nucleus  possibly  as  a  complex.  Once  in  the  nucleus  the  P  complex  is  involved  in 
transcription  of  viral  mRNAs  and  in  replication  of  RNA(-).  In  short,  the  PB,  portion  of 
the  complex  binds  to  capped  RNA  primers  (derived  from  the  host  cell)  containing  the 
sequence  rriGpppNm.  Binding  of  this  complex  to  the  3'  end  of  RNA(-)  leads  to 
endonuclease  activity  rendering  a  mature  transcription  complex  which  is  the  substrate  for 
initiation/elongation  of  transcripts  by  PB,  it  is  not  known  which  protein(s)  in  the 
complex  are  responsible  for  cleavage  of  mature  complexes  and  for  polyadenylation  of 
mRNAs  (Lamb  and  Krug,  1996). 
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b)  RNA  segment  4  encodes  the  haemagglutinin  (HA)  glycoprotein.  HA  is 
synthesised  as  a  precursor  polypeptide  (562  to  566  a.  a.  ),  containing  a  N-terminal 
hydrophobic  signal  peptide  (16  a.  a.  )  which  is  cleaved  from  HA  following  insertion  in  the 
rough  endoplasmic  reticulum.  This  cleavage  gives  rise  to  a  mature  protein  consisting  of 
two  portions  HA,  (319  to  326  a.  a.  )  and  HA2  (221  to  222  a.  a.  )  separated  by  a  proteolytic 
cleavage  site.  Mature  HA  monomers  associate  non  covalently  to  form  functional  HA 
trimers.  The  trimer  spike  is  composed  of  a  long  fibrous  stem  (HA2)  extending  from  the 
lipid  bilayer  connected  by  a  disulfide  bond  to  the  HAI  globular  domain.  The  N-terminal 
portion  of  HA2  contains  a  hydrophobic  motif  termed  fusion  peptide.  Six  N-linked 
carbohydrate  chains  are  attached  to  HA,  and  one  chain  to  HA2.  These  are  likely  to  be 
needed  for  correct  folding  of  the  HA  molecule  in  its  native  form  (Skehel  et  al,  1994). 
HA  has  three  major  functions  in  the  replicative  cycle  of  influenza  virus  (Ada  and  Jones, 
1986;  Lamb,  1989;  Nobusawa  et  al,  1991;  Lamb  and  Krug,  1996): 
-  binds  infectious  virus  particles  to  sialic  acid  residues  on  the  surface  of 
susceptible  host  cells.  The  receptor  binding  site  of  the  HA  molecule  is  a  pocket 
located  in  the  distal  tip  of  the  spike  (HAI)  and  defined  by  a  number  of  conserved 
amino  acid  residues  (Tyr9g,  TrPI53,  His,  93and 
Leu, 
94); 
-  mediates  the  fusion  (through  the  fusion  peptide)  of  the  endocytosed  virus 
particle  with  the  endosomal  membrane,  releasing  the  virus  core  into  the 
cytoplasm.  For  this  to  occur  the  HA  molecule  has  to  be  activated  by  proteolytic 
cleavage  between  HAI  and  HA2,  prior  to  anchorage  of  the  protein  to  the  host  cell 
membrane; 
-  is  the  major  antigen  responsible  for  the  generation  of  neutralising  antibodies  by 
the  host.  Changes  in  its  antigenic  structure  are  associated  with  recurrent  influenza 
epidemics.  There  are  15  antigenic  subtypes  of  HA  infecting  humans  and  animals: 
H1  to  H15. 
c)  RNA  segment  5  is  1565  nucleotides  in  length  and  encodes  the  498  amino  acid 
nucleocapsid  protein  (NP).  The  protein  is  rich  in  arginine  residues  but  there  are  no 
clusters  of  basic  residues  as  it  might  have  been  expected  for  interaction  with  the  acidic 
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phosphate  groups  of  RNA  (Winter  and  Fields,  1981).  Evidence  points  to  the  protein  being 
phosphorylated  at  one  serine  residue  per  molecule  (Kamata  and  Watanabe,  1997), 
although  the  percentage  of  molecules  phosphorylated  and  its  importance  in  the 
functionality  of  the  protein  is  still  unclear.  NP  is  a  type-specific  antigen  with  a  high 
degree  of  conservation  amongst  subtypes  as  confirmed  by  sequencing.  Following 
synthesis  in  the  cytoplasm,  NP  proteins  have  the  ability  of  self  targeting  to  the  nucleus 
(Lin  and  Lai,  1983).  Nuclear  accumulation  is  achieved  due  to  a  group  of  a.  a.  contained 
within  the  NP  protein  (Davey  et  al,  1985),  known  as  karyophilic  sequence.  The 
mechanisms  of  assembly  of  the  nucleocapsid  are  not  yet  understood  but  it  is  known  that 
once  in  the  nucleus,  NP  associates  with  viral  RNA  forming  a  heterogeneous  collection  of 
structures  which  include  free  protein  and  ribonucleoproteins  [RNP-RNA(+)  and  RNP- 
RNA(-)].  Due  to  the  fact  that  NP  does  not  associate  with  mRNAs  it  has  been  argued  that 
a  putative  nucleation  site  is  a  stretch  of  13  nucleotides  conserved  in  the  5'  end  of  all  the 
RNA(-)  and  RNA(+)  segments  but  absent  from  mRNAs  (Hay  et  al,  1977). 
d)  RNA  segment  6  codes  for  Neuraminidase  (NA)  or  acylneuraminyl  hydrolase. 
NA  is  composed  of  a  single  polypeptide  chain.  The  spike  of  NA  is  a  tetramer  with  four 
identical  disulfide-linked  subunits.  It  has  a  mushroom  like  structure  composed  of  a 
"head"  containing  four  planar  and  approximately  spherical  units  attached  to  a  central 
"staW'  which  features  a  transmembrane  hydrophobic  region.  NA  contains  five  potential 
N-linked  glycosylation  sites  and  the  cytoplasmic  tail  N-Met-Asn-Pro-Asn-Gly-Lys-C 
tends  to  be  conserved  amongst  subtypes  (Lamb  and  Krug,  1996).  NA  catalyses  the 
cleavage  of  the  cc-ketosidic  linkage  between  the  terminal  sialic  acid  and  an  adjacent  sugar 
residue  (normally  D-galactose  or  D-galactosamine).  This  permits  transport  of  the  virus 
through  mucin  and  prevents  self-aggregation  of  the  virus.  Additionally,  it  destroys  the 
HA  receptor  of  the  host  cell,  enabling  elution  of  the  progeny  of  virus  particles  from  the 
infected  cell.  In  short,  NA  confers  mobility  of  the  virus  to  and  from  the  site  of  infection 
and  replication  (Laver  et  al,  1984).  NA  (like  HA)  is  also  a  major  subtype  specific 
glycoprotein  contributing  to  some  of  the  antigenic  variability  revealed  by  influenza 
viruses.  There  are  9  distinct  subtypes  of  NA,  NI  to  N9  (Ada  and  Jones,  1986). 
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e)  RNA  segment  7  encodes  the  matrix  protein  (N11)  and  the  integral  membrane 
protein  (M2).  MI  is  the  most  abundant  protein  of  the  virion,  it  underlies  the  lipid  envelop 
and  confers  rigidity  to  the  membrane.  Additionally  it  interacts  with  the  cytoplasmic 
portions  of  HA,  NA  and  M2  proteins  and  with  the  RNP  structures.  M1  is  a  type-specific 
antigen  of  influenza  virus,  highly  conserved  cross  subtypes  (Lamb,  1989).  The  M2 
protein  is  predominantly  expressed  in  the  cytoplasmic  membrane  of  infected  cells,  with 
only  a  few  copies  being  incorpomted  by  the  virion.  It  is  phosphorylated  at  Ser-64  and 
palmitylated  at  Cys-50.  The  active  form  of  the  protein  is  a  homotetramer  consisting  of  a 
pair  of  disulfide-linked  dimers  (Scholtissek,  1984).  M2  functions  as  an  ion  channel  that 
permits  entrance  of  ions  to  the  virion  during  uncoating,  and  modulates  the  pH  of 
intracellular  compartments,  facilitating  the  budding  process  (Lamb  and  Krug,  1996). 
f)  RNA  segment  8  encodes  two  proteins,  non-structural  proteins  NS  I  and  NS2, 
present  in  influenza  virus  infected  cells.  NSI  protein  binds  specifically  to  poly(A) 
sequences,  regulating  nuclear  export  of  mRNA,  and  to  spliceosomes,  inhibiting  pre 
mRNA  splicing.  The  NS2  protein,  initially  thought  to  be  non  structural,  was  recently 
identified  in  association  with  MI  protein  underlining  the  virion  envelope.  Its  function  is 
not  known  (Lamb  and  Krug,  1996). 
Viral  replication 
The  interaction  of  cellular  sialic  acid  residues  with  the  distal  portion  of  viral  HA  leads  to 
adsorption  of  infectious  virus  to  the  target  cell.  The  virus  enters  the  cell  by  a  process 
known  as  receptor-mediated  endocytosis.  After  intemalisation,  endocytotic  vesicles  fuse 
to  a  cascade  of  endosomes  of  increasingly  acidic  pH  that  facilitate  uncoating  of  the  virion, 
followed  by  fusion  of  the  viral  membrane  to  the  cellular  membrane  remnant,  mediated  by 
HA.  This  enables  the  RNPs  to  penetrate  the  cytoplasm  and  migrate  to  the  nucleus,  where 
they  enter  through  the  nuclear  pore.  In  the  nucleus  viral  RNA  is  transcribed  to  mRNAs 
and  replicated  in  a  process  catalysed  by  the  viral  RNA  polymerases.  Newly  assembled 
RNPs  and  mRNAs  are  exported  from  the  nucleus  to  the  cytoplasm  where  translation 
occurs.  Viral  integral  membrane  proteins  (HA,  NA  and  M2)  are  synthesised  on  membrane 
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bound  ribosomes  and  translocated  trough  the  endoplasmic  reticulum  where  carbohydrate 
chains  are  added.  Once  correctly  folded  and  assembled,  these  proteins  are  further 
processed  in  the  Golgi  apparatus  and  fmally  expressed  at  the  plasma  membrane. 
Conversely,  newly  synthesised  NP  migrates  back  to  the  nucleus  to  associate  with 
emerging  viral  RNAs.  In  polarised  epithelial  cells  the  virions  assemble  and  bud  at  the 
apical  surface  of  the  cell.  The  precursor  budding  structure  is  a  fragment  of  cell  membrane 
with  embedded  viral  envelope  proteins.  The  MI  protein  associates  with  the  lipid  bilayer 
and  with  RNP  structures  promoting  interaction  of  the  integral  membrane  proteins  with  the 
internal  viral  components.  Release  of  fully  formed  virions  from  the  plasma  membrane  is 
achieved  by  the  destruction  of  cellular  sialic  acid  receptors  mediated  by  viral  NA 
(reviewed  in  Lamb  and  Krug,  1996). 
5.1.2  Immune  response  to  influenza  virus  infection 
The  immune  response  to  influenza  virus  infection  involves  nonspecific  and  specific 
components.  Nonspecific  mechanisms  include  fever,  macrophages,  natural  killer  (NK) 
cells,  and  interferon  (Ada  and  Jones,  1986).  The  specific  immune  response  mounted  by 
hosts  towards  influenza  virus  infection  is  both  humoral  and  cell  mediated. 
Humoral  response 
During  infection  with  influenza  A,  antibodies  to  HA,  NA,  NP  and  M  proteins  are 
produced.  Antibodies  to  HA  and  NA  are  normally  associated  with  protection,  whereas 
antibodies  to  NP  and  MI  are  not.  (Couch  and  Kasel,  1983).  Neutralising  antibodies  to  HA 
are  easier  to  detect  and  thus  more  comprehensively  studied. 
Different  types  and  forms  of  HA-specific  neutralising  antibodies  are  found  in  nasal  and 
bronchial  secretions  and  in  the  serum  of  hosts  infected  with  influenza  virus.  Serum  IgG 
and  monomeric  IgA  and  IgM  subtypes  can  be  detected  after  a  primary  infection,  whereas 
IgG  and  IgA  antibodies  are  predominant  in  secondary  responses.  In  the  case  of  mucosal 
antibodies,  whilst  oligomeric  IgM,  secretory  IgA  (sIgA)  and,  less  frequently,  IgG  are 
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present  in  primary  infection,  after  secondary  infection,  local  antibody  is  mainly  of  the  IgA 
isotype  (Murphy  and  Clements,  1989;  Ada  and  Jones,  1986). 
Antibodies  exert  their  antiviral  activity  either  by  mediating  lysis  of  infected  cells  or  by 
viral  neutralisation.  Lysis  of  infected  cells  is  achieved  by  both  the  alternate  pathway  of 
complement  and  antibody-dependent  cell-mediated  cytotoxicity  (ADCC)  accomplished 
by  NK  cells  and  to  lesser  scale  by  neutrophils  and  monocytes  (Ada  and  Jones,  1986). 
Neutralising  IgM  and  sIgA  prevent  the  attachment  and/or  internafisation  of  virus  into  the 
cells  by  sterical  blockage  of  cell  receptors.  In  contrast,  IgG  and  monomeric  IgA  do  not 
affect  binding  and  internalisation  of  the  virus,  inhibiting  viral  replication  through 
inactivation  of  the  viral  transcriptase  (Possee  et  al,  1982;  Taylor  and  Dimmock,  1985). 
The  generation  of  anti-HA  antibodies  results  in  host  protection  against  influenza 
infection,  demonstrated  by  the  correlation  between  antibody  titres  and  resistance  to 
infection.  This  resistance  whilst  very  potent  to  homologous  challenge  is  not  cross 
protective  to  other  subtypes  of  the  virus.  Antibodies  also  appear  to  have  an  additive  but 
not  essential  role  in  the  recovery  from  influenza  infection  (Ada  and  Jones,  1986). 
Cell-mediated  immune  response 
Influenza  virus-specific  cellular  immune  functions  are  mediated  by  two  subsets  of  T 
lymphocytes.  The  first  subset,  cytotoxic  T  lymphocytes  (CTLs)  have  a  CD8+  phenotype 
and  only  recognise  antigens  processed  by  target  cells  in  the  context  of  the  class  I  major 
histocompatibility  complex  (Male  et  al,  1996).  Influenza  antigens  recognised  by  CTL 
clones  include  HA  and  the  internal  proteins  NP,  M  and  PB2.  Recognition  of  HA  accounts 
for  the  subtype  specificity  of  some  clones,  whereas  recognition  of  internal  proteins  and  in 
particular  NP,  is  responsible  for  cross-reactivity  between  subtypes  of  virus  and  for  the 
generation  of  memory.  (Yewdell  and  Hackett,  1989). 
The  second  subset  of  T  lymphocytes,  belong  to  the  T  helper  (Th)  class  of  T  cells,  bearing 
CD4+  phenotype.  These  cells  are  MHC  class  II  restricted  and  their  functional  properties 
are  two  fold:  firstly,  providing  help  for  antibody  production  by  B  cells  and  for 
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proliferation  of  CD8+  T  cells  and  secondly  having  cytolytic  activity  with  similar 
specificity  to  that  of  the  MHC  I  restricted  T  cells  (Roitt  et  al,  1998).  In  addition,  Th  cells 
specific  to  NP  can  provide  help  to  B  cells  secreting  anti-HA  antibody  (Scherle  and 
Gerhard,  1986). 
The  development  of  cell  mediated  responses  has  been  proposed  as  the  single  most 
important  host  factor  responsible  for  recovery  from  influenza  virus  infection  (Ghendon  et 
al,  1989).  Indeed,  the  level  of  memory  CTLs  is  associated  with  increased  clearance  of 
virus  from  the  respiractory  tract  following  secondary  infection  (Mumford  et  al,  1983). 
Mechanism  of  immune  evasion 
A  direct  consequence  of  the  selective  pressure  influenced  by  host  immunocompetence  is 
the  frequent  and  progressive  antigenic  variation  that  influenza  viruses  undergo  (Smith  and 
Palese,  1989).  These  antigenic  changes  are  achieved  by  the  phenomena  known  as 
antigenic  drift  and  antigenic  shift  and  occur  predominantly  in  the  haemagglutinin  and 
neuraminidase  glycoproteins  (reviewed  in  Webster  et  al,  1982;  Russell  and  Edington, 
1985;  Both  et  al,  1983;  Lamb  and  Krug,  1996). 
Antigenic  drift  is  caused  by  occasional  mutations  that  determine  accumulation  of  amino 
acid  changes  leading  to  minor  differences  in  the  antigenic  character  of  the  virus.  If  the 
mutations  take  place  in  epitopes  recognised  by  neutralising  antibodies  they  will  be 
serologically  detected  by  alterations  in  haemagglutination  inhibition  and  neutralisation 
titres. 
Antigenic  shift  is  the  main  source  of  antigenic  diversity  of  influenza  virus  and  is 
characterised  by  extensive  changes  in  the  HA  and/or  NA  proteins  leading  to  the 
emergence  of  new  subtypes  of  virus.  There  are  three  mechanisms  thought  to  be  involved, 
acting  independently  or  in  conjunction.  The  first  is  an  increased  mutation  rate  due  to  an 
augmented  selective  pressure.  The  second  is  the  adaptation  of  virus  from  one  species  to 
another,  chiefly  from  the  avian  pool  to  mammalian  populations,  supporting  the  concept 
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that  avian  populations  serve  as  virus  reservoir  for  other  hosts.  The  third  is  a  mechanism 
named  genetic  reassortment,  which  is  the  shuffling  of  RNA  segments  taking  place 
between  viruses  of  the  same  or  even  different  host  species  and  is  a  direct  consequence  of 
the  segmented  nature  of  the  influenza  virus  genome. 
5.1.3  Equine  Influenza 
History  and  evolution 
Equine  influenza  is  an  acute  respiratory  disease  of  horses  caused  by  infection  with 
influenza  virus  type  A.  Only  two  antigenic  subtypes  have  been  isolated  from  horses  to 
date:  A/equine/I  virus  of  the  H7N7  subtype  and  A/equine/2  virus  of  H3N8.  The  first 
virus  of  the  H7N7  type  was  isolated  during  an  outbreak  in  Czechoslovakia  in  1956  and 
was  named  A/equine/Praguell/56  (Sovinova  et  al,  1958).  Based  on  genetic  and  antigenic 
analyses,  type  I  viruses  were  divided  into  two  subgroups  with  minor  antigenic  changes, 
due  to  antigenic  drift.  The  first  subgroup  isolated  between  1956  and  1963  (e.  g. 
A/Cambridge/l/63)  and  the  second,  with  isolations  in  1964-77  (e.  g.  A/Detroit/l/67) 
(Gibson  et  al,  1992).  Type  I  virus  have  not  been  detected  since  the  late  1970's,  although 
antibodies  to  this  virus  can  still  be  detected  in  unvaccinated  horses,  supporting  the  idea 
that  they  continue  to  circulate  in  a  subclinical  form  (Mumford,  199  1). 
During  a  major  outbreak  in  the  United  States  in  1963  the  isolates  were  antigenically  very 
distinct  from  the  type  I  viruses,  representing  an  antigenic  shift,  resulting  in  the 
substitution  of  both  HA  and  NA  glycoprotein  antigens,  probably  due  to  reassortment  with 
influenza  virus  of  other  species.  They  were  designated  A/equine/2  (H3N8)  viruses  and  the 
first  isolate  was  A/equine/Miami/l/63  (Wadell  et  al,  1963).  Two  antigenic  variants  have 
been  recognised  one  having  the  Miami  isolate  as  prototype  and  the  second  represented  by 
the  prototype  variant  A/Fontainblue/79  (Kawaoka  et  al,  1989).  Since  1987  these  antigenic 
variants  have  further  diverged,  being  currently  classified  in  two  distinct  groups.  The  first 
circulating  mainly  in  the  Americas  (American-like,  e.  g.  A/Kentucky/l/94)  and  the  other 
circulating  in  Europe  and  Asia  (European-like,  e.  g.  A/Newmarket/2/93).  Nevertheless, 
there  is  evidence  for  significant  intermingling  in  the  distribution  of  these  viruses.  An 
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example,  of  American-like  viruses  isolated  in  Europe  is  the  A/Newmarket/l/93  (Daly  et 
al,  1996). 
In  1989  a  severe  outbreak  in  northern  China,  with  unusually  high  morbidity  and  mortality 
rates,  led  to  the  emergence  of  a  new  H3N8  virus  very  different  from  previous  isolates. 
The  isolate  was  named  A/Jillin/89  (Guo  et  al,  1992)  and  phylogenetic  analysis  revealed  it 
was  closely  related  to  avian  viruses,  suggesting  it  may  have  been  directly  transferred  to 
horses  from  ducks  without  genetic  reassortment  (Guo  et  al,  1992).  Although  H3N8 
viruses  enjoy  a  significantly  greater  antigenic  variability  then  those  of  the  H7N7  subtype, 
they  remain  relatively  similar  to  the  prototype  reference  strains  with  homologies  greater 
then  70%  (Ada  and  Jones,  1986). 
Epidemiology 
Influenza  viruses  are  a  major  cause  of  equine  respiratory  disease  worldwide.  The  only 
significant  equine  populations  in  which  influenza  has  not  been  reported  are  in  Australia, 
New  Zealand  and  Iceland.  The  disease  is  endemic  in  the  U.  S.  and  some  areas  of  Europe 
with  localised  outbreaks  every  year  and  more  extensive  and  severe  outbreaks  at  intervals 
(Powell  et  al,  1991).  Horses  of  all  ages,  not  previously  exposed  or  vaccinated,  are 
susceptible.  Infection,  however,  is  more  common  in  young  (2  to  3  years)  race  and  show 
horses  due  to  stressful  live  style,  frequent  transport  and  concentration  in  confined  spaces 
with  horses  of  different  provenience.  Outbreaks  commonly  start  when  large  numbers  of 
susceptible  horses  are  brought  together  at  sales  or  shows  (Ames,  1995).  Infection  may 
occur  in  vaccinated  horses,  with  virus  shedding  but  reduced  or  absent  clinical  signs, 
contributing  significantly  to  the  propagation  of  the  disease  (Mumford,  1991).  Affected 
horses  shed  large  amounts  of  aerosolised  virus  through  respiratory  secretions.  The 
incubation  period  is  short  and  shedding  of  virus  persists  for  up  to  ten  days  (Ames,  1995). 
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Pathogenesis 
Virus  present  in  aerosols  is  inhaled  and  deposits  on  the  mucosa  of  the  upper  and  lower 
respiratory  tracts.  The  mucus  barrier  is  penetrated  by  the  enzymatic  activity  of  the  viral 
NA.  The  virus  attaches  through  the  HA  spikes  to  receptors  on  the  epithelial  cells,  is 
endocytosed  and  released  in  the  cell  cytoplasm.  The  virus  replicates  in  the  host  cells  with 
budding  of  new  virion  particles  that  are  spread  throughout  the  respiratory  tract  (within  I 
to  3  days)  aided  by  ciliary  action,  infecting  other  cells  or  being  expelled  by  cough.  This 
process  causes  extensive  epithelial  damage  leading  to  inflammation,  clamping  of  cilia  and 
focal  erosions.  Pulmonary  alveolar  macrophage  function  is  compromised  and  secondary 
bacterial  bronchopneumonia  may  result  (Coggins  et  al,  1979;  Ames,  1995). 
Clinical  signs 
The  onset  of  clinical  manifestations  is  sudden  with  a  rapid  spread.  The  severity  and 
duration  of  the  signs  is  dependent  on  the  immune  status  of  the  host,  dose  and  virulence  of 
the  strain,  and  management  and  environmental  conditions.  Clinical  findings  include: 
harsh,  dry  and  frequent  cough;  fever;  lethargy;  anorexia  and  serous  bilateral  nasal 
discharge,  becoming  mucopurulent  in  secondary  bacterial  complications  (Powell,  1991; 
Ames,  1995).  Partially  immune  or  vaccinated  horses  usually  have  mild  clinical  signs  or  a 
subclinical  process  manifested  only  by  intolerance  to  exercise. 
Diagnosis 
A  presumptive  diagnosis  may  be  made  on  the  basis  of  the  clinical  signs  and  rapid  spread 
of  the  disease.  Confirmation  is  achieved  by  virus  isolation  from  nasopharyngeal  swabs 
and  demonstration  of  a  significant  rise  in  specific  antibody  titre  in  paired  sera  collections, 
14  to  21  days  apart  (Powell,  1991).  Methods  of  viral  detection  include  culture  of  virus  in 
embryonated  specific  pathogen  free  eggs  and  more  recently  in  Madin-Darby  canine 
kidney  (MDCK)  cell  lines,  antigen-capture  indirect  ELISA  for  the  detection  of  the  NP 
antigen  and  immunofluorescent  staining  of  infected  epithelial  cells  in  air-dried  nasal 
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smears  (Mumford,  1991).  More  recently  a  method  has  been  described  for  the  detection  of 
influenza  virus  infection  by  RT-PCR  using  internal  primers  for  the  segment  7,  MI  gene 
(Donofrio  et  al,  1994).  Serological  tests,  used  in  the  diagnosis  of  influenza  virus  infection 
(Powell,  1991;  Mumford,  1991)  include  the  detection  of  neutralising  antibodies  against 
HA  glycoprotein  by  haemagglutination  inhibition  (HI),  single  radial  haemolysis  (SRH)  or 
virus  neutralisation  (VN),  and  the  quantification  of  virus-specific  IgM  and  IgG 
antibodies  by  radioisotopic  anti-globulin  binding  assay  (RABA).  By  7  days  after  infection 
antibodies  are  detectable,  peaking  at  about  3  weeks  as  assessed  by  HI,  SRH  and  VN. 
Titres  remain  detectable  for  up  to  18  months  using  RABA. 
Treatment 
Treatment  is  mainly  symptomatic  and  comprises  complete  rest  for  a  minimum  of  3  to  4 
weeks  in  a  clean  and  well  ventilated  environment  with  minimum  dust,  antibiotics  in 
significant  secondary  bacterial  infections,  non-steroidal  anti-inflammatory  drugs  to  treat 
fever,  depression  and  muscle  stiffiess  and  bronchodilators  and  mucolytics  to  ease  cough 
and  improve  breathing  (Coggins,  1979;  Powell,  1991;  Ames,  1995).  In  uncomplicated 
cases  the  clinical  signs  improve  within  a  week  and  most  horses  show  complete  clinical 
recovery  in  2  to  3  weeks,  although  performance  may  be  suboptimal  for  a  prolonged 
period  of  time. 
Prevention  and  control 
Measures  to  be  taken  if  a  group  of  horses  is  to  be  maintained  free  of  influenza  involve 
quarantine  of  new  arrivals  for  a  minimum  of  3  weeks,  maintenance  of  adequate 
ventilation  in  the  stables  and  routine  vaccination  (Ames,  1995).  Current  commercial 
vaccines  (Glennon  et  al,  1996)  contain  both  equine  influenza  subtypes  as  inactivated 
whole  virus  antigens  added  to  adjuvants  or  presentation  systems  (Table  5.2).  Adjuvants 
like  polymers  (e.  g.  Carbomer)  or  presentation  systems  composed  by  immune-stimulating 
complexes  (ISCOMs)  were  included  in  vaccine  formulations  due  to  observations  that  they 
195 lt!  fluen.  -a  Virus 
significantly  enhance  and  prolong  the  antibody  response  stimulated  by  inactivated 
viruses.  The  efficacy  of  vaccines  against  equine  influenza  virus  is  discussed  in  Chapter  6. 
Equine  influenza  Haemagglutinin  (HA)  and  Nucleoprotein  (NP)  were  selected  for  use  as 
immunogens  in  a  DNA  vaccination  experiment  in  horses  (Chapter  6).  The  choice  of  these 
two  proteins  is  based  on  the  fact  that  they  stimulate  different  "arms"  of  the  immune 
system  of  infected  hosts.  As  previously  discussed  HA  predominantly  gives  rise  to  the 
production  of  neutralizing  antibodies  whereas  NP  mainly  stimulates  cross-reactive 
cytotoxic  T  lymphocyte  activity.  Additionally  the  influenza  strain  Newmarket/2/93  was 
chosen  to  reflect  circulating  virus  in  Europe's  equine  population.  Below  is  a  description 
of  the  strategy  employed  for  the  isolation  and  cloning  of  the  HA  and  NP  genes. 
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5.2  Materials  and  Methods 
5.2.1  Cloning  of  influenza  virus  genes 
The  genes  encoding  the  influenza  virus  proteins  HA  and  NP  were  recovered  by  RT-PCR 
of  the  viral  RNA  genome  and  cloned  into  a  vector  designed  for  the  transfection  of 
mammalian  cells,  promoting  expression  of  the  foreign  genes  of  interest. 
Extraction  of  Viral  RNA 
RNA  from  the  virus  strain  A/Equine/Newmarket/2/93  was  extracted  from  a  320X 
concentrated  suspension  of  virus  supplied  by  Intervet  International  B.  V.  (Boxmeer,  The 
Netherlands)  using  the  following  protocol  (modified  from  Sambrook  et  al,  1989). 
In  a  Falcon  50  ml  tube,  I  ml  of  virus  suspension  was  added  to  9  ml  of  Guanidinium. 
Extraction  Buffer  (4M  Guanidine  Thiocyanate;  5mM  Sodium  citrate  [pH  7.0];  0.5% 
Sarkosyl  [w/v];  DEPC  treated  dH20  to  100  ml,  adding  0.7%  [v/v]  P-mercaptoethanol 
immediately  before  use).  The  mixture  was  homogenised  by  passing  through  a  23-gauge 
needle  not  less  then  10  times.  To  the  homogenate  was  added  in  this  order:  0.9  ml  of  2M 
Sodium  Acetate  (pH  4),  9  ml  of  water  saturated  phenol  (pH  8)  and  2  ml  of  Chloroform: 
Isoamyl  alcohol  (24:  1),  after  which  it  was  shaken  vigorously  for  10  sec.  and  incubated  on 
ice  for  15  min.  This  was  then  centrifuged  at  3,500  rpm  (2,800  g)  for  15  min  at  41'C  in  a 
benchtop  centrifuge  (Beckman  GS-6).  After  centrifugation  the  upper  aqueous  phase  was 
harvested  to  a  fresh  tube  and  10  ml  of  phenol:  chloroform:  isoamyl  alcohol  (25:  24:  1)  was 
added.  The  mixture  was  once  again  shaken,  incubated  on  ice  and  centrifuged  as  before. 
The  aqueous  phase  was  transferred  to  a  Beckman  centrifuge  bottle  (16x8Omm)  and 
precipitated  by  the  addition  of  1/10  volumes  of  2M  Sodium  acetate  and  2.5  volumes  of 
ice  cold  100%  ethanol  and  freezing  at  -20*C  for  I  hour.  The  RNA  was  pelleted  by 
centrifugation  at  10,000  rpm  (7,800  g)  for  20  min  at  4*C  in  a  Beckman  J2-21centrifuge 
using  a  Beckman  ýA-20  rotor.  The  pellet  was  resuspended  in  400  ptl  of  Guanidinum 
extraction  buffer  and  transferred  to  an  eppendorf  tube.  50  pl  of  2M  Sodium  acetate  and  I 
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ml  of  ice  cold  100%  ethanol  was  added  and  the  tube  was  incubated  at  -20"C  for  I  hour 
and  centrifuged  for  10  min  in  a  microcentrifuge  at  maximum  speed  (13,000  rpm).  The 
supernatant  was  discarded  and  the  resulting  pellet  was  washed  with  ice  cold  70%  ethanol 
and  centrifuged  for  5  min  at  13,000  rpm.  The  pelleted  RNA  was  then  freeze-dried  and 
resuspended  in  50  jil  of  DEPC  treated  water.  Upon  completion  of  extraction  5  pl  of  RNA 
suspension  was  diluted  to  1  ml  with  ddH20  and  its  yield  and  purity  assessed  by 
spectrophotometry.  N.  B.  To  minimise  RNA  degradation,  all  the  reagents  were  made  up 
and  all  the  tubes  washed  with  DEPC  treated  water. 
Primer  design 
Primer  sequences  were  required  for  the  amplification  of  the  Newmarket/2/93  HA  and  NP 
genes.  To  that  effect,  known  sequences  of  HA  and  NP  from  various  Equine  influenza 
H3N8  isolates  were  aligned  using  the  Pileup  program  (UW-GCG  software  package), 
therefore  enabling  the  design  of  primers  from  conserved  regions  upstream  and 
downstream  the  open  reading  frames 
.  In  the  case  of  the  HA  gene,  primers  (Table  5.3) 
were  designed  on  the  basis  of  the  alignment  (Figure  5.3)  of  the  following  list  of 
sequences  with  respective  accession  numbers  and  citations:  A/Equine/Kentucky/l/90- 
L39915  (Daly  et  al,  1995  unpublished);  A/Equine/Newmarket/l/93-X85088  and 
Newmarket/2/93-X85089  (Daly  et  al,  1996  unpublished);  France/l/76-M73773  (Bean  et 
al,  1992);  Santiago/l/85-M24725  and  Algiers/72-M24721  (Kawaoka  et  al,  1989).  As  for 
NP,  the  primers  shown  in  Table  5.4  were  generated  from  aligned  sequences  as  follows 
(figure  5.4):  A/Equine/Kentucky/2/86-M30751  and  Tennessee/2/86-M30758  (Gorman  et 
al,  1990);  Miami/l/63-M22575  (Gammelin  et  al,  1989)  and  Jillin/l/89-M63786  (Gorman 
et  al,  1991).  The  primers  designed  in  this  fashion  were  synthesised  by  a  departmental 
contractor  (MWG-Biotech,  Germany).  Melting  temperatures  were  determined  for  the 
binding  sequences  of  each  primer,  using  the  formula:  Tm  =  4x(G+C)  +  2x(A+T)  (Itakura 
et  al,  1984). 
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1  FLUI  primer  RA-RT  &  RAl  primers  50 
Kentucky9o  AGCAAAAGCA  GGGGATATTT  CTq3rAATCA  ýTQa  CATTATTTTG 
Newmarket293  ----------  ----------  --------  0,4,  AA40A  ',  -ýTTATTTTG 
Newmarket193 
----------  ----------  --------  A 
'CAAIZ5`CATTATTTTG 
France76  AGCAAAAGCA  GGGGATATTT  CTGTCAA'TCA  ZWOM-AAC'ýCATTATTTTG 
Santiago85  AGCAAAAGCA  GGGGATATTT  C'lWqlý&Tt(ýA,,  TOAAGACAAC,,  V-DTTATTTTG 
AlgierS72  AGCAAAAGCA  GGGGATATTT  Cw  CATTATTTTG 
ýTCA4TCA 
TG  C 
1701  FLU2/HA2  primer  1762 
Kentucky90  AACATCAGAT  GCAACATTTG  CATTTaAUA  AACTdATAGT  TAAAAACACC  CTTGTTTCTA  CT 
Newmarket293  ----------  ----------  ----------  ----------  ----------  ----------  -- 
Newmarketl93  ----------  ----------  ----------  ----------  ----------  ----------  -- 
France76  AACATCAGAT  GCAACATTTG  CATTT(;,  A 
, 
q!  rA:  ý,  ýACTPATAGT-TAAAAACACC  CTTGTTTCTA  CT 
Santiago85  AACATCAGAT  GCAACATTTG  CATTTGAOTý.  AACTGATAGT,  MkAA.  AACACC  CTTGTTTCTA  CT 
AlgierS72  AACATCAGGT  GCAACATTTG  CATTTGAATj&,  ý4!  ZCZAAM'  T,.  TAAAAACACC  CTTGTTTCTA  CT 
Figure  5.3  Fragment  of  HA  sequence  aligm-nent  showing  conserved  regions  used 
for  primer  design. 
Table  5.3  Primers  for  amplification  of  HA. 
Primer  Sequence  Tm  Use 
FLUI  5'-  NNACTAGTAGCAAAAGCAGGGGATATTTCTG-3'  66*C  cDNA  /5'PCR 
FLU2  5'-  NNGCGGCCGCTTAACTATCAGTTTACTT-3'  46'C  3'  PCR 
HA-RT  5'-  CTGTCAATCATGAAGACAACC  -3' 
60'C  cDNA  Synthesis 
HAI  5'-  GGACGCGTCTGTCAATCATGAAGACAAC  -3' 
56*C  5'  PCR 
HA2  5'-ATGCGGCCGCTTAACTATCAGTTTACTC-3'  46*C  3'PCR 
HAI  and  HA2  primers  contain  5'  restriction  enzyme  sites,  respectively  Mlul  and  Notl  (underlined).  Primer 
binding  sequence  is  depicted  in  bold.  These  primers,  used  in  conjunction,  should  produce  a  fragment  of 
approximately  1740  bp,  containing  the  HA  coding  region. 
1  NP-RT  primer  NPI  primer  50 
Kentucky86  AGCAAAAGC-A  GGGTAGATAA  TCACTCACTG  AGTGACATCA  AACTCATGGC 
Tennessee86  AGCAAAAGCA  C,  =AGATAAýTCACTCACTG  AGTGACATCA  AAGTCATGGC 
Miami63  AGCAAAAGCA  GGGTAGATAA  TCACTCACTG  AGTGACATCA  AAGCCATGGC 
Jillin89  AGCAAAAGCA  GGGTAGATAA  TCACTCACTG  AGTGACATCA  ACATCATGGC 
1501  NP2  primer  1565 
Kentucky86  TCTTATTTCT  TCGGAGACAA  TGCTGAGGAG  TTTGACAGTT  AAAGAAAAAT  ACCCTTGTTT  CTACT 
Tennessee86  TCTTATTTCT  TCGGAGACAA  TGCTGAGGAG  TTTGACAGTT  AAAGAAAAAT  ACCCTTGTTT  CTACT 
Miami63  TCTTATTTCT  TCGGAGACAA  TGCAGAGGAG  TATGACAATT  AAAGAAAAAT  ACCCTTGTTT  CTACT 
Jillin89  TCTTATTTCT  TCGGAGACAA  TGCAGAGGAA  TATGACAATT  AAAGAAAAAT  ACCCTTGTTT  CTXCT 
Figure  5.4  Fraction  of  NP  sequence  alignment  displaying  conserved  motifs  used 
for  primer  design. 
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Table  5.4  Primers  for  the  amplification  of  NP. 
Promer  Sequence  Tm  I  Js  e 
NP-RT  5'-  AGCAAAAGCAGGGTAGATAATCAC  -3'  680C  cDNA  Synthesis 
NPI  5'-  GTAAGCTrCCGCCATGTCACTGAGTGACATCA 
-3'  46"C  5'PCR 
NP2  5'-  NNgfQGC_CgCGTAGAAACAAGGGTATTTTTCT  -3'  580C  3'PCR 
NPI  has  a  S'  HindIll  site  followed  by  a  Kozak  sequence  element  whereas  NP2  contains  a  5'  Nod 
restriction  site.  Primer  binding  sequence  is  depicted  in  bold.  NPI  and  NP2  should  generate  a  PCR  produst 
of  apporximately  1570  bp. 
cDNA  synthesis 
cDNA  was  synthesised  using  "First  Strand  cDNA  Synthesis  Kit"  (Pharmacia)  with 
Newmarket/2/93  RNA  as  template,  primed  with  FLUI  or  HA-RT  and  NP-RT  primers 
respectively,  following  the  manufacturer  instructions  (mat&meth).  The  cDNA  was 
denatured  at  940C  for  5  min  and  incubated  on  ice  for  2  min  immediately  before  being 
used  as  template  for  PCR  amplification. 
PCR  amplification 
PREPARATION  OF  PCR  "MASTER  MIXES" 
Pfu  DNA  polymerase  (Stratagene)  proofreading  enzyme  was  used  for  the  amplification  of 
HA  and  NP.  The  same  "master  mix"  was  used  for  the  amplification  of  both  genes  due  to 
the  fact  that  the  templates  have  the  same  origin  and  therefore  equal  purity,  having 
additionally  a  very  similar  size,  permitting  optimisation  factors  such  as  concentration  of 
dNTP's,  salts  and  enzyme  to  remain  constant.  The  final  composition  of  master  mix  per 
aliquot  was  as  follows:  5  jil  of  10  X  Reaction  buffer;  I  R1  of  dNTP's  at  10  MM  each  (to 
obtain  a  final  concentration  of  200  ýiM  each);  5  ptl  of  DMSO  and  26  ul  of  miliQ  H,  O. 
Aliquots  were  stored  at  -20"C  until  n9eded. 
REACTION  CONDITIONS 
To  each  aliquot  of  master  mix  was  added  I  ýtl  of  each  primer  HAI  and  HA2  or  NP  I  and 
NP2  (at  a  final  concentration  of  0.3  ýM  each)  and  10  ýd  of  cDNA  template.  A  hot  start 
was  performed  at  95"C  for  5  min,  followed  by  the  addition  of  I  ýtl  of  Pfu  polymerase  (2.5 
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U).  Cycling  was  performed  in  a  Perkin  Elmer  9600  Thermal  Cycler  with  the  following 
parameters:  30  cycles  of  denaturation  at  940C  for  45  sec,  annealing  at  62*C  for  I  min 
(55'C  for  I  min  in  the  case  of  NP)  and  extension  at  72"C  for  5  min;  followed  by  an  extra 
extension  step  at  72*C  for  7  min  and  by  chilling  at  4"C.  Conditions  detailed  are  the  result 
of  optimization  leading  to  increased  specificity  and  reproducibility  of  amplification. 
Cloning  of  PCR  products 
PCR  products  were  cloned  into  pCR-Script  vector  using  pCR-Script  Amp  SK(+)  Cloning 
Kit  (Stratagene).  This  vector  system  is  designed  for  the  cloning  of  blunt-end  fragments 
such  as  the  ones  generated  by  Pfii  polymerase.  Fragments  are  cloned  into  a  predigested 
vector  at  the  Srfl  restriction  site  (5'-  GCCC  /  GGGC  -3').  The  ligation  reaction  includes  the 
enzyme  Srfl  that  maintains  a  high  concentration  of  digested  vector  therefore  reducing 
dramatically  the  recircularization  of  nonrecombinant  vector.  This  obviously  requires  that 
the  fragment  to  be  cloned  is  free  of  Srfl  recognition  sites.  To  finther  increase  cloning 
efficiency  the  manufacturer  recommends  the  purification  of  PCR  products  by  selective 
precipitation,  removing  excess  of  primers. 
PURIFICATION  OF  PCR  PRODUCTS 
To  the  PCR  products,  in  a  eppendorf  tube,  was  added  1/10  volume  of  IOX  STE  buffer 
(IM  NaCl;  200mM  Tris-HCI  [pH  7.5];  100mM  EDTA)  and  an  equal  volume  of  4M 
ammonium  acetate.  To  this  was  added  2.5  volumes  of  100%  (v/v)  ethanol  at  room 
temperature  and  the  tube  was  centrifuged  in  a  microcentrifuge  at  10,000  xg  for  20  min  at 
room  temperature.  The  supernatant  was  discarded  and  the  DNA  pellet  washed  with  200 
pI  of  70%  (v/v)  ethanol  and  centrifuged  at  10,000  xg  for  10  min  at  room  temperature. 
The  ethanol  was  carefully  removed  and  the  pellet  freeze-dried.  The  DNA  was 
resuspended  to  the  original  volume  (40  gl)  with  TE  buffer  (10mM  Tris-HCI  [pH  7.5]; 
1  m.  M  EDTA)  and  stored  at  4"C  until  needed. 
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INSERTION  OF  PCR  PRODUCTS  INTO  PCR-SCRIPT 
To  a  0.5  ml  microcentrifuge  tube  the  following  reagents  were  added  in  order:  1  ý11  of 
pCR-Script  DNA  (at  10  ng/gl);  I  gl  of  10X  reaction  buffer;  0.5  gl  of  JOMM  rATP;  200 
ng  of  PCR  products  HA  or  NP  (for  a  insert:  vector  ratio  of  approximately  40:  1);  1  ýd  of 
Srfl  (5  U/gl);  I  gl  of  T4  DNA  ligase  and  dH20  to  a  final  volume  of  10  gl.  The  reaction 
was  gently  mixed  and  incubated  at  room  temperature  for  I  hour.  Following  completion  of 
incubation  time  the  reaction  was  heated  at  65*C  for  10  min  and  stored  on  ice. 
TRANSFORMATION  OF  BACTERIA  AND  SCREENING  OF RECOMBINANTS 
The  E.  coli  strain  Max  Efficiency  DH  I  OB  was  transformed  using  a  routine  transformation 
protocol  (mat&meth).  Plasmid  DNA  was  prepared  from  the  bacterial  cultures  by  the 
"STET  method"  (mat&meth).  For  the  screening  of  HA  clones  the  DNA  was  digested  by 
EcoRV.  Digestion  of  HA  recombinant  clones  cuts  DNA  in  two  places  (once  in  the  vector 
and  once  in  the  HA  gene  releasing  a  band  of  approximately  650bp  for  genes  cloned  in 
sense  orientation  and  a  band  of  1150bp  for  antisense.  In  the  screening  of  NP  recombinant 
clones  was  used  YhoL  Similarly,  digestion  of  NP  positive  clones  produces  a  band  of 
approximately  1300bp  for  sense  orientation  and  a  band  of  300bp  for  antisense. 
Sequencing  of  cloned  PCR  products 
PREPARATION  OF  DNA 
Four  positive  clones  for  either  HA  and  NP  were  subcultured  by  diluttion  at  I/  1000  in  20 
ml  of  LB  ampicillin  (at  100  ug/ml)  and  shaken  overnight  at  371C.  Small  scale  DNA 
preparations  of  the  subcultures  were  obtained  using  QIAprep  Miniprep  kit  (Qiagen), 
observing  manufacturers  instructions  (mat&meth).  DNA  was  analysed  by  ethidum 
bromide  stained  agarose  gel  electrophoresis  (mat&meth)  and  was  quantified  by 
spectrophotometry. 
DESIGN  OF  SEQUENCING  PPJMERS 
As  in  the  case  of  PCR  primers,  oligonucleotide  sequences  obtained  from  conserved 
regions  of  the  genes  were  utilised  for  the  synthesis  of  sequencing  primers  for  both  HA 
and  NP  (figure  5.5  and  table  5.5). 
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T7  HAseq3  HAseq4  1737 
HA 
0  HAseql  HAseq2  T3 
T7  NPseql  1560 
NP  0  10  MbI 
0  NPseq2  T3 
Figure  5.5  Schematic  representation  of  HA  and  NP  sequences  showing 
sequencing  primers. 
Table  5.5  Sequencing  primers  for  HA  and  NP. 
Primer  Sequence  Tm  Target 
T3  5'-  CAT  TAA  CCC  TCA  CTA  AAG  GG  -3'  58'C  Vector 
T7  5'-  T`TA  ATA  CGA  CTC  ACT  ATA  GG  -3'  54'C  Vector 
HA  seq  1  5'-  GTT  TGA  GCT  CGG  GTG  ATG  AAT  C-3'  66'C  HA  gene 
HA  seq2  5'-  TTG  ATG  GAA  TT7  CTC  AT-F  GG  -3'  54'C  HA  gene 
HA  seq3  5'-  AAT  TGG  CTA  ACA  CAA  TCT  GG  -3'  56'C  HA  gene 
HA  seq4  5'-'FGT  GAT  AAT  GCA  TGC  AAT  GG  -3'  56'C  HA  gene 
NP  Seq  1  5'-  CCA  CAT  ACC  AAA  GAA  CAA  GG  -3'  58'C  NP  gene 
NP  Seq2  5'-  GTT  CTG  GAG  TAG  TTT  GAA  AGG  -3' 
60'C  NP  gene 
Care  was  taken  to  space  the  primers  in  sense  and  antisense  orientation,  taking  in 
consideration  that  each  run  of  sequencing  generates  between  500  and  700  bases  of  good 
quality  sequence,  as  previous  experience  showed.  All  sequencing  pnmers  were 
synthesised  by  MWG-Biotech  (Germany)  and  were  modified  by  5'  labelling  with  the 
fluorochrome  IRD-800. 
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SEQUENCING  REAMONS  AND  GEL  RUN 
Plasmid  DNA  templates  and  appropriate  primers  for  HA  and  NP  were  mixed  to  produce 
sequencing  reactions  (mat&  meth)  using  "IbermoSequenase  Cycle  Sequencing  Kit" 
(Amersham).  Cycle  sequencing  was  performed  in  a  Perkin  Elmer  9600  thermal-cycler. 
Cycling  conditions  were:  94*C  for  5  min  followed  by  25  cycles  of  denaturing  at  98*C  for 
30  sec;  annealing  at  21C  below  melting  temperature  of  respective  primer  for  30  sec.  and 
extension  at  72*C  for  40  sec;  followed  by  chilling  at  4*C.  Sequencing  reactions  were  run 
in  a  DNA  automated  sequencer  (Li-Cor  4000L)  using  gel  running  conditions,  solutions 
and  buffers  specified  in  the  accompanying  protocols  (mat&meth). 
DATA  ANALYSIS 
Sequence  data  generated  from  all  the  template  :  primer  combinations,  respectively  for  HA 
and  NP,  was  analysed  using  UW-GCG  software  package.  Consensus  sequences  for  both 
HA  and  NP  were  produced  using  "Pileup"  and  "Pretty"  programs.  The  consensus 
sequences  were  then  translated  using  "Map"  to  derive  the  respective  predicted  amino  acid 
sequences.  The  percentage  of  homology  that  the  nucleotide  and  derived  amino  acid 
sequences  exhibited  towards  other  H3N8  influenza  virus  isolate  sequences  published  or 
deposited  in  databases  was  determined  using  "Fasta"  program. 
5.2.2  Expression  of  influenza  virus  genes 
Subeloning  of  HA  and  NP 
The  HA  and  NP  genes  were  subcloned  into  pCI-Neo  (Promega).  As  a  preparatory  step 
one  clone  from  both  HA  and  NP  (showing  100%  conservation  relatively  to  the  respective 
consensus  sequences)  was  seeded  at  1/1000  dilution  in  20  ml  of  LB  ampicilin  (100ug/ml) 
and  incubated  overnight  at  37*C  with  agitation.  Two  plasmid  DNA  minipreparations 
were  performed  for  each  using  QlAprep  Miniprep  kit  (Qiagen).  Resulting  DNA  of  each 
clone  was  pooled,  analysed  by  ethidium  bromide  stained  agarose  gel  and  quantified  by 
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spectrophotometry.  Figures  5.6  and  5.7  show  a  graphical  representation  of  the  subcloning 
procedure. 
T3 
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Figure  5.6  -  Schematic  of  HA  subcloning  process.  pCR-Script-HA  recombinant 
DNA  was  cut  with  MluI  and  NotI.  The  resulting  1740  bp  band  was  gel  purified 
(mat&meth)  and  inserted  into  a  MluI  /  NotI  digested  pCI-Neo. 
pCR-Script 
TI 
S.  1 
Nod 
smal 
- 
UART 
N 
Ip0 
-  smp 
Nod 
F-RV 
H.  WU 
Xhal 
T7 
pCI-NP 
T7 
Nbel 
Empi 
M1.1 
SAI 
Nail 
START 
N 
p 
STOP 
Noll 
T3 
Figure  5.7  -  Subdoning  of  TjP.  pCR-Script-NP  was  diggested  with  Notl  and  the 
1580bp  product  ligated  into  the  NotI  site  of  pCI-Neo 
The  bacterial  cell  strain  Max  Efficiency  DHIOB  was  transformed  with  both  chimeras.  In 
both  cases,  recombinant  clones  were  screened  with  the  restriction  enzyme  SstI  with  buffer 
with  and  BSA,  producing  the  following  band  pattern:  for  HA  1000  bp  for  sense 
orientation  and  1500  bp  for  antisense;  for  NP  900  bp  for  sense  and  450  bp  for  antisense. 
205 Itýfluenza  Virus 
DNA  from  one  clone  (in  sense  orientation)  for  each  chimera  was  large  scale  purified 
using,  thoroughly  checked  by  sequencing  and  taken  through  to  the  next  stage. 
Transfection  of  mammalian  cells  and  RNA  analysis 
To  investigate  if  the  cloned  genes  were  functional  the  highly  transfectable  COS-7  cell 
line  was  used  for  transient  expression  of  HA  and  NP.  Cells  were  transfected  using  the 
calcium-phosphate  based  "Mammalian  Transfection  Kit"  (Stratagene)  with  the 
manufacturer  guidelines.  As  a  negative  control  cells  were  also  transfected  with  empty 
pCI-Neo  plasmid. 
Transfected  cells  were  collected  by  trypsinisation  and  centrifugation  at  different  time 
points  (24,48  and  72  hours).  Total  RNA  was  extracted  from  cells  using  "Rneasy  Midi 
Kit"  (Qiagen).  The  RNA  was  quantified  by  spectrophotometry  and  analysed  by  northern 
blot  (mat&meth)  using  gene  specific  radiolabelled  probes.  The  probes,  consisted  of 
fragments  of  HA  and  NP,  generated  by  restriction  enzyme  digestion  of  plasmid  DNA  and 
were  labelled  with  [a32P]dCT?  (Amersham)  using  "Oligolabelling  Kit"  (Pharmacia).  A 
probe  for  the  housekeeping  enzyme  GAP-DH  was  used  as  quality  control  of  the  RNA 
preparations. 
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5.3  Results 
5.3.1  Amplification  of  HA  and  NP 
Amplification  of  the  HA  gene  was  originally  attempted  using  FLUI  primer  for  both 
cDNA  first  strand  synthesis  and  upstream  priming  of  the  PCR  and  FLU2  primer  for 
downstream  priming.  The  PCR  reaction  was  performed  using  Taq  polymerase  and 
resulted  in  a  multiple  band  product  (result  not  shown).  This  product  was  cloned  and  3  of 
the  clones  corresponding  to  a  full  length  HA  gene  were  sequenced.  These  clones  were 
later  discarded  due  to  the  consistent  presence  of  point  mutations.  Sequencing  data  derived 
from  these  clones  was  nonetheless  useful  in  the  design  of  improved  gene  specific  primers 
(HAI  and  HA2).  In  the  case  of  NP,  the  primer  NP-RT  was  used  for  cDNA  first  strand 
synthesis  and  primers  NPI  and  NP2  for  5'  and  3'  PCR  priming,  respectively. 
Amplification  of  the  genes  of  interest  was  optimised  through  the  titration  of  primer 
concentration,  manipulation  of  cycling  parameters  and  by  the  inclusion  of  DMSO  in  the 
PCR  mix.  Products  of  the  expected  size:  approximately  1740  bp  for  HA  and  1570  bp  for 
NP  were  obtained  (Figures  5.8  and  5.9).  In  both  cases  was  included  a  negative  control, 
consisting  of  dH20  in  place  of  cDNA  template,  to  check  for  contamination  of  the  reaction 
mix  with  foreign  DNA. 
5.3.2  Nucleotide  and  a.  a.  sequence  of  HA  and  NP 
Nucleotide  sequence  of  4  HA  clones  and  4  NP  clones  was  obtained  using  a  series  of  gene 
specific  and  vector  specific  primers.  Analysis  of  the  resulting  overlapping  sequences  was 
used  to  generate  the  consensus  nucleotide  and  predicted  amino  acid  sequences  for  HA 
and  NP  shown  in  figures  5.10  and  5.11,  respectively. 
5.3.2.1  Haemagglutinin 
The  sequence  for  nu 
, 
cleotides  I  through  27  was  originally  obtained  from  the  cloned  HA 
PCR  product  amplified  using  FLU  I  as  a  5'  primer,  those  clones  were  discarded  as  they 
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contained  a  point  mutation  (C  substituted  by  T)  in  position  1120,  which  resulted  in  the 
introduction  of  a  stop  codon  (TGA). 
The  open  reading  frame  begins  at  the  ATG  codon  (position  16)  and  ends  at  the  TGA 
codon  (position  1711),  encoding  a  HA  precursor  of  565  amino  acids.  Newmarket/2/93 
HA,  shares  between  98.1%  and  99.4%  nucleotide  sequence  and  between  97.7%  and 
98.8%  amino  acid  sequence  identity  with  recent  European  and  American  isolates  (Daly  et 
al,  1995  and  1996  unpublished;  Binns  et  al,  1993;  Bean  et  al,  1992;  Kawaoka  et  al, 
1989).  Further  analysis  of  the  amino  acid  sequence  revealed  conservation  of  the  predicted 
N-terminal  signal  sequence  cleavage  site  between  positions  15  and  16  as  well  as  the 
cleavage  site  that  separates  HA,  from  HA,  that  occurs  between  positions  344  and  345. 
Also  conserved  cross  isolates  are  nine  potential  N-linked  glycosylation  sites,  eight  of 
them  situated  in  the  HA,  portion  of  the  molecule  (at  positions  18,23,37,53,68,78,180 
and  300)  and  only  one  in  the  HA,  portion  in  position  498  (reviewed  in  Daniels  et  al, 
1985).  Changes  in  the  amino  acid  sequence  across  isolates  take  place  predominantly  in 
the  HA,  portion  of  the  protein,  reflecting  selection  pressure  in  the  most  antigenic  portion 
of  the  molecule  (Wiley  et  al,  1987). 
5.3.2.2  Nucleoprotein 
Analysis  of  the  sequence  revealed  that  the  cloned  NP  product  was  amplified  by  primers 
NP2  and  RT-NP  (rather  then  the  NP1  primer  used  in  the  PCR  reaction).  RT-NP  primer 
carried  over  from  first  strand  cDNA  reaction  had  presumably  a  competitive  binding 
advantage  over  NPI  primer.  As  described  before  the  NPI  primer  included  a  5'  tag 
containing  HindIII  and  Kozak's  sequence  elements. 
The  predicted  translation  product  of  Newmarket/2/93  NP  contains  498  amino  acids, 
starting  at  codon  ATG  (position  46)  and  ending  at  codon  TAA  (position  1540).  When 
compared  with  published  NP  sequences  of  different  virus  isolates  (Gorman  et  al,  1990 
and  Gammelin  et  al,  1989),  the  nucleotide  sequence  and  derived  amino  acid  sequence  of 
isolate  Neumarket/2/93  exhibit  an  identity  of  95,0-98.4%  and  91.3%-93.4%,  respectively. 
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The  karyophilic  sequence  motif,  responsible  for  nuclear  accumulation  of  NP  (Davey  et  al, 
1985),  which  tends  to  be  conserved  among  subtypes  of  human  influenza  A  virus  is 
present:  336-A-A-F/Y-E-D-L-R-V-L-344.  Also  a  motif  that  resembles  an  epitope  presented 
by  infected  cells  to  MHC  class  I-  restricted  CTL's  (Gould  et  al,  1989)  is  present:  366-  A- 
S-N-E-N-M-E-T-I-D-R-S-T-L-379. 
5.3.3  Evidence  of  expression  of  HA  and  NP 
Investigation  of  expression  of  HA  and  NP  in  a  manimalian'system,  was  only  attempted 
by  northern  blot  analysis.  Figures  5.12-A  and  5.13-A  show  auto-radiographs  exposed  to 
blots  of  RNA  from  cells  transfected  for  24,48  and  72  hours,  with  plasmid  encoding  HA 
and  NP  respectively,  labelled  with  gene  specific  probes.  In  each  case  is  included  a 
negative  control  consisting  of  cells  transfected  with  empty  expression  vector  (PCI-Neo). 
Figures  5.12-B/C  and  5.13-B/C  show  the  same  blots  labelled  with  a  GAPDH  probe,  as  a 
positive  control  for  the  RNA  purification  procedure. 
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Figure  5.8  1  laemagglutiniin  amplification  products.  Fthidium  bromide  staincd  agarose 
gel  (1.2%).  lOpl  of  each  reaction  loaded  per  lane.  Lane]-lkb  ladder,  Lane2-11A 
product;  Lane3-  template  control. 
1 
1600bp 
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Figure  5.9  Nucleoprotein  amplification  products.  Ethidium  bromide  stained  agarosc 
gel  (1.2%).  10[d  of  each  reaction  loaded  per  lane.  Lane]-lkb  ladder;  Lane2-NP 
product;  Lane3-  template  control. 
1 1  ACGCGTCTOTCAAT  TCAAGAr-AArCATTATTTTGATACTACTGACCCATTGGGTCTACAGTCAAAACCCAACCAGTGGC  81 
MKTTIILILLTHWVYSQNPTSG  (22) 
AACAACACAr,  CCACAI"rATGTCTGGGACACCATGCAGTAGCAAA7r.  GAACATTGGTAAAAACAATAACrGATGACCAAATT  162 
NNTATLCLGHHAVANGTLVKTITDDQ1  (4  9) 
GAGGTGACAAATGCTACrGAATTAGTCCAGAGCATTTCAATAGGGAAAATATGCAACAACTCATATAGGGTTCTAGATGGA  243 
EVTNATELVQSISIGKICNNSYRVLDG  (76) 
AGAAATTGCACATTAATAGATGCAATGCTAGGAr.  ACCCCCATTGTGATGATTTTCAGTATGAGAATTGGGACCTCTTCATA  324 
RNCTLIDAMLGDPHCDDFQYENWDLF1  (103) 
GAAAGAAGCAGCGCTTTCAGCAATTGcTAcccATATGAcATcccTr.  AcrATGCATCGCTCCGGTCCATTrTAGCATCCTCA  405 
ERSSAFSNCYPYDIPDYASLRSIVASS  (130) 
GGAACATTAGAATTCAcAGCAGAGGGGrTcACATGr.  AcAGGT,  cTcAcrCAAAACGC,  AAGAAGTGGAGCCTGCAAAAGGGGA  486 
GTLEFTAEGFTWTGVTQNGRSGACKRG  (157) 
TCAGCCGATAGTTTCTTTAGCCGACTGAATTGGCTAACACAATCrGGAAATrCrTACCCCATATTGAATGTr-ACAATGCCT  567 
SADSFFSRLNWLTQSGNSYPILNVTMP  (184) 
AACAATAAAAATTTCGATAAACTATACATC7r,  GGGGATTCATCACCCGAGcrcAAAcAAAGAGCAGACAAAATTATATATC  648 
NNKNFDKLYIWGIHHPSSNKEQTKLY1  (211) 
CAAGAATCAGGACGAGTAACAGTCTCAACAGAAAGAAGTCAACAAACAGTAATCCCrAACATCGGATCrAGGCCGGGGGTC  729 
QESGRVTVSTERSQQTVIPNIGSRPGV  (238) 
AGGGGTCAATcAGr.  cAGGATAAGcATATAcrGr.  AccATTGTAAAAccrGGAGATATTCTAATGATAAACAGTAATGGCAAC  810 
RGQSGRISIYWTIVKPGDILMINSNGN  (265) 
TTA.  GTTGCACCGCGGGGATA=AAATTGAGAACAGGGAAAAGCrCrGTAATGAGATCAGATGCACTCATAGACACTTGT  e9l 
LVAPRGYFKLRTGKSSVMRSDALIDTC  (292) 
CTGTCrGAATGTATTACACcAAATGGAAGcATCCCcAACC,  ACAAACCATTTCAAAATGTGAACAAAATTACATATGGAAAA  972 
VSECITPNGSIPNDKPFQNVNKITYGK  (319) 
TGCCCCAAGTATATCAGGCAAAAcAcTTTAAAGCTGGCCACrGGGATGAGGAATGTACCAGAAAAGCAAATCAGAGGAATC  1053 
CPKYIRQNTLKLATGMRNVPEKQIRG1  (346) 
TTTGGAGCAATAGCGGGATTCATAGAAAACGGCTGGGAAGC,  AATGGTTr,  ATGGC;  TGGTATGGATTCCGATATCAAAACrCG  1134 
FGAIAGFIENGWEGMVDGWYGFRY0NS  (373) 
GAAGGAACAGGACAAGCTGcAGATcTAAAr.  AGcAcrcAAGCAGCCATAGACCA(3ATCAATGGAAAATTAAACAGAGTGATT  1215 
EGTGQAADLKSTQAAIDQINGKLNRV1  (400) 
GAAAGGACCAATGAGAAATTCCATCAAATAGAAAAGGAATTCTCAGAAGTAGAAGGGAC,  AATCCAGGATTTGGAGAAGTAT  1296 
ERTNEKFHQIEKEFSEVEGRIQDLEKY  (427) 
GTAGAAGACACCAAAATAGACCTATC-GTCCrACAATGCAGAATTGCTGGTGGCTCTAGAAAATCAACATACAA7TGACTTA  1377 
VEDTKIDLWSYNAELLVALEN0HTIDL  (454) 
ACAGATGCAGAAATGAATAAATTATTCGAGAAGAcrAGGCGCCAGTTAAGAGAAAACGcr,  GAAGACATGGGAGGTGGATGT  1458 
TDAEMNKLFEKTRRQLRENAEDMGGGC  (481) 
TTCAAGATTTACCACAAATGTGATAATGCATGCATTGGATCAATAAGAAATGGGAcATATGACCATTACATATACAGAGAT  1539 
FKIYHKCDNACIGSIRNGTYDHYIYRD  (508) 
GAAGC,  ATTAAACAACCGA=CAAATCAAAAGTGTTGAGTTC,  a.  AATCAGGCTACAAAGATTGGATACTGTGGATTTCATTC  1620 
EALNNRF01KSVELKSGYKDWILWISF  (535) 
GCCATATCATGCTTCTTAATTTGCGTTGTTCTATTGGGTTTCATTATGTGGGCTTGCCAAAAAGGCAACATCAGATGCAAC  1701 
AISCFLICVVLLGFIMWAC0KGNIRCN  (562) 
ATTTGCATTT  1737 
1cI*  (565) 
Figure  5.10  -  Nucleotide  and  predicted  amino  acid  sequences  of  the  HA  gene  for 
the  A/Equine/Newmarket/2/93  (H3N8)  influenza  virus  isolate.  Nucleotides  are  numbered 
in  bold  and  amino  acids  in  brackets.  The  symbol  -  identifies  the  stop  codon.  Primers  used 
for  PCR  amplification  are  underlined. I  ACCAAAAGCAGGGTAGATAATCACTCACTGAGTGACATCAAAGTCATGGCGTCTCAAGGcAccAAAcGATcrTATGAGCAG  81 
MASQGTKRSYEQ  (12) 
ATGGAAACTGATGGC,  GAACGCCAC,  AATGCAACTGAAATCAGAGCATCrGTCGGAAGGATGGTGGGAGGAATCGGCCGGTTT  162 
METDGERQNATEIRASVGRMVGGIGRF  (39) 
TATGTTCAGATGTGTACrGAGCTTAAATTAAACGACCATGAAGGGCGGCTGATTCAGAACAGCATAACAATAGAAAGGATG  243 
YV0MCTELKLNDHECRL10NSITIERM  (66) 
GTACTTTCGGCATTCGACGAAAGAAGAAACAAGTACCTCGAGGAGCATCCCAGTGCTGGGAAAGACCCTAAGAAAACGGGA  324 
VLSAFDERRNKYLEEHPSAGKDPKKTG  (93) 
GGCCCGATATACAGAAGGAAAGATGGGAAATGGATAAGAGAACTCATCCrCCATGATAAAGAGGAAATCATGAGGGTCTGG  405 
GPIYRRKDGKWIRELILHDKEEIMRVW  (120) 
CGTCAGGCCAACAATGGTGAAGATGCrACTGCTGGTCrTACCCATATGATGATCTGGCACTCCAATCTCAATGACACCACA  486 
RQANNCEDATAGLTHMMIWHSNLNDTT  (147) 
TACCAAAC,  AACAAGGGCrCTTGTTCGGACTGGGATGGATCCCAGAATGTGCTCTC7r.  ATGCAAGGATCAACCCTCCCACGG  567 
YQRTRALVRTGMDPRMCSLMQGSTLPR  (174) 
AGATCTGGAGCTGCCGGTGCTGCAGTAAAAGGTGTTGGAACAATGATAATGGAACTCATCAGGATGATCAAACGCGGGATA  648 
RSGAAGAAVKGVGTMIMELIRMIKRG1  (201) 
AATGATCGAAATTTCTGGAGAGGTGAAAaTGGTCGAAGAACCAGAATTGCTTATGAAAGAATGTGCAATATCCTCAAAGGG  729 
NDRNFWRGENGRRTRIAYERMCNILXG  (228) 
AAATTTCAAACAGCAGCACAACGGGCTATGATGGACCAAG7r.  AGGGAGGGCCGCAATCCTGGAAATGCrGAGATTGAGGAT  810 
KF0TAAQRAMMDQVREGRNPGNAEIED  (255) 
CTCATTTTCTTGGCACGATCAGCACTCATTTGAGAGGATCAGTAGCCCATAAATCATGCCrACCTGCCTGTGTTTATGGCT  891 
LIFLARSALILRGSVAHKSCLPACVYG  (282) 
CTTGCAGTAACCAGTGGGTATGACTTTGAGAAGGAAGGATACTCTCTGGTTGGGATrGATCCT7TCAAACTACTCCAGAAC  972 
LAVTSCYDFEKEGYSLVGIDPFKLLQN  (309) 
AGCCAAA7=CAGTCTAATCAGACCGAAAGAAAATCCAGCACACAAGAGCCAGTTGGTGTGGATGgCATGCCATTCTGCA  1053 
S01FSLIRPKENPAHKSQLVWMACHSA  (336) 
GCATTTGAGGACCTGAGAG=GAATTTCATTAGAGGAACAAAAGTAATCCCAAGAGGACAGTTGGCAACCAGAGGAGTG  1134 
AFEDLRVLNFIRGTKVIPRG0LATRGV  (363) 
CAGATTGCTTCAAATGAAAACATGGAGACAATAGA7TCTAGCACACTCGAACTGAGAAGCAGATATTGGGCAATAAGGACC  1215 
QIASNENMETIDSSTLELRSRYWAIRT  (390) 
AGAAGTGGAGGAAACACCAGTCAACAGAGACCATCTGCAGGACAGATAAGTGTGCAACCTACTTTCTCAGTGCAGAGAAAT  1296 
RSGGNTSQQRASAGQISV0PTFSVQRN  (417) 
CTTCCCTTTGAAAGAGCAACCATTATGGCTGCATTTACTGGGAACACTGAGGGGAGGACTTCCGACATGAGAACGGAAATC  1377 
LPFERATIMAAFTGNTEGRTSDMRTE1  (444) 
ATAAGGATGATGGAAAATGCCAAATCAGAAGATGTGTCTTTCCAGGGGCGGGGAGTCTTCGAGCrCTCGGACGAAAAGGCA  1458 
1RMMENAKSEDVSF0GRGVFELSDEKA  (471) 
ACGAACCcGATCGTGC=CC=GACATGAGCAATGAAGGGTCTTA77TCTTCGGAGACAATGCTGAGGAGT7TGACAGT  1539 
TNPIVPSFDMSNEGSYFFGDNAEEFDS  (498) 
1572 
Figure  5.11  -  Nucleotide  and  predicted  amino  acid  sequences  of  the  NP  gene  for  the 
A/Equine/Newmarket/2/93  (H3N8)  influenza  virus  isolate.  Nucleotides  are  numbered  in  bold 
and  amino  acids  in  brackets.  The  symbol  -  identifies  the  stop  codon.  Primers  used  for  PCR 
amplification  are  underlined. 23456 
C 
GAPDH 
Figure  5.12  Expression  of  haernagglutinin  in  mammalian  cells. 
A-  RNA  derived  from  transfected  COS-7  cells  was  probed  with  a  RA  gene  specific 
probe.  RNA  (15ýtg/lane)  was  loaded  as  follows:  Lanes  1,2,3  pci-FIA  at  24,48  and  72 
hours  post-transfection,  respectively;  Lanes  4,5,6  pCI-neo  parental  plasmid  at  24,48 
and  72  hours  post-transfection,  respectively. 
B  and  C-  The  same  samples  as  in  gel  A,  loaded  in  the  same  order,  were  probed  with  a 
GAPDH  probe. A23456 
GAPDH 
B  1! 
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Figure  5.13  Expression  of  nucleoprotein  in  mammalian  cells. 
A-  RNA  derived  from  transfected  COS-7  cells  was  probed  with  a  NP  gene  specific 
probe.  RNA  (15Vtg/lane)  was  loaded  as  follows:  Lanes  1,2,3  pCI-NP  at  24,48  and  72 
hours  post-transfection,  respectively;  Lanes  4,5,6  pCI-neo  parental  plasmid  at  24,48 
and  72  hours  post-transfection,  respectively. 
B  and  C-  The  same  samples  as  in  gel  A,  loaded  in  the  same  order,  were  probed  with  a 
GAPDH  probe. Influenza  17rus 
5.4  Discussion 
The  purpose  of  this  part  of  the  project  was  to  clone  genes  of  equine  influenza  virus 
that  could  be  used  as  a  source  of  antigen  in  a  DNA  vaccination  trial.  The  antigens 
selected  for  this  experiment  were  the  haernagglutinin  representing  the  external  and 
highly  variable  portion  of  the  virus  particle  and  the  nucleoprotein  representing  the 
internal  and  conserved  region  of  the  virion.  A  discussion  on  the  importance  of  these 
antigens  in  the  elicitation  of  immune  responses  against  influenza  virus,  particularly 
following  DNA  vaccination  is  presented  in  chapter  6. 
The  genes  amplified  and  cloned  show  a  high  degree  homology  with  corresponding 
sequences  of  other  isolates  both  at  the  nucleotide  and  at  the  araino  acid  level. 
Futhcrmore  there  is  conservation  of  functionally  important  features  such  as  the 
proteolytic  cleavage  sites  in  HA  and  kariophilic  sequence  in  NP.  These  observations 
attest  for  the  authenticity  of  the  cloned  genes. 
The  HA  and  NP  genes  were  subcloned  into  pCI-Neo  and  the  capacity  of  the  vector  in 
driving  their  expression  following  transfection  of  COS7  cells  was  assessed  by 
northern  blot.  The  identity  of  the  expressed  proteins  was  later  confirmed  elsewhere  by 
indirect  fluorescent  labbeling  of  transfected  cells  using  a  serum  of  influenza  positive 
horses  as  the  primary  antibody  (Dr.  Paul  Sondermeijer,  personal  communication). 
The  cloning  and  expression  of  HA  and  NP  will  permit  the  assessment  of  their  role  in 
eliciting  protection  against  influenza  virus 
:  01 
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DNA  VACCINATION  AGAINST 
EQUINE  INFLUENZA  VIRUS AIVA  vaccination 
6.1  Introduction 
6.1.1  DNA  vaccines 
Recent  developments  in  the  understanding  of  antigen  recognition  by  T  cells  have 
established  that  an  efficient  immune  response  to  most  intracellular  pathogens 
(especially  viruses)  is  mounted  only  if  CD8+  precursor  cells  are  activated  to  generate 
MHC  class  I  restricted  cytolytic  T  cells  (CTLs),  along  with  an  effective  humoral 
response,  in  the  shape  of  neutralising  antibodies  (Hassett  and  Valitton,  1996). 
Elicitation  of  humoral  responses  is  easily  achieved  by  using  inactivated  pathogens  or 
subunit  vaccines  (e.  g.  recombinant  proteins  or  synthetic  peptides  representing 
antigenic  determinants)  that  can  be  directly  recognised  by  B  cells  and  processed  by 
APCs  for  presentation  to  CD4+  T  cells,  providing  help  and  memory  for  antibody 
formation  (reviewed  in  Ahmed  and  Gray,  1996).  In  contrast,  particularities  in  the 
processing  of  antigens  for  MHC  class  I  presentation,  suggest  that  polypeptides  are 
efficiently  presented  only  when  expressed  de  novo  in  infected  cells  (Braciale,  1993). 
Until  recently  methods  to  promote  in  vivo  expression  of  antigens  had  to  rely  on  the 
infection  of  hosts  with  live  (or  attenuated)  pathogens  or  replicating  viral  vectors 
encoding  the  gene  of  interest,  with  all  the  safety  implications  that  they  entail. 
In  1990,  Wolf  et  al,  reported  that  plasmid  DNA  encoding  the  gene  for  a  marker 
protein  injected  in  striated  muscle  resulted  in  persistent  expression  of  the  gene  at  the 
site  of  injection.  This  observation  led  to  the  development  of  a  new  immunisation 
strategy  named  DNA  vaccination  (also  known  as  genetic  or  polynuclcotide 
immunisation)  that  consists  of  the  inoculation  of  hosts  with  plasmid  DNA,  under  the 
control  of  an  appropriate  promoter,  encoding  individual  or  collections  of  antigens, 
leading  to  the  induction  of  specific  immune  responses  to  the  antigens  uptaken  and 
expressed  in  vivo  (Cohen  et  al,  1998). 
Although  most  of  the  evidence  on  efficacy  of  this  method  of  immunisation  has  been 
derived  from  studies  in  mice,  increasing  reports  demonstrate  its  potential  for 
vaccination  of  larger  species  including  ferrets  (Donnelly  et  A  1995),  pigs  (Macklin  et 
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al,  1998),  cattle  (Schrijver  et  al,  1997),  dogs  and  cats  (Osorio  et  al,  1999)  and  non- 
human  primates  (McCluskie  et  al,  1999). 
The  advantages  presented  by  this  method  of  immunisation  (Robinson  and  Torres, 
1997;  Montgomery  et  al,  1997)  besides  its  low  cost  are: 
-  the  ease  of  production,  as  gene  inserts  can  be  recovered  by  PCR  eliminating 
the  need  for  production  and  purification  of  recombinant  proteins  and  even  the 
culture  of  the  pathogen  if  PCR  is  performed  using  tissue  extracts  from  infected 
hosts; 
-  the  safety,  as  the.  plasmid  will  contain  only  selected  antigenic  determinants  of 
the  pathogen,  practically  abolishing  the  risk  of  pathogenicity  and  also  the 
potential  risk  of  genome  integration  associated  with  replicating  live  vectors; 
-  the  simplicity  of  manipulating  constructs  using  standard  molecular  biology 
techniques  enables  the  investigation  of  alternative  vaccination  conditions  such 
as  the  effect  of  the  antigen  form  (secreted  or  bound  to  membranes),  by 
inclusion  of  targeting  signals  in  the  construct,  or  the  effect  of  co-expressed 
cytokines,  by  either  engineering  cytokine  genes  into  the  construct  or  co- 
administrating  plasmids  encoding  cytokines; 
-  the  fidelity  of  the  expressed  proteins,  at  both  structural  and  conformational 
levels,  ensures  that  the  immune  responses  will  be  comparable  to  those  elicited 
by  the  wild  type  pathogens,  increasing  therefore  the  likelihood  of  protection 
following  challenge; 
-  the  efficacy,  as  DNA  vaccinations  have  been  shown  to  be  useful  in 
immunisation  against  bacteria,  virus,  and  parasites  in  animal  models,  giving 
rise  to  long  lived  cell  mediated  and/or  humoral  immune  responses; 
-  the  stability  of  DNA  over  temperatures  ranging  from  sub  zero  to  just  under 
boiling. 
The  versatility  of  this  technique  is  finther  emphasised  by  its  use  as  a  powerful  tool  for 
expressing  antigens  in  vivo  that  overcomes  the  need  for  the  production  and 
purification  of  large  quantities  of  recombinant  protein  to  serve  as  inoculum  in  such 
instances  as  the  production  of  monoclonal  and  polyclonal  antibodies  (Barry  et  al, 
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1994)  and  in  the  screening  of  complex  mixtures  of  antigens  for  immunogenic 
potential,  as  is  the  case  in  the  definition  of  protective  antigens  in  diseases  for  which 
little  is  known  about  the  mechanisms  of  protection  (Barry  et  al,  1995). 
Vectors  for  DNA  vaccination 
Plasmids  for  DNA  vaccination  (figure  6.1)  are  commercially  available  and  were 
initially  developed  for  recombinant  protein  expression  by  mammalian  cell  transfection 
in  vitro,  sharing  features  (reviewed  in  Montgomery  et  al,  1997;  Robinson  and  Torres, 
1997;  Tighe  et  al,  1998)  that  include: 
-a  backbone  consisting  of  an  origin  of  replication  (ori)  for  high  copy  number 
production  in  E.  coli  and  an  antibiotic  resistance  gene  (e.  g.  ampicillin)  for 
selection  also  in  E.  coli.  Because  the  bacterial  origin  of  replication  is  not 
functional  in  mammalian  cells  the  plasmid  does  not  replicate  when  injected 
into  hosts,  therefore  greatly  reducing  the  risk  of  genome  integration; 
Antigen  or 
immune  modulator 
viral 
promotei 
polyA 
sequence 
ori 
ampR 
Figure  6.1  Features  of  plasmid  suitable  for  DNA  immunisation  (  modified 
from  Robinson  and  Torres,  1997;  Tighe  et  al,  1998). 
-a  promoter  capable  of  directing  high  levels  of  gene  expression  in  mammalian 
cells,  normally  strong  viral  promoters,  including  the  human  cytornegalovirus 
immediate  early  promoter  (  CMV-lE)  and  the  Rous  sarcoma  virus  long 
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terminal  repeat  (RSV-LTR).  Some  plasmids  also  include  an  intron  and 
splicing  elements  as  this  was  found  to  increase  gene  expression.  A  strong 
promoter  is  required  as  small  amounts  of  plasmid  are  available  for  expression 
due  to  the  low  efficiency  of  plasmid  uptake  in  vivo  and  to  the  absence  of 
replication  in  mammalian  cells; 
-a  Y-untranslated  region  from  genes  of  mammalian  (e.  g.  bovine  growth 
hormone)  or  viral  (e.  g.  SV40)  origin,  for  efficient  transcription  termination 
and  polyadenylation  (polyA). 
-  because  of  its  bacterial  origin,  plasmid  DNA  contains  immunostimulatory 
sequences  (ISS)  with  a  consensus  sequence  consisting  of  two  purines  (G/A), 
an  unmethylated  CpG  motif  and  two  pyrimidines  (C/T).  These  sequences  are 
rare  in  eukaryotic  DNA  and  are  therefore  perceived  as  danger  signals  by  the 
host  immune  system,  evoking  powerful  cell  mediated  responses  (Pisetski, 
1997;  Tighe  et  al,  1998).  Most  plasmids  used  for  DNA  immunisation  have  at 
least  two  of  these  sequences  in  the  ampicillin  resistance  gene  (ampR). 
Antigens 
Sufficient  knowledge  of  the  biology  of  natural  infection  is  required  for  choosing  a 
correct  antigen  (or  antigens)  that  will  elicit  an  appropriate  immune  response,  not  only 
to  achieve  protection,  but  also  to  prevent  the  development  of  immunopathology. 
Following  choice  of  antigens  and  insertion  of  the  appropriate  genes  into  the  plasmid 
vector  it  is  important  to  assess  expression  of  the  protein  of  interest.  This  is 
conveniently  done  by  transient  transfection  in  vitro  of  a  suitable  cell  line  followed  by 
measurement  of  RNA  and/or  protein  expression  (Ulmer  et  al,  1996).  This  might 
reveal  the  need  for  inclusion  of  posf-transcriptional  or  post-translational  modification 
signals  such  as  an  optimal  sequence  of  translation  initiation  (Kozak  sequence)  for 
maximal  expression,  or  a  signal  sequence  for  efficient  trafficking  or  secretion  of  the 
protein  (reviewed  in  Montegomery  et  al,  1997). 
219 D.  XA  vaccination 
Administration  of  DNA  vaccines 
When  deciding  on  a  vaccination  protocol,  parameters  such  as  route  of  administration, 
dose  of  plasmid  DNA  and  number  and  interval  between  immunisations  should  be 
addressed. 
DNA  vaccines  have  been  administered  by  a  variety  of  routes  either  injected  (e.  g. 
intramuscular,  intradermal,  intravenous,  intraperitoneal,  subcutaneous)  or  non  injected 
(e.  g.  intranasal,  ocular,  oral  by  feeding)  and  by  using  special  apparatus  (gene  gun). 
Most  studies  have  however  been  designed  around  the  intramuscular  or  intradermal 
routes,  because  of  early  reports  that  these  routes  induce  potent  and  long  lived  immune 
responses  (  reviewed  in  Fynan  et  al,  1993;  McCluskie  et  al,  1999). 
Intramuscular  inoculation  is  generally  performed  by  needle  injection  of  plasmid  DNA 
in  saline.  Striated  muscle  is  100  to  1000  times  more  efficient  in  uptake  of  injected 
DNA  than  other  tissues  (Wolf  et  al,  1990).  This  is  in  part  due  to  the  regeneration 
process  of  the  injured  muscle  following  injection  as  delivery  of  DNA  to  muscle 
previously  damaged  (e.  g,  by  toxins  or  bupivacaine)  results  in  an  increased  number  of 
cells  expressing  the  antigen  and  enhanced  immune  responses  (Hassett  and  Whitton, 
1996).  The  role  of  muscle  fibres  in  antigen  presentation  is  still  unclear.  Reports  that 
transplantation  of  myoblasts  stably  transfected  with  antigen  can  induce  both  antibody 
and  CTL  responses  and  the  fact  that  myoblasts  can  be  activated  (e.  g.  by  IFN-y)  to 
express  MHC  class  II  molecules  make  a  case  for  the  function  of  muscle  cells  as  APCs. 
On  the  other  hand  observations  that  surgical  ablation  of  the  inoculated  muscle  as  soon 
as  I  minute  post-inoculation  has  no  effect  on  the  development  of  immune  responses 
and  that  muscle  fibres  are  not  able  to  express  costimulatory  molecules  (e.  g.  B-7), 
suggests  that  the  immune  responses  are  mediated  by  professional  APCs  recruited  to 
the  injured  muscle  or,  alternatively,  by  direct  transfection  of  APCs  at  the  injection  site 
or  by  plasmid  carried  through  blood  to  distal  lymphoid  tissues  (reviewed  in  Hohlfeld 
and  Engel,  1994;  Robinson,  1997;  Cohen  et  al,  1998). 
Although  less  efficient  than  the  muscle  in  uptake  of  DNA,  the  skin  constitutes,  along 
with  mucous  membranes,  the  site  where  most  antigens  are  first  encountered  and  is 
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therefore  specialised  in  supporting  the  initiation  of  immune  responses.  The  skin 
immune  system  (SIS)  is  composed  of  several  exclusive  effector  cells  including 
keratinocytes  that  produce  a  number  of  cytokines  (e.  g.  IL-1,  IL-3,  IL-6,  IL-18,  IFN- 
oc/0,  GM-CSF,  TNF-cc,  TGF-P)  upon  non-specific  stimulation,  T  cells,  both 
infiltrating  and  resident  (expressing  cutaneous  lymphocyte  associated  antigen)  and 
Langerhans  cells,  constituting  around  8%  of  the  live  cells  of  the  epidermis,  that 
differentiate  into  dendritic  cells  (professional  APCs).  An  additional  feature  of  the  skin 
is  the  dermal  perivascular  units,  structures  with  high  concentration  of  immune  cells 
(mostly  T  cells)  in  close  association  with  blood  vessels.  These  characteristics  lead  to 
the  notion  that  the  skin  is  a  unique  immunological  microenvironment  able  to  quickly 
and  efficiently  direct  both  innate  and  acquired  immune  responses  (reviewed  in  Bos 
and  Kapsenberg,  1993;  Salmon  et  al,  1994).  Plasmid  DNA  can  be  transfected 
intradermally  in  two  forms.  In  a  saline  solution  either  by  needle  injection  or  by 
needless  inoculation  using  a  device  driven  by  compressed  gas  to  deliver  a  thin  stream 
of  inoculum  under  high  pressure,  capable  of  penetrating  tissue.  Alternatively  DNA 
can  be  coated  onto  gold  particles  and  accelerated  into  the  epidermis  using  an 
apparatus  named  gene  gun,  which  uses  chemical  expansion  of  water  vapour  or 
compressed  gas  as  propellant  (reviewed  in  Donnelly'  et  al,  1997). 
The  comparison  of  several  routes  and  methods  of  delivery  has  established  that 
efficiency  of  transfection  does  not  always  correlate  with  efficacy  in  the  development 
of  immune  responses.  For  instance  the  greater  ability  of  muscle  to  uptake  DNA  was 
not  associated  with  an  enhanced  efficacy  of  vaccination  (Fynan  et  al,  1993).  In 
contrast,  gene  gun  mediated  bombardment  is,  by  far,  the  most  efficient  method  of 
immunisation  eliciting  similar  levels  of  CTL  and  antibodies  with  100  to  5000-fold 
less  DNA  than  required  by  injection.  An  amount  of  DNA  as  little  as  16ng  (in  mice)  or 
200ng  (in  larger  animals)  delivered  by  gene  gun  induces  immune  responses  only 
obtainable  with  the  inoculation  of  10  and  100lig  (respectively  in  mice  and  larger 
animals)  by  intramuscular  or  intradermal  injection  (Montgomery  et  al,  1997,  Cohen  et 
al,  1998).  These  5tudies  also  showed  that  the  way  in  which  DNA  is  delivered  has  a 
bearing  on  the  type  of  immune  response  elicited.  Intramuscular  injection  produces 
predominantly  a  Thl  type  response  whereas  repeated  gene  gun  inoculation  culminates 
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in  the  induction  of  a  Th2  type  response.  Intradennal  injection  appears  to  be  able  to 
induce  both  Thl  and  Th2  responses  (Robinson,  1997;  Cohen  et  al,  1998). 
The  number  and  frequency  of  immunisations  is  interrelated  and  dependent  on  the 
efficacy  of  the  route  adopted.  While  large  numbers  of  inoculations  (4  or  more)  are 
generally  given  at  short  time  intervals  (e.  g.  4  weeks),  smaller  numbers  of  inoculations 
(2  or  3)  will  correspond  to  larger  intervals  (8  to  12  weeks).  A  longer  rest  period 
between  immunisations  has  been  found  to  enhance  immune  responses  (Prayaga  et  al, 
1997;  McCluskie  et  al,  1999). 
Due  to  similarities  between  the  immune  systems  and  pathways  of  antigen  presentation 
of  mammals  some  extrapolations  for  vaccination  protocols  can  be  made  from  murine 
model  studies  (Robinson  and  Torres,  1997).  Nevertheless,  results  in  mice  were  found 
to  be  not  always  predictive  to  those  in  higher  mammalian  species  (e.  g.  monkey  ( 
McCluskie  et  al,  1999);  dogs  and  cats  (Osorio  et  al,  1999)].  Therefore,  optimal  dose, 
route  and  immunisation  schedule  should  ideally  be  assessed  for  each  antigen/host 
system  to  be  used. 
Mechanism  of  action  and  immune  responses 
Delivery  of  DNA  results  in  the  transfection  of  cells  in  the  target  tissue.  Upon  entry  in 
the  cells,  plasmid  DNA  is  transported  to  the  nucleus  where  it  directs  expression  of  the 
inserted  gene.  The  protein  antigen  expressed  in  this  fashion  is  acted  upon  by  cells  of 
the  immune  system,  following  membrane  presentation  or  secretion  by  the  transfected 
cell.  It  has  been  calculated  that  an  efficient  immune  response  can  be  initiated  by  the 
transfection  of  a  single  APC  with  approximately  100  molecules  of  plasmid  DNA  out 
of  the  10'0  molecules  delivered  by  injection  of  100gg  of  DNA  or  the  10'  gold/DNA 
complexes  delivered  by  gene  gun  (Robinson  and  Torres,  1997). 
In  the  skin,  the  amount  of  tissue  specific  dendritic  cells  (Langerhans  cells)  and  other 
immune  competent  cells  (discussed  above)  is  consistent  with  high  efficiency  in  the 
initiation  of  immune  responses  following  DNA  delivery.  In  the  muscle  it  is  more 
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difficult  to  define  the  role  of  dendritic  cells  (due  to  their  small  numbers)  in  uptake  of 
DNA  for  de  novo  expression  of  protein  required  for  MHC  I  presentation.  It  was 
nevertheless  shown  that  following  DNA  delivery  APCs  do  express  MHC  class  I 
molecules  (Doe  et  al,  1996).  It  is  also  difficult  to  concede  that  muscle  fibres  are  able 
to  professionally  present  MHC  class  Il  molecules.  It  is  probable  that  both  cell  types 
play  a  role  in  the  initiation  of  immune  responses  following  in  vivo  transfection  of 
DNA.  One  hypothesis  that  attempts  to  reconcile  this  dispute  is  presented  in  figure  6.2. 
plasmid 
C)  0  C) 
C)  C) 
secreted 
antigen 
myocyte  "A 
keratinocyte  NIHC  1 
AF 
NEUTRALISING  CTL  D8+ 
ANTIBODIES  ly  ACTIVITY 
ýThl  HELP 
CD- 
Th2  HELP 
B  cell 
MHC  11 
Figure  6.2  Immune  responses  triggered  by  DNA  immunisation  (modified 
from  Cohen  et  al,  1998).  The  two  alternatives  for  MHC  class  I  presentation  by 
APCs  are  depicted  in  broken  lines. 
In  this  hypothesis  a  tissue  cell  (e.  g.  myocyte,  keratinocyte)  is  transfected  and 
expresses  the  encoded  protein.  The  protein  is  then  processed  by  the  cell  and  presented 
in  the  context  of  MHC  class  I  to  CD8+  T  cells.  However,  this  assumption  is  rather 
dubious  since  it  is  now  accepted  that  efficient  priming  of  T  cells  only  occurs  after 
migration  of  antigen  presenting  cells  to  draining  lymph  nodes.  Soluble  protein 
released  by  the  cell  can  elicit  antibody  responses  and,  after  phagocytosis  and 
processing  by  APCs,  be  presented  to  CD4+  T  cells  as  MHC  class  11  molecules.  At  the 
same  time  or  alternatively,  bone  marrow  derived  APCs  (e.  g.  dendritic  cells), 
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infiltrating  or  resident  in  the  target  tissue,  can  be  directly  transfected,  presenting 
antigen  via  MHC  class  I,  while  humoral  and  T  helper  responses  would  be  generated 
by  soluble  antigen  produced  either  by  APCs  or  tissue  specific  cells  (reviewed  in 
Donnelly  et  al',  1997;  Robinson  and  Torres,  1997;  Cohen  et  al,  1998).  An  alternative 
mechanism  in  which  following  intemalisation  by  APCs  some  peptide  antigen  might 
cross-over  to  the  MHC  class  I  pathway  is  gaining  supporters  (Kovacsovics- 
Bankowski  and  Rock,  1995).  This  mechanism  would  imply  that  transfection  of 
myocytes/  keratinocytes  is  sufficient  to  sustain  both  MHC  class  I  and  class  Il 
presentation  by  professional  APCs. 
6.1.2  Vaccination  against  influenza  virus 
Equine  influenza  vaccines 
Current  vaccines  against  equine  influenza  virus  are  composed  of  inactivated  whole 
virus  representing  strains  circulating  in  the  equine  population  (Mumford  et  al,  1995). 
One  of  the  major  limitations  of  these  vaccines  is  the  failure  in  maintaining  sufficiently 
high  levels  of  neutralising  antibodies  between  doses,  therefore  compromising 
protection  (Mumford  and  Hannant,  1993).  Secondly,  although  major  shifts  in  the 
antigenic  nature  of  the  virus  are  infrequent  in  equine  influenza,  the  accumulation  of 
small  variations  (drifts)  that  regularly  occur  in  circulating  viruses  (particularly  of  the 
H3N8  subtype)  is  responsible  for  the  reduced  efficacy  of  the  vaccines  used.  This  not 
only  requires  a  constant  antigenic  surveillance  of  the  circulating  viruses,  but,  more 
importantly,  dictates  the  alteration  of  vaccine  formulations  every  time  a  significant 
variation  is  detected,  with  all  the  cost  implications  that  it  brings.  Recently,  the  world 
health  organisation  (WHO)  has  made  two  recommendations  to  include  new  variants  in 
equine  vaccines.  The  first,  in  1992,  for  the  inclusion  of  an  A/equine2  (H3N8)  isolated 
in  1989  in  Britain  and  the  second  in  1995  for  the  inclusion  of  a  Newmarket/2/93  -like 
virus  also  representing  the  European  group  of  H3N8  viruses  (Mumford  and  Wood, 
1993).  Additionally,  the  unreliability  of  the  method  commonly  used  to  measure  the 
antigenic  content  of  vaccine  preparations  creates  difficulties  in  the  correlation  of 
protection  with  dose  of  antigen  (haemagglutinin)  in  the  vaccine.  The  method,  based 
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on  the  ability  of  HA  to  agglutinate  chick  red  blood  cells,  is  still  used  by  many  vaccine 
manufacturers,  despite  recommendations,  by  the  WHO,  that  a  more  reproducible 
assay  (single  radial  diffusion)  should  be  adopted  (Mumford  et  al,  1995). 
Natural  infection  by  equine  influenza  virus  generates  a  short  lived  antibody  response 
that  declines  to  low  levels  in  a  period  of  3  months.  Nevertheless,  infection-induced 
immunity  promotes  long  lasting  protection,  unlike  that  induced  by  vaccination 
(Hannant  et  al,  1988).  Furthermore,  following  equine  influenza  infection,  both 
respiratory  tract  antibody  responses  in  the  shape  of  secretory  IgA  (sIgA)  (Mumford 
and  Hannant,  1993),  and  CTLs,  showing  similar  MHC  class  I  restriction,  to  those 
seen  in  humans  and  mice,  have  been  identified  in  horses  (McMichael  et  al,  1983).  The 
evolutionary  proximity  between  equine  and  human  influenza  viruses  and  the 
similarities  in  the  immune  responses  elicited  imply  that  the  lessons  learned  from  both 
human  vaccinology  and  that  of  animal  models  are  useful  resources  in  defining  new 
strategies  for  equine  influenza  vaccine  development. 
Immune  response  to  human  influenza  vaccines 
It  has  been  known  for  some  time  that  specific  immunity  to  influenza  virus  is 
associated  with  humoral  immune  responses,  both  systemic  (serum  virus  neutralising 
IgG)  and  of  the  respiratory  tract  (  virus  specific  sIgA  and  IgG  antibodies  in  nasal 
secretions)  and  with  cell  mediated  immune  responses  (reviewed  in  chapter  5). 
Antibody  responses  protect  humans  against  homologous  challenge,  i.  e.,  with  virus 
possessing  the  same  antigenic  specificity  (Clements  et  al,  1984)  while  CTL  responses 
have  been  associated  not  only  with  recovery  from  infection  (with  clearance  of  the 
virus)  but  also  with  protection  against  heterologous  challenge,  i.  e.  following  infection 
with  antigenic  variants  of  the  virus  (reviewed  in  Ada  and  Jones,  1986). 
Due  to  the  difficulty  in  securing  human  individuals  naive  to  influenza  virus,  most 
vaccine  trials  rely  on  the  use  of  primed  recipients  and  have  been  conducted  in 
volunteer  children,  less  likely  to  have  had  repeated  contact  with  the  virus  (Ghendon, 
1989).  In  such  studies,  it  has  been  found  that  both  inactivated  vaccines  and  cold 
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adapted  (temperature  sensitive)  live  attenuated  vaccines  are  extremely  efficient  in 
generating  neutralising  antibodies  (Jonhnson  et  al,  1985).  In  contrast,  stimulation  of 
CTL  responses  using  live  vaccines  is  superior  to  that  obtained  with  inactivated 
vaccines  (Webster  and  Askonas,  1980).  In  the  case  of  inactivated  vaccines,  responses 
are  highly  irregular  appearing  to  be  related  with  the  pre-immunisation  level  of  T  cell 
memory.  In  addition,  CTL  responses  generated  by  live  vaccines  were  reported  to 
increase  protection  to  heterologous  challenge  (McMichael  et  al,  1983). 
DNA  vaccination  against  influenza  in  animal  models 
The  limitations  imposed  by  safety  considerations  and  the  non  availability  of  unprimed 
human  individuals  have  prompted  the  pursuit  of  animal  models  that  would  allow  for 
immune  responses  to  be  correlated  with  protective  efficacy  of  human  influenza 
vaccines  in  preclinical  studies.  Some  animal  models  (e.  g.  ferrets)  are  readily  infected 
with  strains  of  human  influenza,  however,  due  to  practicability  and  cost  the  murine 
model  continues  to  be  preferred.  Because  most  human  influenza  strains  are  not  able  to 
naturally  infect  mice,  the  generation  of  murine  challenge  models  had  to  rely  on  the 
adaptation  of  virus  to  this  species.  Such  is  the  efficiency  of  these  models  to  respond  to 
influenza  virus,  that  high  morbidity  and  even  death  can  be  induced  with  appropriate 
doses  of  challenge  virus  (reviewed  in  Donnelly'  et  al,  1997).  Infection  of  mice  with 
adapted  virus  in  sublethal  doses  leads  to  the  development  of  protective  antibody  and 
cell  mediated  responses.  These  models  have  been  particularly  useful  in  the  dissection 
of  the  involvement  of  CTLs  in  recovery  from  infection  and  protection  to  influenza 
challenge,  by  allowing  experiments  such  as  the  treatment  with  anti-CD8+  antibodies, 
the  knockout  of  the  P2-microglobulin  gene  or  the  adoptive  transfer  of  CTL  clones 
from  infected  mice  to  severely  compromised  immunodeficient  (SCID)  mice,  that  lack 
mature  T  and  B  cells.  Similar  experiments  were  performed  in  relation  to  Thl  clones 
that  were  also  found  to  be  important  for  protection  against  influenza  infection 
(reviewed  in  Donnelly'  et  al,  1997). 
An  initial  report,  on  DNA  vaccination  against  human  influenza  virus  in  mice,  showed 
that  intramuscular  injection  of  plasmid  encoding  nucleoprotein  (NP)  generated  NP 
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specific  CTLs  and  protection  against  lethal  heterologous  challenge  (Ulmer  et  al, 
1993).  These  results  were  confirmed  and  expanded  to  demonstrate  that  plasmid 
encoding  haernagglutinin  (HA)  promoted  high  titres  of  anti-HA  antibodies  that 
protected  mice  from  lethal  homologous  challenge  (Montgomery  et  al,  1993). 
Subsequently  Donnelly  et  al  (1995)  have  carried  out  similar  experiments  in  ferrets 
with  comparable  results.  Because  ferrets  can  be  naturally  infected  by  human 
influenza,  they  exhibit  a  analogous  pattern  of  pathogenesis  that  includes  viral 
shedding.  In  this  study  HA  DNA  vaccinated  ferrets  presented  significantly  reduced 
shedding  following  homologous  challenge,  when  compared  to  control  animals.  In  the 
same  study,  the  authors  used  non-human  primates  to  compare  the  efficacy  of  DNA 
vaccines  to  that  of  current  vaccines  licensed  for  human  use.  They  found  that  the 
injection  of  as  little  as  10ýLg  of  HA  encoding  plasmid  induced  titres  of 
haemagglutination  inhibition  equal  or  higher  than  those  produced  by  a  full  dose  of 
human  vaccine. 
In  summary,  DNA  vaccination  with  influenza  HA  and  NP  genes  generates  high  titres 
of  virus  neutralising  antibodies  (as  assessed  by  haemagglutination  inhibition)  that 
protect  from  homologous  challenge  (with  reduction  of  clinical  signs  and  virus 
shedding)  as  well  as  specific  cell  mediated  responses  (capable  of  lysing  target  cells 
infected  with  influenza  virus)  protective  against  heterologous  challenge  in  both  mice 
and  ferrets,  constituting  a  viable  alternative  for  current  human  vaccines,  as  determined 
for  non-human  primates.  If  these  results  can  be  verified  in  natural  hosts  of  influenza 
(e.  g.  human,  horse)  they  will  dictate  a  revolution  in  the  vaccination  against  these 
viruses,  for  two  main  reasons.  Firstly  the  efficient  homologous  protection  conferred 
by  vaccination  with  the  HA  gene,  together  with  the  ease  of  production  and 
standardisation  of  these  vaccines,  means  that  influenza  vaccines  can  be  quickly  and 
inexpensively  updated.  Secondly,  the  cross-strain  protection  obtained  by  vaccination 
with  the  NP  gene  will  reduce  the  need  for  constant  vaccine  update. 
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6.1.3  DNA  vaccination  of  horses  against  influenza  virus 
In  the  light  of  findings,  chiefly  in  mice  but  also  in  other  species,  that  plasmid  DNA 
innoculation  of  antigens  is  an  efficient  way  of  protecting  hosts  from  influenza  virus 
challenge,  its  reasonable  to  assume  that  this  technology  will  also  be  applicable  to 
horses.  Results  by  Donnelly  et  al  (1995)  and  others,  suggest  that  the  HA  and  NP 
antigens  are  useful  in  the  immunisation  against  influenza  virus  and  these  were  chosen 
to  serve  as  immunogens  in  an  equine  influenza  model  of  DNA  vaccination.  In 
addition,  the  cloning  of  a  variety  of  equine  cytokines,  particularly  those  involved  in 
Thl  responses  (chapters  3  and  4),  has  facilitated  their  inclusion  in  the  vaccine  trial, 
ensuing  reports  that  these  molecules,  when  co-administrated  with  plasmid  encoding 
antigen,  can  significantly  increase  cell  mediated  immunity  without  affecting  humoral 
responses  to  soluble  antigens  (reviewed  in  chapter  1). 
Below  is  a  description  of  a  feasibility  study  for  the  DNA  vaccination  of  horses  against 
influenza  virus,  where  the  efficacy  of  these  vaccines  is  compared  to  that  of  a  classical 
vaccine,  composed  of  whole  inactivated  virus  strains.  The  optimisation  of  factors  such 
as  route  of  inoculation,  co-administration  of  different  combinations  of  cytokines  and 
use  of  adjuvant  vehicles  is  pondered. 
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6.2  Materials  and  Methods 
The  present  vaccine  trial  was  a  collaborative  study  between  the  Department  of 
Veterinary  Pathology  (Glasgow,  UK),  Intervet  Virology  R&D  (Boxmeer, 
Netherlands)  and  Intervet  Magyar  (Budapest,  Hungary).  The  responsibility  of  the 
Department  of  Veterinary  Pathology  in  this  study  was  the  production  of  the  plasmid 
DNA  constructs  used  for  inoculation  and  evaluation  of  the  authenticity  of  the  genes 
inserted.  This  fact  is  reflected  in  the  description  of  the  methods.  An  account  of  the 
methods  performed  elsewhere  was  distributed  in  memorandums  by  Intervet 
International  and  is  summarised  below,  and  the  names  of  those  involved 
acknowledged,  when  known. 
6.2.1  DNA  constructs 
The  DNA  constructs  used  for  vaccination  purposes  were  based  on  the  pCI-neo 
expression  vector  (Promega)  by  insertion  of  the  coding  sequences  of  the  equine 
cytokines  IFN-y  (as  described  in  chapter  3),  IL-12  and  IL-18  (chapter  4)  and  of  the 
influenza  antigens  HA  and  NP  derived  from  the  isolate  A/equine/Newmarket/2/93  of 
the  H3N8  subtype  (chapter  5).  The  pCI-neo  plasmid  features  include  a 
cytomegalovirus  immediate  early  (CMV-IE)  enhancer/promoter  with  a  chimeric 
intron  that  drives  expression  of  the  inserted  genes,  a  SV40  late  polyadenylation  signal 
sequence  for  mRNA  processing,  a  fl  origin  of  replication  and  an  ampicillin  resistance 
gene  for  replication  and  selection  in  E.  coli. 
After  production,  the  constructs  were  sequenced  for  verification  of  integrity  of  the 
genes  inserted  and  tested  for  the  ability  to  express  the  encoded  proteins  by  transient 
transfection  of  appropriate  cell  lines.  Investigation  of  biological  activity  (where 
applicable)  of  the  expressed  products  was  also  attempted.  At  the  time  of  the  vaccine 
trial,  the  status  of  the  DNA  constructs  in  these  regards  is  presented  in  table  6.1. 
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Table  6.1  Venification  procedures  of  DNA  constructs. 
Procedure 
Detection  f  expression 
Construct  Sequencing  RNA  Protein  Bioassay 
pCI-neo  n.  a.  n.  a.  n.  a.  n.  a. 
pCI-IFN-y  +  +  + 
pCI-IL  12  +  +  n.  d.  n.  d. 
pCI-IL  18  +  +  +  n.  d. 
pCI-HA  +  +  +  n.  a. 
pCI-NP  +-  +  +  n.  a. 
Notes:  n.  a.  -  not  applicable;  n.  d.  -  not  done.  Detection  of  RNA  expression  was  done  by 
northern  blot.  Detection  of  protein  expression  was  done  by  western  blot  in  the  case  of  IFN-7 
and  IL-  18  and  by  indirect  immunofluorescence  of  transfected  cells  for  HA  and  NP  (Intervet, 
Boxmeer).  For  details  on  results  refer  to  individual  chapters. 
6.2.2  Trial  design 
In  the  experimental  design,  conditions  such  as  the  vaccination  schedule,  inoculation 
dose,  and  route  were  based  on  parameters  used  for  similar  studies  in  other  animal 
species  (reviewed  in  6.1).  Thirty  horses  (see  6.2.4)  were  randomised  and  assigned  to 
eight  vaccination  groups  of  3  to  4  horses  each.  Assignment  of  horses  to  groups  and 
respective  vaccines  are  shown  in  table  6.2  and  a  diagram  of  the  trial  is  displayed  in 
figure  6.3. 
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Figure  6.3  Schematic  of  vaccine  tnal  showing  vaccination,  challenge  and 
sampling  timings. 
Six  group-  received  DNA  vaccinations  consisting  of  plasmid  encoding  HA  and  NP, 
co-administered  or  not  with  plasmids  encoding  different  cytokines.  Animals  were 
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vaccinated  three  times  at  t=0,8  and  12  weeks.  A  group  of  4  animals  was  inoculated, 
at  the  same  times,  with  plasmid  lacking  a  coding  region  (empty  plasmid)  to  serve  as 
negative  control.  A  further  group  of  4  animals  received  a  classical  subunit  vaccine  at 
times  t=8  and  12  weeks.  The  vaccines  (refer  to  6.2.3  for  formulations)  were 
inoculated  in  Iml  volumes  by  one  of  the  following  routes  (table  6.2),  intradermally 
OA)  at  five  different  spots  (5  X  200gl),  by  means  of  a  needless  intradermal  injector 
(IDAL,  Intervet)  or  intramuscularly  (i.  m.  )  by  injection  using  a  2ml  syringe  with  green 
needle  (21  gauge). 
Table  6.2  Experimental  groups  and  respective  vaccine  tests. 
Group  no  No.  of  horses 
__(assigned 
no.  ) 
Vaccine  Vehicle  Route 
(a) 
Dose 
(b) 
1  4  (18,21,26,30)  HA+NP  PBS  i-d-  2xlOOgg 
2  3(2,22,28)  HA+NP  Diluvac  Forte  i-d- 
- 
2xlOOgg 
3  4  (12,15,23,24)  HA+NP+EFNy  PBS  i-d-  3xlOOgg 
4  3(9,11,16)  HA+NP+EFNy  PBS  I.  M.  3xlOOgg 
5  4  (5,14,27,29)  HA+NP+IL18  PBS  i-d-  3xlOOgg 
6  4  (8,10,13,20)  HA+NP+IL12+IL18  PBS  i.  d.  4xlOOgg 
7  4  (1,4,17,19)  empty  plasmid  PBS  i.  d.  500gg 
8 
I 
4  (3,6,7,25)  classical  vaccine 
I 
Buffer  + 
QuilA  I 
i.  m. 
I 
(a)  intradermal.  (i.  d.  )  or  intramuscular  (i.  m.  ).  (b)  in  a  total  volume  of  I  ml  per  dose. 
All  animals  were  challenged,  at  t  =16  weeks,  with  a  homologous  influenza  virus  strain 
(A/equine  Newmarket/2/93).  The  contents  of  one  vial  of  freeze-dried  virus  (refer  to 
6.2.3)  was  resuspended  in  5ml  of  ice  cold  PBS  and  transferred  to  a  disposable 
chamber  in  the  ultrasonic  nebuliser  (Ultra-Neb  2000,  Devilbis).  The  virus  was  then 
applied  to  the  horses  by  nebulisation  using  a  head  hood. 
6.2.3  Inoculates 
DNA  VACCINES 
Following  characterisation,  all  constructs  were  propagated  in  the  E.  coU  DH5a  strain 
and  prepared  by  plasmid  DNA  large  scale  purification  procedures  and  in  all  cases 
endotoxin  levels  were  found  to  be  inferior  to  20  EU/100ýtg  of  DNA  (performed  by  Dr. 
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P.  Sondermeijer,  Intervet,  Boxmeer).  The  vaccine  preparations  were  re-sequenced.  to 
rule  out  the  occurrence  of  mutations  during  the  replication  process.  Different  vaccine 
preparations  (table  6.2)  were  produced  by  combination  of  appropriate  plasmid  DNAS 
(100lig  each)  and  dilution  to  a  total  volume  of  Iml,  per  dose,  in  endotoxin-free  PBS 
or  Diluvac  Forte  and  stored  at  -20"C.  Diluvac  Forte  is  an  adjuvant  formulation  based 
on  tocopherol  acetate  patented  by  Intervet  (see  below). 
CLASSICAL  VACCINE 
The  vaccine  (produced  by  Dr.  H.  Powels  et  al,  at  Intervet,  Boxmeer)  comprised 
inactivated  viral  subunits  adjuvanted  by  Quil  A.  The  viral  strains  A/equine/Prague/56, 
Newmarket/l/93  and  Newmarket/2/93,  with  a  HA  content  of  928,1000  and  1000 
antigenic  units,  respectively  (as  assessed  by  standard  antigen  ELISA)  were  added  to 
125pg  of  Quil  A  and  diluted  to  a  total  volume  of  I  ml,  per  dose,  in  Nobi-Equenza 
vaccine  buffer  (Intervet  patented  formulation)  and  stored  at  4*C. 
CHALLENGE  MATERIAL 
The  challenge  virus  (A/equine/Newmarket/2/93)  was  propagated  by  repeated  passage 
in  specific  pathogen  free  (SPF)  embryonated  chicken  eggs  to  an  infectivity  titre  of  106 
to  106.  '  EID50/ml  (as  assessed  by  haemagglutination  of  chicken  red  blood  cells, 
CRBQ.  Vials  containing  Iml  of  virus  suspension  were  freeze-dried  and  stored  until 
used  at  -20'C  (  Dr.  E.  Verblakt  et  al,  Intervet,  Boxmeer). 
6.2.4  Animal  husbandry  and  veterinary  control 
Thirty  warm-blooded,  Hungarian  half-bred  horses  (27  males  and  3  females)  with  ages 
ranging  9-13  months,  were  purchased.  Before  purchase,  the  horses  were  found  to  be 
seronegative  to  influenza  virus  in  two  to  three  successive  screenings.  On  arrival  the 
animals  were  numbered  (I  to  30)  and  identified  (by  numbered  tags),  randomised 
(using  "Random  Generatoe'  computer  software),  assigned  to  vaccination  groups  and 
housed  in  a  designated  stable  (at  the  Budapest  School  of  Veterinary  Medicine, 
Hunga.  ryjl.  The  diet  consisted  of  meadow  hay  ad  libitum,  oat  (2-3  kg  daily),  carrots 
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(0.5-1  kg  daily,  if  available)  and  tap  water  ad  libitum.  Before  the  trial  the  animals 
were  acclimatised  for  a  period  of  two  weeks. 
The  horses  were  subject  to  a  daily  clinical  examination  to  assess  general  state  of 
health.  From  two  days  before  and  until  five  days  after  vaccine  applications,  horses 
were  submitted  to  a  thorough  veterinary  inspection  including  detection  of  body 
temperature,  inappetancc,  loss  of  appetite,  abnormal  behaviour,  sickness,  malaise  and 
other  abnormal  signs.  From  the  day  of  vaccination  and  for  five  days,  local  reactions 
were  scored  by  size  (cms)  and  by  palpation  (cold/warm,  painful/not  painful, 
hard/soft).  Also  from  two  days  before  and  up  to  seven  days  after  challenge  animals 
were  examined  for  evidence  of  abnormal  behaviour,  inappetance,  sickness,  malaise, 
coughing,  nasal  discharge  and  dyspnoea.  Animal  handling  and  veterinary 
examinations  were  performed  by  Dr.  J.  Foldi  et  al  (Intervet  Magyar). 
6.2.5  Sampling  and  analyses 
SAMPLING 
Blood  samples  for  serology  were  taken  at  t=0,4,8,12,16,17,18  and  20  weeks. 
Blood  (10  ml)  was  collected  from  the  jugular  vein  into  gel-filled,  vacuum-sealed, 
plastic  tubes  and  the  tubes  were  labelled  with  the  date  and  respective  animal  number. 
The  blood  was  left  to  clot  for  four  hours  at  room  temperature  (or  overnight  at  4"C), 
the  tubes  centrifuged  for  10  min.  at  1500  xg  to  pellet  cells  and  despatched  to  Intervet 
(Boxmeer)  as  soon  as  possible  at  4C.  Alternatively,  when  more  convenient,  following 
centriffigation,  serum  was  transferred  to  polypropylene  tubes  (cryotubes),  which  were 
labelled  and  stored  at  -20*C  until  transport. 
Swabs  for  virus  isolation  were  collected  from  day  1  up  to  day  7  post-challenge.  A 
separate  swab  was  used  for  each  nostril  and  transferred  to  cryotubes  containing  1.5  ml 
of  2.5%  tryptose  and  antibiotics  (1000  IU/ml  of  penicillin  and  100011g/ml  of 
streptomycin).  Tubes  were  stored  at  -70'C  before  transport  to  Boxmeer. 
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ANALYSES 
All  analysis  were  performed  by  Dr.  H.  Pouwcls  et  A  at  Intcrvet  virology  R&D 
(Boxmcer)  and  the  protocols  presented  summarised  from  Intervct's  standard  operating 
procedures. 
Serology  was  mainly  performed  by  titration  of  serum  by  haernagglutination  inhibition 
against  four  HA  antigenic  units  of  the  strain  A/equine/Newmarket/2/93.  In  summary, 
serum  samples  are  pre-treated  in  kaolin,  mixed  with  a  5%  CRBC  suspension  and 
incubated  at  37C  for  I  hour.  Tween/ether  treated  equine  influenza  antigens  are  diluted 
to  4  haernagglutinin  units  and  added  to  the  first  row  of  a  microtitre  plate  (v-shaped 
wells).  The  haernagglutinin  is  diluted  in  twofold  increments  and  the  pre-treated 
serum-CRBC  mixture  added  to  the  plate.  Following  1  hour  incubation  at  room 
temperature  the  plates  are  scored  by  naked  eye  inspection  for  the  presence  of 
agglutination  in  individual  wells.  The  assay  is  performed  in  triplicate  and  the  quantity 
of  haernagglutination  inhibiting  (HI)  antibodies,  named  HI  titre,  is  expressed  as  -log2 
of  the  sample  dilution.  For  samples  collected  at  t=  16  weeks,  two  additional 
serological  procedures  were  employed.  The  first  was  a  blocking-antibody-ELISA, 
using  a  mAb  raised  against  the  haernagglutination  inducing  site  of  the  HA  protein  of 
strain  A/equine/Newmarket/2/93  and  the  second,  an  indirect  immunofluorescence 
assay  on  Madin  Darby  bovine  kidney  (MDCK)  cells  infected  with 
A/equine/Newmarket/2/93. 
Virus  in  swabs  was  detected  and  titrated  in  9-11  day  old  embryonated  SPF  chicken 
eggs.  In  short,  five  eggs  were  used  per  each  of  5  tenfold  dilutions  of  the  swabs.  Eggs 
were  inoculated,  in  the  allantoic  cavity,  with  200gl  of  corresponding  swab  dilution 
and  incubated  at  37'C  in  a  humidified  egg  incubator  for  72  hours.  Embryo  death  in 
the  first  24  hours  was  considered  unspecific  and  the  eggs  discarded.  After  incubation, 
allantoic  fluid  was  harvested  from  each  egg  and  added  to  an  equal  amount  of  5% 
CRBC  for  detection  of  haemagglutination  and  calculation  of  virus  titre.  The  titre  is 
given  in  egg  infectious  dose  (EID,  dml)  using  the  formula: 
Titre  =  10'  x1  0('-")(-c)  EIDdO.  2  ml, 
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where  A=  first  dilution  at  which  more  than  50%  of  the  eggs  is  positive;  B= 
percentage  of  positive  eggs  above  50%;  C=  percentage  of  positive  eggs  bellow  50%. 
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6.3  Results 
CLIMCAL  SIGNS 
Veterinary  observation  of  the  animals  during  the  period  of  trial  did  not  detect  any 
abnormalities  in  clinical  signs  that  could  be  correlated  with  both  the  vaccinations  and 
the  challenge. 
SEROLOGY 
Serological  responses  were  monitored  by  haemagglutination  inhibition  (HI)  of  the 
trial  horses  and  the  results  are  given  in  antibody  log2  titre.  Treatment  of  the  data 
revealed  that,  in  general,  the  DNA  vaccinated  groups  had  a  poor  response  to 
inoculation,  in  terms  of  neutralising  antibody  production.  This  was  confirmed  both  by 
the  higher  antibody  levels,  pre-challenge,  presented  by  the  group  vaccinated  with 
inactivated  virus  (group  8)  and  by  the  fact  that,  following  challenge,  all  groups  had  a 
significant  rise  in  the  average  titres  of  antibodies  (table  6.3,  figures  6.4  and  6.5) 
presumably  triggered  by  the  challenge  virus.  It  was  also  found  that  the  administration 
of  vaccine  by  an  alternative  route  (i.  m.,  group  4)  or  the  use  of  a  classical  adjuvant 
(Diluvac  Forte,  group  2)  did  not  affect  the  antibody  production  when  compared  with 
groups  3  and  1,  respectively. 
However,  analysis  of  the  results  in  individual  animals  revealed  that  trial  horses  can  be 
divided  into  three  groups:  responsive  to  vaccination,  non-responders  and  responders 
to  challenge,  the  basis  of  the  division  being  the  time  (in  weeks)  at  which  a  clear 
elevation  in  antibody  titres  is  observed  (table  6.3)  and  assuming  that  all  trial  horses 
were  equally  exposed  to  the  challenge  virus.  Horses  responsive  to  vaccination  (with 
an  elevation  of  titre  before  challenge)  are  all  animals  vaccinated  with  classical  vaccine 
(group  8)  and  numbers  18,23  and  16  respectively  from  groups  1,3  and  4.  Non- 
responsive  horses  (with  no  significant  elevation  of  antibody  titres  and  specified  by  an 
arrow  in  table  6.3)  are  present  in  all  groups  except  group  8.  Late  responders  (with 
titres  raising  only  after  challenge)  are  also  evenly  distributed  between  the  groups 
including  the  oric  that  served  as  negative  control  (group  7). 
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Also,  horses  numbers  18,23  and  16,  respectively  from  groups  1,3  and  4,  had  HI-titres 
pre-challenge  that  not  only  were  higher  than  the  average  of  the  respective  group  but 
were  also  in  line  with  average  titre  of  the  group  vaccinated  with  classical  vaccine. 
Additionally,  the  antibody  titre  of  animals  18  and  23  was  not  increased  following 
challenge  (figure  6.6). 
Results  obtained  by  alternative  serological  procedures  on  week  16  (table  6.4)  revealed 
that  group  3,  had  on  average  antibody  titres  (as  assessed  by  ELISA)  superior  to  the 
rest  of  the  groups,  although  still  inferior  to  the  values  observed  in  animals  receiving 
inactivated  vaccine.  Individual  analysis  of  the  ELISA  results  were  even  more 
encouraging,  showing  that  horses  18  (of  group  1),  23  (of  group  3),  16  (of  group  4)  5 
(of  group  5)  and  13  (of  group  6)  had  antibody  titres  in  line  with  those  of  the  group 
vaccinated  with  classical  vaccine,  whereas  animals  in  the  control  group  had  negligible 
antibody  titres.  Indirect  immunofluorescence  showed  that  all  horses  of  group  3,  as 
well  as  the  above  cited  animals  in  the  other  groups  had  positive  serum  as  did  the  ones 
in  the  positive  control  group  (group  8).  Once  again  all  sera  from  the  negative  control 
group  were  negative  to  immunofluorescence. 
VIRUS  ISOLATION 
Virus  isolation  from  swabs  collected  post-challenge  was  largely  negative  (results  not 
shown).  Most  importantly,  in  the  unvaccinated  group  only  2  of  4  animals  were  virus 
isolation  positive  with  the  maximum  virus  titre  obtained  being  10"  EID/ml,  for  horse 
17,  at  day  3  post-challenge. 
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is  highlighted. 
L,  og2  titre  against  A/equine/Newmarket/2/93 
Group  Vaccine  Animal  '  TO  I  T4  TS  I  T12  T16  T17  T18  T20 
30  3  3  3  3  4  3  3  3 
HA+NP  18  3  3  3  3  5  5  5  4 
1  21  3  3  3  3  3  4  4  4 
26  3  3  3  3  3  5  7  7 
average  3.0  3.0  3.0  3.0  3.8  4.3  4.8  4.5 
2  3  3  4  3  3  3  9  8 
2  HA+NP  22  3  3  3  3  3  3  3  9 
(Diluvac  Forte)  28  3  3  3  3  3  3  3  8 
average  3.0  3.0  3.3  1  3.0  3.0  3.0  5.0  1  8.3 
12  3  3  3  3  4  4  5  8 
15  3  3  3  3  3  5  7  8 
3  HA+NP+IFNY  23  3  3  3  5  7  7  6  6 
24  3  3  3  3  3  4  4  5 
average  3.0  3.0  3.0  3.5  4.3  5.0  1  5.5  6.0 
9  3  3  3  3  3  4  8  7 
4  HA+NP+IFNy  11  3  3  3  3  3  3  4  d 
(intramuscular)  16  3  3  3  3  6  6  9  9 
average  3.0  3.0  3.0  3.0  4.0  4.3  7.0  8.0 
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48  12  16  17  18  20 
Week  c Table  6.4  Comparative  serology  at  t=  16  weeks. 
Serological  procedures 
Group  Vaccine  Animal  HI  assay  ELISA  Immunofluor. 
(log2  titre)  (log2  titre)  (115  serum  dilution) 
30  4  <  1.6 
HA+NP  18  5  6.3  +/- 
1  21  3  4.7  +/- 
26  3  <  1.6  - 
2  3  <  1.6  - 
2  HA+NP  22  3  <  1.6  - 
(Diluvac  Forte)  28  3  <  1.6  - 
12  4  4.7  + 
15  3  4.7  + 
3  HA+NP+IFNy  23  7  9.5  + 
24  3  4.7  +/- 
9  3  <  1.6 
4  HA+NP+IFNy  11  3  <  1.6 
(Intramuscular)  16  6  6.3  +/- 
5  4  6.3  + 
14  3  <  1.6 
5  HA+NP+IL18  27  3  <  1.6 
29  3  <  1.6 
8  3  3.1  + 
10  3  3.1 
6  HA+NP+IL]2+IL18  13  3  6.3 
20  3  <  1.6 
4  3  _  <  1.6 
17  3  <  1.6 
7  empty  vector  19  3  <  1.6 
1  3  <  1.6 
3  7  11.1  + 
6  6  9.5  + 
8  classical  vaccine  7  7  9.5  + 
1  1  25  1  7  6.3  1  + DNA  raccination 
6.4  Discussion 
The  poor  pre-challenge  production  of  antibodies  in  the  great  majority  of  horses  in 
response  to  DNA  vaccination  and  the  higher  HI  antibody  titres  present  after 
challenge,  suggests  that  the  level  of  immunity  produced  was  not  sufficient  to 
completely  prevent  challenge  virus  replication.  In  contrast,  vaccination  of  horses  16, 
18  and  23  induced  levels  of  antibodies  before  challenge,  similar  to  those  of  the  group 
vaccinated  with  classical  vaccine.  Additionally,  and  only  in  the  case  of  horses  18  and 
23,  the  titres  remained  constant  following  homologous  challenge. 
However  the  challenge  virus  failed  to  promote  infection,  as  assessed  both  by  the 
observation  of  clinical  signs  and  by  virus  isolation  from  nasal  secretions.  This  could 
be  due  to  the  immune  status  of  the  trial  horses,  improper  dosing  or  alteration  of  the 
challenge  inoculum.  after  assessment  of  infectivity. 
Consequently,  the  antibody  titres  pre  and  post-challenge  could  not  be  correlated  with 
protection,  or  lack  of  it.  Nevertheless,  it  has  been  reported  that  the  elicitation  of  high 
HI  titres  following  DNA  vaccination  against  influenza  is  not  an  absolute  requirement 
for  protection  to  challenge  (Fynan  et  al,  1993)  and  that  the  efficient  priming  of  both  B 
and  Th  cell  memory  by  DNA  vaccination  is  the  underlying  mechanism  of  protection. 
It  is  therefore  particularly  unfortunate  that  the  challenge  failed  in  this  trial,  as 
protection  against  challenge  was  the  indicator  for  the  development  of  protective 
immunity  following  vaccination. 
The  fact  that  only  horses  16,18  and  23  developed  pre-challenge  antibody  titre 
comparable  to  that  of  animals  receiving  classical  vaccine  might  be  related  to  low 
efficiency  of  DNA  transfer  by  the  system  used.  Additionally,  the  use  of  the  adjuvant 
Diluvac  Forte  (group  2),  that  nonspecifically  boosts  immune  responses,  and  the  use  of 
intramuscular  injection  (group  4)  as  an  alternative  route  (reportedly  more  efficient  in 
the  transfection  of  DNA  in  vivo)  did  not  have  an  effect  in  the  immune  response  to  the 
vaccines  when  compared  to  results  of  groups  I  and  3,  respectively.  Therefore,  the  use 
of  a  more  reliable  means  of  DNA  transfer  (e.  g.  gene  gun)  would  verify  if  the 
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responses  observed  in  horses  16,18  and  23  are  due  to  casual  increased  DNA  uptake 
or  simply  reflect  an  increased  immune  responsiveness  of  these  horses. 
The  choice  of  cytokines  co-delivered  (IFN-y,  IL-12  and  IL-18)  was  intended  to  shift 
the  immune  response  to  a  Thl  setting.  Thl  responses  not  only  promote  cell  mediated 
immunity  but  also  skew  antibody  production,  disfavoring  neutralising  antibodies.  The 
latter  is  suggested  by  results  obtained  for  group  3,  where  IFN-y  was  co-administered 
and  also  for  animals  5  and  8  (receiving  IL-18  and  IL-12  +  IL-18  co-administration, 
respectively).  The  serum  of  all  these  animals  was  able  to  significantly  bind  antigen 
both  in  ELISA  and  expressed  by  infected  MDCK  cells,  despite  the  poor  inhibition  of 
haernagglutination,  suggesting  that  at  least  some  of  the  specific  antibodies  produced 
were  not  neutralising.  In  this  context,  it  would  be  interesting  to  subtype  the  IgG 
response  in  the  animals  of  group  3  and  compare  it  to  that  of  groups  I  and  8, 
investigating  if  there  was  a  shift  towards  the  equine  equivalent  of  murine  IgG2a 
subisotype.  This  would  be  in  line  with  the  observation  that  natural  infection  in  horses 
gives  rise  to  serum  IgGa  and  IgGb  protective  responses  (that  mediate  complement 
activation  and  ADCC  in  the  horse)  whereas  conventional  vaccination  serum  responses 
are  restricted  to  IgG(T)  (Nelson  at  al,  1998). 
The  hypothesis  that  these  cytokines  had  operated  a  transformation  in  the  type  of 
immune  response  would  be  confirmed  if  horses  of  group  3,5  and  6  were  found  to 
have  increased  CTL  responses  in  comparison  to  those  of  group  I  (receiving  the  same 
vaccine  without  cytokines)  and  especially  to  those  receiving  classical  vaccine  (group 
8)  known  to  induce  mostly  humoral  responses.  Unfortunately  the  elicitation  of  cell 
mediated  responses  was  not  investigated  and  therefore  this  conjecture  remains 
unconfirmed. 
In  summary,  the  results  obtained,  particularly  for  horses  in  group  3,  suggest  that  there 
is  some  promise  that  co-administration  of  plasmids  encoding  HA,  NP  and  Thl 
cytokines  would  result  in  protection  against  influenza  virus  infection.  If  the  trial  is  to 
be  repeated,  the  following  considerations  should  be  addressed.  Limiting  the  number 
of  experimental  groups  and  increasing  the  number  of  animals  per  group  would  result 
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in  an  increased  statistical  relevance  of  the  results.  The  use  of  a  more  reliable  method 
of  delivery  (e.  g.  gene  gun)  would  address  plasmid  DNA  transfer  efficiency.  The 
optimisation  of  the  challenge  material  would  allow  proper  assessment  of  protection 
and  its  correlation  with  antibody  titres.  The  detection  and  measurement  of  CTL 
activity  or  at  the  very  least,  the  isolation  of  T  cells  and  investigation  of  their  ability  to 
proliferate  in  the  presence  of  viral  antigens,  would  facilitate  the  dissection  of  cytokine 
activity  and  protection  mechanisms.  Finally,  the  challenge  of  vaccinated  animals  with 
an  heterologous  influenza  virus  strain  would  assess  the  potential  of  cross  protection 
attributed  to  these  vaccines. 
On  a  study  published  after  completion  of  the  present  trial,  Lunn  et  al  (1999)  report 
that  DNA  vaccination  of  ponies  with  the  equine  influenza  hemagglutinin  gene 
resulted  in  partial  to  complete  protection  from  homologous  challenge  infection,  which 
was  accompanied  by  a  reduction  in  challenge  virus  shedding.  Additionally,  serology 
of  responsive  horses  showed  a  marked  increase  in  antibodies  of  the  IgGa  and  IgGb 
isotypes  with  no  detectable  IgG(T)  responses.  The  authors  conclude  that  "DNA 
vaccination  has  the  potential  to  protect  horses  against  influenza  virus  infection". 
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7.1  Introduction 
This  project  had  two  main  objectives.  Firstly,  the  recombinant  expression  of  equine 
interferon  gamma  and  the  development  of  biological  assays  suitable  for  the  evaluation 
of  equine  interferon  gamma  activity  in  vitro.  These  objectives  were  largely  attained 
with  successful  expression  of  equine  interferon  gamma  in  a  variety  of  heterologous 
systems  (E.  coli,  insect  and  mammalian  cells),  the  production  and  characterisation  of 
antibodies  elicited  against  the  recombinant  protein  and  evidence  for  activity  of  the 
expressed  protein  in  a  diversity  of  assays  based  on  well  characterised  cellular 
responses  to  interferon  gamma  exposure  (chapter  3).  The  second  objective  was  to 
clone  additional  equine  Thl  type  cytokines,  i.  e.,  interleukin-12  and  interleukin-18 
(chapter  4)  and  use  them  in  a  naked  DNA  vaccination  trial  against  equine  influenza 
virus  (chapter  6),  by  co-administration  with  the  cloned  viral  genes  haemagglutinin  and 
nucleoprotein  (chapter  5).  These  experiments  were  devised  not  only  to  assess  the 
feasibility  of  delivering  equine  cytokine  genes  in  vivo  but  also  to  investigate  the 
potential  of  the  cloned  genes  to  be  used  as  modulators  of  immune  responses  to 
vaccination.  Equine  interleukins  12  and  18,  as  well  as  the  nucleoprotein  and 
haemagglutinin  genes  of  equine  influenza  virus,  were  successfully  cloned. 
Additionally  expression  of  the  cloned  viral  genes  was  demonstrated  by  transient 
plasmid  transfection  of  mammalian  cells.  The  results  of  the  vaccination  trial  were 
mostly  inconclusive,  due  to  failure  of  the  challenge  and  to  the  inadequacy  of  the 
process  used  for  validation  of  the  immune  responses  to  vaccination.  Nevertheless,  the 
implementation  of  the  trial  made  available  considerable  expertise,  in  the  group,  for  the 
development  and  use  of  constructs  for  DNA  immunisation.  In  addition,  the  data 
generated  will  be  invaluable  for  future  optimisation  of  trial  specifications  and  efficacy 
assessment. 
In  summary  the  present  project  has  provided  several  equine  specific  cytokine 
reagents,  the  development  of  a  number  of  molecular  and  cell  biology  techniques  and  a 
model  for  the  eliýitation  of  virus  specific  immune  responses  in  the  horse.  These  tools 
will  be  useful  in  the  study  of  the  equine  immune  system  as  a  whole  and  of  the 
response  to  intracellular  pathogens  in  particular.  The  applicability  of  these  and  other 
cytokine  reagents  is  discussed  below. 
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7.2  Cytokines  in  equine  immunology 
The  use  of  non  species  specific  cytokine  reagents  in  veterinary  medicine  is  often  met 
with  limited  success,  due  to  the  low  interspecies  homology  which  translates  as  a  lack 
of  cross  reactivity  of  these  molecules  between  species.  The  cloning  and  expression  of 
equine  cytokine  genes  and  downstream  production  of  reagents  will  therefore  be 
extremely  useful  to  dissect  equine  immune  responses  in  health  and  disease  and  to 
understand  how  cytokines  influence  such  processes.  Examples  of  reagents  commonly 
used  in  cytokine  research  are  cDNAs  used  for  the  production  of  primers  and  probes 
for  mRNA  quantitation  by  northern  blot  or  real  time  PCR,  polyclonal  and  monoclonal 
antibodies  for  the  quantitation  of  protein  by  western  blot  or  flow  cytometry  and 
responsive  cell  lines  for  the  implementation  of  bioassays  that  measure  biological 
potency. 
The  study  of  cytokine  expression  patterns  and  their  functions  is  paramount  to  our 
understanding  of  the  proper  function  of  a  healthy  immune  system  and  the  basis  for 
any  attempt  to  influence  disease  onset  and  progression.  From  an  evolutionary 
perspective  it  makes  sense  to  predict  that  immunological  effector  and  regulatory 
mechanisms  established  for  one  species  are  likely  to  be  found  in  other  species.  In  the 
case  of  equine  medicine,  studies  performed  in  other  ungulates  and  even  primates  are, 
in  principle,  more  relevant  than  studies  derived  from  more  distant  species,  like 
rodents.  Nevertheless,  it  is  necessary  to  verify,  rather  than  assume,  the  validity  of  key 
immunological  concepts  on  an  individual  species  basis. 
Very  little  is  known  about  the  involvement  of  cytokines  in  equine  immune  responses 
apart  from  the  well  characterised  influence  of  TNF-a,  IL-1  and  IL-6  in  the 
pathogenisis  of  equine  septic  shock  (Hannant  D,  1998).  The  emergence  of  equine 
cytokine  reagents  will  help  elucidate  questions  that  remain  unanswered  but  for  which 
there  is  seminal  evidence.  Is  there  a  Thl/Th2  dichotomy  in  equine  immune  responses 
and  is  it  possible  to  polarise  equine  T  cell  clones  in  vitro  to  one  or  the  other 
phenotype?  There  is  some  evidence  that  vaccination  of  ponies  against  the  metazoan 
parasite  Strongylus  vulgaris  has  different  outcomes  following  challenge,  depending 
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on  the  form  and  route  of  administration.  While  animals  vaccinated  by  oral 
administration  of  radiation-attenuated  S.  vulgaris  larvae  were  protected  from  challenge 
infection  and  displayed  eosinophilia,  characteristic  of  Th2  responses,  parenteral 
administration  of  purified  S.  vulgaris  antigens  induced  post  challenge  exacerbation  of 
clinical  signs  with  no  detectable  eosinophilia  (Monahan  et  al,  1994).  Additionally,  as 
mentioned  before,  recovery  from  equine  influenza  infection  is  associated  with  the 
elicitation  of  complement  fixing  antibodies  and  cell  mediated  immune  responses  to 
viral  antigens  in  vitro  (Hannant  and  Mumford,  1989),  which  is  consistent  with  a  Th 
type  I  response.  Are  cytokines  responsible  for  isotype  class  switching  in  antibody 
production  in  the  horse?  The  fact  that  horses  produce  different  isotypes  of  antibodies 
against  influenza  virus  following  vaccination  or  infection  is  an  indication  that  the 
equine  immune  system  is  able  to  direct  class  switching.  Whether  this  phenomenon  is 
influenced  by  cytokines  remains  to  be  proven.  We  can  now  also  begin  to  address  other 
questions.  Are  equine  cytokines  involved  in  T  cell  regulatory  mechanisms?  Are  there 
any  pathologies  of  the  horse  associated  with  an  incorrect  bias  in  the  T  helper,  T 
suppressor  and/or  B  cell  repertoires? 
7.3  Equine  cytokines  for  diagnosis  and  therapy 
Cytokine  production  is  in  most  cases  a  short-lived  event,  reflecting  the  activation 
status  of  the  producing  cell  in  response  to  microenvironmental  stimuli  triggered  by 
immune  aggression.  Cytokines  tend  to  have  a  short  radius  of  action  and  are  active  in 
minute  amounts  on  the  surface  of  target  cells.  It  is  this  space  and  time  restriction  that 
enables  cytokines  to  shift  local  immune  responses  influencing  the  type  of  protective 
effector  mechanisms  elicited  without  compromising  subsequent  regulation  by 
antagonistic  signals.  However,  this  same  constraint  constitutes  a  major  difficulty  in 
the  analysis  of  cytokine  expression.  If  we  are  to  correlate  cytokine  profiling  with 
protective  versus  non-protective  immunity  or  with  disease  susceptibility,  it  is 
important  to  correlate  levels  of  cytokine  mRNA  expression  with  actual  protein  output 
and  often  with  evidence  of  cellular  activity  attributable  to  stimulation  by  the  measured 
cytokines.  Studies  like  this  will  increase  our  understanding  of  cytokine  functional 
synergism,  overlap  and  antagonism,  narrowing  the  concept  of  redundancy  in  cytokine 
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activity.  This  in  turn  will  be  of  value  in  the  diagnosis  and  prognosis  of  disease 
processes  and  in  the  design  and  application  of  immune-therapy  regimens. 
The  main  drive  for  cytokine  research  in  veterinary  medicine  is  their  potential  for  the 
development  of  new  and  better  drugs.  Cytokines  and  cytokine  reagents  can  not  only 
be  used  as  drugs  themselves  but  also  to  assess  the  efficacy  of  immuno-stimulatory 
compounds  (e.  g.  vaccine  adjuvants,  steroids,  antiviral  drugs)  in  the  treatment  or 
prevention  of  disease.  The  use  of  recombinant  cytokines  as  therapeutical  agents  for 
ungulates  has  been  very  limited  and  non-existent  in  the  case  of  the  horse.  Bovine  IL-2 
(rBoIL-2)  reduced  severity  of  clinical  disease  in  vaccinated  calves  challenged  with 
bovine  herpes  virus  (BHV)-I(Reddy  et  al,  1989).  BHV  infected  cattle  treated  with 
both  IFN-oc  and  IFN-y  had  a  marked  reduction  in  the  severity  of  illness  and  mortality 
(Babiuk  et  al,  1991).  Also  BoIFN-y  was  found  to  reduce  the  severity  of  pneumonia 
caused  by  Haemophilus  somnus  (Peel  et  al,  1990)  and  the  degree  of  septicaernia  due 
to  Salmonella  typhimurium  (Chiang  et  al,  1990).  BoIFN-y,  IL-lP  and  IL-2  have  also 
been  used  in  the  control  of  mastitis,  having  promoted  lower  infection  rates  (Daley  et 
al,  1991). 
The  delivery  of  recombinant  cytokines  in  vivo,  usually  produced  in  bacterial 
expression  systems,  has  certain  disadvantages.  It  promotes  variable  levels  of  systemic 
toxicity  that  can  modify  or  dilute  the  activity  of  the  administered  cytokine.  It  can  elicit 
immune  responses,  in  the  form  of  antibodies,  to  the  inoculated  cytokine,  therefore 
rendering  it  inactive.  These  proteins  are  produced  in  heterologous  expression  systems 
and  as  such  post-translation  modifications  are  not  always  authentic.  This  has  a  bearing 
in  the  biological  activity,  immunogeneticity  and  pharmacokinetics  of  the  inoculated 
cytokine.  Recent  developments  in  minimal  viral  and  bacterial  vectors  and  DNA 
vaccination  technologies  allow  cytokine  genes  to  be  delivered  and  expressed  in  vivo, 
providing  an  effective  and  inexpensive  commercial  delivery  method  via  feed,  water  or 
aerosol.  Such  systems  allow  cytokines  to  be  produced  in  their  native  form,  as 
delivered  cytokine  genes  are  transcribed  and  translated  using  the  host  cellular 
enzymatic  machinery.  Cytokines  like  IL-2,  IL-4,  IFN-y  and  IL-12  delivered  by  these 
systems  in  murine  models  have  proven  to  be  potent  immunomodulators,  particularly 
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when  used  as  adjuvants  for  vaccine  formulations  (Braciak  et  al,  1993;  Kurilla  et  al, 
1993;  York  et  al,  1996;  Cohen  et  al  1998;  reviewed  in  chapter  6)  and  are  held  as 
apromising  resource  in  the  fight  against  cancer  and  infectious  diseases. 
7.4  Future  directions 
Future  work  in  equine  cytokine  research  will  have  to  pass  through  the  development  of 
more  and  better  reagents.  Of  great  importance  is  the  establishment  of  equine  cell  lines, 
particularly  of  haematapoetic  origin  and  of  neutralising  monoclonal  antibodies  that 
will  facilitate  the  characterisation  of  native  cytokines  and  the  assessment  of  biological 
activity  of  recombinant  forms  of  these  proteins.  The  manipulation  of  cytokine 
expression  in  vivo  will  benefit  from  the  cloning  of  soluble  forms  of  cytokine  receptors 
for  specific  blocking  of  particular  cytokines,  and  from  tissue-targeted  delivery  of 
cytokines  and  anti-cytokines.  This  can  be  achieved  either  by  using  vectors  with 
specific  tissue  tropism  (e.  g.  containing  the  adenovirus  fiber  gene)  or  containing  host 
tissue-specific  promoters. 
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Transforming  growth  factor  beta  (TGF-P)  belongs  to  a 
family  of  peptide  growth  factors  which  control  critical 
stages  of  cell  proliferation  and  differentiation.  We 
report  the  cloning  and  sequencing  of  the  cDNA  for 
TGF-P  type  1  isoform  of  the  horse.  The  predicted  mature 
equine  TGFP-l  peptide  is  112  amino  acids  in  length  and 
exhibits  99%  identity  to  mature  human  TGFfý-L 
Keywords:  Cytokine,  molecular  cloning,  polymerase  chain 
reaction,  sequencing,  transforming  growth  factor 
Transforming  growth  factor  beta  (TGF-0)  is  a 
ubiquitous  and  multifunctional  cytokine  pro- 
duced  by  normal  and  transformed  tissues.  Its 
biological  activities  include  modulation  of  cell 
growth  and  differentiation  and  a  role  in  immune 
and  inflammatory  responses  (reviewed  in 
Derynck,  1994).  TGF-P  is  present  in  high  concen- 
tration  in  platelets  (Childs  et  al.,  1982),  kidney 
(Roberts  et  al.,  1983),  placenta  (Frolik,  1983)  bone 
and  spleen  (Roberts  and  Sporn,  1992)  and  is  also 
released  in  significant  amounts  by  activated  lym- 
phocytes  and  macrophages  (Kehrl  et  al.,  1986). 
Three  isoforms  of  this  cytokine  (TGF-pl,  TGF-P2 
and  TGF-03)  have  been  identified  in  mammalian 
species  (Derynck,  1994).  A  wide  range  of  biologi- 
cal  activities  have  been  associated  with  TGFps 
in  vivo  including  involvement  in  processes  as  dis- 
tinct  as  embryogenesis,  tissue  repair,  wound 
healing,  immunosuppression  and  carcinogenesis 
(Roberts  and  Sporn,  1990;  Wahl,  1994).  TGFO  may 
have  clinical  application  in  immunosuppressive 
regimes,  as  a  therapeutic  agent  in  wound  and 
fracture  healing  and  ýn  the  treatment  of  acute 
inflammatory  processes  (Sporn  et  al.,  1986). 
Human  TGF-01  is  synthesised  as  a  precursor 
polypeptide  of  390  amino  acids,  containing  an 
N-terminal  signal  peptide,  a  pro-segment  (the 
latency-associated  polypeptide,  LAP)  and  a  112 
amino  acid  C-terminal  peptide  (mature  TGF-P 
monomer). 
TGF-0  is  usually  secreted  as  an  inactive  com- 
plex  composed  of  two  pro  segments  nonco- 
valently  associated  with  a  covalently  linked 
homodimer  of  the  C-terminal  peptide.  The  biolog- 
ically  active  form  is  a  25kDa  homodimer  of  the 
Corresponding  author. 
375 I  A=CCCCCCTCCGGCCTGCGGCTGCTGCCGCTGCTGCTGCCACTGCTGTGGCTACTAGTG 
MPPSGLRLLPLLLPLLWLLV 
SPT 
61  CTCACGCCTGGCCGGCCAGCCGCCGGACTGTCCACCTGCAAGACCATCGACATGGAGCTG 
LTPCRPAAGLSTCKTIDMEL 
LAPT 
121  GTGAAGCGCAAGCCCATCGAGGCCATCCGCGGCCAGATCCTGTCCAAGTTGCGGCTCGCC 
VKRKRIEAIRG01LSKLRLA 
181  AGCCCCCCGAGCCAGGGGGAGGTTCCGCCCGGCCCGCTGCCCGAGCCCGTCCTGGCCCTT 
SPPS0GEVPPGPLPEAVLAL 
241  TACAACACTACCCGCGCCCAGGTGGCCCCCGACAGCCCTGACACCGAGCCCGACCCTGAG 
YNTRA  VAGESAETEPEPE 
301  GCGGACTACTACGCCAAGCAGCTCACCCGCGTGCTAATGGTGGAAAAGGAAAACCAAATC 
ADYYAKEVTRVLMVEKENEI 
361  TATAAGACTGTCGACACCGCCTCACACACCATATATATCTTCTTCAACACCTCGGAGCTC 
YXTVETGSHSIYMFFNTSEL 
421  CCGGCACCAGTGCCCGATCCCATGCTGCTCTCCCGGGCAGAGCTGCCCCTCCTAAGGCTC 
RAAVPDPMLLSRAELRLLRL 
481  AAGTTAAGCGTGGAGCAGCATGTGGAGCTGTACCAGAAATACAGCAATAATTCCTGGCGC 
XLSVE0HVELY0XYSNNSWR 
541  TACCTCACTAACCGGCTGCTCACCCCCAGCGACTCGCCGGAATGGCTGTCCTTTGATCTC 
YLSNRLLTPSDSPEWLSFDV 
601  ACTGCAGTCGTGCCGCAGTGCCTGAGCCAGGGAGGGGCAATGGAGGGCTTTCGCCTCAGT 
TCVVR0WLS2GGAMEGFRLS 
661  CCCCACTCCTCCTGTGACAGCAAACATAACACACTCCGCGTGCCCATCAACGGGTTCAGT 
AHCSCDSKDNTLRVGINGFS 
721  TCCACTCGCCGCGGTGATCTCGCCACCATTGATGGCATGAACCGGCCCTTCCTGCTCCTC 
SSRRGDLATIDGMNRPFLLL 
781  ATCGCCACCCCACTGGAGACCCCCCAGCAGCTGCACAGCTCCCGCCACCGCCGAGCTCTG 
MATPLERALHSSRHRRAL 
MPT 
841  GACACCAACTACTGTTTCAGCTCCACAGAGAAGAACTGCTGCGTACGGCAGCTCTACATT 
DTNYCFSSTEXNCCVRQLY1 
901  CACTTTCCCAAGGATCTCGGCTCCAAGTGGATCCACCACCCCAAGGGCTACCACGCCAAC 
DFRKDLGWKWIHEPKGYHAN 
961  TTCTGCCTGGGGCCCTGCCCCTACATTTGGAGCCTGGACACGCAGTACAGCAAGGTCCTG 
FCLCPCPYIWSLDTQ.  Y  SKVL 
1021  GCCCTGTACAACCAGCACAACCCGGGCGCGTCGGCGGCGCCGTGCTGCGTGCCGCAGGTG 
ALYN0HNPGASAAPCCVPQV 
1081  CTGGAGCCGCTGCCCATCGTGTACTACGTGGGTCGCAAGCCCAAGGTGGAGCAGCTGTCC 
LEPLPIVYYVGRKPXVEQLS 
1141  AACATGATCGTGCGCTCýTGCAAGTrC!  AGCTC:  A  1173 
NMIVRSCKCS* 
FIGURE  1  Nucleotide  sequence  of  the  equine  TGFP-1  cDNA  and  predicted  amino  acid  sequence  of  its  product.  Primers  flanking 
the  entire  open  reading  frame  were  5'-  TTAGATATCGCCTCCCCCATG-3'and  5'-  TCAGCTGCACTTGCAGGAG  -3'.  PCR  reaction 
mix  was:  1x  buffer,  200gM  dNTP,  2mM  MgC6  2  units  of  Taq  polymerase,  50pmol  of  each  primer  and  101t]  of  cDNA.  Thermal  cycling 
conditions  were  94*C  5min,  then  35  cycles  of  94*C  30sec,  45*C  45sec,  72'C  2min,  terminating  with  a  single  cycle  of  72*C  for  7min. 
Primer  deiermined  nucleotide  sequence  and  potential  N-linked  glycosylation  sites  are  underlined.  Amino  acids  which  differ  from 
those  of  human  TGFO-1  (Derynck  et  al.,  1985)  are  asterisked  (*).  Arrows  indicate  predicted  first  amino  acid  in  signal  peptide  (SPT), 
latency-associated  polypeptide  (LAPT)  and  mature  peptide  (MPT). 
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mature  C-terminal  peptide  (Assoian  et  al.,  1983) 
which  is  highly  conserved  (>99%)  in  amino  acid 
sequence  cross  species.  To  date  the  sequences  of 
TGF-01  cDNAs  or  genes  isolated  from  more  than 
ten  species,  including  human  (Derynck  et  al., 
1985),  bovine  (Obberghen-Schilling  et  al.,  1987), 
porcine  (Demyck  et  al.,  1987)  and  canine  (Manning 
et  al.,  1995),  have  been  published  or  deposited  in 
databases. 
In  order  to  isolate  equine  TGF-01  cDNA,  lym- 
phocytes  were  recovered  from  spleen  and  lymph 
node  and  stimulated  for  six  hours  with  con- 
canavalin  A  (7.5gg/ml)  or  lipopolysaccharide 
(10lig/ml).  mRNA  was  isolated  using  "Quick 
prep  mRNA  isolation  Kit"  (Pharmacia)  and  subse- 
quently  treated  with  methylmercury  hydroxide 
(10mM).  cDNA  synthesised  using  "First  Strand 
cDNA  Synthesis  Kit"  (Pharmacia)  primed  with  an 
oligo-dT,  served  as  template  for  amplification 
using  Taq  based  Perkin  Elmer  PCR  System  and  a 
series  of  primers  derived  from  published  human 
and  bovine  TGF-P1  sequences  (Derynck  et  al., 
1985;  Obberghen-Schilling  et  al.,  1987).  PCR 
products  were  cloned  into  TA  Cloning  Vector 
(Invitrogen).  A  total  of  thirty  five  clones  from  eight 
independent  PCR  reactions  were  sequenced  by 
automated  sequencing  using  "ThermoSequenase 
Cycle  Sequencing  Yjt"(Amersham)  and  M13  for- 
ward  and  reverse  primers  labelled  with  IRD41- 
GCG  programs  were  used  to  analyse  sequencing 
data  and  to  generate  the  consensus  sequence 
shown  in  Figure  1. 
Analysis  of  the  sequence  data  revealed  an  open 
reading  frame  encoding  a  390  amino  acid  equine 
TGF-01  precursor  which  possesses  the  following 
features  conserved  throughout  all  TGF-01  pre- 
cursors  analysed  to  date-a  region  of  hydropho- 
bic  amino  acids  (position  8-21)  within  the  signal 
peptide  (1-29),  twelve  cysteine  residues  (nine 
within  the  mature  peptide),  an  argir-dne  doublet 
(277-278)  preceding  the  proteolytic  cleavage  site 
utilised  in  the  generation  of  the  mature  peptide 
sequence  (C-terminal  112  amino  acids,  279-390) 
and  a  CXCX  motif  at  the  extreme  C-terminus 
(Fig.  1). 
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The  nucleotide  sequence  and  derived  amino 
acid  sequence  exhibit  homology  in  the  range 
90-92%  and  89-92%,  respectively,  with  other 
published  mammalian  TGF-01  sequences.  With- 
in  the  predicted  mature  region  the  equine  se- 
quence  differs  from  the  human  at  one  position. 
Equine  TGF-P1  is  thus  the  only  characterised 
non-rodent  mammalian  TGF-P1  which  is  not 
100%  conserved  in  sequence  to  human  TGF-01 
within  the  biologically  active  peptide. 
Cloning  of  equine  TGF-P1  cDNA  will  facilitate 
the  study  of  the  role  of  this  cytokine  in  the  patho- 
genesis  of  equine  diseases.  For  instance  TGF-01 
has  been  implicated  in  the  fibrosis  associated 
with  chronic  pneumonia  in  the  horse  (Rodriguez 
et  al.,  1996)  and  abnormal  expression  of  this 
cytokine  may  be  associated  with  the  pathogene- 
sis  of  osteochondrosis  in  the  horse  since,  along 
with  insulin  like  growth  factor  II,  TGF-01  is 
required  for  endochondral  ossification.  (Welin, 
1993).  Furthermore  the  expression  of  recombi- 
nant  TGF-01  will  permit  the  evaluation  of  the 
therapeutic  role  of  this  cytokine  in  equine  medi- 
cine  particularly  in  the  treatment  of  chronic  soft 
tissue  wounds. 
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Caspases  are  a  family  of  cysteine  proteases  which 
have  important  roles  in  activation  of  cytokines  and 
in  apoptosis.  Caspase-1,  or  interleukin-10  converting 
enzyme  (ICE),  promotes  maturation  of  inter- 
leukin-1P  (IL-1p)  and  interleukin-18  UL-18)  by  prote- 
olytic  cleavage  of  precursor  forms  to  generate 
biologically  active  peptides.  We  report  the  cloning 
and  sequencing  of  equine  caspase-1  cDNA.  Equine 
caspase-1  is  405  amino  acids  in  length  and  has  727o 
and  637o  identity  to  human  and  mouse  caspase-1, 
respectively,  at  the  amino  acid  level.  Sites  of  proteo- 
lytic  cleavage  and  catalytic  activity  as  identified  in 
human  caspase-1,  are  conserved. 
Keywords:  caspase,  interleukin-1p,  equine,  protease, 
sequence 
Caspases  are  a  family  of  more  than  ten  cysteine 
proteases;  which  play  an  important  role  in 
inflammatory  processes  and  in  apoptosis  (Wong, 
1998).  Family  members  are  characterised.  by  a 
specificity  for  aspartic  acid  in  the  P,  position  and 
n  conserved  OACXG  active  site  t)entar)et)tide 
prointerleukin-  10  from  its  inactive  31kDa  form 
to  the  bioactive  17kDa  cytokine  IL-10  which  is  a 
key  mediator  of  inflammation  (Black  et  al.,  1989). 
More  recently  a  role  in  the  maturation  of  inter- 
leukin  18  (IL-18,  previously  known  as  inter- 
feron-y  inducing  factor,  IGIF)  has  been  identified 
(Gu  et  al.,  1997;  Ghayur  et  al.,  1997).  Caspase-1 
cleaves  inactive  24kDa  proIL-18  to  release  a  bio- 
active  18.2kDa  peptide  which  has  a  critical  role 
in  the  development  of  a  Th  1  type  cell-mediated 
immune  response  (Okamura  et  al.,  1995).  Immu- 
noelectron  microscopic  staining  techniques  sug- 
gest  that  active  caspase  is  localised  on  the 
plasma  membrane  of  cells,  while  proenzyme  in 
mainly  found  in  the  cytoplasm  (Ayala  et  al., 
1994,  Singer  et  al.,  1995)  and  it  has  therefore  been 
postulated  that  caspase-  1  may  be  part  of  a  trans- 
membrane  complex  required  for  IL-1p,  and  pos- 
sibly  IL-18,  secretion  (Tocci,  1997). 
region  (X=Q  R  or  G)  (Cohen,  1997).  Inter-  A  role  for  caspase-1  in  apoptosis  was  inferred 
leukin-10  converting  enzyme  (ICE),  or  caspase-1,  due  to  sequence  homology  with  the  C.  elegans 
was  the  first  discovered  member  of  the  family  cell  death  gene  (ced-3).  This  was  supported  by 
(Thornberry  et  al.,  1992).  Caspase-1  processes  demonstration  of  apoptosis  in  cells  transfected 
*  Corresponding  Author:  L.  Nicolson,  Department  of  Veterinary  Pathology,  University  of  Glasgow  Veterinary  School, 
Bearsden  Rd,  Glasgow  G61  1QH,  Scotland,  UK.  Telephone:  0141-339-8855  ext  2258,  FAX:  0141-330-56OZ  e.  mail:  L.  Nicol- 
songvet.  gla.  ac.  uk 
133 134  S.  WARDLOW  et  al. 
Asp  Asp  Asp  Asp 
103  119  297  316 
p2  P" 
Human  DD  HG  QACRG  DDHM 
Equine  DD  HO  QACRG  DDST 
FIGURE  I  Schematic  diagram  of  human  caspase-1  (adapted 
from  Tocci,  1997).  Human  caspase-1  amino  acid  residues 
involved  in  autoproteolytic  cleavage,  catalytic  activity  and 
binding  of  substrates  or  inhibitors  are  indicated  and  the  cor- 
responding  residue  in  equine  caspase-I  detailed  below  (see 
text  for  details) 
with  caspase-1  and  by  inhibition  of  this  activity 
through  mutation  of  the  catalytic  site  (Miura  et 
al.,  1993;  Yuan  et  al.,  1993).  However,  the  mecha- 
nism  of  apoptotic  induction  by  caspase-1  is  indi- 
rect  and  its  physiological  importance  is 
unknown  and  it  appears  that  other  cysteine  pro- 
teases,  such  as  caspase-3,  may  play  a  more  criti- 
cal  role  in  apoptosis  (Miller,  1997,  Nicholson  et 
al.,  1995). 
The  functional  human  caspase-1  enzyme  com- 
prises  two  heterodimers  composed  of  20kD  and 
10kDa  subunits  derived  from  a  45kDa  proen- 
zyme  by  autoproteolytic  cleavage  at  4  aspartate 
(Asp)  residues  at  positions  103,119,297  and  316 
(Thornberry  et  al.,  1992;  Ramage  et  al.,  1995; 
Tocci,  1997)  [Figure  1]. 
Nucleotide  sequences  are  available  for  a 
number  of  mammalian  caspase-1  cDNAs  includ- 
ing  human  (Thornberry  et  al.,  1992),  mouse 
(Casano  et  al.,  1994)  and  rat  (Kaushal  et  al., 
1998).  An  RT-PCR  strategy  using  primers 
derived  from  conserved  regions  of  these 
sequences  was  used  to  amplify  equine  caspase-1 
cDNA.  Ce)ls  recovered  from  equine  lung  washes 
were  stimulated  with  concanavalin  A  (7.5pg/ml) 
or  lipopolysaccharide  (10pg/ml)  and  mRNA  iso- 
lated  (Quick  prep  mRNA  isolation  kit,  Pharma- 
cia  Biotech).  First  strand  cDNA  (First  Strand 
Synthesis  kit,  Pharmacia  Biotech)  was  used  as  an 
initial  template  in  a  2-round  PCR  protocol  [see 
legend  Figure  21.  PCR  products  were  cloned  into 
pcDNA3.1/V5/His-TOPO  mammalian  expres- 
sion  vector  (Invitrogen)  and  sequencing  per- 
formed  using  a  Thermosequenase  Cycle 
Sequencing  Kit  (Amersharn),  IRD-800  modified 
primers  (MWG  Biotech)  and  a  LICOR-4000  auto- 
mated  sequencer.  Consensus  sequence  was 
derived  from  analysis  of  both  strands  of  10 
equine  caspase-1  cDNA  clones  isolated  by  PCR 
of  templates  derived  from  6  independent  pri- 
mary  PCRs.  Three  positions  of  allelic  difference 
were  detected  at  which  30%  to  70%  of  clones 
possessed  one  of  two  nucleotides  [Table  11. 
The  1218bp  consensus  equine  caspase-1 
sequence  [Figure  2]  encodes  a  predicted  405 
amino  acid  polypeptide,  one  amino  acid  more 
than  full  length  human  caspase-1.  No  attempt 
was  made  to  determine  whether  isoforms  of 
equine  caspase  exist  analogous  to  those  identi- 
fied  for  human  caspase-1.  The  three  allele-spe- 
cific  bases  at  positions  555,607  and  914  [Table  1, 
Figure  2]  result  in  conservative  differences  or  no 
amino  acid  difference.  The  predicted  sequences 
have  82%  /  72%  identity  with  human  caspase-1, 
747o/63%  identity  with  mouse  caspase-1  and 
737o  /64%  with  rat  at  the  nucleotide/  amino  acid 
level  respectively. 
Equine  caspase-1  contains  the  conserved 
QACRG  active  site  pentapeptide  in  the  predicted 
p20  subunit  (Cohen,  1997).  Catalytic  site  resi- 
dues  CyS285,  HiS237  and  G238  (Walker  et  al.,  1994; 
Wilson  et  al.,  1994)  are  conserved  along  with 
those  forming  the  carboxylate  binding  domain  in 
human  caspase-1  (Arg179,  Arg341,  Gln283  and 
Ser  347) 
. 
The  four  Asp  residues  associated  with 
autoproteolytic  cleavage  of  human  caspase-1  are 
conserved  in  equine  caspase-1,  therefore  it 
would  be  reasonable  to  predict  that  these  pro- 
teins  have  closely  related  processing  pathways 
and  structural  features.  Divergence  at  potential 
inhibitor  binding  residues,  His  to  Ser  at  342 
(equine  343)  and  Met  to  Thr  at  345  (equine  346) 
[Figure  1],  has  been  observed  in  other  members 
of  the  caspase-1  (ICE)  family  (Miller  et  al.,  1997). EQUINE  CASPASE-1  cDNA  SEQUENCE  135 
atggccgacaaggtcctgaaggAAAAGAGGAGCCMTTTATCCGCTCAGTGGGCACGGGT  60 
MADXVLXEKRRLFIRSVGTG 
ACACTAAATAGCT'lýWTGGA7rý"CTGTTAGAGAAAAGGGT,  GcTGAACCAGC,  "GAGATG  120 
TVNSLLDELLEKRVLNQEEM 
GAGAAAGTAAGAGATGAAAATGCTACAGTTATGr-ATAAGGCCCGAGCTTTGATTGATGCT  180 
EKVRDENATVMDXARALIDA 
GTCATTCGGAAAGGGccCCAGGCATr,  CCAAATTTTTATCGGTCACATTTGTGAAGATGAC  240 
VIRXGPQACQIFIGHICEDD 
CCCCACCTTGCAGAGACACTGCGCCTATICCTCAGGTCCACAATCTC;  GAAATTTTCTTAAA  300 
PHLAETLRLSSGPQSGNFLK 
ACACAAGACTICCCAAGCAGTGGTTCATTCCTCCCCAGCTCT;  CAGGCAATGCCGGATGAC  360 
TQDSQAVVRSSPALQAMPDD 
CTGGCTAAGCTTGCATTGTCAGGGCCAAAAGTGAGCCTCAAGCTTTGTTCACCAGAAGTG  420 
LAKLALSGPKVSLKLCSPEV 
GTCGAAAGGATATGGAAAGAAAAGTCAGCAGAGATGTACCCAATAATGGGAAAGTCGATG  480 
VERIWKEXSAEMYPIMGKSM 
ACCCGCACACGGCTTGCGCTCATTATCTGCAACACAGAGTTTGACAATCTTTCCAGGAGA  540 
TRTRLALIICNTEFDNLSRR 
GCTGGAGCTGAAGTTGATATIr.  CAAGTATGAAGGTGCTGCTAGAAGGTCTGGGGTACAGT  600 
AGAEVDIASNKVLLEGLGYS 
GTGGAAGTGAAAGAAAATCTCACCGCTTTGGACATGACTACAGAGCTGAAGGCATTTr,  CT  660 
VEVKENLTALDMTTELKAFA 
GCCCGCCCAGACCACCGGTCCTCTGACAGCACTTTCCTGGTGTTCATGTCTCATGGTATT  720 
ARPEHRSSDSTFLVFMSHGI 
CGAGAAGGCATTTGTGGGAAGAAATTCTCTGAGAAAGTCCCAGATGTATTAGAAGTCAAC  780 
REGICGKKFSEKVPDVLEVN 
ACCATCTTTCAAATTTTTAACACCAGGAACTGTCCAAATTTGAGGGACAAACCCAAGGTG  840 
TIFQIFNTRNCPNLRDKPKV 
ATCATTATCCAGGCCTGCCGTGGTGAGAATCAAGGGGTAGTGTGGTTAAAAGACTCAACA  900 
IIIQACRGENQGVVWLKDST 
GGAACTTCTGGAAATAGCTCCTCACTGGCTCCAGACGATTTTGAGGATGATGCCATTAAG  960 
GTSGNSSSLAPDDFEDDAIK 
AAAGCCCATGTAGAGAAAGATTTTATTGCTTTCTGCTCTTCAACACCAGATACTGTTTCT  1020 
KAHVEKDFIAFCSSTPDTVS 
TGGCGAAGTCCCACAACGGGCTCTGTTTTCATTGAGAAACTCATTGAAAATTTGCAACAA  1080 
WRfPTTGSVFIEKLIENLQE 
TATGCCTGGTCCTGTGATCTr.  GAGGAAATTTTCCGAAAGGTCCGATTATCATTTGAGTTG  1140 
YAWSCDLEEIFRKVRLSFEL 
CCAGATGCTAGGGCACAGATGCCCACTGCCGAAAGAGTGACTTTGACAAGACGCTTCTAC  1200 
PDARA0MPTAERVTLTRRFY 
ctcttcccaggacattaa  1218 
LFPGH* 
FIGURE  2  Nucleotide  sequence  of  equine  caspase-1  and  predicted  amino  acid  sequence  of  its  product.  Primer-derived  sequence 
is  in  lower  case.  The  essential  QACXG  active  site  pentapeptide  motif  is  underlined  along  with  key  residues  associated  with  cat- 
alytic  activity,  autoproteolytic  cleavage,  and  inhibitor  binding  -  these  are  1  position  further  from  the  N-terminus  than  the  corre- 
sponding  human  caspase-1  residues  as  equine  caspase-I  has  an  an-Lino  acid  insertion  at  position  160.  Positions  of  allelic 
variation  are  underlined.  Primary  PCRs  were  performed  using  10gl  cDNA  template,  1  unit  BioTaq  (Bioline)  and  primers 
5ý-GATATCATGGCCGACAAGGTCCTGAAGG-3'and5'-GCGCCCGGGT'ITCMAGTTTAATG-3',  in  a  50gl  reaction  volume 
containing  lx  Bioline  core  reagents.  Secondary  PCRs  were  performed  using  0.5gl  of  primary  PCR  reaction  product  as  template, 
1  unit  BioTaq  or  Pfu  (Stratagene)  and  primers  5-GGCGTTTAAACCCATGGCCGACAAG-3and  5'a-GCAGCTGTTAATGTCCT- 
GGGAAGAG-3'  in  a  5OgI  reaction  volume  containing  1x  Bioline  core  reagents  or  Stratagene  core  reagents.  Thermocycling  con- 
ditions  were  as  follows:  950C  Ymin  then  for  primary  PCRs  30  cycles  of  95'C  30s,  37'C  30s,  72*C  V20s  and  for  secondary  PCRs 
25  cycles  of  95'C  30s,  45'C,  30s,  72*C  I'20s.  The  final  extension  time  for  both  primary  and  secondary  PCRs  was  72'C  for  7  min 136  S.  WARDLOW  et  A 
TABLE  I  Allelic  differences  within  equine  caspase-1  coding 
sequence  and  effect  on  amino  acid  sequence  of  expressed 
peptides 
Nucleotide  Nucleotide  Amino  acid  Coding 
position  position  potential 
555  A/T  185  no  change 
607  G/T  203  L/V  neutral,  nonpolar 
914  A/G  305  S/N  neutral,  polar 
Caspase-1  inhibitors  may  have  potential  in  the 
treatment  of  inflammatory  disease  and  in  antiap- 
optotic  regimes.  Determination  of  the  primary 
sequence  of  equine  caspase-1  and  production  of 
expression  cassettes  will  facilitate  in  vitro  studies 
and  ultimately  an  investigation  of  equine  cas- 
pase-1  or  inhibitors  as  prophylactic  or  therapeu- 
tic  agents  in  the  horse. 
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Interleukin-12  (IL-12)  and  interleukin-18  (IL-18)  are 
key  cytokines  in  the  modulation  of  cell-mediated  im- 
mune  responses.  IL-12  is  produced  primarily  by  macro- 
phages  and  dendritic  cells  in  response  to  intracellular 
parasites,  bacteria,  and  their  products  (reviewed  in 
Trinchieri  1995).  First  identified  by  its  synergy  with  IL- 
2  in  the  stimulation  of  the  activity  of  T  cells  (Gately  et 
al.  1986)  and  natural  killer  (NK)  cells  (Kobayashi  et  al. 
1989),  it  is  now  known  that  this  molecule  plays  a  central 
role  in  the  modulation  of  immune  responses.  The  ef- 
fects  of  IL-12  include  the  enhancement  of  lytic  activity 
and  IFN-y  secretion  by  NK  and  T  cells,  the  inhibition 
of  IL-2-driven  proliferation  of  NK  cells,  the  potent 
proliferation  induction  of  both  naive  and  memory  T 
cells,  and  the  induction  of  T-helper  type  1  (THI.  )  differ- 
entiation  (Murphy  et  al.  1994;  Trinchieri  1997).  Biolog- 
ically  active  human  IL-12  is  a  70  000  M,  heterodimer 
comprising  covalently  linked  glycosylated  peptides  of 
approximately  40  000  and  35  0000  M,.,  designated  p40 
and  p35  respectively  (Trinchieri  1995).  Sequence  simi- 
The  nucleotide  sequence  data  reported  in  this  paper  have  been 
submitted  to  the  GenBank  nucleotide  sequence  database  and 
have  been  assigned  the  accession  numbers  YI  1129,  YI  1130,  and 
YI  1131 
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larity  of  p35  to  IL-6  and  granulocyte  colony  stimulating 
factor  (G-CSF)  (Merberg  et  al.  1992)  and  of  p40  to  the 
IL-6  and  G-CSF  receptors  (Gearing  and  Cosman  1991) 
are  suggestive  of  evolution  from  a  common  primordial 
cytokine  and  a  p70  structure  akin  to  a  soluble  cyto- 
kine:  cytokine  receptor  complex. 
Interleukin-18,  originally  termed  interferon-gamma 
inducing  factor  (IGIF),  is  a  cytokine  functionally  iden- 
tified  by  Okamura  and  co-workers  (1982)  as  a  factor 
which  induced  interferon  gamma  production  in  mice 
with  endotoxic  shock.  Primarily  produced  by  macro- 
phage-like  cells,  it  is  regarded  as  functionally  similar  to 
IL-12.  Activities  include  the  induction  of  IFN-y  and 
GM-CSF,  repression  of  IL-10  production,  stimulation 
of  T-cell  proliferation,  and  enhancement  of  NK  cell  cy- 
totoxicity  (reviewed  in  Kohno  and  Kurimoto  1998; 
Ushio  et  al.  1996).  Human  IL-18  is  synthesized  as  a  bio- 
logically  inactive  precursor  protein,  proIL-18,  of  193 
amino  acids  which  is  processed  into  an  18  000  M,  ma- 
ture  peptide  devoid  of  N-linked  glycosylation  by  pro- 
teolytic  cleavage  of  an  N-terminal  36  amino  acid  leader 
sequence.  Cleavage  is  catalyzed  by  caspase-1  (interleu- 
kin-1,6  converting  enzyme,  ICE)  and  associated  events 
may  facilitate  export  of  the  bioactive  monomeric  18  000 
M,  peptide  (Ghayur  et  al.  1997;  Gu  et  al.  1997).  IL-18 
shares  no  significant  similarity  at  the  primary  sequence 
level  to  any  other  cytokines.  However,  analysis  of  the 
sequence  using  fold  recognition  algorithms  has  re- 
vealed  a  distant  relationship  to  the  interleukin-1  super- 
family  (Bazan  et  al.  1996).  While  IL-12  and  IL-18  both 
induce  IFN-y,  IL-18  is,  in  the  presence  of  appropriate 
costimuli,  a  more  potent  inducer  of  IFN-y  than  IL-12 
(Kohno  et  al.  1997).  Receptor  binding  and  signalling 
pathways  are  distinct  and  IL-12  and  IL-18  can  act  sy- 
nergistically  in  the  induction  of  IFN-y,  an  effect  which 
may  be  contributed  to  by  the  ability  of  IL-12  to  up-reg- 
ulate  IL-18  receptor  expression  (Ahn  et  al.  1997;  Ro- 
binson  et  al.  1997). 
The  potent  IFN-y  induction  of  IL-12  and  IL-18  and 
associated  immune  effects  have  been  elicited  in  pro- 
phylactic  and  therapeutic  regimes  through  exogenous 95 
administration  of  recombinant  cytokines.  With  a  view 
to  evaluation  of  IL-18  and  IL-12  as  immune  modulators 
in  domestic  animals  we  have  cloned  and  sequenced  the 
horse,  dog  [D.  J.  Argyle  and  co-workers  (1999),  and  cat 
L.  Hanlon  and  co-workers,  unpublished  data,  accession 
number  Y13923]  IL-12,  IL-18,  and  caspase-1  cDNAs 
(Wardlow  et  al.  1999;  accession  numbers  AF090119, 
AF135967,  and  AF135968).  We  report  here  the  nucleo- 
tide  sequence  of  horse  IL-12  and  IL-18  cDNAs  derived 
by  reverse  transcription-polymerase  chain  reaction 
(PCR)  of  mRNA  isolated  from  adherent  cells  recov- 
ered  from  horse  lung  washes.  Cell  pellets  were  resus- 
pended  at  1x  10'  cells/ml  in  complete  medium  (RPMI 
1640,10  mM  Hepes,  2  mM  glutamine,  5X  10-5M  G-mer- 
captoethanol,  2%  fetal  bovine  serum,  100  I.  U.  /ml  peni- 
cillin/streptomycin)  and  adherent  cells  subsequently 
washed  and  incubated  for  6h  with  lipopolysaccharide 
(10  I.  Lg/ml).  Cells  were  lysed  and  mRNA  isolated  using 
a  Quick  Prep  mRNA  Isolation  Kit  (Amersham  Phar- 
macia  Biotech,  Bucks,  UK)  followed  by  treatment  with 
methylmercury  hydroxide  (10  mM).  mRNA  was  re- 
verse  transcribed  using  a  First  Strand  cDNA  Synthesis 
Kit  (Amersham  Pharmacia  Biotech)  with  oligo-dT  4s 
primer.  Primers  designed  from  homologous  regions  of 
other  mammalian  p35  and  p40  cDNAs  were  used  to 
amplify  horse  IL-12  cDNA  by  Perkin  Elmer  Taq-based 
PCR  (Table  1)  in  a  nested  PCR  strategy.  PCR  reaction 
mixes  comprised  template  (10  jL1  of  cDNA  for  primary 
PCRs  and  1  pl  of  primary  PCR  product  for  secondary 
PCRs),  50  pmol  of  each  primer,  200  pM  dNTP,  2  mM 
MgC12,  and  2  units  of  Taq  polymerase  in  1X  buffer. 
Thermal  cycling  conditions  were  94*C  for  5  min,  then 
30  cycles  of  94  QC:  1  min,  37  *C  (primary  PCRs)  or  55  "C 
(secondary  PCRs):  1.5  min  and  72  *02  min,  terminating 
with  a  single  cycle  of  72  *C  for  7  min.  Overlapping  sub- 
fragments  of  each  cDNA  were  generated  as  full-length 
p35  and  p40  cDNAs  could  not  be  amplified:  full-length 
p35  and  p40  were  subsequently  derived  by  convention- 
al  cloning  strategies.  PCR  products  were  cloned  into 
TA  cloning  vector  pCR3.1  (Invitrogen,  Groningen,  The 
Netherlands)  and  15  p40  clones  and  15  p35  clones  were 
sequenced  across  both  strands  using  a  Thermosequen- 
ase  Cycle  Sequencing  Kit  (Amersham  Pharmacia  Bio- 
tech),  IRD-800  modified  primers  (MWG  Biotech,  Mil- 
ton  Keynes,  UK)  and  a  LICOR-4000  automated  se- 
quencer.  Recovery  of  fragments  representing  the  entire 
horse  IL-18  cDNA  sequence  required  a  nested  PCR 
strategy  using  primers  A+B  or  A+D  for  primary  PCR 
and  A+B  or  C+D  for  secondary  PCR  (Table  1).  Tem- 
plates  used  were  cDNA  for  primary  PCRs  and  I  pl  pri- 
mary  PCR  reaction  mix  for  secondary  PCRs.  Primary 
PCR  conditions  were  94"C  for  45s,  45"CAmin, 
72*C:  1.5  min  for  30  cycles,  and  secondary  PCR  condi- 
tions  were  94  *C:  45  s,  45  *C:  1  min,  72  *C:  2  min  for  30  cy- 
cles.  PCR  products  were  cloned  into  pCR3.1  and  10 
clones  sequenced  across  both  strands.  Full-length  horse 
IL-18  cDNA  was  subsequently  recovered  by  PCR  using 
primer  A  and  a  horse-specific  primer,  5'- 
GCTAGTTCTGGT=GAACA-3'.  Template  used 
was  cDNA  and  the  following  thermocycling  conditions 
were  applied  :  94  *C:  55  s,  47  *C:  40  s,  72  *C:  2  min  for  30 
cycles.  Consensus  Sequences,  generated  using  GCG 
software  (Wisconsin  package),  were  deduced  from 
clones  derived  from  multiple  independent  primary  and 
secondary  PCR  reactions  to  exclude  contribution  by 
Taq-induced  errors  (Figs.  1-3). 
The  predicted  horse  p35  peptide  is  222  amino  acids 
in  length  with  a  putative  N-terminal  signal  peptide  se- 
quence  and  four  potential  N-linked  (N-X-S/T)  glycosy- 
lation  sites  (Fig.  1).  Comparison  with  human  and 
mouse  p35  peptides  revealed  identities  of  82%  and 
59%,  respectively.  The  predicted  horse  p40  peptide  is 
329  amino  acids  in  length  and  features  a  putative  signal 
peptide  sequence  and  three  potential  N-Iinked  glycosy- 
lation  sites  (Fig.  2).  A  presumed  allelic  difference,  oc- 
curs  at  base  714  (A  or  G),  as  clones  from  several  inde- 
pendent  PCR  reactions  varied  in  sequence  at  this  posi- 
tion.  The  amino  acid  encoded  is  unaffected  by  the  sub- 
stitution.  Identities  of  86%  and  66%  exist  with  human 
and  mouse  p40  peptides,  respectively.  The  horse  IL-18 
cDNA  possesses  an  open  reading  frame  of  582  base 
pairs  encoding  a  193  amino  acid  protein  lacking  N- 
linked  glycosylation  sites  (N-X-SIT)  (Fig.  3).  Identity  of 
the  predicted  sequence  to  human  and  mouse  IL-18 
cDNAs  is  87%  and  77%  at  the  nucleotide  level  and 
79%  and  67%  at  the  amino  acid  level,  respectively.  Pro- 
duction  of  bioactive  human  IL-18  is  associated  with 
cleavage  of  full-length  proIL-18  between  ASP36  and 
Table  1.  Key  primers  used  for  amplification  of  horse  IL-12  p35 
and  p40  and  IL-18  cDNAs.  IL-12  primer  sequences  were  derived 
from  published  human  (Gubler  et  at.  1991),  cattle  (Zarlenga  et  al. 
1995)  and  dog  IL-12  sequences  (D.  J.  Argyle,  personal  communi- 
cation;  Buttner  et  at.  1998)  and  from  Rottman  and  co-workers 
(1996).  IL-18  primers  were  derived  from  human  IL-18  sequence 
(Ushio  et  at.  1996) 
N-terminal  primers  (5'-3')  C-terminal  primers  (5'-3') 
p4O  CAGAGCAAGATGTGTCACCAG  CATACrGAGGTrAGAACC 
AGATGCrGGCCAGTACACCr  GGGAGAAGTAGGAATGTGGAG 
ATGTGTCACCAGTGGTrGGTC  CAGGTGAGAATGGCrCAGAAC 
p35  CAGTGCCGGCrCAGCATGTG  GAAGTATGCAGAGCTTGA 
GGATATGTGCCCGCCGCGCG  GCTT=AGGAAGCATrCAGATAGC 
CA(A/C)GAATGAGAGTTGCCr  CCGGTTCrrCAAGGGAGG 
IL-18  GCAGGAATAAAGATGGCrGC  [A]  GCGTMGAACAGTGAACAT  [B] 
GACAATACG=ACMAT  [C)  GGCATGAAATTffAATAGCTA  [D] 96 
ATGTGCCCCCCGCGCGGCCTCCTCCTTGTGGCCATCCTGGTCCTCCTAAACCACCTGGAC  60  ATGGCTr.  CTOCACCAOTAGAAGACkArrGCATTAGCT7r-GTGGAAATGAAATTTATTGAC  S0  MCPVLLNHLDHAA0PVEDNCX5LV2MXrID 
20 
CACCTCAGTTTGGCCAGGAACCTCCCCACAGCCACACCAGGCCCAGGAATGTTCCAGTGC  120  AACACACTTTACTTTGTAGCTGAAAACGATGAAAACCTOGAATCAGATTACTTTGGCAGO  120  HLSLARNLPTATP0P0MT0CNTLYTVA2NDZNLB8 
DTY  FQR  40 
CTCAACCACTCCCAAAACCTGCTIGAGGACCGTCAGCAACACGCTTICAGA.  AGGCCAGGCAA  180 
LNHSQNLLRTV3NTLQKARQ 
ACCCTAGAATTCTACTCCTGCACTTCTC,  AAGAGATCGATCATGAGGATATCACAAAAGAC  240 
TLEFYSCTSEEIDHEDITKD 
JkAGAGCAGCACCGTr.  GCGGCCTIGCCTCCCCCTGGAACTCr-CCCCr-kACGAGAGTTGCCTO  300 
KSSTVAACLPL3LAPNE5CL 
GCTTCCAGAr.  AGATCTCTTTCATAACTAATC,  G=TTGCCTGACCCCCGGAAAGGCCTCT  360 
ASRZISFITNGSCLTPGXAS 
TCTATOATGACGCTOTGCCTTAGCAGCATCTATGAGGACTTGAAGATGTACCAGOTGOAG  420 
SMMTLCLSSIYEDLXMY0VR 
TTCAAGGCCATGAATGCCAAGCTGTTGATAGATCCTCAGAGGCAGATCTTTCTGGATGAG  480 
FXANNAXLLXDP9RQIFLD9 
AACATGCTGACAGCCATTGACAAGCTGATGCAGOCCCTGAACTTCAACAGTGAGACTGTG  540 
NNLTAIDKLNQALNPNS9TV 
CTTGAACCT)LAACTCTC)LATCATACCAAATTTC;  AACGACCAAGTTCTCTTCATTAACCAG  180 
LEPKL311RNLND0VLFINQ  60 
GGAAATCAACCTGTGTTTGAGGATATr.  CCTGA7*rMATTCTACAGACAACGCACCCCAG  240 
0NQPVFEDMPD3DCTDNAPQ  80 
ACCGTATTTATCATATATATGTATAAAGATAGCCTICACTAGAGGTCTAGCGOTAACCATC  300 
TVTIXYMYKD9LTRGLAVT1  100 
TCTGTGAAGTGTGAGAAAACGTCTACTCTCTCCTGTAAGAACAAAATTATTTCCTTTAAG  360 
3VXC8XTSTLSCKNRIISFX  120 
GAAATGA  =  CTC  CAGAGA  420 
ENSPP9NINDEGNDIIFF0R  140 
AGTGTTCCAGGACATC;  ATGATAAGATACAGTTTGAGTCTTCACTGTATAAAGGATACTTT  460 
9VP0HDDX19FESSLYKGYT  160 
CTA=%X;  lýGAGAATGATCTTTTCAAACTCATTTTGAAAGAAAAGGATGAAAAT  540 
LAC3X3NDLPXLILXEXDEN  180 
CCACAAAAGCCCTCCC  ATC  600 
PQXP3LZGLDFYKTXVXLCI  GGGGATAAATCTGTAATr.  TTCACTGTTCAAAACCAGAACTA(3  582 
GDXSVMFTV0NQN  i-  193 
CTTCTTCATr,  CCTTCAGAATCCGCGCAGTGACCATCAACAGGATIGAT13GGCTATCTGAAT  660 
LLHAFRIRAVTINRMMGYLN  Fig.  3  Nucleotide  sequence  of  horse  IL-18  (accession  number 
GCMCTAA  669  Y11131).  Primer-determined  sequence  and  the  region  related  to 
AS  the  IL-1  signature  sequence  is  underlined.  An  arrow  indicates  the 
position  of  the  predicted  cleavage  site,  31  to  the  N-terminal  lead- 
Fig.  1  Nucleotide  sequence  of  horse  IL-12  subunit  p35  (accession  ersequence 
number  Y11130).  Primer-determined  nucleotide  sequence  and 
potential  N-linkcd  glycosylation  sites  are  underlined 
ATGTGTCACCAOTGGTTGGTCCTCTCCTGGTTTTCCCTGGTTTTGCTGGCGTCTCCCCTC  60 
M  CH  QWLVLSWF3LVLLA3PL 
AT'GWCATATGGGAACTGGAGAAAGATý.  TGTATGTTOTAG)LATTGGATTGGTACCCTGAT  120 
HAIW9L2XDVYVVELDWYPD 
GCCCCTGGAGAAATGGTOGTCCTCACCTGCAATACCCCTGAAGAAGAAGGCATCACCTGO  180 
APGEMVVLTCNTPE2EGITW 
ACCTCGGCCCAGAGCAATGAGGTCTTAGGCTCTGGCAAAACCTTGA,  CCATCCAACTCAAA  240 
TSAQSNEVL03GKTLTIQVX 
GAGTTTGGAGATOCTGGCTGGTACACCTGTCACAAAGGAGGCGAGGTTCTGAGCCATTCT  300 
ZF0DAGWYTCHXGG3VL5HS 
CACCTGCTGCTTCACAAGAAGGAACAT13GAATrr,  GGTCCACTGACATTTTAAAAGACCAG  360 
HLLLHKKEDGINSTDILXDQ 
AMGAATCCAAAAATAAGACCTTTCTAAAATOTGAGGCAAAGAA7rATTCCGGACGTTTC  420 
K9SXNXTTLXC3AXNYSGRr 
ACATOCTOGTGGCTGACAGCAATCAGTACTGATTTGAAATTCAGTGTCAAAAGCAC,  CAGA  480 
TCWWLTA15TDLXF5V9SSR 
OGTTCCTCTGACCCCCGAGGGGTGACGTGTGC,  XGCAGCGACACTCTCCGCAGAGAGGGTC  540 
03SDPR0VTC0AATL3A8RV 
AGCGTGGA=ACA=AGTATAAGAAGTACACGGTGGAGTOTCAGGAGGGCAGTGCCT(;  C  600 
5VDDR3YXXYTVZCQ90SAC 
CCGGCCGCCGAGGAGAGCCTGCCCATTGAGATCGVGGTGr-ATGCTGTTCACAAGCTCAAG  660 
PAA92SLPX31VVDAVHXLK 
TATGAAAACTACACCAGCGGCTTCTTCATCAGGGACATCATCAAhCCAGACCCACCCAAG  120 
YENYT90F71RDIIKPDPPR 
JkACCTGCAGCTGAAGCCATTAAAGAATTCTCGGCAGGTGGAGGTCAr--Tr,  GGAGTACCCC  780 
NLQLXPLXNSRQVRV5W9YP 
Tyr37  by  caspase-1  (interleukin-1,8  converting  enzyme 
(ICE)  (Ghayur  et  al.  1997).  Horse  IL-18  has  a  leader 
sequence  of  36  amino  acids  terminating  in  Asp  and  in- 
vestigation  of  the  processing  and  secretion  of  horse  IL- 
18  will  be  facilitated  by  availability  of  horse  caspase-1 
expression  constructs  (WardloNV  et  al.  1999).  As  for  all 
IL-18  sa  region  of  sequence  related  to  IL-1  signature 
sequence  (F-Xio-F-X-S-[ALVJ-XZ-[AP]-X2ý-[FYLIV]- 
[LIV]-X-T),  F-Xj2-F-X-S-X6-F-L,  occurs  at  amino 
acids  138-161  (Fig.  3). 
Horse  Thl-type  cytokines  IFN-y  (Curran  et  al.  1994; 
Grunig  et  al.  1994),  IL-12,  and  IL-18  are  associated 
with  a  range  of  convergent  IFN-7-related  bioactivities 
and  distinct  additional  biological  effects.  The  potential 
now  exists  for  a  serious  investigation  of  their  use,  alone 
and  in  combination,  in  prophylactic  and  therapeutic  re- 
gimes  in  the  horse  and  related  species. 
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